


**CUMULATIVE  
SUPPLEMENT 10  
OCTOBER 2019**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**39th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2019**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**39<sup>th</sup> EDITION**

**Cumulative Supplement 10  
October 2019**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	ix
1.5 Availability of the Edition .....	x
1.6 Report of Counts for the Prescription Drug Product List.....	xi
1.7 Cumulative Supplement Legend .....	xii
 DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**39<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 10  
OCTOBER 2019**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 39<sup>th</sup> Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a

"@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been

discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to: FDA/CDER Orange Book Staff  
Office of Generic Drugs  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME  
(FORMER ABBREVIATED NAME)

AMNEAL PHARMACEUTICALS CO GMBH  
(AMNEAL PHARMS CO)

G AND W LABORATORIES INC  
(G AND W LABS)

NEW APPLICANT NAME  
(NEW ABBREVIATED NAME)

AMNEAL EU LTD  
(AMNEAL EU)

ACP NIMBLE BUYER INC  
(ACP NIMBLE)

G AND W LABORATORIES INC (G AND W LABS INC)	ACP NIMBLE BUYER INC (ACP NIMBLE)
INVATECH PHARMA SOLUTION INC (INVATECH)	ATHEM HOLDINGS LLC (ATHEM)
IVAX PHARMACEUTICALS INC (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA (IVAX PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
LUITPOLD PHARMACEUTICALS INC (LUITPOLD)	AMERICAN REGENT INC (AM REGENT)
MIKART LLC (MIKART)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
PD PARTNERS IV LLC (PD PARTNERS)	PHARMACEUTICAL ASSOCIATES INC (PHARM ASSOC)
RISING HOLDINGS INC (RISING)	ANDA REPOSITORY LLC (ANDA REPOSITORY)
RISING PHARMACEUTICALS INC (RISING PHARMS)	RISING PHARMA HOLDINGS INC (RISING)
SUN PHARMA GLOBAL FZE (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
SUN PHARMA GLOBAL INC (SUN PHARMA GLOBAL)	SUN PHARMACEUTICAL INDUSTRIES LTD (SUN PHARM)
TEVA PHARMACEUTICALS USA (TEVA PHARMS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA (TEVA PHARMS USA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
TEVA PHARMACEUTICALS USA INC (TEVA)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	ANI PHARMACEUTICALS INC (ANI PHARMS INC)
WATSON LABORATORIES INC (WATSON LABS)	DR REDDYS LABORATORIES LTD (DR REDDYS)
WATSON LABORATORIES INC (WATSON LABS)	HERITAGE PHARMA LABS INC (HERITAGE PHARMA)

WATSON LABORATORIES INC  
(WATSON LABS)

WATSON LABORATORIES INC  
(WATSON LABS INC)

WATSON LABORATORIES INC  
(WATSON LABS INC)

ANI PHARMACEUTICALS INC  
(ANI PHARMS INC)

WATSON LABORATORIES INC  
(WATSON LABS INC)

DR REDDYS LABORATORIES INC  
(DR REDDYS)

WATSON LABORATORIES INC  
(WATSON LABS INC)

HERITAGE PHARMA LABS INC  
(WATSON LABS INC)

WATSON LABORATORIES INC AN  
INDIRECT WHOLLY OWNED SUB OF  
TEVA PHARMACEUTICALS USA INC  
(WATSON LABS TEVA)

ANI PHARMACEUTICALS INC  
(ANI PHARMS INC)

WATSON LABORATORIES INC AN  
INDIRECT WHOLLY OWNED SUB OF  
TEVA PHARMACEUTICALS USA INC  
(WATSON LABS TEVA)

DR REDDYS LABORATORIES LTD  
(DR REDDYS)

WATSON LABORATORIES INC AN  
INDIRECT WHOLLY OWNED SUB OF  
TEVA PHARMACEUTICALS USA INC  
(WATSON LABS TEVA)

HERITAGE PHARMA LABS INC  
(HERITAGE PHARMA)

WEST-WARD PHARMACEUTICALS  
INTERNATIONAL LTD  
(WEST-WARD PHARMS INT)

HIKMA PHARMACEUTICALS USA  
INC  
(HIKMA)

#### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), Levo-T (Cediprof Inc NDA 021342), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Stevens J NDA 021210) tablets.

Levo-T (Cediprof Inc NDA 021342), Euthyrox (Provell Pharma LLC NDA 021292), Levothyroxine Sodium (Mylan ANDA 076187), Unithroid (Stevens J NDA 021210), Thyro-tabs (Alvogen NDA 021116), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Cediprof Inc NDA 021342), Unithroid (Stevens J NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Lupin Atlantis ANDA 209713) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-tabs (Alvogen NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	<b>021210</b>	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	CEDIPROF INC	0.025MG	AB1	021342	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB1	209713	001
SYNTHROID	ABBVIE	0.025MG	AB2	<b>021402</b>	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
EUTHYROX	PROVELL PHARMS	0.025MG	AB2	021292	001
LEVO-T	CEDIPROF INC	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
THYRO-TABS	ALVOGEN	0.025MG	AB2	021116	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB2	209713	001
LEVOXYL	KING PHARMS	0.025MG	AB3	<b>021301</b>	001
LEVO-T	CEDIPROF INC	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	LUPIN ATLANTIS	0.025MG	AB3	209713	001
THYRO-TABS	ALVOGEN	0.025MG	AB4	<b>021116</b>	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been

available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month

period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

## DEFINITIONS

### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2018</u>	<u>MAR 2019</u>	<u>JUN 2019</u>	<u>SEP 2019</u>	<u>DEC 2019</u>
DRUG PRODUCTS	20295	20580	20693	20688	
LISTED SINGLE	2724	2713	2729	2713	
SOURCE	(13.4%)	(13.2%)	(13.2%)	(13.1%)	
MULTISOURCE	17571	17867	17964	17975	
	(86.6%)	(86.8%)	(86.8%)	(86.9%)	
THERAPEUTICALLY	17483	17777	17964	17892	
EQUIVALENT	(86.1%)	(86.4%)	(86.8%)	(86.5%)	
NOT THERAPEUTICALLY	88	90	85	83	
EQUIVALENT	(0.4%)	(0.4%)	(0.4%)	(0.4%)	
EXCEPTIONS <sup>1</sup>	58	58	58	54	
	(0.3%)	(0.3%)	(0.3%)	(0.3%)	
NEW MOLECULAR	25	3	16	21	
ENTITIES APPROVED					
NUMBER OF	1133	1129	1132	1140	
APPLICANTS					

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## **1.7 CUMULATIVE SUPPLEMENT LEGEND**

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug

Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
NFTG	New first time generic approval.
CAHN**	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CHRS	Change. Reference Standard.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

**\*\*Note:**

The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 240 character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the

collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

ABACAVIR SULFATE AND LAMIVUDINE

@ ZYDUS PHARMS

EQ 600MG BASE;300MG

A208990 001 Nov 15, 2018 Mar DISC

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

AB GLENMARK PHARMS 250MG

A209227 001 Oct 16, 2019 Sep NEWA

AB MSN LABS PVT LTD 250MG

A210686 001 Jul 10, 2019 Jun NEWA

AB QILU PHARM CO LTD 250MG

A212462 001 Sep 27, 2019 Sep NEWA

AB WOCKHARDT BIO AG 250MG

A208380 001 Feb 27, 2019 Feb NEWA

ACARBOSE

TABLET;ORAL

ACARBOSE

@ MYLAN

25MG

A091053 001 Jan 06, 2011 Jun DISC

@

50MG

A091053 002 Jan 06, 2011 Jun DISC

@

100MG

A091053 003 Jan 06, 2011 Jun DISC

&gt;D&gt; AB STRIDES PHARMA 25MG

A090912 001 Jul 27, 2011 Oct CHRS

&gt;A&gt; AB ! 25MG

A090912 001 Jul 27, 2011 Oct CHRS

&gt;D&gt; PRECOSE

&gt;D&gt; AB +! BAYER HLTHCARE 25MG

N020482 004 May 29, 1997 Oct DISC

&gt;A&gt; + @ 25MG

N020482 004 May 29, 1997 Oct DISC

&gt;D&gt; AB + 50MG

N020482 001 Sep 06, 1995 Oct DISC

&gt;A&gt; + @ 50MG

N020482 001 Sep 06, 1995 Oct DISC

&gt;D&gt; AB + 100MG

N020482 002 Sep 06, 1995 Oct DISC

&gt;A&gt; + @ 100MG

N020482 002 Sep 06, 1995 Oct DISC

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

ACEBUTOLOL HYDROCHLORIDE

@ ANI PHARMS INC

EQ 200MG BASE

A074007 001 Oct 18, 1995 Jul CAHN

@

EQ 400MG BASE

A074007 002 Oct 18, 1995 Jul CAHN

ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

TABLET;ORAL

APADAZ

+ KEMPHARM 325MG;EQ 4.08MG BASE

N208653 002 Jan 04, 2019 Jan NEWA

+ 325MG;EQ 8.16MG BASE

N208653 003 Jan 04, 2019 Jan NEWA

+ KVK TECH INC 325MG;EQ 4.08MG BASE

N208653 002 Jan 04, 2019 Feb CAHN

+ 325MG;EQ 6.12MG BASE

N208653 001 Feb 23, 2018 Feb CAHN

+! 325MG;EQ 8.16MG BASE

N208653 003 Jan 04, 2019 Aug CHRS

+ 325MG;EQ 8.16MG BASE

N208653 003 Jan 04, 2019 Feb CAHN

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

! LARKEN LABS INC 325MG;25MG

A203484 001 Dec 04, 2015 Sep CHRS

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LANNETT CO INC

120MG/5ML;12MG/5ML

A091238 001 Nov 10, 2011 Jan DISC

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA ELITE LABS INC 300MG;15MG

A212418 001 Sep 10, 2019 Aug NEWA

AA 300MG;30MG

A212418 002 Sep 10, 2019 Aug NEWA

AA 300MG;60MG

A212418 003 Sep 10, 2019 Aug NEWA

AA EYWA 300MG;15MG

A211610 001 Jun 27, 2019 Sep CAHN

AA 300MG;30MG

A211610 002 Jun 27, 2019 Sep CAHN

AA 300MG;60MG

A211610 003 Jun 27, 2019 Sep CAHN

AA WES PHARMA INC 300MG;15MG

A211610 001 Jun 27, 2019 Jun NEWA

AA 300MG;30MG

A211610 002 Jun 27, 2019 Jun NEWA

AA 300MG;60MG

A211610 003 Jun 27, 2019 Jun NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

## SOLUTION; ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	WES PHARMA INC	325MG/15ML; 7.5MG/15ML	A211023	001	Mar 08, 2019	Feb	NEWA
----	----------------	------------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@	ALVOGEN PINE BROOK	300MG; 5MG	A208540	001	Nov 08, 2018	Apr	DISC
@		300MG; 7.5MG	A208540	002	Nov 08, 2018	Apr	DISC
@		300MG; 10MG	A208540	003	Nov 08, 2018	Apr	DISC
@		325MG; 2.5MG	A209958	001	Oct 24, 2018	Apr	DISC
@		325MG; 5MG	A209958	002	Oct 24, 2018	Apr	DISC
@		325MG; 7.5MG	A209958	003	Oct 24, 2018	Apr	DISC
@		325MG; 10MG	A209958	004	Oct 24, 2018	Apr	DISC
@	ELITE LABS INC	325MG; 2.5MG	A209924	001	Nov 16, 2018	May	DISC
@		325MG; 5MG	A209924	002	Nov 16, 2018	May	DISC
@		325MG; 7.5MG	A209924	003	Nov 16, 2018	May	DISC
@		325MG; 10MG	A209924	004	Nov 16, 2018	May	DISC
@	LANNETT CO INC	300MG; 5MG	A207171	001	Jun 20, 2017	Sep	DISC
@		300MG; 7.5MG	A207171	002	Jun 20, 2017	Sep	DISC
@		300MG; 10MG	A207171	003	Jun 20, 2017	Sep	DISC
@		325MG; 5MG	A207172	001	Jun 22, 2017	Sep	DISC
@		325MG; 7.5MG	A207172	002	Jun 22, 2017	Sep	DISC
@		325MG; 10MG	A207172	003	Jun 22, 2017	Sep	DISC
@	UPSHER SMITH LABS	325MG; 5MG	A206484	001	Mar 24, 2017	Jan	DISC
@		325MG; 7.5MG	A206484	002	Mar 24, 2017	Jan	DISC
@		325MG; 10MG	A206484	003	Mar 24, 2017	Jan	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## SOLUTION; ORAL

## OXYCODONE AND ACETAMINOPHEN

@	MIKART INC	300MG/5ML; 10MG/5ML	A202142	001	Nov 27, 2018	May	DISC
---	------------	---------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## OXYCODONE AND ACETAMINOPHEN

AA	ANDA REPOSITORY	325MG; 5MG	A207834	001	Aug 15, 2019	Sep	CAHN
AA		325MG; 7.5MG	A207834	002	Aug 15, 2019	Sep	CAHN
AA		325MG; 10MG	A207834	003	Aug 15, 2019	Sep	CAHN
>A> AA	GRANULES PHARMS	325MG; 2.5MG	A211708	001	Oct 31, 2019	Oct	NEWA
>A> AA		325MG; 5MG	A211708	002	Oct 31, 2019	Oct	NEWA
>A> AA		325MG; 7.5MG	A211708	003	Oct 31, 2019	Oct	NEWA
>A> AA		325MG; 10MG	A211708	004	Oct 31, 2019	Oct	NEWA
AA	HALO PHARM CANADA	325MG; 5MG	A207834	001	Aug 15, 2019	Aug	NEWA
AA		325MG; 7.5MG	A207834	002	Aug 15, 2019	Aug	NEWA
AA		325MG; 10MG	A207834	003	Aug 15, 2019	Aug	NEWA
AA	XIROMED	325MG; 5MG	A207574	001	Dec 13, 2016	Aug	CAHN

ACETAZOLAMIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## ACETAZOLAMIDE

@	ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr	DISC
AB	ALEMBIC PHARMS LTD	500MG	A210423	001	Feb 19, 2019	Feb	NEWA
AB	CADILA	500MG	A205301	001	Jan 16, 2019	Mar	CAHN
AB	HERITAGE PHARMA	500MG	A040904	001	Dec 10, 2008	Jul	CAHN
AB	! HERITAGE PHARMS INC	500MG	A090779	001	Jul 14, 2011	Jul	CHRS
@	MYLAN	500MG	A203917	001	Jun 18, 2019	Jul	DISC
AB		500MG	A203917	001	Jun 18, 2019	Jun	NEWA

## DIAMOX

+	@ TEVA BRANDED PHARM	500MG	N012945	001		Jul	DISC
---	----------------------	-------	---------	-----	--	-----	------

## INJECTABLE; INJECTION

## ACETAZOLAMIDE SODIUM

AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Apr	NEWA
----	--------------	--------------------	---------	-----	--------------	-----	------

## TABLET; ORAL

## ACETAZOLAMIDE

>A> AB	EYWA PHARMA	125MG	A211556	001	Oct 18, 2019	Oct	NEWA
>A> AB		250MG	A211556	002	Oct 18, 2019	Oct	NEWA
>A> AB	NOVITIUM PHARMA	125MG	A210588	001	Oct 17, 2019	Oct	NEWA
>A> AB		250MG	A210588	002	Oct 17, 2019	Oct	NEWA
>D> AB	SUN PHARM INDUSTRIES	125MG	A089753	002	Jun 22, 1988	Oct	DISC
>A>	@	125MG	A089753	002	Jun 22, 1988	Oct	DISC

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION  
ACETAZOLAMIDE SODIUM

	@ PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	Apr DISC
AP	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206533	001	Apr 15, 2019	Jun CAHN

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC  
ACETIC ACID

AT	MLV	2%	A040607	001	Feb 24, 2005	Sep CAHN
AT	SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	May CAHN

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC  
ACETASOL HC

	@ ACTAVIS MID ATLANTIC	2%; 1%	A087143	001	Jan 13, 1982	Jun DISC
--	------------------------	--------	---------	-----	--------------	----------

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS  
ACETYLCYSTEINE

	@ MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Mar DISC
--	-----------------------	---------------------	---------	-----	--------------	----------

TABLET, EFFERVESCENT; ORAL  
CETYLEV

	+ @ ARBOR PHARMS LLC	500MG	N207916	001	Jan 29, 2016	Mar DISC
	+ @	2.5GM	N207916	002	Jan 29, 2016	Mar DISC

ACITRETIN

CAPSULE; ORAL  
SORIATANE

	+ @ STIEFEL LABS INC	17.5MG	N019821	003	Aug 06, 2009	Jan DISC
	+ @	22.5MG	N019821	004	Aug 06, 2009	Jan DISC

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION  
TUDORZA PRESSAIR

	+! CIRCASSIA	0.4MG/INH	N202450	001	Jul 23, 2012	Jun CAHN
--	--------------	-----------	---------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION  
DUAKLIR PRESSAIR

	ASTRAZENECA PHARMS	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Mar NEWA
	CIRCASSIA	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Apr CAHN

ACYCLOVIR

CAPSULE; ORAL  
ACYCLOVIR

AB	CADILA	200MG	A204313	001	Mar 25, 2016	Aug CAHN
AB	KENTON	200MG	A075090	001	Jan 26, 1999	Mar CAHN

CREAM; TOPICAL  
ACYCLOVIR

AB	PERRIGO UK FINCO	5%	A208702	001	Feb 04, 2019	Jan NFTG
----	------------------	----	---------	-----	--------------	----------

AB	+! BAUSCH	5%	N021478	001	Dec 30, 2002	Feb CAHN
AB	+! VIB	5%	N021478	001	Dec 30, 2002	Jan CFTG

OINTMENT; OPHTHALMIC  
AVACLYR

	+ @ FERA PHARMS LLC	3%	N202408	001	Mar 29, 2019	Aug DISC
	+!	3%	N202408	001	Mar 29, 2019	Mar NEWA

OINTMENT; TOPICAL  
ACYCLOVIR

AB	APOTEX	5%	A210774	001	Sep 06, 2019	Aug NEWA
>A> AB	CADILA	5%	A205974	001	Mar 15, 2019	Oct CAHN
AB	CIPLA	5%	A211794	001	Jan 18, 2019	Jan NEWA
AB	GLENMARK PHARMS SA	5%	A205510	001	Jul 31, 2017	Jun CAHN
	@ PERRIGO UK FINCO	5%	A205659	001	Feb 20, 2019	Aug DISC
AB		5%	A205659	001	Feb 20, 2019	Feb NEWA
>D> AB	ZYDUS PHARMS	5%	A205974	001	Mar 15, 2019	Oct CAHN
AB		5%	A205974	001	Mar 15, 2019	Mar NEWA
	ZOVIRAX					
AB	+! BAUSCH	5%	N018604	001	Mar 29, 1982	Feb CAHN

	TABLET;ORAL							
	ACYCLOVIR							
AB	SQUARE PHARMS LTD	400MG	A209366	001	Oct 07, 2019	Sep	NEWA	
AB		800MG	A209366	002	Oct 07, 2019	Sep	NEWA	
	<u>ACYCLOVIR SODIUM</u>							
	INJECTABLE;INJECTION							
	ACYCLOVIR SODIUM							
!	ZYDUS PHARMS	EQ 500MG BASE/VIAL	A206535	001	Aug 31, 2018	Jan	CHRS	
!		EQ 1GM BASE/VIAL	A206535	002	Aug 31, 2018	Jan	CHRS	
	<u>ACYCLOVIR; HYDROCORTISONE</u>							
	CREAM;TOPICAL							
	XERESE							
+	BAUSCH	5%;1%	N022436	001	Jul 31, 2009	Feb	CAHN	
	<u>ADAPALENE</u>							
	GEL;TOPICAL							
	ADAPALENE							
AB	P AND L	0.1%	A090962	001	Jun 02, 2010	Jul	CAHN	
	<u>ADAPALENE; BENZOYL PEROXIDE</u>							
	GEL;TOPICAL							
	ADAPALENE AND BENZOYL PEROXIDE							
>A>	AB	GLENMARK PHARMS LTD	0.1%;2.5%	A208108	001	Nov 08, 2019	Oct	NEWA
	AB	PERRIGO UK FINCO	0.1%;2.5%	A205033	001	Jan 23, 2018	May	CAHN
	@	TARO	0.3%;2.5%	A209148	001	Oct 17, 2018	May	DISC
	<u>ADENOSINE</u>							
	INJECTABLE;INJECTION							
	ADENOSINE							
	@	LUITPOLD	3MG/ML	A090010	001	Apr 28, 2009	Mar	DISC
>A>	<u>AFAMELANOTIDE</u>							
>A>	IMPLANT;SUBCUTANEOUS							
>A>	SCENESSE							
>A>	+	CLIVUNEL INC	16MG	N210797	001	Oct 08, 2019	Oct	NEWA
	<u>ALBENDAZOLE</u>							
	TABLET;ORAL							
	ALBENDAZOLE							
AB	ACTAVIS ELIZABETH	200MG	A208094	001	May 20, 2019	May	NEWA	
AB	EDENBRIDGE PHARMS	200MG	A211117	001	May 14, 2019	Apr	NEWA	
AB	STRIDES PHARMA	200MG	A210011	001	Dec 07, 2018	Aug	CAHN	
	<u>ALBUTEROL SULFATE</u>							
	POWDER, METERED;INHALATION							
	PROAIR DIGIHALER							
+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Jan	NEWA	
	PROAIR RESPICLICK							
+	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Jan	CPOT	
	SYRUP;ORAL							
	ALBUTEROL SULFATE							
AA	QUAGEN	EQ 2MG BASE/5ML	A212197	001	Sep 06, 2019	Aug	NEWA	
	TABLET;ORAL							
	ALBUTEROL SULFATE							
AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Mar	NEWA	
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Mar	NEWA	
AB	APPCO PHARMA LLC	EQ 2MG BASE	A207046	001	Jun 29, 2018	Feb	CAHN	
AB		EQ 4MG BASE	A207046	002	Jun 29, 2018	Feb	CAHN	
AB	ARISE	EQ 2MG BASE	A210948	001	Mar 15, 2019	Sep	CAHN	
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Sep	CAHN	
	<u>ALENDRONATE SODIUM</u>							
	TABLET;ORAL							
	ALENDRONATE SODIUM							
	@	MYLAN	EQ 5MG BASE	A076584	001	Aug 04, 2008	Jul	DISC
	@		EQ 10MG BASE	A076584	002	Aug 04, 2008	Jul	DISC
	TABLET, EFFERVESCENT;ORAL							
	BINOSTO							
+	ASCEND THERAPS US	EQ 70MG BASE	N202344	001	Mar 12, 2012	Sep	CAHN	

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

ALFUZOSIN HYDROCHLORIDE

	@ HERITAGE PHARMA	10MG	A079056	001	Jul 18, 2011	Sep DISC
AB		10MG	A079056	001	Jul 18, 2011	May CAHN
>D> AB	MYLAN	10MG	A079014	001	Jul 18, 2011	Oct DISC
>A>	@	10MG	A079014	001	Jul 18, 2011	Oct DISC

ALISKIREN HEMIFUMARATE

TABLET; ORAL

ALISKIREN HEMIFUMARATE

AB	ANCHEN PHARMS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Mar NFTG
AB		EQ 300MG BASE	A206665	002	Mar 22, 2019	Mar NFTG
	TEKTURNA					
AB	+ NODEN PHARMA	EQ 150MG BASE	N021985	001	Mar 05, 2007	Mar CFTG
AB	+!	EQ 300MG BASE	N021985	002	Mar 05, 2007	Mar CFTG

ALITRETINOIN

GEL; TOPICAL

PANRETIN

+!	CONCORDIA	EQ 0.1% BASE	N020886	001	Feb 02, 1999	Jul CAHN
----	-----------	--------------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

>D> AB	SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007	Oct DISC
>A>	@	100MG	A078390	001	Aug 30, 2007	Oct DISC
>D> AB		300MG	A078390	002	Aug 30, 2007	Oct DISC
>A>	@	300MG	A078390	002	Aug 30, 2007	Oct DISC
AB	UNICHEM LABS LTD	100MG	A211820	001	Mar 12, 2019	Feb NEWA
AB		300MG	A211820	002	Mar 12, 2019	Feb NEWA

ALLOPURINOL; LESINURAD

TABLET; ORAL

DUZALLO

+ @	IRONWOOD PHARMS INC	200MG; 200MG	N209203	001	Aug 18, 2017	Apr DISC
+ @		300MG; 200MG	N209203	002	Aug 18, 2017	Apr DISC

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	! AJANTA PHARMA LTD	EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Sep CHRS
	AXERT					
	+ @ JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Sep DISC
	+ @	EQ 12.5MG BASE	N021001	002	May 07, 2001	Sep DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

AB	EYWA PHARMA	EQ 0.5MG BASE	A211621	001	Sep 16, 2019	Sep NEWA
AB		EQ 1MG BASE	A211621	002	Sep 16, 2019	Sep NEWA

ALPELISIB

TABLET; ORAL

PIQRAY

+	NOVARTIS	50MG	N212526	001	May 24, 2019	May NEWA
+		150MG	N212526	002	May 24, 2019	May NEWA
+!		200MG	N212526	003	May 24, 2019	May NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

SOLUTION; INTRAVENOUS

INFUVITE ADULT

+!	SANDOZ CANADA INC	2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 0.03MG/ML	N021163	001	May 18, 2000	Jul CAHN
+!		2 IU/ML; 40MG/ML; 12MCG/ML; 40 IU/ML; 1MCG/ML; 3MG/ML; 120MCG/ML; 8MG/ML; 1.2MG/ML; 0.72MG/ML; 1.2MG/ML; 660 IU/ML; 30MCG/ML	N021163	002	Jun 16, 2003	Sep CMS1

ALTRETAMINECAPSULE;ORAL  
HEXALEN

+ @ EISAI INC 50MG N019926 001 Dec 26, 1990 Feb DISC

AMANTADINE HYDROCHLORIDECAPSULE;ORAL  
AMANTADINE HYDROCHLORIDEAB INVAGEN PHARMS 100MG A207570 001 Sep 30, 2016 Sep CAHN  
AB UPSHER SMITH LABS 100MG A070589 001 Aug 05, 1986 Jul CAHNTABLET;ORAL  
AMANTADINE HYDROCHLORIDEAB INVAGEN PHARMS 100MG A207571 001 Jan 31, 2017 Sep CAHN  
AB ! UPSHER SMITH LABS 100MG A076186 001 Dec 16, 2002 Jul CAHNAMBRISENTANTABLET;ORAL  
AMBRISENTANAB CIPLA 5MG A210715 001 Apr 26, 2019 Apr NEWA  
AB 10MG A210715 002 Apr 26, 2019 Apr NEWA  
AB MYLAN 5MG A208441 001 Mar 28, 2019 Mar NFTG  
AB 10MG A208441 002 Mar 28, 2019 Mar NFTG  
AB PAR PHARM INC 5MG A209509 001 Apr 10, 2019 Mar NEWA  
AB 10MG A209509 002 Apr 10, 2019 Mar NEWA  
AB SIGMAPHARM LABS LLC 5MG A208354 001 Apr 10, 2019 Mar NEWA  
AB 10MG A208354 002 Apr 10, 2019 Mar NEWA  
AB SUN PHARM 5MG A210784 001 Mar 28, 2019 Mar NFTG  
AB 10MG A210784 002 Mar 28, 2019 Mar NFTG  
AB WATSON LABS INC 5MG A208252 001 Mar 28, 2019 Mar NFTG  
AB 10MG A208252 002 Mar 28, 2019 Mar NFTG  
AB ZYDUS PHARMS 5MG A210058 001 Mar 28, 2019 Mar NFTG  
AB 10MG A210058 002 Mar 28, 2019 Mar NFTG  
LETAIRIS  
AB + GILEAD 5MG N022081 001 Jun 15, 2007 Mar CFTG  
AB +! 10MG N022081 002 Jun 15, 2007 Mar CFTGAMIFAMPRIDINETABLET;ORAL  
RUZURGI

+! JACOBUS PHARM CO INC 10MG N209321 001 May 06, 2019 May NEWA

AMIKACIN SULFATEINJECTABLE;INJECTION  
AMIKACIN SULFATE

@ TEVA PHARMS USA EQ 250MG BASE/ML A064045 002 Sep 28, 1993 Sep DISC

AMILORIDE HYDROCHLORIDETABLET;ORAL  
AMILORIDE HYDROCHLORIDE

AB WINDLAS HLTHCARE 5MG A204180 001 Aug 07, 2015 Feb CAHN

AMINO ACIDSINJECTABLE;INJECTION  
AMINOSYN 10%

@ ICU MEDICAL INC 10% (10GM/100ML) N017673 003 Jul DISC

AMINOSYN 8.5%

@ ICU MEDICAL INC 8.5% (8.5GM/100ML) N017673 004 Jul DISC

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDEINJECTABLE;INJECTION  
AMINOSYN 3.5% M

@ ICU MEDICAL INC 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML N017789 003 Jul DISC

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASICINJECTABLE;INJECTION  
AMINOSYN 8.5% W/ELECTROLYTES

@ ICU MEDICAL INC 8.5%;102MG/100ML;487MG/100ML;28MG/100ML;425MG/100ML N017673 009 Oct 25, 2002 Jul DISC

AMINOCAPROIC ACID

SYRUP;ORAL

AMICAR

AA	+	CLOVER PHARMS	1.25GM/5ML	N015230	002		Aug CTEC
		AMINOCAPROIC ACID					
AA		AMNEAL PHARMS LLC	1.25GM/5ML	A212780	001	Aug 23, 2019	Aug NEWA
		TABLET;ORAL					
		AMICAR					
AB	+	CLOVER PHARMS	1GM	N015197	002	Jun 24, 2004	Feb CHRS
		AMINOCAPROIC ACID					
AB	!	SUNNY PHARMTECH INC	1GM	A209060	002	Nov 27, 2018	Feb CHRS

AMINOPHYLLINE

INJECTABLE;INJECTION

AMINOPHYLLINE

!	HOSPIRA	25MG/ML	A087242	001	Oct 26, 1983	Feb CTEC
@	LUITPOLD	25MG/ML	A087600	001		Feb DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE;INJECTION

AMIODARONE HYDROCHLORIDE

	@	DR REDDYS	50MG/ML	A076163	001	Sep 05, 2003	May CAHN
		TABLET;ORAL					
		AMIODARONE HYDROCHLORIDE					
AB		RUBICON	200MG	A078578	001	Nov 06, 2008	Jul CAHN

AMLODIPINE BENZOATE

SOLUTION;ORAL

KATERZIA

+	SILVERGATE PHARMS	EQ 1MG BASE/ML	N211340	001	Jul 08, 2019	Jul NEWA
---	-------------------	----------------	---------	-----	--------------	----------

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB		STRIDES PHARMA	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr CAHN
AB			EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr CAHN
AB			EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr CAHN
>D> AB		SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Oct DISC
>A>	@		EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Oct DISC
>D> AB			EQ 5MG BASE	A078231	002	Nov 30, 2007	Oct DISC
>A>	@		EQ 5MG BASE	A078231	002	Nov 30, 2007	Oct DISC
>D> AB			EQ 10MG BASE	A078231	003	Nov 30, 2007	Oct DISC
>A>	@		EQ 10MG BASE	A078231	003	Nov 30, 2007	Oct DISC
>D> AB		TEVA	EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Oct DISC
>A>	@		EQ 2.5MG BASE	A076846	001	Jun 28, 2007	Oct DISC
>D> AB			EQ 5MG BASE	A076846	002	Jun 28, 2007	Oct DISC
>A>	@		EQ 5MG BASE	A076846	002	Jun 28, 2007	Oct DISC
>D> AB			EQ 10MG BASE	A076846	003	Jun 28, 2007	Oct DISC
>A>	@		EQ 10MG BASE	A076846	003	Jun 28, 2007	Oct DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

@	ZYDUS PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A207762	001	Jan 11, 2019	Jun DISC
@		EQ 2.5MG BASE;EQ 20MG BASE	A207762	002	Jan 11, 2019	Jun DISC
@		EQ 2.5MG BASE;EQ 40MG BASE	A207762	003	Jan 11, 2019	Jun DISC
@		EQ 5MG BASE;EQ 10MG BASE	A207762	004	Jan 11, 2019	Jun DISC
@		EQ 5MG BASE;EQ 20MG BASE	A207762	005	Jan 11, 2019	Jun DISC
@		EQ 5MG BASE;EQ 40MG BASE	A207762	006	Jan 11, 2019	Jun DISC
@		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Jun DISC
@		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Jun DISC
@		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Jun DISC
@		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Jun DISC
@		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Jun DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	CIPLA	EQ 2.5MG BASE;10MG	A077215	001	Dec 07, 2018	May DISC
@		EQ 5MG BASE;10MG	A077215	002	Dec 07, 2018	May DISC
@		EQ 5MG BASE;20MG	A077215	003	Dec 07, 2018	May DISC

## CAPSULE;ORAL

## AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	EQ 10MG BASE;20MG	A077215	004	Dec 07, 2018	May DISC
@ MYLAN	EQ 2.5MG BASE;10MG	A077375	001	May 21, 2010	Feb DISC
@	EQ 5MG BASE;10MG	A077375	002	May 21, 2010	Feb DISC
@	EQ 5MG BASE;20MG	A077375	003	May 21, 2010	Feb DISC
@	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Feb DISC
@	EQ 10MG BASE;20MG	A077375	004	May 21, 2010	Feb DISC
@	EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Feb DISC
@ TEVA PHARMS	EQ 2.5MG BASE;10MG	A077179	001	May 18, 2007	Jun DISC
@	EQ 5MG BASE;10MG	A077179	002	May 18, 2007	Jun DISC
@	EQ 5MG BASE;20MG	A077179	003	May 18, 2007	Jun DISC
@	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun DISC
@	EQ 10MG BASE;20MG	A077179	004	May 18, 2007	Jun DISC
@	EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun DISC

AMLODIPINE BESYLATE; CELECOXIB

## TABLET;ORAL

## CONSENSI

+	COEPTIS	EQ 2.5MG BASE;200MG	N210045	001	May 31, 2018	Mar CAHN
+		EQ 5MG BASE;200MG	N210045	002	May 31, 2018	Mar CAHN
+	!	EQ 10MG BASE;200MG	N210045	003	May 31, 2018	Mar CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

@ TEVA PHARMS USA	EQ 5MG BASE;12.5MG;20MG	A202491	001	Nov 03, 2016	Jul DISC
@	EQ 5MG BASE;12.5MG;40MG	A202491	002	Nov 03, 2016	Jul DISC
@	EQ 5MG BASE;25MG;40MG	A202491	003	Nov 03, 2016	Jul DISC
@	EQ 10MG BASE;12.5MG;40MG	A202491	004	Nov 03, 2016	Jul DISC
@	EQ 10MG BASE;25MG;40MG	A202491	005	Nov 03, 2016	Jul DISC

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

## TABLET;ORAL

## AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

@ TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012	Jul DISC
@	5MG;25MG;160MG	A200435	002	Sep 25, 2012	Jul DISC
@	10MG;12.5MG;160MG	A200435	005	Sep 25, 2012	Jul DISC
@	10MG;25MG;160MG	A200435	003	Sep 25, 2012	Jul DISC
@	10MG;25MG;320MG	A200435	004	Sep 25, 2012	Jul DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## AMLODIPINE AND OLMESARTAN MEDOXOMIL

@ ACCORD HLTHCARE INC	EQ 5MG BASE;20MG	A209600	001	Aug 30, 2018	Mar DISC
@	EQ 5MG BASE;40MG	A209600	003	Aug 30, 2018	Mar DISC
@	EQ 10MG BASE;20MG	A209600	002	Aug 30, 2018	Mar DISC
@	EQ 10MG BASE;40MG	A209600	004	Aug 30, 2018	Mar DISC
@ TEVA PHARMS USA	EQ 5MG BASE;20MG	A091154	001	Oct 26, 2016	Jun DISC
@	EQ 5MG BASE;40MG	A091154	002	Oct 26, 2016	Jun DISC
@	EQ 10MG BASE;20MG	A091154	003	Oct 26, 2016	Jun DISC
@	EQ 10MG BASE;40MG	A091154	004	Oct 26, 2016	Jun DISC

AMLODIPINE BESYLATE; PERINDOPRIL ARGinine

## TABLET;ORAL

## PRESTALIA

+	ADHERA	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015	Apr CAHN
+		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015	Apr CAHN
+	!	EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015	Apr CAHN

AMLODIPINE BESYLATE; VALSARTAN

## TABLET;ORAL

## AMLODIPINE BESYLATE AND VALSARTAN

@ TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Jul DISC
@	EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Jul DISC
@	EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Jul DISC
@	EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Jul DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS  
AMMONIA N 13

AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Apr CAHN
>A> AP	UNIV TX SW MEDCTR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A209507	001	Nov 01, 2019	Oct NEWA

AMMONIUM LACTATE

CREAM; TOPICAL  
AMMONIUM LACTATE  
! PERRIGO ISRAEL  
LOTION; TOPICAL  
AMMONIUM LACTATE  
! PERRIGO ISRAEL

AB	EQ 12% BASE	A075774	001	May 01, 2002	May CAHN
AB	EQ 12% BASE	A075570	001	Jun 23, 2004	May CAHN

AMOXICILLIN

FOR SUSPENSION; ORAL  
AMOXICILLIN  
@ TEVA

125MG/5ML	A061931	001		Jun DISC
-----------	---------	-----	--	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL  
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	125MG/5ML; EQ 31.25MG BASE/5ML	A209371	001	Apr 19, 2019	Apr NFTG
AB		250MG/5ML; EQ 62.5MG BASE/5ML	A209371	002	Apr 19, 2019	Apr NEWA
	AUGMENTIN '125'					
AB	+ NEOPHARMA	125MG/5ML; EQ 31.25MG BASE/5ML	N050575	001	Aug 06, 1984	Apr CFTG
	TABLET; ORAL					
	AUGMENTIN '875'					
AB	+ NEOPHARMA	875MG; EQ 125MG BASE	N050720	001	Feb 13, 1996	Feb CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL  
DEXTROAMP SACCHARATE, AMP ASPARTATE, DETROAMP SULFATE AND AMP SULFATE

AB	PAR PHARM INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	May NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	May NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	May NEWA
AB		5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	May NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	May NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	May NEWA
	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE					
AB	AMERIGEN PHARMS LTD	1.25MG; 1.25MG; 1.25MG; 1.25MG	A205401	001	Jan 22, 2019	Jan NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Jan NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019	Jan NEWA
AB		5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019	Jan NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019	Jan NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019	Jan NEWA
AB	NESHER PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210080	001	Jul 17, 2019	Jul NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210080	002	Jul 17, 2019	Jul NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210080	003	Jul 17, 2019	Jul NEWA
AB		5MG; 5MG; 5MG; 5MG	A210080	004	Jul 17, 2019	Jul NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210080	005	Jul 17, 2019	Jul NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210080	006	Jul 17, 2019	Jul NEWA
AB	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	May NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	May NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	May NEWA
AB		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	May NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	May NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	May NEWA
AB	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Apr NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Apr NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Apr NEWA
AB		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Apr NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Apr NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Apr NEWA
AB	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	May NEWA
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	May NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	May NEWA
AB		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	May NEWA
AB		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	May NEWA
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211715	006	May 17, 2019	May NEWA

AMPHETAMINE SULFATE

## TABLET; ORAL

## AMPHETAMINE SULFATE

AA	AUROLIFE PHARMA LLC	5MG	A211639	001	Apr 17, 2019	Apr NEWA
AA		10MG	A211639	002	Apr 17, 2019	Apr NEWA
AA	GRANULES PHARMS	5MG	A212619	001	Aug 05, 2019	Jul NEWA
AA		10MG	A212619	002	Aug 05, 2019	Jul NEWA

## TABLET, ORALLY DISINTEGRATING; ORAL

## EVEKEO ODT

+	ARBOR PHARMS LLC	5MG	N209905	001	Jan 30, 2019	Jan NEWA
+		10MG	N209905	002	Jan 30, 2019	Jan NEWA
+		15MG	N209905	003	Jan 30, 2019	Jan NEWA
+		20MG	N209905	004	Jan 30, 2019	Jan NEWA

AMPICILLIN SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN SODIUM

>D>	AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Oct DISC
>A>	@		EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Oct DISC
>D>	AP		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Oct DISC
>A>	@		EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Oct DISC
>D>	AP		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Oct DISC
>A>	@		EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Oct DISC
>D>	AP		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Oct DISC
>A>	@		EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Oct DISC
	@		EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Sep DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN AND SULBACTAM

@	HOSPIRA INC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A090375	001	Dec 21, 2011	Sep DISC
@		EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A090653	001	Dec 21, 2011	Sep DISC
@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A090375	002	Dec 21, 2011	Sep DISC
@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A090653	002	Dec 21, 2011	Sep DISC
@		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A090646	001	Dec 21, 2011	Sep DISC
@	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	Sep DISC
@		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	Sep DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

## CAPSULE; ORAL

## AMPICILLIN TRIHYDRATE

@	HERITAGE PHARMA	EQ 250MG BASE	A061502	001		May CAHN
@		EQ 500MG BASE	A061502	002		May CAHN

ANASTROZOLE

## TABLET; ORAL

## ANASTROZOLE

AB	FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Feb CAHN
AB	KENTON	1MG	A078944	001	Jun 28, 2010	Mar CAHN

APREPITANT

## CAPSULE; ORAL

## EMEND

>D>	AB	+ MERCK	40MG	N021549	003	Jun 30, 2006	Oct DISC
>A>		+ @	40MG	N021549	003	Jun 30, 2006	Oct DISC

ARIPIRAZOLE

## SOLUTION; ORAL

## ARIPIRAZOLE

AA	AUROBINDO PHARMA LTD	1MG/ML	A210479	001	Jan 29, 2019	Jan NEWA
----	----------------------	--------	---------	-----	--------------	----------

## TABLET; ORAL

## ARIPIRAZOLE

AB	ALKEM LABS LTD	2MG	A207105	001	Feb 21, 2019	Feb NEWA
AB		5MG	A207105	002	Feb 21, 2019	Feb NEWA
AB		10MG	A207105	003	Feb 21, 2019	Feb NEWA
AB		15MG	A207105	004	Feb 21, 2019	Feb NEWA
AB		20MG	A207105	005	Feb 21, 2019	Feb NEWA
AB		30MG	A207105	006	Feb 21, 2019	Feb NEWA
	@ TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Jun DISC

## TABLET; ORAL

## ARIPIPIRAZOLE

@	5MG	A078607	002	Apr 28, 2015	Jun	DISC
@	10MG	A078608	001	Apr 28, 2015	May	DISC
@	15MG	A078708	001	Apr 28, 2015	May	DISC
@	20MG	A078708	002	Apr 28, 2015	May	DISC
@	30MG	A078708	003	Apr 28, 2015	May	DISC
@ ZYDUS PHARMS	2MG	A090472	001	Jan 07, 2019	Jun	DISC
@	5MG	A090472	002	Jan 07, 2019	Jun	DISC
@	10MG	A090472	003	Jan 07, 2019	Jun	DISC
@	15MG	A090472	004	Jan 07, 2019	Jun	DISC
@	20MG	A090472	005	Jan 07, 2019	Jun	DISC
@	30MG	A090472	006	Jan 07, 2019	Jun	DISC

ARMODAFINIL

## TABLET; ORAL

## ARMODAFINIL

@ APOTEX INC	50MG	A201514	001	Mar 25, 2019	Sep	DISC
AB	50MG	A201514	001	Mar 25, 2019	Mar	NEWA
@	150MG	A201514	002	Mar 25, 2019	Sep	DISC
AB	150MG	A201514	002	Mar 25, 2019	Mar	NEWA
@	250MG	A201514	003	Mar 25, 2019	Sep	DISC
AB	250MG	A201514	003	Mar 25, 2019	Mar	NEWA
AB AUROBINDO PHARMA LTD	200MG	A206069	004	Dec 07, 2018	Mar	NEWA
AB MYLAN PHARMS INC	100MG	A200043	004	May 09, 2019	Apr	NEWA
AB	200MG	A200043	005	May 09, 2019	Apr	NEWA
AB NATCO PHARMA LTD	100MG	A202768	004	Sep 28, 2017	Apr	CTEC

ARSENIC TRIOXIDE

## INJECTABLE; INJECTION

## ARSENIC TRIOXIDE

AP STI PHARMA LLC	1MG/ML	A209873	001	May 06, 2019	Apr	NEWA
AP ZYDUS PHARMS	2MG/ML	A206228	002	Aug 30, 2019	Aug	NFTG
TRISENOX						
AP +! CEPHALON	2MG/ML	N021248	002	Oct 13, 2017	Aug	CFTG

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

## INJECTABLE; INJECTION

## ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE

@ HOSPIRA	4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)	A079138	001	Jun 18, 2010	Sep	DISC
-----------	---	---------	-----	--------------	-----	------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

## INJECTABLE; INTRAVENOUS

## INFUVITE PEDIATRIC

+! SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	001	Feb 21, 2001	Jul	CAHN
----------------------	--	---------	-----	--------------	-----	------

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL HYDROCHLORIDE; VITAMIN A; VITAMIN K

## INJECTABLE; INTRAVENOUS

## INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+! SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400 IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14 MG/VIAL; 17MG/VIAL; 1MG/VIAL; 1.4MG/VIAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300 IU/VIAL; 0.2MG/VIAL	N021265	002	Jan 29, 2004	Sep	CMS1
----------------------	--	---------	-----	--------------	-----	------

>A> ASENAPINE

## &gt;A&gt; SYSTEM; TRANSDERMAL

## &gt;A&gt; SECUADO

>A> + HISAMITSU	3.8MG/24HR	N212268	001	Oct 11, 2019	Oct	NEWA
>A> +	5.7MG/24HR	N212268	002	Oct 11, 2019	Oct	NEWA
>A> +!	7.6MG/24HR	N212268	003	Oct 11, 2019	Oct	NEWA

ASENAPINE MALEATETABLET;SUBLINGUAL  
SAPHRIS

>A>	+	ALLERGAN	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Oct CAHN
>A>	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Oct CAHN
>A>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Oct CAHN
>D>	+	FOREST LABS LLC	EQ 2.5 BASE	N022117	003	Mar 12, 2015	Oct CAHN
>D>	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Oct CAHN
>D>	+		EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb CTEC
>D>	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Oct CAHN
	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb CTEC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA		BRECKENRIDGE	325MG;50MG;40MG	A204195	001	Sep 22, 2016	Aug CAHN
----	--	--------------	-----------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

AB	!	SANDOZ	770MG;60MG;50MG	A074654	002	Dec 31, 1996	May CTEC
AB		GALT PHARMS	770MG;60MG;50MG	A075141	002	May 29, 1998	May CMFD

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

ASPIRIN AND DIPYRIDAMOLE

AB		GLENMARK PHARMS LTD	25MG;200MG	A210318	001	May 24, 2019	May NEWA
AB		GLENMARK PHARMS SA	25MG;200MG	A210318	001	May 24, 2019	Jun CAHN
AB		LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Mar NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB		HLTHCARE	25MG	A074052	001	May 01, 1992	Sep CAHN
AB			50MG	A073025	001	Sep 17, 1991	Sep CAHN
AB			100MG	A073026	001	Sep 17, 1991	Sep CAHN
>D> AB		SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007	Oct DISC
>A>	@		25MG	A078210	001	Jul 10, 2007	Oct DISC
>D> AB			50MG	A078210	002	Jul 10, 2007	Oct DISC
>A>	@		50MG	A078210	002	Jul 10, 2007	Oct DISC
>D> AB			100MG	A078210	003	Jul 10, 2007	Oct DISC
>A>	@		100MG	A078210	003	Jul 10, 2007	Oct DISC
>D> AB		SUN PHARM INDUSTRIES	25MG	A074499	001	Jul 30, 1997	Oct DISC
>A>	@		25MG	A074499	001	Jul 30, 1997	Oct DISC
>D> AB			50MG	A073475	001	Mar 30, 1993	Oct DISC
>A>	@		50MG	A073475	001	Mar 30, 1993	Oct DISC
>D> AB			100MG	A073476	001	Mar 30, 1993	Oct DISC
>A>	@		100MG	A073476	001	Mar 30, 1993	Oct DISC

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

>D> AB		SUN PHARM INDUSTRIES	50MG;25MG	A073582	002	Apr 29, 1993	Oct DISC
>A>	@		50MG;25MG	A073582	002	Apr 29, 1993	Oct DISC
>D> AB			100MG;25MG	A073582	001	Apr 29, 1993	Oct DISC
>A>	@		100MG;25MG	A073582	001	Apr 29, 1993	Oct DISC
AB		ZYDUS PHARMS	50MG;25MG	A210028	001	Mar 08, 2019	Feb NEWA
AB			100MG;25MG	A210028	002	Mar 08, 2019	Feb NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	18MG	A079017	001	Sep 17, 2010	Mar CMFD
AB			25MG	A079017	002	Sep 17, 2010	Mar CMFD
AB			40MG	A079017	003	Sep 17, 2010	Mar CMFD
AB			60MG	A079017	004	Sep 17, 2010	Mar CMFD
AB			80MG	A079017	005	Sep 17, 2010	Mar CMFD
AB			100MG	A079017	006	Sep 17, 2010	Mar CMFD

ATORVASTATIN CALCIUM

## TABLET; ORAL

## ATORVASTATIN CALCIUM

>D>	AB	LUPIN LTD	EQ 10MG BASE	A204991	001	Mar 06, 2019	Oct DISC
>A>		@	EQ 10MG BASE	A204991	001	Mar 06, 2019	Oct DISC
	AB		EQ 10MG BASE	A204991	001	Mar 06, 2019	Feb NEWA
>D>	AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Oct DISC
>A>		@	EQ 20MG BASE	A204991	002	Mar 06, 2019	Oct DISC
	AB		EQ 20MG BASE	A204991	002	Mar 06, 2019	Feb NEWA
>D>	AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Oct DISC
>A>		@	EQ 40MG BASE	A204991	003	Mar 06, 2019	Oct DISC
	AB		EQ 40MG BASE	A204991	003	Mar 06, 2019	Feb NEWA
>D>	AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Oct DISC
>A>		@	EQ 80MG BASE	A204991	004	Mar 06, 2019	Oct DISC
	AB		EQ 80MG BASE	A204991	004	Mar 06, 2019	Feb NEWA
>A>	AB	MICRO LABS LTD INDIA	EQ 10MG BASE	A205945	001	Nov 07, 2019	Oct NEWA
>A>	AB		EQ 20MG BASE	A205945	002	Nov 07, 2019	Oct NEWA
>A>	AB		EQ 40MG BASE	A205945	003	Nov 07, 2019	Oct NEWA
>A>	AB		EQ 80MG BASE	A205945	004	Nov 07, 2019	Oct NEWA
	AB	MSN LABS PVT LTD	EQ 10MG BASE	A211933	001	Feb 08, 2019	Feb NEWA
	AB		EQ 20MG BASE	A211933	002	Feb 08, 2019	Feb NEWA
	AB		EQ 40MG BASE	A211933	003	Feb 08, 2019	Feb NEWA
	AB		EQ 80MG BASE	A211933	004	Feb 08, 2019	Feb NEWA

ATOVAQUONE

## SUSPENSION; ORAL

## ATOVAQUONE

AB	ABHAI LLC	750MG/5ML	A210510	001	May 31, 2019	May NEWA
----	-----------	-----------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

## INJECTABLE; INJECTION

## ATRACURIUM BESYLATE

AP	HONG KONG	10MG/ML	A091489	001	Feb 17, 2012	Feb CAHN
	@ MYLAN LABS LTD	10MG/ML	A206096	001	Jun 22, 2017	Sep DISC
		ATRACURIUM BESYLATE PRESERVATIVE FREE				
AP	HONG KONG	10MG/ML	A091488	001	Feb 17, 2012	Feb CAHN
	@ MYLAN LABS LTD	10MG/ML	A206001	001	Apr 07, 2017	Sep DISC

ATROPINE

## SOLUTION; INTRAMUSCULAR

## ATROPEN

+	!	MERIDIAN MEDCL TECHN	EQ 0.25MG SULFATE/0.3ML	N017106	004	Sep 17, 2004	Mar CPOT
+	!		EQ 0.5MG SULFATE/0.7ML	N017106	003	Jun 19, 2003	Mar CPOT
+	!		EQ 1MG SULFATE/0.7ML	N017106	002	Jun 19, 2003	Mar CPOT
+	!		EQ 2MG SULFATE/0.7ML	N017106	001		Mar CPOT
		ATROPINE					
		@ ABBVIE	EQ 2MG SULFATE/0.7ML	A071295	001	Jan 30, 1987	Mar CDFR

ATROPINE SULFATE

## SOLUTION; INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL

## ATROPINE SULFATE

+	!	FRESENIUS KABI USA	8MG/20ML (0.4MG/ML)	N209260	001	Jan 26, 2018	May CDFR
---	---	--------------------	---------------------	---------	-----	--------------	----------

AZACITIDINE

## POWDER; INTRAVENOUS, SUBCUTANEOUS

## AZACITIDINE

	@	LUPIN LTD	100MG/VIAL	A210748	001	Feb 27, 2019	Sep DISC
AP			100MG/VIAL	A210748	001	Feb 27, 2019	Feb NEWA

AZELAIC ACID

## CREAM; TOPICAL

## AZELEX

+	!	ALMIRALL	20%	N020428	001	Sep 13, 1995	Apr CAHN
---	---	----------	-----	---------	-----	--------------	----------

## GEL; TOPICAL

## AZELAIC ACID

AB	TARO	15%	A210549	001	Aug 23, 2019	Aug NEWA
----	------	-----	---------	-----	--------------	----------

AZELASTINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
AZELASTINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	0.05%	A209620	001	Mar 20, 2019	Mar NEWA
AT	SOMERSET THERAPS LLC	0.05%	A207411	001	Mar 29, 2019	Mar NEWA
SPRAY, METERED;NASAL						
AZELASTINE HYDROCHLORIDE						
AB	HI TECH	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	May NEWA
AB		EQ 0.1876MG BASE/SPRAY	A210032	001	Aug 23, 2019	Aug NEWA

AZITHROMYCIN

TABLET;ORAL

AZITHROMYCIN

AB	BIONPHARMA INC	EQ 250MG BASE	A210000	001	Feb 26, 2019	Feb NEWA
AB		EQ 500MG BASE	A210001	001	Feb 26, 2019	Feb NEWA
AB	CSPC OUYI	EQ 250MG BASE	A208250	001	Apr 17, 2019	Apr NEWA
AB	! PLIVA	EQ 600MG BASE	A065218	001	Nov 14, 2005	Jul CHRS
	@ TEVA	EQ 250MG BASE	A065153	001	Nov 14, 2005	Jul DISC
	@	EQ 600MG BASE	A065150	001	Nov 14, 2005	Jul DISC

AZTREONAM

INJECTABLE;INJECTION

AZACTAM IN PLASTIC CONTAINER

+	@ BRISTOL MYERS SQUIBB	20MG/ML	N050632	002	May 24, 1989	Jul DISC
+	@	40MG/ML	N050632	001	May 24, 1989	Jul DISC

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP	MAIA PHARMS INC	0.5MG/ML	A210048	001	Sep 11, 2019	Aug NEWA
AP		1MG/ML	A210315	001	Jul 30, 2019	Jul NEWA
AP		2MG/ML	A210048	002	Sep 11, 2019	Aug NEWA
GABLOFEN						
AP	PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Aug CAHN
AP		0.5MG/ML	N022462	002	Nov 19, 2010	Aug CAHN
AP	+	1MG/ML	N022462	004	Jun 22, 2012	Aug CAHN
AP		2MG/ML	N022462	003	Nov 19, 2010	Aug CAHN

SOLUTION;ORAL

OZOBAX

+	! METACEL PHARMS LLC	5MG/5ML	N208193	001	Sep 18, 2019	Sep NEWA
---	----------------------	---------	---------	-----	--------------	----------

TABLET;ORAL

BACLOFEN

AB	EYWA PHARMA	10MG	A211555	001	Feb 01, 2019	Jan NEWA
AB		20MG	A211555	002	Feb 01, 2019	Jan NEWA
>D> AB	SUN PHARM INDS INC	10MG	A077862	001	Aug 14, 2006	Oct DISC
>A>	@	10MG	A077862	001	Aug 14, 2006	Oct DISC
>D> AB		20MG	A077862	002	Aug 14, 2006	Oct DISC
>A>	@	20MG	A077862	002	Aug 14, 2006	Oct DISC
AB	UPSHER SMITH LABS	10MG	A074584	001	Aug 19, 1996	Jul CAHN
AB		20MG	A074584	002	Aug 19, 1996	Jul CAHN

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

@ MYLAN 750MG

A077807 001 Dec 28, 2007 Feb DISC

TABLET;ORAL

BALSALAZIDE DISODIUM

@ PAR PHARM INC 1.1GM

A206336 001 Sep 08, 2015 Apr DISC

GIAZO

+	@ VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Apr DISC
---	-----------------------	-------	---------	-----	--------------	----------

BARICITINIB

TABLET;ORAL

OLUMIANT

>A>	+	ELI LILLY AND CO	1MG	N207924	002	Oct 08, 2019	Oct NEWA
-----	---	------------------	-----	---------	-----	--------------	----------

BARIUM SULFATEFOR SUSPENSION; ORAL  
VARIBAR THIN LIQUID

+!	BRACCO	81% (120GM/BOT)	N208036	004	Apr 30, 2019	May NEWA
----	--------	-----------------	---------	-----	--------------	----------

SUSPENSION; ORAL  
READI-CAT 2 SMOOTHIE

+!	BRACCO	2% (9GM/BOT)	N208143	002	Jan 15, 2016	Sep CMS1
----	--------	--------------	---------	-----	--------------	----------

BELINOSTATPOWDER; INTRAVENOUS  
BELEODAQ

+!	ACROTECH	500MG/VIAL	N206256	001	Jul 03, 2014	Mar CAHN
----	----------	------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDETABLET; ORAL  
BENAZEPRIL HYDROCHLORIDE

@	HERITAGE PHARMA	5MG	A076267	001	Feb 11, 2004	Feb CAHN
@		10MG	A076267	002	Feb 11, 2004	Feb CAHN
@		20MG	A076267	003	Feb 11, 2004	Feb CAHN
@		40MG	A076267	004	Feb 11, 2004	Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDETABLET; ORAL  
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ANI PHARMS INC	5MG; 6.25MG	A076342	001	Feb 11, 2004	May CAHN
@		10MG; 12.5MG	A076342	002	Feb 11, 2004	May CAHN
@		20MG; 12.5MG	A076342	003	Feb 11, 2004	May CAHN
@		20MG; 25MG	A076342	004	Feb 11, 2004	May CAHN

BENDAMUSTINE HYDROCHLORIDEPOWDER; IV (INFUSION)  
TREANDA

+!	CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Feb CTEC
+!		100MG/VIAL	N022249	001	Mar 20, 2008	Feb CTEC

BENZONATATECAPSULE; ORAL  
BENZONATATE

AA	ASCENT PHARMS INC	100MG	A211518	001	Feb 22, 2019	Feb NEWA
AA		150MG	A211518	002	Feb 22, 2019	Feb NEWA
AA		200MG	A211518	003	Feb 22, 2019	Feb NEWA
AA	CSPC OUYI	100MG	A202765	002	Aug 25, 2017	Feb CAHN
AA		200MG	A202765	001	Jul 31, 2015	Feb CAHN
AA	QINGDAO BAHEAL PHARM	100MG	A210562	001	Nov 09, 2018	May CAHN
AA		150MG	A210562	002	Nov 09, 2018	May CAHN
AA		200MG	A210562	003	Nov 09, 2018	May CAHN
>D> AA	SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Oct DISC
>A>	@	100MG	A040587	001	Mar 19, 2008	Oct DISC
>D> AA		200MG	A040587	002	Mar 19, 2008	Oct DISC
>A>	@	200MG	A040587	002	Mar 19, 2008	Oct DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEGEL; TOPICAL  
ACANYA

AB	+!	BAUSCH	2.5%; EQ 1.2% BASE	N050819	001	Oct 23, 2008	Aug CAHN
----	----	--------	--------------------	---------	-----	--------------	----------

BENZACLIN

AB	+!	BAUSCH	5%; EQ 1% BASE	N050756	001	Dec 21, 2000	Aug CAHN
	@		5%; EQ 1% BASE	N050756	002	Apr 20, 2007	Aug CAHN

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>D> AB	ANDA REPOSITORY	2.5%; EQ 1.2% BASE	A207194	001	Aug 19, 2019	Oct DISC	
>A>	@	2.5%; EQ 1.2% BASE	A207194	001	Aug 19, 2019	Oct DISC	
AB		2.5%; EQ 1.2% BASE	A207194	001	Aug 19, 2019	Aug NEWA	
AB	GLENMARK PHARMS	5%; EQ 1% BASE	A209252	001	Mar 14, 2019	Jun CMS1	
AB		5%; 1% BASE	A209252	001	Mar 14, 2019	Mar NEWA	
AB	PERRIGO ISRAEL	2.5%; EQ 1.2% BASE	A205397	001	Sep 09, 2019	Aug NEWA	
AB	PERRIGO UK FINCO	5%; EQ 1% BASE	A202440	001	Sep 21, 2015	May CAHN	
AB	TARO	2.5%; EQ 1.2% BASE	A206575	001	Aug 19, 2019	Aug NEWA	
	@	3.75%; EQ 1.2% BASE	A208683	001	Jun 05, 2018	May DISC	
	ONEXTON						
	+!	BAUSCH	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	Aug CAHN
	+!	DOW PHARM	3.75%; EQ 1.2% BASE	N050819	002	Nov 24, 2014	May CTEC

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

AKTIPAK

+ @ BIOFRONTERA 5%;3%

N050769 001 Nov 27, 2000 Aug DISC

+! 5%;3%

N050769 001 Nov 27, 2000 May CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

@ LUITPOLD 1MG/ML

A091152 001 Mar 29, 2010 Feb DISC

TABLET; ORAL

BENZTROPINE MESYLATE

AA ! ASPEN GLOBAL INC 0.5MG

A204713 001 Apr 14, 2015 Apr CHRS

AA ! 1MG

A204713 002 Apr 14, 2015 Apr CHRS

AA ! 2MG

A204713 003 Apr 14, 2015 Apr CHRS

@ OXFORD PHARMS 0.5MG

A040706 002 Feb 14, 2008 Mar DISC

@ 1MG

A040706 003 Feb 14, 2008 Mar DISC

@ UPSHER SMITH LABS 0.5MG

A040103 001 Dec 12, 1996 Jul CAHN

@ 1MG

A040103 002 Dec 12, 1996 Jul CAHN

@ 2MG

A040103 003 Dec 12, 1996 Jul CAHN

@ USL PHARMA 0.5MG

A040103 001 Dec 12, 1996 Apr DISC

@ 1MG

A040103 002 Dec 12, 1996 Apr DISC

@ 2MG

A040103 003 Dec 12, 1996 Apr DISC

BENZYL ALCOHOL

LOTION; TOPICAL

ULESFIA

+ @ SHIONOGI INC 5%

N022129 001 Apr 09, 2009 Sep DISC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPOTASTINE BESILATE

@ APOTEX 1.5%

A206066 001 Mar 05, 2019 Sep DISC

AT APOTEX INC 1.5%

A206066 001 Mar 05, 2019 Feb NFTG

AT MICRO LABS 1.5%

A206220 001 Mar 18, 2019 Mar NEWA

AT MYLAN 1.5%

A206220 001 Mar 18, 2019 Apr CAHN

BEPREVE

AT +! BAUSCH AND LOMB INC 1.5%

N022288 001 Sep 08, 2009 Feb CFTG

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB PERRIGO ISRAEL EQ 0.05% BASE

A076592 001 Dec 09, 2003 May CAHN

LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB HI TECH EQ 0.05% BASE

A208849 001 Oct 11, 2019 Sep NEWA

SPRAY; TOPICAL

SERNIVO

+! ENCORE DERMAT EQ 0.05% BASE/SPRAY

N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

OINTMENT; TOPICAL

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

AB PERRIGO ISRAEL 0.064%;0.005%

A200174 001 Dec 12, 2014 Mar CAIN

AB PERRIGO UK FINCO 0.064%;0.005%

A200174 001 Dec 12, 2014 May CAHN

AB TOLMAR 0.064%;0.005%

A201615 001 Jan 14, 2013 Mar CAIN

TACLONEX

AB +! LEO PHARMA AS 0.064%;0.005%

N021852 001 Jan 09, 2006 Mar CAIN

SUSPENSION; TOPICAL

TACLONEX

+! LEO PHARMA AS 0.064%;0.005%

N022185 001 May 09, 2008 Mar CAIN

BETAMETHASONE VALERATE

LOTION; TOPICAL

BETAMETHASONE VALERATE

AB ANIMA EQ 0.1% BASE

A070052 001 Jul 31, 1985 Sep CAHN

BETHANECHOL CHLORIDETABLET; ORAL  
DUVOID

AA	CHARTWELL RX	10MG	A086262	001		Mar	CAHN
AA		25MG	A086263	001		Mar	CAHN
AA		50MG	A085882	003		Mar	CAHN

BEXAROTENEGEL; TOPICAL  
TARGRETIN

+!	BAUSCH	1%	N021056	001	Jun 28, 2000	Jun	CAHN
----	--------	----	---------	-----	--------------	-----	------

BICALUTAMIDETABLET; ORAL  
BICALUTAMIDE

>D>	AB	FRESENIUS KABI USA	50MG	A079045	001	May 13, 2010	Oct	DISC
>A>	@		50MG	A079045	001	May 13, 2010	Oct	DISC
	AB		50MG	A079045	001	May 13, 2010	Feb	CAHN
	AB	KENTON	50MG	A091011	001	Jun 10, 2015	Jun	CAHN
	@	TEVA	50MG	A076932	001	Jul 06, 2009	Sep	DISC

BIMATOPROSTSOLUTION/DROPS; OPHTHALMIC  
BIMATOPROST

AT	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Apr	NEWA
AT	GLAND PHARMA LTD	0.03%	A210126	001	Mar 22, 2019	Mar	NEWA
	@ HI-TECH PHARMA CO	0.03%	A203299	001	Nov 08, 2018	Jul	DISC
AT	SOMERSET THERAPS LLC	0.03%	A207601	001	Jun 19, 2019	Jun	NEWA

BISOPROLOL FUMARATETABLET; ORAL  
BISOPROLOL FUMARATE

AB	FRONTIDA BIOPHARM	5MG	A075474	001	Oct 25, 2002	Jul	CMFD
	@	5MG	A075474	001	Oct 25, 2002	Jan	CAHN
AB		10MG	A075474	002	Oct 25, 2002	Jul	CMFD
	@	10MG	A075474	002	Oct 25, 2002	Jan	CAHN
AB	! UNICHEM PHARMS (USA)	10MG	A078635	002	Aug 18, 2009	Jul	CHRS

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDETABLET; ORAL  
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	MYLAN	2.5MG; 6.25MG	A075768	001	Sep 25, 2000	Jul	DISC
@		5MG; 6.25MG	A075768	002	Sep 25, 2000	Jul	DISC
@		10MG; 6.25MG	A075768	003	Sep 25, 2000	Jul	DISC

BIVALIRUDININJECTABLE; INTRAVENOUS  
BIVALIRUDIN

>A>	AP	HAINAN	250MG/VIAL	A210031	001	Oct 23, 2019	Oct	NEWA
-----	----	--------	------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS  
ANGIOMAX RTU

+!	MAIA PHARMS INC	250MG/50ML (5MG/ML)	N211215	001	Jul 25, 2019	Jul	NEWA
----	-----------------	---------------------	---------	-----	--------------	-----	------

BLEOMYCIN SULFATEINJECTABLE; INJECTION  
BLEOMYCIN SULFATE

AP	CIPLA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Feb	NEWA
----	-------	-----------------------	---------	-----	--------------	-----	------

BORTEZOMIBPOWDER; INTRAVENOUS  
BORTEZOMIB

>A>		DR REDDYS LABS LTD	3.5MG/VIAL	N206927	001	Oct 04, 2019	Oct	NEWA
-----	--	--------------------	------------	---------	-----	--------------	-----	------

POWDER; INTRAVENOUS, SUBCUTANEOUS  
BORTEZOMIB

+	@	HOSPIRA INC	1MG/VIAL	N209191	002	Dec 28, 2018	Mar	DISC
---	---	-------------	----------	---------	-----	--------------	-----	------

BOSENTANTABLET; ORAL  
BOSENTAN

>D>	AB	ALVOGEN PINE BROOK	62.5MG	A206002	001	Apr 26, 2019	Oct DISC
>A>	@		62.5MG	A206002	001	Apr 26, 2019	Oct DISC
	AB		62.5MG	A206002	001	Apr 26, 2019	Apr NFTG
>D>	AB		125MG	A206002	002	Apr 26, 2019	Oct DISC
>A>	@		125MG	A206002	002	Apr 26, 2019	Oct DISC
	AB		125MG	A206002	002	Apr 26, 2019	Apr NFTG
	AB	AMNEAL PHARMS CO	62.5MG	A209742	001	Apr 26, 2019	Apr NFTG
	AB		125MG	A209742	002	Apr 26, 2019	Apr NFTG
	AB	NATCO PHARMA LTD	62.5MG	A206987	001	Apr 26, 2019	Apr NFTG
	AB		125MG	A206987	002	Apr 26, 2019	Apr NFTG
	AB	PAR PHARM INC	62.5MG	A205699	001	Apr 26, 2019	Apr NFTG
	AB		125MG	A205699	002	Apr 26, 2019	Apr NFTG
	AB	SUN PHARM	62.5MG	A209324	001	Apr 26, 2019	Apr NFTG
	AB		125MG	A209324	002	Apr 26, 2019	Apr NFTG
	AB	WATSON LABS INC	62.5MG	A207110	001	Apr 26, 2019	Apr NFTG
	AB		125MG	A207110	002	Apr 26, 2019	Apr NFTG
	AB	ZYDUS PHARMS	62.5MG	A207760	001	Apr 26, 2019	Apr NFTG
	AB		125MG	A207760	002	Apr 26, 2019	Apr NFTG
		TRACLEER					
AB	+	ACTELION PHARMS LTD	62.5MG	N021290	001	Nov 20, 2001	Apr CFTG
AB	+	!	125MG	N021290	002	Nov 20, 2001	Apr CFTG

BREMELANOTIDE ACETATESOLUTION; SUBCUTANEOUS  
VYLEESI (AUTOINJECTOR)

+	!	AMAG PHARMS INC	EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML)	N210557	001	Jun 21, 2019	Jun NEWA
---	---	-----------------	--	---------	-----	--------------	----------

BRETYLIUM TOSYLATEINJECTABLE; INJECTION  
BRETYLIUM TOSYLATE

!		BAS ANDA	50MG/ML	A204386	001	Dec 21, 2018	Jun CAHN
!		BRECKENRIDGE	50MG/ML	A204386	001	Dec 21, 2018	Aug CAHN

BREXANOLONESOLUTION; INTRAVENOUS  
ZULRESSO

+	!	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jun NEWA
---	---	-------------	---------------------	---------	-----	--------------	----------

BRIMONIDINE TARTRATESOLUTION/DROPS; OPHTHALMIC  
BRIMONIDINE TARTRATE

AT		SOMERSET THERAPS LLC	0.2%	A208992	001	Mar 11, 2019	Feb NEWA
----	--	----------------------	------	---------	-----	--------------	----------

BROMFENAC SODIUMSOLUTION/DROPS; OPHTHALMIC  
BROMFENAC SODIUM

AT2		ALEMBIC PHARMS LTD	EQ 0.09% ACID	A210560	001	Jun 21, 2019	Jun NEWA
AT2	!	HI TECH	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC

BUDESONIDECAPSULE; ORAL  
BUDESONIDE

AB		APPCO PHARMA LLC	3MG	A207367	001	Apr 07, 2017	Feb CAHN
		CAPSULE, EXTENDED RELEASE; ORAL					
		ORTIKOS					

+		SUN PHARMA GLOBAL	6MG	N211929	001	Jun 13, 2019	Jun NEWA
+	!		9MG	N211929	002	Jun 13, 2019	Jun NEWA

SUSPENSION; INHALATION  
BUDESONIDE

AN		NEPHRON	0.25MG/2ML	A078202	001	Mar 30, 2009	Sep CAHN
AN			0.5MG/2ML	A078202	002	Mar 30, 2009	Sep CAHN

TABLET, EXTENDED RELEASE; ORAL  
UCERIS

AB	+	!	SALIX	9MG	N203634	001	Jan 14, 2013	Mar CAHN
----	---	---	-------	-----	---------	-----	--------------	----------

BUMETANIDETABLET; ORAL  
BUMETANIDE

AB	HERITAGE PHARMA	0.5MG	A074225	001	Apr 24, 1995	Feb CAHN
AB		1MG	A074225	002	Apr 24, 1995	Feb CAHN
AB		2MG	A074225	003	Apr 24, 1995	Feb CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

	@ MYLAN ASI	0.25%	A091503	001	Oct 18, 2011	Sep DISC
	@	0.5%	A091503	002	Oct 18, 2011	Sep DISC
	@ NOVOCOL HEALTHCARE	0.5%	A211096	001	Feb 19, 2019	Jun DISC
AP		0.5%	A211096	001	Feb 19, 2019	Feb NEWA
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ MYLAN ASI	0.25%	A091487	002	Oct 18, 2011	Sep DISC
	@	0.5%	A091487	001	Oct 18, 2011	Sep DISC
	@	0.75%	A091487	003	Oct 18, 2011	Sep DISC

INJECTABLE; SPINAL

BUPIVACAINE HYDROCHLORIDE

AP	B BRAUN MEDICAL INC	0.75%	A209087	001	Apr 02, 2019	Mar NEWA
----	---------------------	-------	---------	-----	--------------	----------

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE

+	@ HOSPIRA	0.5%; 0.0091MG/ML	N022046	001	Jul 13, 1983	Sep CMS1
!	SEPTODONT	0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Sep CHRS
		0.5%; 0.0091MG/ML	A077250	001	Sep 27, 2006	Sep CTEC
	BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE					
+	@ HOSPIRA	0.5%; 0.0091MG/ML	N022046	001	Jul 13, 1983	Sep DISC

BUPRENORPHINE HYDROCHLORIDE

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

@	BARR	EQ 2MG BASE	A090360	001	May 07, 2010	Jul DISC
@		EQ 8MG BASE	A090360	002	May 07, 2010	Jul DISC
@	MYLAN	EQ 2MG BASE	A201066	001	Mar 06, 2015	Sep DISC
@		EQ 8MG BASE	A201066	002	Mar 06, 2015	Sep DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALVOGEN PINE BROOK	EQ 2MG BASE; EQ 0.5MG BASE	A205954	001	Jan 24, 2019	Jan NEWA
AB		EQ 4MG BASE; EQ 1MG BASE	A205954	002	Jan 24, 2019	Jan NEWA
AB		EQ 8MG BASE; EQ 2MG BASE	A205954	003	Jan 24, 2019	Jan NEWA
AB		EQ 12MG BASE; EQ 3MG BASE	A205954	004	Jan 24, 2019	Jan NEWA

FILM; SUBLINGUAL

CASSIPA

+	@ TEVA PHARMS USA	EQ 16MG BASE; EQ 4MG BASE	N208042	001	Sep 07, 2018	Mar DISC
---	-------------------	---------------------------	---------	-----	--------------	----------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@	TEVA PHARMS USA	EQ 2MG BASE; EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Jan DISC
@		EQ 8MG BASE; EQ 2MG BASE	A091149	002	Sep 08, 2014	Jan DISC

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB	APNAR PHARMA LP	75MG	A075584	001	Feb 07, 2000	Jun CAHN
AB		100MG	A075584	002	Feb 07, 2000	Jun CAHN
	@ HERITAGE PHARMA	75MG	A075310	001	Nov 29, 1999	May CAHN
	@	100MG	A075310	002	Nov 29, 1999	May CAHN

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB2	!	ACTAVIS LABS FL INC	150MG	A079094	001	Mar 24, 2009	Jul CHRS
AB3		GRAVITI PHARMS	150MG	A211020	001	Jan 28, 2019	Jan NEWA
AB3			300MG	A211020	002	Jan 28, 2019	Jan NEWA
	@	MYLAN	150MG	A090942	001	Jul 14, 2010	Jul DISC
>D> AB3			300MG	A090942	002	Jul 14, 2010	Oct DISC
>A>	@		300MG	A090942	002	Jul 14, 2010	Oct DISC
	@	SUN PHARM	150MG	A200695	001	Dec 18, 2014	Sep DISC
	@	YICHANG HUMANWELL	100MG	A211347	001	Oct 16, 2018	Apr DISC

TABLET, EXTENDED RELEASE;ORAL  
BUPROPION HYDROCHLORIDE

	@	150MG	A211347	002	Oct 16, 2018	Apr	DISC
	@	200MG	A211347	003	Oct 16, 2018	Apr	DISC
AB3	ZHEJIANG JUTAI PHARM	300MG	A211200	001	Sep 05, 2019	Aug	NEWA
	ZYBAN						
	+ @ GLAXOSMITHKLINE	150MG	N020711	003	May 14, 1997	Jul	DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL  
BUSPIRONE HYDROCHLORIDE

AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Apr	NEWA
AB		7.5MG	A208972	002	Apr 16, 2019	Apr	NEWA
AB		10MG	A208972	003	Apr 16, 2019	Apr	NEWA
AB		15MG	A208972	004	Apr 16, 2019	Apr	NEWA
AB		30MG	A208972	005	Apr 16, 2019	Apr	NEWA
	@ RUBICON	5MG	A075521	001	Apr 05, 2002	Aug	CAHN
	@	10MG	A075521	002	Apr 05, 2002	Aug	CAHN
	@	15MG	A075521	003	Apr 05, 2002	Aug	CAHN
>A> AB	UNICHEM LABS LTD	5MG	A210907	001	Nov 14, 2019	Oct	NEWA
>A> AB		10MG	A210907	002	Nov 14, 2019	Oct	NEWA
>A> AB		15MG	A210907	003	Nov 14, 2019	Oct	NEWA
>A> AB		30MG	A210907	004	Nov 14, 2019	Oct	NEWA

BUSULFAN

INJECTABLE;INJECTION  
BUSULFAN

AP	ACCORD HLTHCARE INC	6MG/ML	A210148	001	Feb 22, 2019	Feb	NEWA
AP	APOTEX	6MG/ML	A210448	001	May 07, 2019	Apr	NEWA
AP	ATHENEX INC	6MG/ML	A205106	001	Sep 21, 2018	Jan	CAHN
AP	HOSPIRA INC	6MG/ML	A205672	001	Jul 31, 2018	Sep	CMFD
	@	6MG/ML	A205672	001	Jul 31, 2018	Feb	DISC
AP	SHILPA MEDICARE LTD	6MG/ML	A210931	001	Apr 18, 2019	Apr	NEWA
	MYLERAN						
AP	MYLAN INSTITUTIONAL	6MG/ML	A208536	001	Nov 20, 2017	Jul	CAHN

CABERGOLINE

TABLET;ORAL  
CABERGOLINE

@	ACTAVIS LABS FL INC	0.5MG	A078035	001	Apr 21, 2008	Aug	DISC
---	---------------------	-------	---------	-----	--------------	-----	------

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS  
CAFCIT

AP	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug	CAHN
	SOLUTION;ORAL						
	CAFCIT						
AA	+! HIKMA	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug	CAHN
	CAFFEINE CITRATE						
	@ LUITPOLD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090064	001	Nov 20, 2009	Mar	DISC

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL  
MIGERGOT

!	COSETTE	100MG;2MG	A086557	001	Oct 04, 1983	Jul	CAHN
---	---------	-----------	---------	-----	--------------	-----	------

CALCITONIN SALMON

INJECTABLE;INJECTION  
MIACALCIN

+ @	MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug	CRLD
-----	-------------------	-----------	---------	-----	--------------	-----	------

CALCITRIOL

CAPSULE;ORAL  
CALCITRIOL

@	SUN PHARM	0.25MCG	A204556	001	Feb 21, 2019	Jul	DISC
AB		0.25MCG	A204556	001	Feb 21, 2019	Feb	NEWA
	@	0.5MCG	A204556	002	Feb 21, 2019	Jul	DISC
AB		0.5MCG	A204556	002	Feb 21, 2019	Feb	NEWA

SOLUTION;ORAL  
CALCITRIOL

AA	ELYSIUM	1MCG/ML	A209798	001	Nov 21, 2018	Sep	CAHN
----	---------	---------	---------	-----	--------------	-----	------

CALCIUM ACETATETABLET; ORAL  
CALCIUM ACETATE

AB	CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Jan CAHN
----	---------------------	-------	---------	-----	--------------	----------

CALCIUM CHLORIDEINJECTABLE; INJECTION  
CALCIUM CHLORIDE 10%

AP	MEDEFIL INC	100MG/ML	A211553	001	May 01, 2019	Apr NEWA
----	-------------	----------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992 Jun CRLD
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992 Aug CTEC
	+		18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992 Jun CRLD
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
	+ @	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992 Sep DISC
	+		18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992 Jun CRLD
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992 Aug CTEC
	+		18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992 Jun CRLD
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	012	Jan 10, 1989 Aug NEWA
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	013	Jul 11, 1990 Aug NEWA
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	014	Jul 11, 1990 Aug NEWA
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	015	Jul 11, 1990 Aug NEWA
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004	Jun CRLD
AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004	Aug CPOT
AT	+		25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	001	Dec 04, 1992 Jun CRLD
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	005	Jun CRLD
AT	+		25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	002	Dec 04, 1992 Jun CRLD
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER						
	+ @	BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985 Jun CRLD
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER						
AT	+	BAXTER HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	006	Jun CRLD
AT	+		25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020163	003	Dec 04, 1992 Jun CRLD

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATEINJECTABLE; INJECTION  
LACTATED RINGER'S IN PLASTIC CONTAINER

AP	FRESENIUS KABI USA	20MG/100ML; 30MG/100ML; 600MG/100ML; 310MG/100ML	A209338	001	Jan 28, 2019	Jan NEWA
----	--------------------	--	---------	-----	--------------	----------

CAPECITABINETABLET; ORAL  
CAPECITABINE

AB	SUN PHARM	150MG	A204668	001	Jun 21, 2019	Jun NEWA
AB		500MG	A204668	002	Jun 21, 2019	Jun NEWA

CAPTOPRILTABLET; ORAL  
CAPTOPRIL

AB	BOSCOGEN	12.5MG	A074677	004	May 30, 1997	Jun	CMFD
AB		25MG	A074677	002	May 30, 1997	Jun	CMFD
AB		50MG	A074677	001	May 30, 1997	Jun	CMFD
AB		100MG	A074677	003	May 30, 1997	Jun	CMFD
>A> AB	SETON PHARMS	12.5MG	A212223	001	Oct 30, 2019	Oct	NEWA
>A> AB		25MG	A212223	002	Oct 30, 2019	Oct	NEWA
>A> AB		50MG	A212223	003	Oct 30, 2019	Oct	NEWA
>A> AB		100MG	A212223	004	Oct 30, 2019	Oct	NEWA

CARBAMAZEPINECAPSULE, EXTENDED RELEASE; ORAL  
CARBAMAZEPINE

	@ MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jul	DISC
	@	200MG	A076697	002	May 20, 2011	Jul	DISC
	@	300MG	A076697	003	May 20, 2011	Jul	DISC
	CARBATROL						
AB	+ SHIRE DEV LLC	100MG	N020712	003	Sep 30, 1997	Jan	CAHN
AB	+	200MG	N020712	001	Sep 30, 1997	Jan	CAHN
AB	+!	300MG	N020712	002	Sep 30, 1997	Jan	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	CARBAMAZEPINE						
AB	ZYDUS PHARMS	100MG	A205571	001	Feb 07, 2019	Jan	NEWA
AB		200MG	A205571	002	Feb 07, 2019	Jan	NEWA
AB		400MG	A205571	003	Feb 07, 2019	Jan	NEWA

CARBIDOPATABLET; ORAL  
CARBIDOPA

>A> AB	AUROBINDO PHARMA LTD	25MG	A211055	001	Oct 21, 2019	Oct	NEWA
--------	----------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

@	WOCKHARDT LTD	12.5MG; 200MG; 50MG	A090786	001	Nov 20, 2012	Aug	DISC
@		18.75MG; 200MG; 75MG	A090833	001	Nov 20, 2012	Aug	DISC
@		25MG; 200MG; 100MG	A090833	002	Nov 20, 2012	Aug	DISC
@		31.25MG; 200MG; 125MG	A090833	003	Nov 20, 2012	Aug	DISC
@		37.5MG; 200MG; 150MG	A090833	004	Nov 20, 2012	Aug	DISC
@		50MG; 200MG; 200MG	A090833	005	Nov 20, 2012	Aug	DISC

STALEVO 125

+	ORION PHARMA	31.25MG; 200MG; 125MG	N021485	006	Aug 29, 2008	Aug	CTEC
---	--------------	-----------------------	---------	-----	--------------	-----	------

STALEVO 200

+!	ORION PHARMA	50MG; 200MG; 200MG	N021485	004	Aug 02, 2007	Aug	CTEC
----	--------------	--------------------	---------	-----	--------------	-----	------

STALEVO 50

+!	ORION PHARMA	12.5MG; 200MG; 50MG	N021485	001	Jun 11, 2003	Aug	CTEC
----	--------------	---------------------	---------	-----	--------------	-----	------

STALEVO 75

+	ORION PHARMA	18.75MG; 200MG; 75MG	N021485	005	Aug 29, 2008	Aug	CTEC
---	--------------	----------------------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE; ORAL

CARBIDOPA AND LEVODOPA

AB	ALEMBIC PHARMS LTD	25MG; 100MG	A210341	001	Jun 05, 2019	May	NEWA
AB		50MG; 200MG	A210341	002	Jun 05, 2019	May	NEWA
>D> AB	SUN PHARM INDS	50MG; 200MG	A077828	002	Aug 23, 2007	Oct	CHRS
>A> AB	!	50MG; 200MG	A077828	002	Aug 23, 2007	Oct	CHRS
>D>	SINEMET CR						
>D> AB	+! MERCK SHARP DOHME	50MG; 200MG	N019856	001	May 30, 1991	Oct	DISC
>A>	+ @	50MG; 200MG	N019856	001	May 30, 1991	Oct	DISC

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

!	MIKART	4MG/5ML	A040458	001	Apr 25, 2003	Jun	CTEC
@	VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Jun	DISC

TABLET; ORAL

CARBINOXAMINE MALEATE

!	MIKART	6MG	A207484	001	May 31, 2016	Mar	CHRS
---	--------	-----	---------	-----	--------------	-----	------

CARBOPLATININJECTABLE; INTRAVENOUS  
CARBOPLATIN

AP	ACCORD HLTHCARE	50MG/5ML (10MG/ML)	A206775	001	Feb 09, 2017	May CDFR
AP		150MG/15ML (10MG/ML)	A206775	002	Feb 09, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A206775	003	Feb 09, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A206775	004	Feb 09, 2017	May CDFR
	@ ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Mar CDFR
	@	150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Mar CDFR
	@	450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Mar CDFR
	@	600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Mar CDFR
AP	AKORN	50MG/5ML (10MG/ML)	A090475	001	Jul 29, 2009	May CDFR
AP		150MG/15ML (10MG/ML)	A090475	002	Jul 29, 2009	May CDFR
AP		450MG/45ML (10MG/ML)	A090475	003	Jul 29, 2009	May CDFR
AP		600MG/60ML (10MG/ML)	A091268	002	Jul 28, 2010	May CDFR
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861	001	Jan 18, 2007	May CDFR
AP		150MG/15ML (10MG/ML)	A077861	002	Jan 18, 2007	May CDFR
AP		450MG/45ML (10MG/ML)	A077861	003	Jan 18, 2007	May CDFR
AP		600MG/60ML (10MG/ML)	A077861	004	Jan 18, 2007	May CDFR
AP	EUGIA PHARMA	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	May CDFR
AP		150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	May CDFR
AP		450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	May CDFR
>D> AP	FRESENIUS KABI USA	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006	Oct DISC
>A>	@	50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006	Oct DISC
AP		50MG/5ML (10MG/ML)	A077432	001	Sep 29, 2006	May CDFR
>D> AP		150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006	Oct DISC
>A>	@	150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006	Oct DISC
AP		150MG/15ML (10MG/ML)	A077432	002	Sep 29, 2006	May CDFR
>D> AP		450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006	Oct DISC
>A>	@	450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006	Oct DISC
AP		450MG/45ML (10MG/ML)	A077432	003	Sep 29, 2006	May CDFR
	@	50MG/5ML (10MG/ML)	A077247	001	Oct 21, 2004	Mar CDFR
	@	50MG/5ML (10MG/ML)	A077266	001	Feb 15, 2006	Mar CDFR
	@	150MG/15ML (10MG/ML)	A077247	002	Oct 21, 2004	Mar CDFR
	@	150MG/15ML (10MG/ML)	A077266	002	Feb 15, 2006	Mar CDFR
AP		450MG/45ML (10MG/ML)	A077247	003	Oct 21, 2004	Mar CDFR
AP		450MG/45ML (10MG/ML)	A077266	003	Feb 15, 2006	May CDFR
AP		600MG/60ML (10MG/ML)	A077266	004	Feb 15, 2006	May CDFR
AP	GLAND PHARMA LTD	150MG/15ML (10MG/ML)	A207324	002	Feb 15, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A207324	003	Feb 15, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A207324	004	Feb 15, 2017	May CDFR
AP	HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	May CDFR
AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	May CDFR
AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	May CDFR
AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	May CDFR
AP	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	May CDFR
AP		150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	May CDFR
AP		450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	May CDFR
AP		600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	May CDFR
AP	INGENUS PHARMS LLC	50MG/5ML (10MG/ML)	A208487	001	Apr 26, 2017	May CDFR
AP		150MG/15ML (10MG/ML)	A208487	002	Apr 26, 2017	May CDFR
AP		450MG/45ML (10MG/ML)	A208487	003	Apr 26, 2017	May CDFR
AP		600MG/60ML (10MG/ML)	A208487	004	Apr 26, 2017	May CDFR
	@ MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Apr CDFR
	@	150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Apr CDFR
	@	450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Apr CDFR
>D> AP	MYLAN LABS LTD	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	Oct DISC
>A>	@	50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	Oct DISC
AP		50MG/5ML (10MG/ML)	A091063	001	Nov 09, 2011	May CDFR
>D> AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	Oct DISC
>A>	@	150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	Oct DISC
AP		150MG/15ML (10MG/ML)	A091063	002	Nov 09, 2011	May CDFR
>D> AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	Oct DISC
>A>	@	450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	Oct DISC
AP		450MG/45ML (10MG/ML)	A091063	003	Nov 09, 2011	May CDFR
>D> AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	Oct DISC
>A>	@	600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	Oct DISC
AP		600MG/60ML (10MG/ML)	A091063	004	Nov 09, 2011	May CDFR
	@	1GM/100ML (10MG/ML)	A091478	001	Nov 23, 2011	Mar CDFR
AP	! PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	May CDFR
	@	50MG/5ML (10MG/ML)	A077679	001	Feb 25, 2009	Mar CDFR
AP	!	150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	May CDFR
	@	150MG/15ML (10MG/ML)	A077679	002	Feb 25, 2009	Mar CDFR

INJECTABLE; INTRAVENOUS  
CARBOPLATIN

AP	!		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	May CDFR
	@		450MG/45ML (10MG/ML)	A077679	003	Feb 25, 2009	Mar CDFR
AP	!		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	May CDFR
AP		PLIVA LACHEMA	50MG/5ML (10MG/ML)	A078631	001	Dec 02, 2008	May CDFR
AP			150MG/15ML (10MG/ML)	A078631	002	Dec 02, 2008	May CDFR
AP			450MG/45ML (10MG/ML)	A078631	003	Dec 02, 2008	May CDFR
AP			600MG/60ML (10MG/ML)	A078631	004	Dec 02, 2008	May CDFR
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	May CDFR
AP			150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	May CDFR
AP			450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	May CDFR
AP		SUN PHARM	50MG/5ML (10MG/ML)	A077926	001	Sep 19, 2008	May CDFR
AP			150MG/15ML (10MG/ML)	A077926	002	Sep 19, 2008	May CDFR
AP			450MG/45ML (10MG/ML)	A077926	003	Sep 19, 2008	May CDFR
	@	TEVA PARENTERAL	50MG/5ML (10MG/ML)	A077389	001	Mar 30, 2007	Mar CDFR
	@		150MG/15ML (10MG/ML)	A077389	002	Mar 30, 2007	Mar CDFR
	@		450MG/45ML (10MG/ML)	A077389	003	Mar 30, 2007	Mar CDFR
AP	!	TEVA PHARMS USA	50MG/5ML (10MG/ML)	A077139	001	Sep 21, 2005	May CDFR
AP	!		150MG/15ML (10MG/ML)	A077139	002	Sep 21, 2005	May CDFR
AP	!		450MG/45ML (10MG/ML)	A077139	003	Sep 21, 2005	May CDFR
AP	!		600MG/60ML (10MG/ML)	A077139	004	Sep 21, 2005	May CDFR
AP		WEST-WARD PHARMS INT	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	May CDFR
AP			150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	May CDFR
AP			450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	May CDFR
AP			600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	May CDFR
		PARAPLATIN					
	+	@ CORDENPHARMA	50MG/5ML (10MG/ML)	N020452	001	Jul 14, 2003	Mar CDFR
	+	@	150MG/15ML (10MG/ML)	N020452	002	Jul 14, 2003	Mar CDFR
	+	@	450MG/45ML (10MG/ML)	N020452	003	Jul 14, 2003	Mar CDFR
	+	@	600MG/60ML (10MG/ML)	N020452	004	Jan 15, 2004	Mar CDFR

## INJECTABLE; IV (INFUSION)

## CARBOPLATIN

AP		GLAND PHARMA LTD	50MG/5ML (10MG/ML)	A207324	001	Feb 15, 2017	May CDFR
AP		HONG KONG	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Feb CAHN
AP			150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Feb CAHN
AP			450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Feb CAHN
AP			600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Feb CAHN
	@	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A077998	001	Apr 24, 2007	Mar DISC
	@		150MG/15ML (10MG/ML)	A077998	002	Apr 24, 2007	Mar DISC
	@		450MG/45ML (10MG/ML)	A077998	003	Apr 24, 2007	Mar DISC

CARBOPROST TROMETHAMINE

## INJECTABLE; INJECTION

## CARBOPROST TROMETHAMINE

AP		DR REDDYS LABS LTD	EQ 0.25MG BASE/ML	A211941	001	Jul 02, 2019	Jun NFTG
		HEMABATE					
AP	+	! PHARMACIA AND UPJOHN	EQ 0.25MG BASE/ML	N017989	001		Jun CFTG

CARFILZOMIB

## POWDER; INTRAVENOUS

## CARFILZOMIB

AP		DR REDDYS	60MG/VIAL	A209422	001	Sep 09, 2019	Aug NFTG
		KYPROLIS					
AP	+	! ONYX THERAP	60MG/VIAL	N202714	001	Jul 20, 2012	Aug CFTG

CARGLUMIC ACID

## TABLET; ORAL

## CARBAGLU

	+	! RECORDATI RARE	200MG	N022562	001	Mar 18, 2010	May CAHN
--	---	------------------	-------	---------	-----	--------------	----------

CARISOPRODOL

## TABLET; ORAL

## CARISOPRODOL

AA		ALLIED	350MG	A040245	001	Sep 08, 1997	Aug CMFD
	@		350MG	A040245	001	Sep 08, 1997	Jun CAHN
>D> AA		SUN PHARM INDUSTRIES	350MG	A089346	001	Oct 17, 1991	Oct DISC
>A>	@		350MG	A089346	001	Oct 17, 1991	Oct DISC
	@	VINTAGE PHARMS	350MG	A040245	001	Sep 08, 1997	Feb DISC

CARMUSTINE

INJECTABLE; INJECTION  
CARMUSTINE

AP	STI PHARMA LLC	100MG/VIAL	A209278	001	Apr 02, 2019	Mar	NEWA
----	----------------	------------	---------	-----	--------------	-----	------

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
CARTEOLOL HYDROCHLORIDE

@ BAUSCH AND LOMB 1%  
! SANDOZ INC 1%

A075546	001	Jan 20, 2000	May	DISC
A075476	001	Jan 03, 2000	May	CTEC

CARVEDILOL

TABLET; ORAL  
CARVEDILOL

AB	RUBICON	3.125MG	A078165	001	Sep 05, 2007	Aug	CAHN
AB		6.25MG	A078165	002	Sep 05, 2007	Aug	CAHN
AB		12.5MG	A078165	003	Sep 05, 2007	Aug	CAHN
AB		25MG	A078165	004	Sep 05, 2007	Aug	CAHN
>D> AB	SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Oct	DISC
>A>	@	3.125MG	A077346	004	Sep 05, 2007	Oct	DISC
>D> AB		6.25MG	A077346	001	Sep 05, 2007	Oct	DISC
>A>	@	6.25MG	A077346	001	Sep 05, 2007	Oct	DISC
>D> AB		12.5MG	A077346	002	Sep 05, 2007	Oct	DISC
>A>	@	12.5MG	A077346	002	Sep 05, 2007	Oct	DISC
>D> AB		25MG	A077346	003	Sep 05, 2007	Oct	DISC
>A>	@	25MG	A077346	003	Sep 05, 2007	Oct	DISC

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS  
CASPOFUNGIN ACETATE

@ CIPLA 50MG/VIAL  
@ 70MG/VIAL

A209489	001	Jul 12, 2018	Jan	DISC
A209489	002	Jul 12, 2018	Jan	DISC

CEFAZOLIN SODIUM

INJECTABLE; INJECTION  
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE EQ 10MG BASE/ML  
+ @ EQ 20MG BASE/ML  
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
+ @ BAXTER HLTHCARE EQ 10MG BASE/ML  
+ @ EQ 20MG BASE/ML

N050566	003	Jun 08, 1983	Aug	CRLD
N050566	004	Jun 08, 1983	Aug	CRLD
N050566	001	Jun 08, 1983	Aug	CRLD
N050566	002	Jun 08, 1983	Aug	CRLD

CEFAZOLIN SODIUM

>D> AP	! HOSPIRA INC	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Oct	DISC
>A>	@	EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Oct	DISC
>D> AP		EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Oct	DISC
>A>	@	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Oct	DISC

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION  
CEFEPIME HYDROCHLORIDE

@ HOSPIRA INC EQ 500MG BASE/VIAL  
@ EQ 1GM BASE/VIAL  
@ EQ 1GM BASE/VIAL  
@ EQ 2GM BASE/VIAL  
@ EQ 2GM BASE/VIAL

A065369	001	Jun 18, 2007	Sep	DISC
A065369	002	Jun 18, 2007	Sep	DISC
A202268	001	Jul 30, 2012	Sep	DISC
A065369	003	Jun 18, 2007	Sep	DISC
A202268	002	Jul 30, 2012	Sep	DISC

CEFIXIME

FOR SUSPENSION; ORAL  
CEFIXIME

@ SANDOZ INC 100MG/5ML  
@ 200MG/5ML  
SUPRAX

A206144	001	Nov 17, 2017	Feb	DISC
A206144	002	Nov 17, 2017	Feb	DISC

AB	! LUPIN PHARMS	200MG/5ML	A065355	001	Apr 10, 2007	Apr	CHRS
----	----------------	-----------	---------	-----	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION  
CEFOTAXIME SODIUM

@ HOSPIRA INC EQ 500MG BASE/VIAL  
@ EQ 1GM BASE/VIAL  
@ EQ 1GM BASE/VIAL  
@ EQ 1GM BASE/VIAL

A065290	001	Aug 11, 2006	Sep	DISC
A065290	002	Aug 11, 2006	Sep	DISC
A065293	001	Aug 10, 2006	Sep	DISC
A203132	001	Feb 19, 2016	Sep	DISC

INJECTABLE; INJECTION  
CEFOTAXIME SODIUM

@	EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Sep DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION  
CEFOXITIN

@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Sep DISC
@	EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Sep DISC
@	EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Sep DISC

CEFPODOXIME PROXETIL

FOR SUSPENSION; ORAL  
CEFPODOXIME PROXETIL

AUROBINDO PHARMA LTD	EQ 50MG BASE/5ML	A065409	001	Jun 08, 2007	Jan CTEC
!	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CHRS
	EQ 100MG BASE/5ML	A065409	002	Jun 08, 2007	Jan CTEC
@ SANDOZ	EQ 50MG BASE/5ML	A090031	001	Jan 14, 2009	Jan DISC
@	EQ 100MG BASE/5ML	A090031	002	Jan 14, 2009	Jan DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION  
CEFUROXIME SODIUM

@ HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Sep DISC
@	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Sep DISC
@	EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Sep DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
CEFUROXIME SODIUM

@ HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Sep DISC
---------------	--------------------	---------	-----	--------------	----------

CELECOXIB

CAPSULE; ORAL  
CELECOXIB

AB	QINGDAO BAHEAL PHARM	50MG	A208856	001	Aug 07, 2019	Jul NEWA
AB		100MG	A208856	002	Aug 07, 2019	Jul NEWA
AB		200MG	A208856	003	Aug 07, 2019	Jul NEWA
AB		400MG	A208856	004	Aug 07, 2019	Jul NEWA

CEPHALEXIN

CAPSULE; ORAL  
CEPHALEXIN

>D> AB	SUN PHARM INDS (IN)	EQ 250MG BASE	A062791	001	Jun 11, 1987	Oct DISC
>A>	@	EQ 250MG BASE	A062791	001	Jun 11, 1987	Oct DISC
>D> AB		EQ 500MG BASE	A062791	002	Jun 11, 1987	Oct DISC
>A>	@	EQ 500MG BASE	A062791	002	Jun 11, 1987	Oct DISC

FOR SUSPENSION; ORAL  
CEPHALEXIN

AB	ALKEM LABS LTD	EQ 125MG BASE/5ML	A210221	001	Mar 26, 2019	Mar NEWA
AB		EQ 250MG BASE/5ML	A210221	002	Mar 26, 2019	Mar NEWA

CERITINIB

CAPSULE; ORAL  
ZYKADIA

+ @ NOVARTIS	150MG	N205755	001	Apr 29, 2014	Jun DISC
--------------	-------	---------	-----	--------------	----------

TABLET; ORAL  
ZYKADIA

+! NOVARTIS	150MG	N211225	001	Mar 18, 2019	Mar NEWA
-------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

>A> SOLUTION; INTRAVENOUS  
>A> QUZYTIR

>A>	+! JDP	10MG/ML (10MG/ML)	N211415	001	Oct 04, 2019	Oct NEWA
-----	--------	-------------------	---------	-----	--------------	----------

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

@ LANNETT CO INC	5MG/5ML	A078496	001	Sep 25, 2009	May DISC
AA MLV	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
AA ! PERRIGO PHARMS CO	5MG/5ML	A078398	001	Jun 17, 2008	May CAHN

CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN

OINTMENT; TOPICAL

ELASE-CHLOROMYCETIN

+ @ PARKE DAVIS	10MG/GM; 666 UNITS/GM; 1 UNITS/GM	N050294	001		Aug	CRLD
-----------------	-----------------------------------	---------	-----	--	-----	------

CHLORDIAZEPOXIDE HYDROCHLORIDE

INJECTABLE; INJECTION

LIBRIUM

@ BAUSCH	100MG/AMP	N012301	001		Mar	CAHN
----------	-----------	---------	-----	--	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

@ ACELLA	4MG/5ML; 5MG/5ML	A206891	001	Jun 09, 2017	Aug	DISC
----------	------------------	---------	-----	--------------	-----	------

VITUZ

+ @ PERSION	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Aug	DISC
-------------	------------------	---------	-----	--------------	-----	------

AA +!	4MG/5ML; 5MG/5ML	N204307	001	Feb 20, 2013	Apr	CAHN
-------	------------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA ! PADDOCK LLC	4MG/5ML; 5MG/5ML; 60MG/5ML	A204627	001	Apr 29, 2014	Jun	CHRS
------------------	----------------------------	---------	-----	--------------	-----	------

@ TORRENT	4MG/5ML; 5MG/5ML; 60MG/5ML	A206660	001	May 15, 2017	Jan	CAHN
-----------	----------------------------	---------	-----	--------------	-----	------

ZUTRIPRO

+ @ PERSION	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Jul	DISC
-------------	----------------------------	---------	-----	--------------	-----	------

AA +!	4MG/5ML; 5MG/5ML; 60MG/5ML	N022439	001	Jun 08, 2011	Apr	CAHN
-------	----------------------------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@ HIKMA	30MG/ML	A088157	001	Apr 27, 1983	Sep	CAHN
---------	---------	---------	-----	--------------	-----	------

@	100MG/ML	A088158	001	Apr 27, 1983	Sep	CAHN
---	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB UPSHER SMITH LABS	10MG	A083386	001		Jul	CAHN
----------------------	------	---------	-----	--	-----	------

AB !	25MG	A084112	001		Jul	CAHN
------	------	---------	-----	--	-----	------

AB	50MG	A084113	001		Jul	CAHN
----	------	---------	-----	--	-----	------

AB !	100MG	A084114	001		Jul	CAHN
------	-------	---------	-----	--	-----	------

AB	200MG	A084115	001		Jul	CAHN
----	-------	---------	-----	--	-----	------

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ MYLAN	100MG	A088549	002	Jun 01, 1984	May	DISC
---------	-------	---------	-----	--------------	-----	------

@	250MG	A088549	001	Jun 01, 1984	May	DISC
---	-------	---------	-----	--------------	-----	------

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

AB AMNEAL PHARMS CO	25MG	A207204	001	Jul 01, 2019	Jun	NEWA
---------------------	------	---------	-----	--------------	-----	------

AB	50MG	A207204	002	Jul 01, 2019	Jun	NEWA
----	------	---------	-----	--------------	-----	------

AB ARISE	25MG	A210742	001	Oct 12, 2018	Sep	CAHN
----------	------	---------	-----	--------------	-----	------

AB	50MG	A210742	002	Oct 12, 2018	Sep	CAHN
----	------	---------	-----	--------------	-----	------

AB UNICHEM LABS LTD	25MG	A211627	001	Aug 06, 2019	Jul	NEWA
---------------------	------	---------	-----	--------------	-----	------

AB	50MG	A211627	002	Aug 06, 2019	Jul	NEWA
----	------	---------	-----	--------------	-----	------

AB ZYDUS PHARMS	25MG	A207813	001	May 10, 2019	Apr	NEWA
-----------------	------	---------	-----	--------------	-----	------

AB	50MG	A207813	002	May 10, 2019	Apr	NEWA
----	------	---------	-----	--------------	-----	------

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA NOVITIUM PHARMA	500MG	A212254	001	Sep 12, 2019	Sep	NEWA
--------------------	-------	---------	-----	--------------	-----	------

AA ! WATSON LABS	500MG	A089859	001	May 04, 1988	Sep	CTEC
------------------	-------	---------	-----	--------------	-----	------

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

AP DECATUR	4-33.1mCi/ML	A206319	001	Nov 13, 2015	Apr	CAHN
------------	--------------	---------	-----	--------------	-----	------

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE;ORAL  
FENOFIBRIC ACID

AB	AUROBINDO PHARMA LTD	EQ 45MG FENOFIBRIC ACID	A212598	001	Jul 25, 2019	Jul NEWA
AB		EQ 135MG FENOFIBRIC ACID	A212598	002	Jul 25, 2019	Jul NEWA
AB	GRAVITI PHARMS	EQ 45MG FENOFIBRIC ACID	A211626	001	Jul 18, 2019	Jul NEWA
AB		EQ 135MG FENOFIBRIC ACID	A211626	002	Jul 18, 2019	Jul NEWA
	@ MYLAN PHARMS INC	EQ 45MG FENOFIBRIC ACID	A200913	001	Mar 25, 2013	May DISC
	@	EQ 135MG FENOFIBRIC ACID	A200913	002	Mar 25, 2013	May DISC
AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A210469	001	Jul 05, 2019	Jun NEWA
AB		EQ 135MG FENOFIBRIC ACID	A210469	002	Jul 05, 2019	Jun NEWA

CHROMIC PHOSPHATE P-32INJECTABLE;INJECTION  
PHOSPHOCOL P32  
@ CURIUM

5mCi/ML

N017084 001

Jan CAHN

CICLESONIDEAEROSOL, METERED;INHALATION  
ALVESCO+! COVIS PHARMA BV 0.08MG/INH  
+! 0.16MG/INHN021658 002 Jan 10, 2008 Mar CAHN  
N021658 003 Jan 10, 2008 Mar CAHNAEROSOL, METERED;NASAL  
ZETONNA

+! COVIS PHARMA BV 0.037MG/INH

N202129 001 Jan 20, 2012 Mar CAHN

SPRAY, METERED;NASAL  
OMNARIS

+! COVIS PHARMA BV 0.05MG/INH

N022004 001 Oct 20, 2006 Mar CAHN

CICLOPIROXCREAM;TOPICAL  
CICLOPIROX

AB PERRIGO ISRAEL 0.77%

A077364 001 Mar 03, 2006 May CAHN

SHAMPOO;TOPICAL  
LOPROX

AT +! BAUSCH 1%

N021159 001 Feb 28, 2003 Apr CAHN

SOLUTION;TOPICAL  
CICLOPIROX

AT ACELLA 8%

A078172 001 Sep 18, 2007 May CAHN

AT ANDA REPOSITORY 8%

A077687 001 Sep 18, 2007 Aug CAHN

AT NOVAST LABS 8%

A078124 001 Sep 18, 2007 Sep CAHN

CILASTATIN SODIUM; IMIPENEMPOWDER;INTRAVENOUS  
IMIPENEM AND CILASTATIN

@ HOSPIRA INC EQ 500MG BASE/VIAL;500MG/VIAL

A090825 002 Nov 16, 2011 Sep DISC

@ EQ 500MG BASE/VIAL;500MG/VIAL

A091007 001 Nov 16, 2011 Sep DISC

CILASTATIN SODIUM; IMIPENEM; RELEBACTAMPOWDER;INTRAVENOUS  
RECARBRIO+! MSD MERCK CO EQ 500MG  
BASE/VIAL;500MG/VIAL;250MG/VIAL

N212819 001 Jul 16, 2019 Jul NEWA

CILOSTAZOLTABLET;ORAL  
CILOSTAZOL

AB SLATE 50MG

A077208 002 Mar 29, 2006 Aug CAHN

AB 100MG

A077208 001 Mar 29, 2006 Aug CAHN

CINACALCET HYDROCHLORIDETABLET;ORAL  
CINACALCET HYDROCHLORIDE

AB ALKEM LABS LTD EQ 30MG BASE

A210570 001 May 17, 2019 May NEWA

AB EQ 60MG BASE

A210570 002 May 17, 2019 May NEWA

AB EQ 90MG BASE

A210570 003 May 17, 2019 May NEWA

AB LUPIN LTD EQ 30MG BASE

A210548 001 Jun 28, 2019 Jun NEWA

AB EQ 60MG BASE

A210548 002 Jun 28, 2019 Jun NEWA

AB EQ 90MG BASE

A210548 003 Jun 28, 2019 Jun NEWA

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@ DR REDDYS 200MG/20ML (10MG/ML)  
 @ 400MG/40ML (10MG/ML)

A077782 001 Aug 28, 2006 May CAHN  
 A077782 002 Aug 28, 2006 May CAHN

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

CIPROFLOXACIN HYDROCHLORIDE

@ RUBICON EQ 0.3% BASE

A075928 001 Jun 09, 2004 Jul CAHN

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB CHARTWELL EQ 250MG BASE  
 AB EQ 500MG BASE  
 AB EQ 750MG BASE  
 AB CHARTWELL MOLECULES EQ 250MG BASE  
 AB EQ 500MG BASE  
 AB EQ 750MG BASE

A076896 001 Nov 04, 2004 Sep CAHN  
 A076896 002 Nov 04, 2004 Sep CAHN  
 A076896 003 Nov 04, 2004 Sep CAHN  
 A076896 001 Nov 04, 2004 Jul CAHN  
 A076896 002 Nov 04, 2004 Jul CAHN  
 A076896 003 Nov 04, 2004 Jul CAHN

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

! ANCHEN PHARMS 212.6MG; EQ 287.5MG BASE  
 AB ! 212.6MG; EQ 287.5MG BASE  
 AB ! 425.2MG; EQ 574.9MG BASE  
 @ ANI PHARMS INC 212.6MG; EQ 287.5MG BASE  
 @ 425.2MG; EQ 574.9MG BASE  
 @ MYLAN PHARMS INC 212.6MG; EQ 287.5MG BASE  
 @ 425.2MG; EQ 574.9MG BASE

A078166 002 Nov 27, 2007 May CTEC  
 A078166 002 Nov 27, 2007 May CHRS  
 A078166 001 Nov 27, 2007 May CHRS  
 A077417 001 Nov 30, 2010 May CAHN  
 A077809 001 Nov 30, 2010 May CAHN  
 A078183 001 Mar 22, 2007 May DISC  
 A078183 002 Mar 22, 2007 May DISC

CISATRACTURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACTURIUM BESYLATE

>D> AP @ ACCORD HLTHCARE EQ 2MG BASE/ML  
 AP ANDA REPOSITORY EQ 2MG BASE/ML  
 AP EQ 2MG BASE/ML  
 AP NANJING KING-FRIEND EQ 2MG BASE/ML  
 AP EQ 2MG BASE/ML  
 AP EQ 10MG BASE/ML  
 >A> AP SOMERSET EQ 2MG BASE/ML  
 AP SOMERSET THERAPS LLC EQ 2MG BASE/ML  
 >A> AP ZYDUS PHARMS EQ 2MG BASE/ML  
 >A> AP EQ 10MG BASE/ML

A205873 001 Jun 16, 2017 Feb DISC  
 A209132 001 Apr 24, 2019 Oct CAHN  
 A209132 001 Apr 24, 2019 Sep CAHN  
 A211668 001 Apr 25, 2019 Apr NEWA  
 A211669 001 Apr 25, 2019 Apr NEWA  
 A211668 002 Apr 25, 2019 Apr NEWA  
 A209132 001 Apr 24, 2019 Oct CAHN  
 A209132 001 Apr 24, 2019 Apr NEWA  
 A212171 001 Nov 04, 2019 Oct NEWA  
 A212171 002 Nov 04, 2019 Oct NEWA

CISATRACTURIUM BESYLATE PRESERVATIVE FREE

@ ACCORD HLTHCARE EQ 2MG BASE/ML  
 @ EQ 10MG BASE/ML  
 AP SOMERSET THERAPS LLC EQ 2MG BASE/ML  
 AP EQ 10MG BASE/ML  
 NIMBEX PRESERVATIVE FREE  
 AP +! ABBVIE EQ 10MG BASE/ML

A205872 001 Jun 16, 2017 Feb DISC  
 A205872 002 Jun 16, 2017 Feb DISC  
 A206791 001 Feb 20, 2019 Feb NEWA  
 A206791 002 Feb 20, 2019 Feb NEWA  
 N020551 002 Dec 15, 1995 Feb CTEC

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

>D> AP MYLAN LABS LTD 1MG/ML  
 >A> @ 1MG/ML

A091062 001 Apr 18, 2012 Oct DISC  
 A091062 001 Apr 18, 2012 Oct DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ HERITAGE PHARMA EQ 10MG BASE  
 @ EQ 10MG BASE  
 AB EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 20MG BASE  
 AB EQ 20MG BASE  
 @ EQ 40MG BASE  
 @ EQ 40MG BASE  
 AB EQ 40MG BASE  
 >D> AB SUN PHARM INDS INC EQ 10MG BASE  
 >A> @ EQ 10MG BASE

A077033 001 Oct 28, 2004 May CAHN  
 A077213 001 Mar 31, 2006 May CAHN  
 A077232 001 Oct 31, 2005 May CAHN  
 A077033 002 Oct 28, 2004 May CAHN  
 A077213 002 Mar 31, 2006 May CAHN  
 A077232 002 Oct 31, 2005 May CAHN  
 A077033 003 Oct 28, 2004 May CAHN  
 A077213 003 Mar 31, 2006 May CAHN  
 A077232 003 Oct 31, 2005 May CAHN  
 A077032 001 Nov 12, 2004 Oct DISC  
 A077032 001 Nov 12, 2004 Oct DISC

## TABLET;ORAL

## CITALOPRAM HYDROBROMIDE

>D>	AB		EQ 20MG BASE	A077032	002	Nov 12, 2004	Oct DISC
>A>		@	EQ 20MG BASE	A077032	002	Nov 12, 2004	Oct DISC
>D>	AB		EQ 40MG BASE	A077032	003	Nov 12, 2004	Oct DISC
>A>		@	EQ 40MG BASE	A077032	003	Nov 12, 2004	Oct DISC

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

## FOR SOLUTION;ORAL

## PREPOPIK

+	@	FERRING PHARMS INC	12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Sep DISC
+	!		12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Jun CMFD
+	@		12GM/PACKET;3.5GM/PACKET;10MG/PACK ET	N202535	001	Jul 16, 2012	Apr DISC

CLADRIBINE

## TABLET;ORAL

## MAVENCLAD

+	!	EMD SERONO INC	10MG	N022561	001	Mar 29, 2019	Mar NEWA
---	---	----------------	------	---------	-----	--------------	----------

CLARITHROMYCIN

## TABLET;ORAL

## CLARITHROMYCIN

		@	AJANTA PHARMA LTD	250MG	A206714	001	Apr 25, 2019	Sep DISC
AB				250MG	A206714	001	Apr 25, 2019	Apr NEWA
		@		500MG	A206714	002	Apr 25, 2019	Sep DISC
AB				500MG	A206714	002	Apr 25, 2019	Apr NEWA
AB		CHARTWELL		250MG	A065384	001	Aug 20, 2007	Aug CAHN
AB				500MG	A065384	002	Aug 20, 2007	Aug CAHN
AB		STRIDES PHARMA		250MG	A202710	001	Jun 10, 2013	Feb CAHN
AB				500MG	A202710	002	Jun 10, 2013	Feb CAHN

## TABLET, EXTENDED RELEASE;ORAL

## CLARITHROMYCIN

AB		NOSTRUM LABS INC	500MG	A203243	001	Feb 29, 2016	Jul CAHN
----	--	------------------	-------	---------	-----	--------------	----------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

## FOR SOLUTION;ORAL

## CLINDAMYCIN PALMITATE HYDROCHLORIDE

	@	MYLAN	EQ 75MG BASE/5ML	A203063	001	May 25, 2016	Mar DISC
--	---	-------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

## GEL;TOPICAL

## CLINDAGEL

BT	+	!	BAUSCH	EQ 1% BASE	N050782	001	Nov 27, 2000	May CAHN
----	---	---	--------	------------	---------	-----	--------------	----------

## SOLUTION;TOPICAL

## CLINDAMYCIN PHOSPHATE

>A>	AT		CADILA	EQ 1% BASE	A208767	001	Jul 16, 2018	Oct CAHN
	AT		ENCUBE ETHICALS	EQ 1% BASE	A209914	001	Jan 28, 2019	Jan NEWA
>D>	AT		ZYDUS PHARMS	EQ 1% BASE	A208767	001	Jul 16, 2018	Oct CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

## GEL;TOPICAL

## VELTIN

BX	+	!	ALMIRALL	1.2%;0.025%	N050803	001	Jul 16, 2010	Feb CAHN
----	---	---	----------	-------------	---------	-----	--------------	----------

CLOBAZAM

## SUSPENSION;ORAL

## CLOBAZAM

		@	TARO	2.5MG/ML	A210978	001	Apr 15, 2019	Sep DISC
AB				2.5MG/ML	A210978	001	Apr 15, 2019	Apr NEWA
AB		VISTAPHARM		2.5MG/ML	A210746	001	Jul 10, 2019	Jun NEWA

## TABLET;ORAL

## CLOBAZAM

AB		ACCORD HLTHCARE	10MG	A212398	001	May 23, 2019	May NEWA
AB			20MG	A212398	002	May 23, 2019	May NEWA
AB		ALKEM LABS LTD	10MG	A212714	001	Sep 06, 2019	Aug NEWA
AB			20MG	A212714	002	Sep 06, 2019	Aug NEWA
>A>	AB	LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Oct NEWA
>A>	AB		20MG	A212092	002	Oct 30, 2019	Oct NEWA
AB		MICRO LABS	10MG	A211711	001	Jan 30, 2019	Jan NEWA

TABLET; ORAL							
CLOBAZAM							
AB		20MG	A211711	002	Jan 30, 2019	Jan	NEWA
	@ TARO	10MG	A209440	001	Oct 22, 2018	Jul	DISC
	@	20MG	A209440	002	Oct 22, 2018	Jul	DISC
<u>CLOBETASOL PROPIONATE</u>							
AEROSOL, FOAM; TOPICAL							
CLOBETASOL PROPIONATE							
AB1	GLENMARK PHARMS LTD	0.05%	A210809	001	Feb 15, 2019	Feb	NEWA
AB2		0.05%	A211450	001	Sep 09, 2019	Aug	NEWA
AB2	PERRIGO UK FINCO	0.05%	A201402	001	Aug 14, 2012	May	CAHN
CREAM; TOPICAL							
CLOBETASOL PROPIONATE							
AB1	RISING	0.05%	A211401	001	Jan 11, 2019	Sep	CAHN
AB1	XIROMED	0.05%	A210034	001	Jun 15, 2018	Aug	CAHN
LOTION; TOPICAL							
CLOBETASOL PROPIONATE							
	@ HI TECH	0.05%	A211348	001	Oct 26, 2018	Jul	DISC
AB	ZYDUS PHARMS	0.05%	A205249	001	Sep 24, 2019	Sep	NEWA
OINTMENT; TOPICAL							
CLOBETASOL PROPIONATE							
AB	ALEOR DERMACEUTICALS	0.05%	A211800	001	Mar 04, 2019	Feb	NEWA
	@ AMNEAL PHARMS LLC	0.05%	A210551	001	Aug 21, 2018	Feb	DISC
AB	TELIGENT PHARMA INC	0.05%	A208589	001	Jan 23, 2019	Jan	NEWA
>A> AB	TORRENT	0.05%	A212926	001	Oct 25, 2019	Oct	NEWA
AB	XIROMED	0.05%	A209701	001	Apr 17, 2018	Aug	CAHN
SOLUTION; TOPICAL							
CLOBETASOL PROPIONATE							
>A> AT	ALEOR DERMACEUTICALS	0.05%	A212881	001	Oct 21, 2019	Oct	NEWA
AT	SAPTALIS PHARMS	0.05%	A211494	001	Oct 02, 2019	Sep	NEWA
SPRAY; TOPICAL							
CLOBETASOL PROPIONATE							
AT	ALEOR DERMACEUTICALS	0.05%	A211191	001	Oct 02, 2019	Sep	NEWA
AT	GLENMARK PHARMS	0.05%	A209004	001	Mar 26, 2018	Aug	CAHN
<u>CLOFARABINE</u>							
SOLUTION; INTRAVENOUS							
CLOFARABINE							
AP	ACCORD HLTHCARE	20MG/20ML (1MG/ML)	A212034	001	Feb 22, 2019	Feb	NEWA
	@ HOSPIRA INC	20MG/20ML (1MG/ML)	A210283	001	Dec 27, 2018	Feb	DISC
<u>CLOMIPRAMINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
CLOMIPRAMINE HYDROCHLORIDE							
>A> AB	JUBILANT CADISTA	25MG	A212218	001	Oct 21, 2019	Oct	NEWA
>A> AB		50MG	A212218	002	Oct 21, 2019	Oct	NEWA
>A> AB		75MG	A212218	003	Oct 21, 2019	Oct	NEWA
>D> AB	MANKIND PHARMA	25MG	A211767	001	Apr 08, 2019	Oct	DISC
>A>	@	25MG	A211767	001	Apr 08, 2019	Oct	DISC
AB		25MG	A211767	001	Apr 08, 2019	Mar	NEWA
>D> AB		50MG	A211767	002	Apr 08, 2019	Oct	DISC
>A>	@	50MG	A211767	002	Apr 08, 2019	Oct	DISC
AB		50MG	A211767	002	Apr 08, 2019	Mar	NEWA
>D> AB		75MG	A211767	003	Apr 08, 2019	Oct	DISC
>A>	@	75MG	A211767	003	Apr 08, 2019	Oct	DISC
AB		75MG	A211767	003	Apr 08, 2019	Mar	NEWA
<u>CLONAZEPAM</u>							
TABLET; ORAL							
CLONAZEPAM							
	@ RUBICON	0.5MG	A075468	001	Oct 06, 2000	Aug	CAHN
	@	1MG	A075468	002	Oct 06, 2000	Aug	CAHN
	@	2MG	A075468	003	Oct 06, 2000	Aug	CAHN
>D> AB	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Oct	DISC
>A>	@	0.5MG	A075423	001	Apr 27, 2001	Oct	DISC
>D> AB		1MG	A075423	002	Apr 27, 2001	Oct	DISC
>A>	@	1MG	A075423	002	Apr 27, 2001	Oct	DISC
>D> AB		2MG	A075423	003	Apr 27, 2001	Oct	DISC
>A>	@	2MG	A075423	003	Apr 27, 2001	Oct	DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
CLONAZEPAM

AB	ALEMBIC PHARMS LTD	0.125MG	A211033	001	Jun 28, 2019	Jun NEWA
AB		0.25MG	A211033	002	Jun 28, 2019	Jun NEWA
AB		0.5MG	A211033	003	Jun 28, 2019	Jun NEWA
AB		1MG	A211033	004	Jun 28, 2019	Jun NEWA
AB		2MG	A211033	005	Jun 28, 2019	Jun NEWA

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION  
CLONIDINE HYDROCHLORIDE

@	LUITPOLD	1MG/10ML (0.1MG/ML)	A091104	001	Oct 08, 2009	Feb DISC
@		5MG/10ML (0.5MG/ML)	A091104	002	Oct 08, 2009	Feb DISC

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

AB	FRONTIDA BIOPHARM	0.1MG	A070923	003	Sep 04, 1987	Apr CMS1
AB		0.2MG	A070923	002	Sep 04, 1987	Apr CMS1
>D> AB	SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Oct DISC
>A>	@	0.1MG	A090329	001	Jul 03, 2014	Oct DISC
>D> AB		0.2MG	A090329	002	Jul 03, 2014	Oct DISC
>A>	@	0.2MG	A090329	002	Jul 03, 2014	Oct DISC
>D> AB		0.3MG	A090329	003	Jul 03, 2014	Oct DISC
>A>	@	0.3MG	A090329	003	Jul 03, 2014	Oct DISC

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

AB1	NOVAST LABS	0.1MG	A209675	001	Mar 05, 2019	Feb NEWA
	@ UPSHER SMITH LABS	0.1MG	A211433	001	Oct 12, 2018	May DISC

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

AB	ANI PHARMS INC	EQ 300MG BASE	A091216	001	May 17, 2012	May CAHN
	@ CADILA	EQ 75MG BASE	A201686	001	Oct 10, 2012	Jun DISC
AB		EQ 75MG BASE	A201686	001	Oct 10, 2012	Apr CAHN
AB	CELLTRION	EQ 75MG BASE	A202266	001	Aug 14, 2012	Aug CAHN
AB		EQ 300MG BASE	A202266	002	Nov 20, 2012	Aug CAHN
	@ MYLAN PHARMS INC	EQ 75MG BASE	A077665	001	May 17, 2012	Sep DISC
	@	EQ 300MG BASE	A077665	002	May 17, 2012	Feb DISC
>D> AB	SUN PHARM INDUSTRIES	EQ 75MG BASE	A078133	001	Jun 10, 2013	Oct DISC
>A>	@	EQ 75MG BASE	A078133	001	Jun 10, 2013	Oct DISC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@	AUROLIFE PHARMA LLC	3.75MG	A072514	002	May 11, 1990	Jan CMS1
@		7.5MG	A072514	003	May 11, 1990	Jan CMS1

CLOTTRIMAZOLE

SOLUTION;TOPICAL

CLOTTRIMAZOLE

AT	NOVITIUM PHARMA	1%	A209815	001	Feb 14, 2019	Feb NEWA
AT	TASMAN PHARMA	1%	A212281	001	Jul 25, 2019	Jul NEWA

CLOZAPINE

TABLET;ORAL

CLOZARIL

AB	+ HERITAGE LIFE	50MG	N019758	003	May 20, 2019	May NEWA
AB	+	200MG	N019758	004	May 20, 2019	May NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

FAZACLO ODT

@	JAZZ	50MG	N021590	003	Jun 03, 2005	Jun CAHN
---	------	------	---------	-----	--------------	----------

COBICISTAT; DARUNAVIR

TABLET;ORAL

PREZCOBIX

+	JANSSEN PRODS	150MG;800MG	N205395	001	Jan 29, 2015	Sep CAIN
---	---------------	-------------	---------	-----	--------------	----------

>D>	<u>COBICISTAT; DARUNAVIR ETHANOLATE; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>									
>D>	TABLET;ORAL									
>D>	SYMTUZA									
>D>	+	JANSSEN PRODS	150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct	CAIN		
>A>	<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>									
>A>	TABLET;ORAL									
>A>	SYMTUZA									
>A>	+	JANSSEN PRODS	150MG;800MG;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct	CAIN		
>A>	+		150MG;EQ 800MG BASE;200MG;EQ 10MG BASE	N210455	001	Jul 17, 2018	Oct	CAIN		
	<u>COLCHICINE</u>									
	CAPSULE;ORAL									
	COLCHICINE									
	@	PAR PHARM INC	0.6MG	A208678	001	Nov 29, 2018	May	DISC		
	MITIGARE									
	+	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	May	CTEC		
	SOLUTION;ORAL									
	GLOPERBA									
	+	AVION PHARMS	0.6MG/5ML	N210942	001	Jan 30, 2019	Jul	CAHN		
	+	ROMEG THERAPS LLC	0.6MG/5ML	N210942	001	Jan 30, 2019	Jan	NEWA		
	TABLET;ORAL									
	COLCHICINE									
AB		ALKEM LABS LTD	0.6MG	A211250	001	Feb 08, 2019	Feb	NEWA		
>D> AB		AMNEAL PHARMS	0.6MG	A204711	001	Sep 28, 2016	Oct	DISC		
>A>	@		0.6MG	A204711	001	Sep 28, 2016	Oct	DISC		
AB			0.6MG	A204711	001	Sep 28, 2016	Jan	NEWA		
AB		DR REDDYS	0.6MG	A209876	001	Sep 06, 2019	Aug	NEWA		
AB		MYLAN	0.6MG	A209470	001	Sep 16, 2019	Sep	NEWA		
AB		WATSON LABS INC	0.6MG	A204461	001	Jul 31, 2019	Jul	NEWA		
	@	ZYDUS PHARMS	0.6MG	A211519	001	Feb 19, 2019	Jul	DISC		
AB			0.6MG	A211519	001	Feb 19, 2019	Feb	NEWA		
	COLCRYS									
AB	+	TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	Jan	CTEC		
	<u>COLESEVELAM HYDROCHLORIDE</u>									
	BAR, CHEWABLE;ORAL									
	WELCHOL									
	+	DAIICHI SANKYO INC	3.75GM	N210895	001	Apr 03, 2019	Apr	NEWA		
	FOR SUSPENSION;ORAL									
	COLESEVELAM HYDROCHLORIDE									
AB		ALKEM LABS LTD	3.75GM/PACKET	A210316	001	May 06, 2019	Apr	NEWA		
		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Mar	CTEC		
	WELCHOL									
	+	@ DAIICHI SANKYO	1.875GM/PACKET	N022362	001	Oct 02, 2009	Mar	DISC		
	TABLET;ORAL									
	COLESEVELAM HYDROCHLORIDE									
AB		BIONPHARMA INC	625MG	A208670	001	Sep 13, 2019	Sep	NEWA		
AB		ZYDUS PHARMS	625MG	A207765	001	Oct 07, 2019	Sep	NEWA		
	<u>CROMOLYN SODIUM</u>									
	SOLUTION;INHALATION									
	CROMOLYN SODIUM									
	@	MYLAN SPECIALITY LP	10MG/ML	A074209	001	Apr 26, 1994	Mar	DISC		
	<u>CROTAMITON</u>									
	CREAM;TOPICAL									
	EURAX									
	+	@ SUN PHARM INDS INC	10%	N006927	001		Aug	DISC		
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>									
	CAPSULE, EXTENDED RELEASE;ORAL									
	AMRIX									
AB	+	TEVA PHARMS INTL	15MG	N021777	001	Feb 01, 2007	Mar	CTEC		
	+		15MG	N021777	001	Feb 01, 2007	Jan	CTEC		
AB	+		30MG	N021777	002	Feb 01, 2007	Mar	CTEC		
	+		30MG	N021777	002	Feb 01, 2007	Jan	CTEC		

CAPSULE, EXTENDED RELEASE;ORAL  
CYCLOBENZAPRINE HYDROCHLORIDE

AB	APOTEX	15MG	A206703	001	Jul 24, 2018	Feb CMFD
AB		30MG	A206703	002	Jul 24, 2018	Feb CMFD
	@ APOTEX INC	15MG	A206703	001	Jul 24, 2018	Jan DISC
	@	30MG	A206703	002	Jul 24, 2018	Jan DISC
AB	TWI PHARMS INC	15MG	A091281	001	Jan 31, 2013	Mar CMFD
AB		30MG	A091281	002	Jan 31, 2013	Mar CMFD

## TABLET;ORAL

## CYCLOBENZAPRINE HYDROCHLORIDE

AB	ANDA REPOSITORY	5MG	A073541	002	Apr 06, 2006	Aug CAHN
AB		10MG	A073541	001	May 23, 1995	Aug CAHN

CYCLOPHOSPHAMIDE

## CAPSULE;ORAL

## CYCLOPHOSPHAMIDE

AB	CIPLA	25MG	A211608	001	Jan 18, 2019	Jan NEWA
AB		50MG	A211608	002	Jan 18, 2019	Jan NEWA
>A> AB	+ HIKMA	25MG	N203856	001	Sep 16, 2013	Oct CAHN
>A> AB	+!	50MG	N203856	002	Sep 16, 2013	Oct CAHN
>D> AB	+ WEST-WARD PHARMS INT	25MG	N203856	001	Sep 16, 2013	Oct CAHN
>D> AB	+!	50MG	N203856	002	Sep 16, 2013	Oct CAHN

CYCLOSERINE

## CAPSULE;ORAL

## SEROMYCIN

!	PURDUE	250MG	A060593	001		Aug CAHN
---	--------	-------	---------	-----	--	----------

CYCLOSPORINE

## CAPSULE;ORAL

## CYCLOSPORINE

AB1	APOTEX	25MG	A210721	001	Jul 10, 2019	Jun NEWA
AB1		50MG	A210721	002	Jul 10, 2019	Jun NEWA
AB1		100MG	A210721	003	Jul 10, 2019	Jun NEWA
AB1	IVAX SUB TEVA PHARMS	50MG	A065110	001	Mar 29, 2005	Jun CTEC

CYPROHEPTADINE HYDROCHLORIDE

## SYRUP;ORAL

## CYPROHEPTADINE HYDROCHLORIDE

AA	ANDA REPOSITORY	2MG/5ML	A204823	001	Dec 27, 2016	Sep CAHN
AA	ELYSIUM	2MG/5ML	A209108	001	Oct 16, 2018	Sep CAHN
AA	PATRIN PHARMA INC	2MG/5ML	A204823	001	Dec 27, 2016	Jul CAHN
AA	QUAGEN	2MG/5ML	A212423	001	May 22, 2019	May NEWA
AA	TORRENT	2MG/5ML	A204823	001	Dec 27, 2016	Jan CAHN

## TABLET;ORAL

## CYPROHEPTADINE HYDROCHLORIDE

AA	BEXIMCO PHARMS USA	4MG	A206676	001	Apr 12, 2019	Apr NEWA
AA	ELYSIUM	4MG	A207555	001	Jan 31, 2017	Sep CAHN
AA	! HERITAGE PHARMA	4MG	A087056	001		Feb CAHN

CYSTEINE HYDROCHLORIDE

## SOLUTION;INTRAVENOUS

## ELCYS

+	!	EXELA PHARMA SCS LLC	500MG/10ML (50MG/ML)	N210660	001	Apr 16, 2019	Apr NEWA
---	---	----------------------	----------------------	---------	-----	--------------	----------

CYTARABINE

## INJECTABLE;INJECTION

## CYTARABINE

@	MYLAN LABS LTD	20MG/ML	A200916	001	Dec 13, 2011	Sep DISC
---	----------------	---------	---------	-----	--------------	----------

DACLATASVIR DIHYDROCHLORIDE

## TABLET;ORAL

## DAKLINZA

+	@	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jun DISC
+	@		EQ 60MG BASE	N206843	002	Jul 24, 2015	Jun DISC
+	@		EQ 90MG BASE	N206843	003	Apr 13, 2016	Feb DISC

DACTINOMYCIN

INJECTABLE; INJECTION  
DACTINOMYCIN

AP	HISUN PHARM HANGZHOU	0.5MG/VIAL	A207232	001	Jul 16, 2019	Jul	NEWA
AP	X-GEN PHARMS INC	0.5MG/VIAL	A203999	001	May 20, 2019	May	NEWA

DALFAMPRIDINE

TABLET, EXTENDED RELEASE; ORAL  
DALFAMPRIDINE

AB	MICRO LABS	10MG	A210158	001	Mar 11, 2019	Feb	NEWA
AB	SUN PHARM	10MG	A208292	001	May 21, 2019	May	NEWA

DANTROLENE SODIUM

INJECTABLE; INJECTION  
DANTROLENE SODIUM

@ MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Mar	DISC
-----------------------	-----------	---------	-----	--------------	-----	------

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
QTERNMET XR

+	ASTRAZENECA AB	2.5MG; 1GM; EQ 2.5MG BASE	N210874	001	May 02, 2019	May	NEWA
+		5MG; 1GM; EQ 2.5MG BASE	N210874	002	May 02, 2019	May	NEWA
+		5MG; 1GM; EQ 5MG BASE	N210874	003	May 02, 2019	May	NEWA
+	!	10MG; 1GM; EQ 5MG BASE	N210874	004	May 02, 2019	May	NEWA

DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL  
QTERN

+	ASTRAZENECA AB	5MG; EQ 5MG BASE	N209091	002	May 02, 2019	May	NEWA
---	----------------	------------------	---------	-----	--------------	-----	------

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
DAPIPRAZOLE HYDROCHLORIDE

>D>	BARADAINA LLC	0.5%	A204902	001	May 30, 2019	Oct	DISC
>A>	@	0.5%	A204902	001	May 30, 2019	Oct	DISC
		0.5%	A204902	001	May 30, 2019	May	NEWA

DAPSONE

TABLET; ORAL  
DAPSONE

AB	SAI LIFE SCIENCES	100MG	A207165	001	May 08, 2019	Apr	NEWA
	@ TARO	25MG	A209430	001	Mar 01, 2019	May	DISC
	@	100MG	A209430	002	Mar 01, 2019	May	DISC
AB	TARO PHARM	25MG	A209430	001	Mar 01, 2019	Feb	NEWA
AB		100MG	A209430	002	Mar 01, 2019	Feb	NEWA

DAPTOMYCIN

>A> POWDER; INTRAVENOUS  
>A> CUBICIN

>A>	@ CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Oct	CDFR
	DAPTOMYCIN						
AP	ACCORD HLTHCARE	500MG/VIAL	A211961	001	Jun 24, 2019	Jun	NEWA
AP	BE PHARMS	500MG/VIAL	A212513	001	Jun 26, 2019	Jun	NEWA
AP	DR REDDYS	500MG/VIAL	A208375	001	May 01, 2019	Apr	NEWA
AP	JIANGSU HENGRUI MED	500MG/VIAL	A212022	001	Aug 22, 2019	Aug	NEWA
AP	XELLIA PHARMS APS	500MG/VIAL	A206005	001	Jun 15, 2016	Mar	CAHN

>D> POWDER; IV (INFUSION)  
>D> CUBICIN

>D>	@ CUBIST PHARMS LLC	250MG/VIAL	N021572	001	Sep 12, 2003	Oct	CDFR
	DAPTOMYCIN						
AP	ACCORD HLTHCARE	350MG/VIAL	A212667	001	Jul 12, 2019	Jul	NFTG
AP	+! SAGENT PHARMS INC	350MG/VIAL	N208385	001	Sep 12, 2017	Jul	CTEC

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL  
DARIFENACIN HYDROBROMIDE

>A> AB	ALAN LABS INC	EQ 7.5MG BASE	A209571	002	Oct 22, 2019	Oct	NEWA
>A> AB		EQ 15MG BASE	A209571	001	Oct 22, 2019	Oct	NEWA

DAROLUTAMIDETABLET; ORAL  
NUBEQA

+! BAYER HEALTHCARE 300MG N212099 001 Jul 30, 2019 Jul NEWA

DARUNAVIRSUSPENSION; ORAL  
PREZISTA

+! JANSSEN PRODS 100MG/ML N202895 001 Dec 16, 2011 Sep CAIN

TABLET; ORAL

&gt;A&gt; DARUNAVIR

&gt;A&gt; AB TEVA PHARMS USA 600MG A202118 001 Nov 21, 2017 Oct CTNA

&gt;D&gt; DARUNAVIR ETHANOLATE

&gt;D&gt; AB TEVA PHARMS USA 600MG A202118 001 Nov 21, 2017 Oct CTNA

AB 600MG A202118 001 Nov 21, 2017 Sep CAIN

PREZISTA

+ JANSSEN PRODS 75MG N021976 004 Dec 18, 2008 Sep CAIN

+ 150MG N021976 005 Dec 18, 2008 Sep CAIN

+ @ 300MG N021976 001 Jun 23, 2006 Sep CAIN

+ @ 400MG N021976 003 Oct 21, 2008 Sep CAIN

AB + 600MG N021976 002 Feb 25, 2008 Sep CAIN

+! 800MG N021976 006 Nov 09, 2012 Sep CAIN

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET, EXTENDED RELEASE; ORAL  
VIEKIRA XR

+ @ ABBVIE INC EQ 200MG BASE; 8.33MG; 50MG; 33.33MG N208624 001 Jul 22, 2016 Apr DISC

DAUNORUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
DAUNORUBICIN HYDROCHLORIDE

AP HISUN PHARM HANGZHOU EQ 5MG BASE/ML A208759 001 Apr 12, 2019 Apr NEWA

&gt;D&gt; AP EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Oct DISC

&gt;A&gt; @ EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Oct DISC

AP EQ 20MG BASE/VIAL A206195 001 Apr 25, 2019 Apr NEWA

DECITABINEINJECTABLE; INTRAVENOUS  
DECITABINE

AP INGENUS PHARMS LLC 50MG/VIAL A210984 001 Sep 16, 2019 Sep NEWA

AP MSN LABS PVT LTD 50MG/VIAL A212265 001 Aug 28, 2019 Aug NEWA

AP WOCKHARDT BIO AG 50MG/VIAL A209056 001 Apr 09, 2019 Mar NEWA

DEFERIPRONETABLET; ORAL  
DEFERIPRONE

AB @ TARO PHARM INDS LTD 500MG A208800 001 Feb 08, 2019 May DISC

AB 500MG A208800 001 Feb 08, 2019 Feb NFTA

FERRIPROX

AB +! APOPHARMA INC 500MG N021825 001 Oct 14, 2011 May CTEC

+! 500MG N021825 001 Oct 14, 2011 Feb CFTG

+ 1GM N021825 002 Jul 25, 2019 Jul NEWA

DELAVIRDINE MESYLATETABLET; ORAL  
RESCRIPTOR

+ @ VIIV HLTHCARE 100MG N020705 001 Apr 04, 1997 Jun DISC

DESIPRAMINE HYDROCHLORIDETABLET; ORAL  
DESIPRAMINE HYDROCHLORIDE

AB NOVAST LABS 10MG A204963 001 Dec 26, 2017 Sep CAHN

AB 25MG A204963 002 Dec 26, 2017 Sep CAHN

AB 50MG A204963 003 Dec 26, 2017 Sep CAHN

AB 75MG A204963 004 Dec 26, 2017 Sep CAHN

AB 100MG A204963 005 Dec 26, 2017 Sep CAHN

AB 150MG A204963 006 Dec 26, 2017 Sep CAHN

DESLORATADINE

TABLET; ORAL

	DESLORATADINE						
	@ MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	May	DISC
AB	PERRIGO	5MG	A078361	001	Dec 22, 2011	Apr	CAHN

DESMOPRESSIN ACETATE

INJECTABLE; INJECTION

	DESMOPRESSIN ACETATE						
AP	TEVA PHARMS USA	0.004MG/ML	A074888	001	Oct 15, 1997	Mar	CMFD
	SOLUTION; NASAL						
	DDAVP						
	+! FERRING PHARMS INC	0.01%	N017922	001		Jul	CTEC
	DESMOPRESSIN ACETATE						
	@ SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Jul	DISC
	SPRAY, METERED; NASAL						
	NOCTIVA						
	+ @ ALYVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Jun	DISC
	+	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Apr	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Jun	DISC
	+!	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Apr	CAHN
	TABLET; ORAL						
	DESMOPRESSIN ACETATE						
AB	ABHAI LLC	0.1MG	A210371	001	Jan 28, 2019	Jan	NEWA
AB		0.2MG	A210371	002	Jan 28, 2019	Jan	NEWA
AB	NOVAST LABS	0.1MG	A208357	001	Jun 06, 2019	May	NEWA
AB		0.2MG	A208357	002	Jun 06, 2019	May	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

	DESOGESTREL AND ETHINYL ESTRADIOL						
	@ ACCORD HLTHCARE	0.15MG; 0.03MG	A207067	001	Sep 13, 2018	Mar	DISC
	ISIBLOOM						
AB	XIROMED	0.15MG; 0.03MG	A202789	001	Aug 12, 2015	Aug	CAHN
	VOLNEA						
AB	XIROMED	0.15MG, N/A; 0.02MG, 0.01MG	A202689	001	Sep 09, 2016	Aug	CAHN

DESONIDEAEROSOL, FOAM; TOPICAL  
VERDESO

	+! ALMIRALL	0.05%	N021978	001	Sep 19, 2006	Feb	CAHN
	OINTMENT; TOPICAL						
	DESONIDE						
>A> AB	ALEOR DERMACEUTICALS	0.05%	A212473	001	Oct 23, 2019	Oct	NEWA
AB	ENCUBE ETHICALS	0.05%	A210998	001	Jan 30, 2019	Jan	NEWA
AB	TELIGENT PHARMA INC	0.05%	A212002	001	Mar 12, 2019	Feb	NEWA

DESOXIMETASONE

CREAM; TOPICAL

	DESOXIMETASONE						
	@ ZYDUS PHARMS	0.25%	A205620	001	Sep 28, 2018	Feb	DISC

DESVENLAFAXINE

TABLET, EXTENDED RELEASE; ORAL

	DESVENLAFAXINE						
	+! ALEMBIC PHARMS LTD	50MG	N204150	001	Mar 04, 2013	May	CTEC
	+!	100MG	N204150	002	Mar 04, 2013	May	CTEC
	KHEDEZLA						
	@ OSMOTICA PHARM CORP	50MG	N204683	001	Jul 10, 2013	May	DISC
	@	100MG	N204683	002	Jul 10, 2013	May	DISC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

	DESVENLAFAXINE SUCCINATE						
AB	INTELLIPHARMACEUTICS	EQ 50MG BASE	A204805	001	May 07, 2019	Apr	NEWA
AB		EQ 100MG BASE	A204805	002	May 07, 2019	Apr	NEWA
AB	MYLAN	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jul	CMFD
	@	EQ 50MG BASE	A204095	001	Jun 29, 2015	May	DISC
	@	EQ 100MG BASE	A204095	002	Jun 29, 2015	May	DISC
	@ YICHANG HUMANWELL	EQ 50MG BASE	A210014	001	Oct 01, 2018	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL  
DESVENLAFAXINE SUCCINATE

@ EQ 100MG BASE A210014 002 Oct 01, 2018 Mar DISC

DEXAMETHASONE

ELIXIR;ORAL  
DEXAMETHASONE

AA ! ANIMA 0.5MG/5ML A084754 001 Sep CAHN

TABLET;ORAL

>A> HEMADY

>A> +! DEXCEL PHARMA 20MG N211379 001 Oct 03, 2019 Oct NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

>D> AP ANDA REPOSITORY EQ 4MG PHOSPHATE/ML A207521 001 Jun 08, 2018 Oct CAHN

AP EQ 4MG PHOSPHATE/ML A207521 001 Jun 08, 2018 Sep CAHN

AP AUROBINDO PHARMA LTD EQ 10MG PHOSPHATE/ML A210967 001 Jun 07, 2019 May NEWA

AP ! FRESSENIUS KABI USA EQ 4MG PHOSPHATE/ML A084916 001 Feb CHRS

@ LUITPOLD EQ 4MG PHOSPHATE/ML A087440 001 Jul 21, 1982 Feb DISC

>A> AP SOMERSET EQ 4MG PHOSPHATE/ML A207521 001 Jun 08, 2018 Oct CAHN

AP SOMERSET THERAPS LLC EQ 10MG PHOSPHATE/ML A211036 001 May 10, 2019 Apr NEWA

SOLUTION/DROPS;OPHTHALMIC, OTIC

DECADRON

>D> @ MERCK EQ 0.1% PHOSPHATE N011984 001 Oct CRLD

>A> + @ EQ 0.1% PHOSPHATE N011984 001 Oct CRLD

DEXAMETHASONE SODIUM PHOSPHATE

! BAUSCH AND LOMB EQ 0.1% PHOSPHATE A040069 001 Jul 26, 1996 May CTEC

@ SANDOZ INC EQ 0.1% PHOSPHATE A088771 001 Jan 16, 1985 May DISC

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

@ CIPLA EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204843 001 Jan 18, 2019 Jul DISC

AP EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204843 001 Jan 18, 2019 Jan NEWA

SOLUTION;INTRAVENOUS

DEXMEDETOMIDINE HYDROCHLORIDE

+ HQ SPCLT PHARMA EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) N206628 003 Jun 22, 2018 Mar CPOT

+ EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) N206628 004 Jun 22, 2018 Mar CPOT

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB ALKEM LABS LTD 2.5MG A212631 001 Jul 19, 2019 Jul NEWA

AB 5MG A212631 002 Jul 19, 2019 Jul NEWA

AB 10MG A212631 003 Jul 19, 2019 Jul NEWA

@ TEVA PHARMS 2.5MG A077107 003 Jan 29, 2007 May DISC

@ 5MG A077107 001 Jan 29, 2007 May DISC

@ 10MG A077107 002 Jan 29, 2007 May DISC

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMPHETAMINE SULFATE

AB ANDA REPOSITORY 5MG A205077 001 Jun 21, 2019 Aug CAHN

AB 10MG A205077 002 Jun 21, 2019 Aug CAHN

AB 15MG A205077 003 Jun 21, 2019 Aug CAHN

@ MYLAN 5MG A206735 001 Jan 27, 2016 Aug DISC

@ 10MG A206735 002 Jan 27, 2016 Aug DISC

@ 15MG A206735 003 Jan 27, 2016 Aug DISC

AB PII 5MG A205077 001 Jun 21, 2019 Jun NEWA

AB 10MG A205077 002 Jun 21, 2019 Jun NEWA

AB 15MG A205077 003 Jun 21, 2019 Jun NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE DM

@ VINTAGE

15MG/5ML; 6.25MG/5ML

A040649 001 Feb 14, 2006 May DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 70% IN PLASTIC CONTAINER

+ @ BAXTER HLTHCARE

70GM/100ML

N017521 006 Mar 26, 1982 Sep DISC

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 224MG/100ML

N018371 003

Jul DISC

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 298MG/100ML

N018371 002

Jul DISC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC

5GM/100ML; 74.5MG/100ML; 225MG/100ML

N018365 002 Jul 05, 1983

Jul DISC

+ @

5GM/100ML; 149MG/100ML; 225MG/100ML

N018365 006 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 74.5MG/100ML; 300MG/100ML

N018876 001 Jan 17, 1986

Jul DISC

@

5GM/100ML; 149MG/100ML; 300MG/100ML

N018876 006 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 224MG/100ML; 225MG/100ML

N018365 008 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 224MG/100ML; 300MG/100ML

N018876 007 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

+ @ ICU MEDICAL INC

5GM/100ML; 298MG/100ML; 225MG/100ML

N018365 009 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 298MG/100ML; 300MG/100ML

N018876 008 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 149MG/100ML; 300MG/100ML

N018876 002 Jan 17, 1986

Jul DISC

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 224MG/100ML; 225MG/100ML

N018365 003 Jul 05, 1983

Jul DISC

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 224MG/100ML; 300MG/100ML

N018876 003 Jan 17, 1986

Jul DISC

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 298MG/100ML; 225MG/100ML

N018365 004 Jul 05, 1983

Jul DISC

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 298MG/100ML; 300MG/100ML

N018876 004 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 74.5MG/100ML; 225MG/100ML

N018365 005 Mar 28, 1988

Jul DISC

@

5GM/100ML; 149MG/100ML; 225MG/100ML

N018365 007 Mar 28, 1988

Jul DISC

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

@ ICU MEDICAL INC

5GM/100ML; 74.5MG/100ML; 300MG/100ML

N018876 005 Mar 28, 1988

Jul DISC

@

5GM/100ML; 149MG/100ML; 300MG/100ML

N018876 009 Mar 28, 1988

Jul DISC

DIAZEPAM

GEL; RECTAL

DIASTAT

+ BAUSCH

2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997

Feb CAHN

+ @

5MG/ML (5MG/ML)

N020648 002 Jul 29, 1997

Feb CAHN

+ @

10MG/2ML (5MG/ML)

N020648 003 Jul 29, 1997

Feb CAHN

+ @

15MG/3ML (5MG/ML)

N020648 004 Jul 29, 1997

Feb CAHN

+ @

20MG/4ML (5MG/ML)

N020648 005 Jul 29, 1997

Feb CAHN

DIASTAT ACUDIAL

+ BAUSCH

10MG/2ML (5MG/ML)

N020648 007 Sep 15, 2005

Feb CAHN

+!

20MG/4ML (5MG/ML)

N020648 006 Sep 15, 2005

Feb CAHN

INJECTABLE; INJECTION

DIAZEPAM

AP BELOTECA INC

10MG/2ML (5MG/ML)

A210363 001 Mar 18, 2019

Mar NEWA

AP ! HOSPIRA

10MG/2ML (5MG/ML)

A072079 001 Dec 20, 1988

Mar CTEC

DICLOFENACCAPSULE; ORAL  
ZORVOLEX

+	EGALET	18MG	N204592	001	Oct 18, 2013	Feb CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Feb CAHN
+	ZYLA	18MG	N204592	001	Oct 18, 2013	Jul CAHN
+	!	35MG	N204592	002	Oct 18, 2013	Jul CAHN

DICLOFENAC EPOLAMINESYSTEM; TOPICAL  
LICART

+	@ IBSA INST BIO	1.3%	N206976	001	Dec 19, 2018	Feb DISC
---	-----------------	------	---------	-----	--------------	----------

DICLOFENAC POTASSIUMTABLET; ORAL  
DICLOFENAC POTASSIUM

AB	AMICI	50MG	A076561	001	Mar 18, 2004	May CAHN
----	-------	------	---------	-----	--------------	----------

DICLOFENAC SODIUMGEL; TOPICAL  
DICLOFENAC SODIUM

AB	MYLAN	1%	A204306	001	May 06, 2019	Apr NEWA
AB	PERRIGO UK FINCO	1%	A211253	001	May 16, 2019	May NEWA

SOLUTION; INTRAVENOUS  
DICLOFENAC SODIUM

@	MYLAN LABS LTD	37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jul DISC
		37.5MG/ML (37.5MG/ML)	A208786	001	Jun 18, 2019	Jun NEWA

SOLUTION; TOPICAL  
DICLOFENAC SODIUM

>D> AT	RICONPHARMA LLC	1.5%	A206715	001	Aug 07, 2017	Oct DISC
>A>	@	1.5%	A206715	001	Aug 07, 2017	Oct DISC

TABLET, EXTENDED RELEASE; ORAL  
DICLOFENAC SODIUM

@	MYLAN	100MG	A076152	001	Dec 13, 2001	Jun DISC
---	-------	-------	---------	-----	--------------	----------

DICLOFENAC SODIUM; MISOPROSTOLTABLET, DELAYED RELEASE; ORAL  
DICLOFENAC SODIUM AND MISOPROSTOL

@	EXELA HOLDINGS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Sep DISC
@		75MG; 0.2MG	A200540	002	Mar 14, 2014	Sep DISC

DICYCLOMINE HYDROCHLORIDEINJECTABLE; INJECTION  
DICYCLOMINE HYDROCHLORIDE

@	APC PHARMS LLC	10MG/ML	A210979	001	Jul 02, 2018	Feb DISC
AP	CUSTOPHARM INC	10MG/ML	A210788	001	Feb 11, 2019	Jan NEWA
@	FOSUN PHARMA	10MG/ML	A210979	001	Jul 02, 2018	Sep CAHN
AP	FRESENIUS KABI USA	10MG/ML	A210257	001	Jan 25, 2019	Jan NEWA
AP	NEXUS PHARMS	10MG/ML	A206468	001	Feb 01, 2019	Jan NEWA
AP	SLATE	10MG/ML	A207076	001	Nov 02, 2018	Feb CAHN

DIETHYLPROPION HYDROCHLORIDETABLET; ORAL  
DIETHYLPROPION HYDROCHLORIDE

AA	! LANNETT CO INC	25MG	A200177	001	Jul 18, 2011	Jul CHRS
----	------------------	------	---------	-----	--------------	----------

TENUATE

+	@ TEVA BRANDED PHARM	25MG	N011722	002		Jul DISC
---	----------------------	------	---------	-----	--	----------

TABLET, EXTENDED RELEASE; ORAL  
DIETHYLPROPION HYDROCHLORIDE

AB	! LANNETT CO INC	75MG	A091680	001	Oct 24, 2011	Jul CHRS
----	------------------	------	---------	-----	--------------	----------

TENUATE DOSPAN

+	@ TEVA BRANDED PHARM	75MG	N012546	001		Jul DISC
---	----------------------	------	---------	-----	--	----------

DIGOXINELIXIR; ORAL  
DIGOXIN

AA	NOVITIUM PHARMA	0.05MG/ML	A213000	001	Oct 04, 2019	Sep NFTG
----	-----------------	-----------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATEINJECTABLE; INJECTION  
D.H.E. 45

AP	+	BAUSCH	1MG/ML	N005929	001		Apr	CAHN
		SPRAY, METERED; NASAL						
		MIGRANAL						
	+	BAUSCH	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Apr	CAHN
	+	VALEANT	0.5MG/SPRAY	N020148	001	Dec 08, 1997	Jan	CPOT

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
CARDIZEM CD

AB3	+	BAUSCH	120MG	N020062	001	Aug 10, 1992	Feb	CAHN
AB3	+		180MG	N020062	002	Dec 27, 1991	Feb	CAHN
AB3	+		240MG	N020062	003	Dec 27, 1991	Feb	CAHN
AB3	+		300MG	N020062	004	Dec 27, 1991	Feb	CAHN
AB3	+		360MG	N020062	005	Aug 24, 1999	Feb	CAHN
		DILTIAZEM HYDROCHLORIDE						
		APOTEX	120MG	A074943	003	Dec 19, 2000	Aug	CTEC
AB2	!		240MG	A074943	001	Aug 06, 1998	May	CHRS
		@ MYLAN	120MG	A075124	002	Mar 18, 1998	Aug	DISC
>D>			180MG	A075124	003	Mar 18, 1998	Oct	DISC
>A>		@	180MG	A075124	003	Mar 18, 1998	Oct	DISC
>D>			240MG	A075124	001	Mar 18, 1998	Oct	DISC
>A>		@	240MG	A075124	001	Mar 18, 1998	Oct	DISC
			240MG	A075124	001	Mar 18, 1998	May	CHRS
AB3		NOVAST LABS	120MG	A208783	001	Jun 14, 2019	Jun	NEWA
AB3			180MG	A208783	002	Jun 14, 2019	Jun	NEWA
AB3			240MG	A208783	003	Jun 14, 2019	Jun	NEWA
AB3			300MG	A208783	004	Jun 14, 2019	Jun	NEWA
AB3			360MG	A208783	005	Jun 14, 2019	Jun	NEWA
		@ PAR PHARM	360MG	A209766	001	May 30, 2018	Mar	DISC
		TIAZAC						
AB4	+	BAUSCH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4	+		180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4	+		240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4	+		300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4	+		360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN
		INJECTABLE; INJECTION						
		DILTIAZEM HYDROCHLORIDE						
		@ DR REDDYS	5MG/ML	A074894	001	Aug 26, 1997	May	CAHN
		TABLET; ORAL						
		CARDIZEM						
AB	+	BAUSCH	30MG	N018602	001	Nov 05, 1982	Mar	CAHN
AB	+		60MG	N018602	002	Nov 05, 1982	Mar	CAHN
AB	+		90MG	N018602	003	Dec 08, 1986	Mar	CAHN
AB	+		120MG	N018602	004	Dec 08, 1986	Mar	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		CARDIZEM LA						
AB	+	BAUSCH	120MG	N021392	001	Feb 06, 2003	Mar	CAHN
AB	+		180MG	N021392	002	Feb 06, 2003	Mar	CAHN
AB	+		240MG	N021392	003	Feb 06, 2003	Mar	CAHN
AB	+		300MG	N021392	004	Feb 06, 2003	Mar	CAHN
AB	+		360MG	N021392	005	Feb 06, 2003	Mar	CAHN
AB	+		420MG	N021392	006	Feb 06, 2003	Mar	CAHN

DIMETHYL SULFOXIDESOLUTION; INTRAVESICAL  
DIMETHYL SULFOXIDE

@ MYLAN INSTITUTIONAL	50%	A076185	001	Nov 29, 2002	Mar	DISC	
RIMSO-50							
+	!	MYLAN INSTITUTIONAL	50%	N017788	001	Mar	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE

>D>		CAPSULE; ORAL						
>D>		DIPHENHYDRAMINE HYDROCHLORIDE						
>D>	!	HERITAGE PHARMA	50MG	A080738	001		Oct	DISC
>A>		@	50MG	A080738	001		Oct	DISC
	!		50MG	A080738	001		May	CAHN

## INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

@ DR REDDYS

10MG/ML

A080873 001

May CAHN

@

50MG/ML

A080873 002

May CAHN

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ DR REDDYS

50MG/ML

A080873 003

May CAHN

DIPYRIDAMOLE

## INJECTABLE; INJECTION

DIPYRIDAMOLE

@ DR REDDYS

5MG/ML

A074952 001 Nov 26, 1997 May CAHN

>A> DIROXIMEL FUMARATE

&gt;A&gt; CAPSULE, DELAYED RELEASE; ORAL

&gt;A&gt; VUMERITY

&gt;A&gt; +! BIOGEN 231MG

N211855 001 Oct 29, 2019 Oct NEWA

DISULFIRAM

## TABLET; ORAL

DISULFIRAM

&gt;D&gt; AB MYLAN 250MG

A203916 001 Mar 04, 2015 Oct DISC

&gt;A&gt; @ 250MG

A203916 001 Mar 04, 2015 Oct DISC

&gt;D&gt; AB 500MG

A203916 002 Mar 04, 2015 Oct DISC

&gt;A&gt; @ 500MG

A203916 002 Mar 04, 2015 Oct DISC

DIVALPROEX SODIUM

## TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

AB CELLTRION EQ 125MG VALPROIC ACID

A077296 001 Jul 31, 2008 Aug CAHN

AB EQ 250MG VALPROIC ACID

A077296 002 Jul 31, 2008 Aug CAHN

AB EQ 500MG VALPROIC ACID

A077296 003 Jul 31, 2008 Aug CAHN

@ TEVA EQ 125MG VALPROIC ACID

A076941 001 Jul 29, 2008 Sep DISC

@ EQ 250MG VALPROIC ACID

A076941 002 Jul 29, 2008 Sep DISC

@ EQ 500MG VALPROIC ACID

A076941 003 Jul 29, 2008 Sep DISC

## TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

@ ANCHEN PHARMS EQ 250MG VALPROIC ACID

A078445 001 Feb 26, 2009 Sep DISC

@ EQ 500MG VALPROIC ACID

A078445 002 Aug 04, 2009 Sep DISC

&gt;A&gt; AB LUPIN LTD EQ 250MG VALPROIC ACID

A209286 001 Oct 18, 2019 Oct NEWA

&gt;A&gt; AB EQ 500MG VALPROIC ACID

A209286 002 Oct 18, 2019 Oct NEWA

DOCETAXEL

## INJECTABLE; INJECTION

DOCETAXEL

AP ACTAVIS LLC 160MG/8ML (20MG/ML)

N203551 004 Sep 21, 2015 Jun NEWA

@ CIPLA 20MG/2ML (10MG/ML)

A209634 001 Aug 24, 2018 Mar DISC

@ 80MG/8ML (10MG/ML)

A209634 002 Aug 24, 2018 Mar DISC

@ 160MG/16ML (10MG/ML)

A209634 003 Aug 24, 2018 Mar DISC

AP MYLAN LABS LTD 160MG/8ML (20MG/ML)

A208137 001 Apr 01, 2019 Mar NEWA

&gt;D&gt; AP SHILPA MEDICARE LTD 20MG/ML (20MG/ML)

A210327 001 May 16, 2019 Oct DISC

&gt;A&gt; @ 20MG/ML (20MG/ML)

A210327 001 May 16, 2019 Oct DISC

AP 20MG/ML (20MG/ML)

A210327 001 May 16, 2019 May NEWA

&gt;D&gt; AP 80MG/4ML (20MG/ML)

A210327 002 May 16, 2019 Oct DISC

&gt;A&gt; @ 80MG/4ML (20MG/ML)

A210327 002 May 16, 2019 Oct DISC

AP 80MG/4ML (20MG/ML)

A210327 002 May 16, 2019 May NEWA

&gt;D&gt; AP 160MG/8ML (20MG/ML)

A210327 003 May 16, 2019 Oct DISC

&gt;A&gt; @ 160MG/8ML (20MG/ML)

A210327 003 May 16, 2019 Oct DISC

AP 160MG/8ML (20MG/ML)

A210327 003 May 16, 2019 May NEWA

AP TEIKOKU PHARMA 20MG/ML (20MG/ML)

N205934 001 Dec 22, 2015 Mar CAHN

AP 80MG/4ML (20MG/ML)

N205934 002 Dec 22, 2015 Mar CAHN

AP 160MG/8ML (20MG/ML)

N205934 003 Dec 22, 2015 Mar CAHN

## SOLUTION; INTRAVENOUS

DOCETAXEL

AP SUN PHARMA GLOBAL 20MG/ML (20MG/ML)

N022534 003 Jan 08, 2019 Jan NEWA

AP 80MG/4ML (20MG/ML)

N022534 004 Jan 08, 2019 Jan NEWA

AP 160MG/8ML (20MG/ML)

N022534 005 Jan 08, 2019 Jan NEWA

DOFETILIDECAPSULE;ORAL  
DOFETILDE

AB	AUROBINDO PHARMA LTD	0.125MG	A210740	001	Jan 22, 2019	Jan NEWA
AB		0.25MG	A210740	002	Jan 22, 2019	Jan NEWA
AB		0.5MG	A210740	003	Jan 22, 2019	Jan NEWA

DOLUTEGRAVIR SODIUM; LAMIVUDINETABLET;ORAL  
DOVATO

+	VIIV HLTHCARE	EQ 50MG BASE;300MG	N211994	001	Apr 08, 2019	Apr NEWA
---	---------------	--------------------	---------	-----	--------------	----------

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

DONEPEZIL HYDROCHLORIDE

AB	CADILA	5MG	A090100	001	Oct 24, 2012	Mar CAHN
AB		10MG	A090100	002	Oct 24, 2012	Mar CAHN
AB	HERITAGE PHARMA	5MG	A077344	001	May 31, 2011	May CAHN
AB		10MG	A077344	002	May 31, 2011	May CAHN
	@ OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Mar DISC
AB	STRIDES PHARMA	5MG	A090551	001	May 31, 2011	Apr CAHN
AB		10MG	A090551	002	May 31, 2011	Apr CAHN
	@ SUN PHARM	23MG	A204293	001	Jun 05, 2015	Jul DISC
	@ WOCKHARDT	5MG	A091267	001	May 31, 2011	Jul DISC
	@	10MG	A091267	002	May 31, 2011	Jul DISC
	TABLET, ORALLY DISINTEGRATING;ORAL					
	DONEPEZIL HYDROCHLORIDE					
	@ HERITAGE PHARMA	5MG	A078388	002	Nov 26, 2010	May CAHN
	@	10MG	A078388	001	Nov 26, 2010	May CAHN

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE	A212639	001	Aug 09, 2019	Jul NEWA
AT	FDC LTD	EQ 2% BASE	A205294	001	Jan 24, 2019	Jan NEWA
	@ LUITPOLD	EQ 2% BASE	A079186	001	Nov 18, 2009	Mar DISC
>A> AT	MICRO LABS	EQ 2% BASE	A204778	001	Nov 08, 2019	Oct NEWA
	@ RUBICON	EQ 2% BASE	A078395	001	Oct 28, 2008	Aug CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>D> AT	ANDA REPOSITORY	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Oct CAHN
AT		EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Sep CAHN
AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Jun NEWA
	@ RUBICON	EQ 2% BASE;EQ 0.5% BASE	A078201	001	Oct 28, 2008	Jul CAHN
>A> AT	SOMERSET	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Oct CAHN
AT	SOMERSET THERAPS LLC	EQ 2% BASE;EQ 0.5% BASE	A207523	001	Jun 25, 2019	Jun NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+	HIKMA	20MG/ML	N014879	001	Mar CAHN
----	---	-------	---------	---------	-----	----------

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 10MG BASE	A212624	001	Sep 13, 2019	Sep NEWA
AB		EQ 25MG BASE	A212624	002	Sep 13, 2019	Sep NEWA
AB		EQ 50MG BASE	A212624	003	Sep 13, 2019	Sep NEWA
AB		EQ 75MG BASE	A212624	004	Sep 13, 2019	Sep NEWA
AB		EQ 100MG BASE	A212624	005	Sep 13, 2019	Sep NEWA
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A211603	001	Mar 27, 2019	Mar NEWA
AB		EQ 25MG BASE	A211603	002	Mar 27, 2019	Mar NEWA
AB		EQ 50MG BASE	A211603	003	Mar 27, 2019	Mar NEWA
AB		EQ 75MG BASE	A211603	004	Mar 27, 2019	Mar NEWA
AB		EQ 100MG BASE	A211603	005	Mar 27, 2019	Mar NEWA
AB	PAR PHARM	EQ 10MG BASE	A071422	002	Nov 09, 1987	Aug CMS1
AB		EQ 25MG BASE	A071422	003	Nov 09, 1987	Aug CMS1
AB		EQ 50MG BASE	A071422	004	Nov 09, 1987	Aug CMS1
AB		EQ 75MG BASE	A071422	005	Nov 09, 1987	Aug CMS1

CAPSULE;ORAL  
DOXEPIN HYDROCHLORIDE

AB		EQ 150MG BASE	A071422	006	Nov 09, 1987	Aug CMS1
	TABLET;ORAL					
	SILENOR					
	+ CURRAX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Apr CAHN
	+!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Apr CAHN
	+ PERNIX	EQ 3MG BASE	N022036	001	Mar 17, 2010	Feb CAHN
	+!	EQ 6MG BASE	N022036	002	Mar 17, 2010	Feb CAHN

DOXERCALCIFEROLINJECTABLE;INJECTION  
DOXERCALCIFEROL

AP	GLAND PHARMA LTD	4MCG/2ML (2MCG/ML)	A210452	001	Sep 26, 2019	Sep NEWA
	+ @ HOSPIRA INC	10MCG/5ML (2MCG/ML)	N208614	002	Jul 24, 2018	Jun DISC

DOXORUBICIN HYDROCHLORIDEINJECTABLE;INJECTION  
DOXORUBICIN HYDROCHLORIDE

>D>	AP	HISUN PHARM HANGZHOU	20MG/VIAL	A206062	001	May 13, 2019	Oct DISC
>A>		@	20MG/VIAL	A206062	001	May 13, 2019	Oct DISC
	AP		20MG/VIAL	A206062	001	May 13, 2019	Apr NEWA
		@ HLTHCARE	2MG/ML	A200146	001	Jul 18, 2012	Sep CAHN
		@ MYLAN LABS LTD	2MG/ML	A200901	001	Feb 14, 2012	Sep DISC
		INJECTABLE, LIPOSOMAL;INJECTION					
		DOXIL (LIPOSOMAL)					
AB	+	BAXTER HLTHCARE CORP	20MG/10ML (2MG/ML)	N050718	001	Nov 17, 1995	Aug CAHN
AB	+		50MG/25ML (2MG/ML)	N050718	002	Jun 13, 2000	Aug CAHN

DOXYCYCLINECAPSULE;ORAL  
DOXYCYCLINE

>D>	AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065053	002	Nov 22, 2000	Oct CHRS
>A>	AB	!	EQ 100MG BASE	A065053	002	Nov 22, 2000	Oct CHRS
>D>		MONODOX					
>D>	AB	+ ALMIRALL	EQ 50MG BASE	N050641	002	Feb 10, 1992	Oct DISC
>A>		+ @	EQ 50MG BASE	N050641	002	Feb 10, 1992	Oct DISC
	AB	+	EQ 50MG BASE	N050641	002	Feb 10, 1992	Feb CAHN
>D>	AB	+	EQ 75MG BASE	N050641	003	Oct 18, 2006	Oct DISC
>A>		+ @	EQ 75MG BASE	N050641	003	Oct 18, 2006	Oct DISC
	AB	+	EQ 75MG BASE	N050641	003	Oct 18, 2006	Feb CAHN
>D>	AB	+!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Oct DISC
>A>		+ @	EQ 100MG BASE	N050641	001	Dec 29, 1989	Oct DISC
	AB	+!	EQ 100MG BASE	N050641	001	Dec 29, 1989	Feb CAHN
		TABLET;ORAL					
		DOXYCYCLINE					
		@ MYLAN	EQ 50MG BASE	A065377	001	Nov 07, 2006	Apr DISC
		@	EQ 75MG BASE	A065377	002	Nov 07, 2006	Apr DISC
		@	EQ 100MG BASE	A065377	003	Nov 07, 2006	May DISC
		@	EQ 150MG BASE	A065427	001	Jun 07, 2007	May DISC

DOXYCYCLINE HYCLATECAPSULE;ORAL  
ACTICLATE CAP

	+	@ ALMIRALL	EQ 75MG BASE	N208253	001	Apr 26, 2016	Feb CAHN
		DOXYCYCLINE HYCLATE					
		@ AJANTA PHARMA LTD	EQ 50MG BASE	A211012	001	Sep 24, 2018	Mar DISC
		@	EQ 100MG BASE	A211012	002	Sep 24, 2018	Mar DISC
AB		CHANGZHOU PHARM	EQ 100MG BASE	A209402	001	Oct 07, 2019	Sep NEWA
		@ MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Apr DISC
		@	EQ 100MG BASE	A062337	002	Mar 29, 1982	Apr DISC
		TABLET;ORAL					
		ACTICLATE					
AB	+	ALMIRALL	EQ 75MG BASE	N205931	001	Jul 25, 2014	Feb CAHN
AB	+	!	EQ 150MG BASE	N205931	002	Jul 25, 2014	Feb CAHN
		DOXYCYCLINE HYCLATE					
AB		APOTEX	EQ 75MG BASE	A209243	001	Apr 15, 2019	Apr NEWA
AB			EQ 150MG BASE	A209243	002	Apr 15, 2019	Apr NEWA
AB		CADILA	EQ 100MG BASE	A207773	001	Oct 30, 2017	Feb CAHN
AB		CHANGZHOU PHARM	EQ 100MG BASE	A211343	001	Oct 09, 2019	Sep NEWA
AB		EPIC PHARMA LLC	EQ 20MG BASE	A065182	001	May 13, 2005	Aug CMFD
AB		HERITAGE PHARMA	EQ 20MG BASE	A065163	001	May 13, 2005	May CAHN

TABLET, DELAYED RELEASE;ORAL  
DOXYCYCLINE HYCLATE

@ MYLAN	EQ 75MG BASE	A090431	001	Dec 28, 2010	Jul DISC
@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Jul DISC
@	EQ 200MG BASE	A090431	005	May 19, 2016	Jul DISC
@ MYLAN PHARMS INC	EQ 150MG BASE	A091052	001	Feb 08, 2012	Sep DISC
@ ZYDUS PHARMS	EQ 75MG BASE	A206772	001	Dec 21, 2018	May DISC
@	EQ 100MG BASE	A206772	002	Dec 21, 2018	May DISC
@	EQ 150MG BASE	A206772	003	Dec 21, 2018	May DISC

DROSPIRENONE

TABLET;ORAL  
SLYND

+! EXELTIS USA INC	4MG	N211367	001	May 23, 2019	May NEWA
--------------------	-----	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

	DROSPIRENONE AND ETHINYL ESTRADIOL						
AB	ANDA REPOSITORY	3MG;0.02MG	A203291	001	Jul 18, 2017	Aug	CAHN
AB	HETERO LABS LTD	3MG;0.02MG	A211944	001	Mar 22, 2019	Mar	NEWA
	KYRA						
AB	SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Jul	NEWA
	LORYNA						
AB	XIROMED	3MG;0.02MG	A079221	001	Mar 28, 2011	Aug	CAHN
	TABLET;ORAL-28						
	KEMEYA						
AB	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Feb	NEWA
	SYEDA						
AB	XIROMED	3MG;0.03MG	A090114	001	Mar 28, 2011	Aug	CAHN

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

AB	AJANTA PHARMA LTD	EQ 40MG BASE	A208706	004	Mar 11, 2019	Feb NEWA
AB	INVENTIA	EQ 20MG BASE	A202336	001	Oct 28, 2015	Aug CAHN
AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Aug CAHN
AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Aug CAHN
AB	QINGDAO BAHEAL PHARM	EQ 20MG BASE	A210599	001	Apr 17, 2019	Apr NEWA
AB		EQ 30MG BASE	A210599	002	Apr 17, 2019	Apr NEWA
AB		EQ 60MG BASE	A210599	003	Apr 17, 2019	Apr NEWA
	@ TEVA PHARMS USA	EQ 20MG BASE	A090783	001	Dec 11, 2013	Aug DISC
	@	EQ 30MG BASE	A090783	002	Dec 11, 2013	Aug DISC
	@	EQ 60MG BASE	A090783	003	Dec 11, 2013	Aug DISC
AB	YAOPHARMA CO LTD	EQ 20MG BASE	A207219	001	Aug 16, 2019	Aug NEWA
AB		EQ 30MG BASE	A207219	002	Aug 16, 2019	Aug NEWA
AB		EQ 60MG BASE	A207219	003	Aug 16, 2019	Aug NEWA
	CAPSULE, DELAYED RELEASE;ORAL					
	DRIZALMA SPRINKLE					
+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Jul NEWA
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Jul NEWA
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Jul NEWA
+		EQ 60MG BASE	N212516	004	Jul 19, 2019	Jul NEWA

DUTASTERIDE

CAPSULE;ORAL  
DUTASTERIDE

	@ BRECKENRIDGE	0.5MG	A204705	001	Nov 20, 2015	Jun DISC
	@	0.5MG	A208227	001	Jun 22, 2018	Jun DISC
AB	CADILA	0.5MG	A204373	001	Oct 04, 2017	Feb CAHN

ECONAZOLE NITRATE

CREAM;TOPICAL  
ECONAZOLE NITRATE

	@ CASI PHARMS INC	1%	A076075	001	Nov 26, 2002	Jun DISC
AB	! PERRIGO ISRAEL	1%	A076479	001	Jun 23, 2004	May CAHN

EFAVIRENZ

TABLET;ORAL  
EFAVIRENZ

@ AUROBINDO PHARMA LTD	600MG	A077673	001	Sep 21, 2018	Feb DISC
------------------------	-------	---------	-----	--------------	----------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

AB	CIPLA	600MG;200MG;300MG	A206894	001	Jun 03, 2019	May NEWA
	@ TEVA PHARMS USA	600MG;200MG;300MG	A091215	001	Nov 09, 2018	May DISC

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

	@ MACLEODS PHARMS LTD	400MG;300MG;300MG	N210649	001	Mar 15, 2019	Jun DISC
		400MG;300MG;300MG	N210649	001	Mar 15, 2019	Mar NEWA

EFINACONAZOLE

SOLUTION; TOPICAL

JUBLIA

	+! BAUSCH	10%	N203567	001	Jun 06, 2014	Feb CAHN
--	-----------	-----	---------	-----	--------------	----------

>A> ELEXACAFITOR, IVACAFITOR, TEZACAFITOR; IVACAFITOR

&gt;A&gt; TABLET, TABLET; ORAL

&gt;A&gt; TRIKAFTA (COPACKAGED)

>A>	+! VERTEX PHARMS INC	100MG,75MG,50MG;N/A,150MG,N/A	N212273	001	Oct 21, 2019	Oct NEWA
-----	----------------------	-------------------------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

TABLET; ORAL

PROMACTA

	+ @ NOVARTIS	EQ 100MG ACID	N022291	005	Nov 16, 2012	Feb DISC
--	--------------	---------------	---------	-----	--------------	----------

EMEDASTINE DIFUMARATE

SOLUTION/DROPS; OPHTHALMIC

EMADINE

	+ @ NOVARTIS	0.05%	N020706	001	Dec 29, 1997	Jul DISC
--	--------------	-------	---------	-----	--------------	----------

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

	@ AMNEAL PHARMS CO	100MG;150MG	A209721	001	Aug 22, 2018	Feb DISC
	@	133MG;200MG	A209721	002	Aug 22, 2018	Feb DISC
	@	167MG;250MG	A209721	003	Aug 22, 2018	Feb DISC
	@	200MG;300MG	A209721	004	Aug 22, 2018	Feb DISC
	@ LAURUS LABS LTD	200MG;300MG	A212114	001	Jul 26, 2019	Aug DISC
AB		200MG;300MG	A212114	001	Jul 26, 2019	Jul NEWA
	TRUVADA					
	+ GILEAD	100MG;150MG	N021752	002	Mar 10, 2016	Feb CTEC
	+	133MG;200MG	N021752	003	Mar 10, 2016	Feb CTEC
	+	167MG;250MG	N021752	004	Mar 10, 2016	Feb CTEC

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

	+ @ SILVERGATE PHARMS	1MG/ML	N204308	001	Aug 13, 2013	Mar DISC
--	-----------------------	--------	---------	-----	--------------	----------

TABLET; ORAL

ENALAPRIL MALEATE

>D> AB	APOTEX	2.5MG	A075178	002	Mar 23, 2001	Oct CAHN
>D> AB		5MG	A075178	001	Mar 23, 2001	Oct CAHN
>D> AB		10MG	A075178	003	Mar 23, 2001	Oct CAHN
>D> AB		20MG	A075178	004	Mar 23, 2001	Oct CAHN
	@ BEXIMCO PHARMS USA	2.5MG	A075621	001	Aug 22, 2000	Feb CAHN
	@	5MG	A075621	002	Aug 22, 2000	Feb CAHN
	@	10MG	A075621	003	Aug 22, 2000	Feb CAHN
	@	20MG	A075621	004	Aug 22, 2000	Feb CAHN
AB	HERITAGE PHARMA	2.5MG	A075479	001	Aug 22, 2000	Feb CAHN
AB		5MG	A075479	002	Aug 22, 2000	Feb CAHN
AB		10MG	A075479	003	Aug 22, 2000	Feb CAHN
AB		20MG	A075479	004	Aug 22, 2000	Feb CAHN
	@ MYLAN	5MG	A075480	002	Aug 22, 2000	Jun DISC
	@	10MG	A075480	003	Aug 22, 2000	Feb DISC
>A> AB	NOSTRUM LABS INC	2.5MG	A075178	002	Mar 23, 2001	Oct CAHN
>A> AB		5MG	A075178	001	Mar 23, 2001	Oct CAHN
>A> AB		10MG	A075178	003	Mar 23, 2001	Oct CAHN
>A> AB		20MG	A075178	004	Mar 23, 2001	Oct CAHN

TABLET;ORAL  
VASOTEC

AB	+	BAUSCH	2.5MG	N018998	005	Jul 26, 1988	Mar CAHN
AB	+		5MG	N018998	001	Dec 24, 1985	Mar CAHN
AB	+		10MG	N018998	002	Dec 24, 1985	Mar CAHN
AB	+	!	20MG	N018998	003	Dec 24, 1985	Mar CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

>D>	AB	APOTEX INC	5MG;12.5MG	A076486	001	Oct 27, 2004	Oct CAHN
>D>	AB		10MG;25MG	A076486	002	Oct 27, 2004	Oct CAHN
>A>	AB	NOSTRUM LABS INC	5MG;12.5MG	A076486	001	Oct 27, 2004	Oct CAHN
>A>	AB		10MG;25MG	A076486	002	Oct 27, 2004	Oct CAHN

VASERETIC

AB	+	BAUSCH	5MG;12.5MG	N019221	003	Jul 12, 1995	Mar CAHN
AB	+	!	10MG;25MG	N019221	001	Oct 31, 1986	Mar CAHN

ENALAPRILAT

INJECTABLE;INJECTION

ENALAPRILAT

AP		DR REDDYS	1.25MG/ML	A075578	001	Aug 22, 2000	May CAHN
----	--	-----------	-----------	---------	-----	--------------	----------

ENCORAFENIB

CAPSULE;ORAL

BRAFTOVI

	+	@	ARRAY BIOPHARMA INC	50MG	N210496	001	Jun 27, 2018	Jul DISC
--	---	---	---------------------	------	---------	-----	--------------	----------

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

ENOXAPARIN SODIUM

AB		AMPHASTAR PHARMS INC	300MG/3ML (100MG/ML)	A208600	001	Mar 14, 2019	Mar NEWA
----	--	----------------------	----------------------	---------	-----	--------------	----------

ENTECAVIR

TABLET;ORAL

ENTECAVIR

AB		BRIGHTGENE	0.5MG	A212126	001	Sep 25, 2019	Sep NEWA
AB			1MG	A212126	002	Sep 25, 2019	Sep NEWA
AB		MYLAN	0.5MG	A206226	001	Mar 26, 2019	Mar NEWA
AB			1MG	A206226	002	Mar 26, 2019	Mar NEWA
>A>	AB	YAOPHARMA CO LTD	0.5MG	A212201	001	Nov 04, 2019	Oct NEWA
>A>	AB		1MG	A212201	002	Nov 04, 2019	Oct NEWA

ENTRECTINIB

CAPSULE;ORAL

ROZLYTREK

	+		GENENTECH INC	100MG	N212725	001	Aug 15, 2019	Aug NEWA
	+	!		200MG	N212725	002	Aug 15, 2019	Aug NEWA

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS

EPHEDRINE SULFATE

>A>	AP	AMNEAL PHARMS CO	50MG/ML (50MG/ML)	A212932	001	Oct 23, 2019	Oct NEWA
-----	----	------------------	-------------------	---------	-----	--------------	----------

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

EPINASTINE HYDROCHLORIDE

	@	CASI PHARMS INC	0.05%	A203384	001	Dec 07, 2016	Jun DISC
	@	SUN PHARM INDS	0.05%	A091626	001	Oct 31, 2011	Jul DISC

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

EPINEPHRINE (AUTOINJECTOR)

AB		TEVA PHARMS USA	0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Jul CMFD
	@		0.15MG/DELIVERY	A090589	002	Aug 16, 2018	Mar DISC

EPIPEN JR.

AB	+	MYLAN SPECIALITY LP	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Jul CTEC
	+	!	0.15MG/DELIVERY	N019430	002	Dec 22, 1987	Mar CTEC

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ADRENALIN

	+	!	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Aug CTEC
AP	+	!		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jan CDFR

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
ADRENALIN

+	!		EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jan CDFR
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS EPINEPHRINE							
	@	AM REGENT	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A207568	001	Jul 06, 2018	Aug DISC
SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS EPINEPHRINE							
+	!	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	May CDFR

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION  
EPIRUBICIN HYDROCHLORIDE

	@	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Sep DISC
		FRESENIUS KABI USA	10MG/5ML (2MG/ML)	A065408	001	Oct 15, 2007	Sep CTEC
			150MG/75ML (2MG/ML)	A065408	003	Oct 15, 2007	Mar CTEC
>D>	AP		200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007	Oct DISC
>A>		@	200MG/100ML (2MG/ML)	A065411	001	Aug 20, 2007	Oct DISC
>D>	AP		50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007	Oct DISC
>A>		@	50MG/25ML (2MG/ML)	A065411	002	Aug 20, 2007	Oct DISC
		@ MYLAN LABS LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Sep DISC
		@	200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Sep DISC
		@ ZENNOVA	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Sep CAHN
		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Sep CAHN

EPTIFIBATIDE

INJECTABLE;INJECTION  
EPTIFIBATIDE

AP		BAXTER HLTHCARE CORP	2MG/ML	A208554	001	Nov 23, 2018	Jan CAHN
AP			75MG/100ML	A208554	002	Nov 23, 2018	Jan CAHN
AP		HAINAN POLY PHARM	2MG/ML	A209864	001	Jan 25, 2019	Jan NEWA
AP			75MG/100ML	A209864	002	Jan 25, 2019	Jan NEWA
>D>	AP	USV	2MG/ML	A204361	001	Mar 14, 2019	Oct DISC
>A>		@	2MG/ML	A204361	001	Mar 14, 2019	Oct DISC
	AP		2MG/ML	A204361	001	Mar 14, 2019	Mar NEWA
>D>	AP		2MG/ML	A204362	001	Mar 11, 2019	Oct DISC
>A>		@	2MG/ML	A204362	001	Mar 11, 2019	Oct DISC
	AP		2MG/ML	A204362	001	Mar 11, 2019	Feb NEWA
>D>	AP		75MG/100ML	A204361	002	Mar 14, 2019	Oct DISC
>A>		@	75MG/100ML	A204361	002	Mar 14, 2019	Oct DISC
	AP		75MG/100ML	A204361	002	Mar 14, 2019	Mar NEWA

ERDAFITINIB

TABLET;ORAL  
BALVERSA

+		JANSSEN BIOTECH	3MG	N212018	001	Apr 12, 2019	Apr NEWA
+			4MG	N212018	002	Apr 12, 2019	Apr NEWA
+	!		5MG	N212018	003	Apr 12, 2019	Apr NEWA

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL  
ERLOTINIB HYDROCHLORIDE

>A>	AB	APOTEX	EQ 25MG BASE	A208396	001	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 100MG BASE	A208396	002	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 150MG BASE	A208396	003	Nov 05, 2019	Oct NEWA
	AB	MYLAN	EQ 25MG BASE	A091002	001	Jun 11, 2014	Feb CMFD
	AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	Feb CMFD
	AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	Feb CMFD
>A>	AB	NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 100MG BASE	A208488	002	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 150MG BASE	A208488	003	Nov 05, 2019	Oct NEWA
>A>	AB	SHILPA MEDICARE LTD	EQ 25MG BASE	A211960	001	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 100MG BASE	A211960	002	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 150MG BASE	A211960	003	Nov 05, 2019	Oct NEWA
>A>	AB	SUN PHARM	EQ 25MG BASE	A210300	001	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 100MG BASE	A210300	002	Nov 05, 2019	Oct NEWA
>A>	AB		EQ 150MG BASE	A210300	003	Nov 05, 2019	Oct NEWA
	AB	TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Mar CMFD
	AB		EQ 150MG BASE	A091059	003	Aug 28, 2015	Mar CMFD
TARCEVA							
AB	+	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	Mar CAHN
AB	+		EQ 25MG BASE	N021743	001	Nov 18, 2004	Feb CTEC
AB	+		EQ 100MG BASE	N021743	002	Nov 18, 2004	Mar CAHN

TABLET;ORAL  
TARCEVA

AB	+	EQ 100MG BASE	N021743	002	Nov 18, 2004	Feb CTEC
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Mar CAHN
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	Feb CTEC

ERTAPENEM SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS  
ERTAPENEM SODIUM

AP		SAVIOR LIFETEC CORP EQ 1GM BASE/VIAL	A207647	001	Mar 19, 2019	Mar NEWA
----	--	--------------------------------------	---------	-----	--------------	----------

ERYTHROMYCIN

OINTMENT;TOPICAL  
AKNE-MYCIN

+	@ BAUSCH	2%	N050584	001	Jan 10, 1985	Apr CAHN
---	----------	----	---------	-----	--------------	----------

SOLUTION;TOPICAL  
ERYTHRA-DERM

@	MLV	2%	A062687	001	Feb 05, 1988	Aug CAHN
@	SAPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Feb CAHN

TABLET, DELAYED RELEASE;ORAL  
ERY-TAB

AB		ARBOR PHARMS LLC 250MG	A062298	001		Jun CTEC
AB		333MG	A062298	003	Mar 29, 1982	Jun CTEC
AB	!	500MG	A062298	002		Jun CTEC
		ERYTHROMYCIN				
AB		AMNEAL PHARMS CO 250MG	A210954	001	Jul 02, 2019	Jun NEWA
AB		333MG	A210954	002	Jul 02, 2019	Jun NEWA
AB		500MG	A210954	003	Jul 02, 2019	Jun NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL  
E.E.S.

AB	+	ARBOR PHARMS LLC EQ 200MG BASE/5ML	N050207	001		Sep CTEC
		ERYPED				

AB	+	ARBOR PHARMS LLC EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep CTEC
		ERYTHROMYCIN ETHYLSUCCINATE				

>A>	AB	AMNEAL PHARMS EQ 200MG BASE/5ML	A211204	001	Nov 01, 2019	Oct NEWA
>A>	AB	EQ 400MG BASE/5ML	A211204	002	Nov 01, 2019	Oct NEWA
	AB	ANI PHARMS INC EQ 200MG BASE/5ML	A062055	001		Sep CTEC
	AB	EQ 200MG BASE/5ML	A062055	003	Nov 02, 2018	Sep CTEC
>A>	AB	PAR PHARM INC EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	Oct NEWA
>A>	AB	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	Oct NEWA

ESCITALOPRAM OXALATE

SOLUTION;ORAL  
ESCITALOPRAM OXALATE

AA		ALLIED EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Sep CAHN
----	--	------------------------	---------	-----	--------------	----------

TABLET;ORAL  
ESCITALOPRAM OXALATE

AB		CADILA EQ 5MG BASE	A077734	001	Sep 11, 2012	Apr CAHN
AB		EQ 10MG BASE	A077734	002	Sep 11, 2012	Apr CAHN
AB		EQ 20MG BASE	A077734	003	Sep 11, 2012	Apr CAHN

ESKETAMINE HYDROCHLORIDE

SPRAY;NASAL  
SPRAVATO

+	!	JANSSEN PHARMS EQ 28MG BASE	N211243	001	Mar 05, 2019	Mar NEWA
---	---	-----------------------------	---------	-----	--------------	----------

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION  
ESMOLOL HYDROCHLORIDE

AP		GLAND PHARMA LTD 10MG/ML	A208538	001	Aug 14, 2019	Jul NEWA
----	--	--------------------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

	@	AMNEAL PHARMS NY EQ 20MG BASE	A209647	001	Apr 10, 2019	Jun DISC
AB		EQ 20MG BASE	A209647	001	Apr 10, 2019	Mar NEWA
	@	EQ 40MG BASE	A209647	002	Apr 10, 2019	Jun DISC
AB		EQ 40MG BASE	A209647	002	Apr 10, 2019	Mar NEWA
AB		GLENMARK PHARMS EQ 20MG BASE	A209495	001	May 10, 2019	Apr NEWA
AB		EQ 40MG BASE	A209495	002	May 10, 2019	Apr NEWA

CAPSULE, DELAYED REL PELLETS;ORAL									
ESOMEPRAZOLE MAGNESIUM									
	@ HEC PHARM	EQ 20MG BASE	A207265	002	May 18, 2018	Mar	DISC		
	@	EQ 40MG BASE	A207265	001	May 18, 2018	Mar	DISC		
AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Jun	CTEC		
AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Jun	CTEC		
AB	ZYDUS PHARMS	EQ 20MG BASE	A206296	001	May 22, 2019	May	NEWA		
AB		EQ 40MG BASE	A206296	002	May 22, 2019	May	NEWA		
<u>ESOMEPRAZOLE STRONTIUM</u>									
CAPSULE, DELAYED RELEASE;ORAL									
ESOMEPRAZOLE STRONTIUM									
	+ @ R2 PHARMA LLC	49.3MG	N202342	002	Aug 06, 2013	Aug	DISC		
<u>ESTRADIOL</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
ESTRADIOL									
AB1	AMNEAL PHARMS LLC	0.025MG/24HR	A211293	001	Feb 04, 2019	Jan	NEWA		
AB1		0.0375MG/24HR	A211293	002	Feb 04, 2019	Jan	NEWA		
AB1		0.05MG/24HR	A211293	003	Feb 04, 2019	Jan	NEWA		
AB1		0.075MG/24HR	A211293	004	Feb 04, 2019	Jan	NEWA		
AB1		0.1MG/24HR	A211293	005	Feb 04, 2019	Jan	NEWA		
GEL;TRANSDERMAL									
DIVIGEL									
	+! VERTICAL PHARMS LLC	0.1%	N022038	001	Jun 04, 2007	Jan	CHRS		
<u>ESTRADIOL VALERATE</u>									
INJECTABLE;INJECTION									
ESTRADIOL VALERATE									
	@ DR REDDYS	40MG/ML	A083714	001		May	CAHN		
<u>ESTRADIOL; NORETHINDRONE ACETATE</u>									
TABLET;ORAL									
ESTRADIOL AND NORETHINDRONE ACETATE									
	@ ACCORD HLTHCARE	1MG;0.5MG	A210233	001	Feb 28, 2018	Mar	DISC		
AB	NOVAST LABS	0.5MG;0.1MG	A210612	001	Apr 03, 2019	Mar	NEWA		
AB		1MG;0.5MG	A210612	002	Apr 03, 2019	Mar	NEWA		
<u>ESTROGENS, CONJUGATED SYNTHETIC A</u>									
TABLET;ORAL									
CENESTIN									
	+ @ ASPEN	0.3MG	N020992	001	Jun 21, 2002	Feb	CAHN		
	+ @	0.45MG	N020992	005	Feb 05, 2004	Feb	CAHN		
	+ @	0.625MG	N020992	002	Mar 24, 1999	Feb	CAHN		
	+ @	0.9MG	N020992	003	Mar 24, 1999	Feb	CAHN		
	+ @	1.25MG	N020992	004	Mar 13, 2000	Feb	CAHN		
<u>ESTROGENS, CONJUGATED SYNTHETIC B</u>									
TABLET;ORAL									
ENJUVIA									
	@ ASPEN	0.3MG	N021443	001	Dec 20, 2004	Feb	CAHN		
	@	0.45MG	N021443	002	Dec 20, 2004	Feb	CAHN		
	@	0.625MG	N021443	003	May 10, 2004	Feb	CAHN		
	@	0.9MG	N021443	005	Apr 27, 2007	Feb	CAHN		
	@	1.25MG	N021443	004	May 10, 2004	Feb	CAHN		
<u>ESZOPICLONE</u>									
TABLET;ORAL									
ESZOPICLONE									
	@ BRECKENRIDGE	1MG	A203087	001	May 08, 2019	May	DISC		
	@	2MG	A203087	002	May 08, 2019	May	DISC		
	@	3MG	A203087	003	May 08, 2019	May	DISC		
AB	BRECKENRIDGE PHARM	1MG	A203087	001	May 08, 2019	Apr	NEWA		
AB		2MG	A203087	002	May 08, 2019	Apr	NEWA		
AB		3MG	A203087	003	May 08, 2019	Apr	NEWA		
<u>ETHACRYNATE SODIUM</u>									
INJECTABLE;INJECTION									
EDECRIN									
AP	+! BAUSCH	EQ 50MG BASE/VIAL	N016093	001		Mar	CAHN		
AP	+! VALEANT PHARMS INTL	EQ 50MG BASE/VIAL	N016093	001		Jan	CAHN		

ETHACRYNIC ACID

TABLET; ORAL

EDECIN

AB	+	!	BAUSCH	25MG	N016092	001		Mar	CAHN
			@	50MG	N016092	002		Mar	CAHN
AB	+	!	VALEANT PHARMS INTL	25MG	N016092	001		Jan	CAHN
			@	50MG	N016092	002		Jan	CAHN
			ETHACRYNIC ACID						
AB			AGNITIO	25MG	A211809	001	Jul 12, 2019	Jul	NEWA
AB			LUPIN LTD	25MG	A211719	001	Sep 06, 2019	Aug	NEWA
AB			SCIEGEN PHARMS INC	25MG	A211232	001	Aug 27, 2019	Aug	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET; ORAL-28

LO-MALMOREDE

AB			NOVAST LABS	0.035MG; 1MG	A209548	001	Feb 11, 2019	Jan	NEWA
----	--	--	-------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

INTROVALE

AB			XIROMED	0.03MG; 0.15MG	A079064	001	Sep 27, 2010	Aug	CAHN
			JAIMI ESS						
AB			XIROMED	0.03MG, 0.01MG; 0.15MG, N/A	A203770	001	Dec 27, 2017	Aug	CAHN
			LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL						
AB			XIROMED	0.02MG, 0.1MG; 0.01MG, N/A	A205131	001	Dec 14, 2017	Aug	CAHN
			SYLEVIA						
AB			SUN PHARM	0.03MG; 0.15MG	A202988	001	Feb 06, 2019	Jan	NEWA
			TABLET; ORAL-28						
			ALTAVERA						
AB			XIROMED	0.03MG; 0.15MG	A079102	001	Aug 03, 2010	Aug	CAHN
			ELIFEMME						
AB			XIROMED	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202507	001	Dec 04, 2015	Aug	CAHN
			LEVONORGESTREL AND ETHINYL ESTRADIOL						
			@ MYLAN LABS LTD	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Jun	DISC
			VIENVA						
AB1			XIROMED	0.02MG; 0.1MG	A201088	001	May 21, 2015	Aug	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHINDRONE AND ETHINYL ESTRADIOL

			@ MYLAN LABS LTD	0.05MG; 1MG	A203006	001	Aug 05, 2013	Sep	DISC
			NORTREL 1/35-28						
AB	!		BARR	0.035MG; 1MG	A072696	001	Feb 28, 1992	Mar	CHRS
			ORTHO-NOVUM 1/35-28						
	+		@ JANSSEN PHARMS	0.035MG; 1MG	N017919	002		Mar	DISC
			TABLET, CHEWABLE; ORAL						
			NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	!		MYLAN LABS LTD	0.035MG; 0.4MG	A202086	001	Apr 01, 2015	Mar	CHRS

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL-21

HAILEY 1.5/30

AB			GLENMARK PHARMS	0.03MG; 1.5MG	A209297	001	Jun 05, 2018	Jan	CDFR
			LOESTRIN 21 1.5/30						
AB	+		APIL	0.03MG; 1.5MG	N017875	001		Jan	CRLD
			LOESTRIN 21 1/20						
AB	+		APIL	0.02MG; 1MG	N017876	001		Jan	CRLD
			TABLET, CHEWABLE; ORAL						
			NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
>D> AB			MYLAN LABS LTD	0.02MG; 1MG	A206120	001	Sep 12, 2017	Oct	DISC
>A>			@	0.02MG; 1MG	A206120	001	Sep 12, 2017	Oct	DISC
AB			XIROMED	0.02MG; 1MG	A209609	001	Jul 16, 2018	Aug	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

ESTARYLLA

AB			XIROMED	0.035MG; 0.25MG	A090794	001	Jan 30, 2013	Aug	CAHN
			NORGESTIMATE AND ETHINYL ESTRADIOL						
			@ MYLAN LABS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG,	A202132	001	Sep 09, 2015	Jan	DISC

TABLET;ORAL-28								
NORGESTIMATE AND ETHINYL ESTRADIOL								
		0.215MG,0.25MG						
AB	NAARI PTE LTD	0.035MG;0.035MG;0.035MG;0.18MG;0.2	A200383	001	Apr 07, 2015	Sep	CAHN	
		15MG;0.25MG						
AB		0.035MG;0.25MG	A200384	001	Apr 07, 2015	Sep	CAHN	
ORTHO CYCLEN-28								
	+ @ JANSSSEN PHARMS	0.035MG;0.25MG	N019653	002	Dec 29, 1989	Apr	DISC	
	SPRINTEC							
AB	! BARR	0.035MG;0.25MG	A075804	001	Sep 25, 2002	Apr	CHRS	
TRI-ESTARYLLA								
AB	XIROMED	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A090793	001	Jan 30, 2013	Aug	CAHN	
		15MG,0.25MG						
TRI-LO-ESTARYLLA								
AB	XIROMED	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A091232	001	Jun 29, 2015	Aug	CAHN	
		15MG,0.25MG						
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE</u>								
RING;VAGINAL								
ANNOVERA								
	+! THERAPEUTICSMD INC	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	May	CMFD	
	+ @	0.013MG/24HR;0.15MG/24HR	N209627	001	Aug 10, 2018	Feb	DISC	
<u>ETHOSUXIMIDE</u>								
CAPSULE;ORAL								
ETHOSUXIMIDE								
AB	STRIDES PHARMA	250MG	A211928	001	Feb 19, 2019	Feb	NEWA	
SYRUP;ORAL								
ETHOSUXIMIDE								
	@ TEVA PHARMS	250MG/5ML	A081306	001	Jul 30, 1993	May	DISC	
<u>ETOMIDATE</u>								
INJECTABLE;INJECTION								
ETOMIDATE								
	@ LUITPOLD	2MG/ML	A078867	001	Dec 22, 2009	Feb	DISC	
	@ PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Apr	DISC	
<u>ETOPOSIDE PHOSPHATE</u>								
INJECTABLE;INJECTION								
ETOPOPHOS PRESERVATIVE FREE								
	+! CHEPLAPHARM	EQ 100MG BASE/VIAL	N020457	001	May 17, 1996	May	CAHN	
<u>EVEROLIMUS</u>								
TABLET;ORAL								
AFINITOR								
	+! NOVARTIS	5MG	N022334	001	Mar 30, 2009	Apr	CHRS	
	+	10MG	N022334	002	Mar 30, 2009	Apr	CHRS	
ZORTRESS								
	+ NOVARTIS	1MG	N021560	004	Aug 10, 2018	Mar	NEWA	
TABLET, FOR SUSPENSION;ORAL								
AFINITOR DISPERZ								
	+ NOVARTIS PHARM	2MG	N203985	001	Aug 29, 2012	Apr	CTEC	
AB	+	2MG	N203985	001	Aug 29, 2012	Apr	CFTG	
	+	3MG	N203985	002	Aug 29, 2012	Apr	CTEC	
AB	+	3MG	N203985	002	Aug 29, 2012	Apr	CFTG	
	+!	5MG	N203985	003	Aug 29, 2012	Apr	CTEC	
AB	+!	5MG	N203985	003	Aug 29, 2012	Apr	CFTG	
EVEROLIMUS								
	@ MYLAN	2MG	A210130	001	Apr 19, 2019	Apr	NFTG	
	@	3MG	A210130	002	Apr 19, 2019	Apr	NFTG	
	@	5MG	A210130	003	Apr 19, 2019	Apr	NFTG	
<u>EXEMESTANE</u>								
TABLET;ORAL								
EXEMESTANE								
	@ AMNEAL PHARMS	25MG	A206421	001	Dec 28, 2018	Jul	DISC	
	@ BRECKENRIDGE	25MG	A211031	001	Feb 21, 2019	May	DISC	
AB	BRECKENRIDGE PHARM	25MG	A211031	001	Feb 21, 2019	Feb	NEWA	
AB	MAYNE PHARMA INC	25MG	A208764	001	Aug 08, 2019	Jul	NEWA	

EZETIMIBE

TABLET; ORAL

EZETIMIBE

	@ ACCORD HLTHCARE	10MG	A211550	001	Oct 26, 2018	Apr DISC
AB	MYLAN	10MG	A201790	001	Apr 26, 2019	Apr NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

AB	GLENMARK PHARMS LTD	10MG; 10MG	A208699	001	Jun 27, 2019	Jun NEWA
AB		10MG; 20MG	A208699	002	Jun 27, 2019	Jun NEWA
AB		10MG; 40MG	A208699	003	Jun 27, 2019	Jun NEWA
AB		10MG; 80MG	A208699	004	Jun 27, 2019	Jun NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

AB	CELLTRION	20MG	A075786	001	Apr 16, 2001	Aug CAHN
AB		40MG	A075786	002	Apr 16, 2001	Aug CAHN
	@ MYLAN	40MG	A075704	002	Apr 16, 2001	Apr DISC

FEBUXOSTAT

TABLET; ORAL

FEBUXOSTAT

AB	ALEMBIC PHARMS LTD	40MG	A205421	001	Jul 01, 2019	Jun NFTG
AB		80MG	A205421	002	Jul 01, 2019	Jun NFTG
AB	MYLAN	40MG	A205385	001	Jul 01, 2019	Jun NFTG
AB		80MG	A205385	002	Jul 01, 2019	Jun NFTG
AB	SUN PHARM	40MG	A205467	001	Jul 01, 2019	Jun NFTG
AB		80MG	A205467	002	Jul 01, 2019	Jun NFTG
AB	WEST-WARD PHARMS INT	40MG	A205414	001	Oct 15, 2019	Sep NEWA
AB		80MG	A205414	002	Oct 15, 2019	Sep NEWA
	ULORIC					
AB	+ TAKEDA PHARMS USA	40MG	N021856	001	Feb 13, 2009	Jun CFTG
AB	+!	80MG	N021856	002	Feb 13, 2009	Jun CFTG

FEDRATINIB HYDROCHLORIDE

CAPSULE; ORAL

INREBIC

	+! IMPACT	EQ 100MG BASE	N212327	001	Aug 16, 2019	Aug NEWA
--	-----------	---------------	---------	-----	--------------	----------

FELBAMATE

SUSPENSION; ORAL

FELBAMATE

AB	VISTAPHARM	600MG/5ML	A211333	001	May 31, 2019	May NEWA
----	------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

FELBAMATE

AB	CADILA	400MG	A208970	001	May 30, 2017	Jul CAHN
AB		600MG	A208970	002	May 30, 2017	Jul CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

>D>	AB	MYLAN	2.5MG	A078855	001	Apr 17, 2008	Oct DISC
>A>		@	2.5MG	A078855	001	Apr 17, 2008	Oct DISC
>D>	AB		5MG	A078855	002	Apr 17, 2008	Oct DISC
>A>		@	5MG	A078855	002	Apr 17, 2008	Oct DISC
>D>	AB	!	10MG	A078855	003	Apr 17, 2008	Oct DISC
>A>		@	10MG	A078855	003	Apr 17, 2008	Oct DISC
>D>	AB	TORRENT PHARMS LTD	10MG	A202170	003	Nov 28, 2011	Oct CHRS
>A>	AB	!	10MG	A202170	003	Nov 28, 2011	Oct CHRS
	AB	YUNG SHIN PHARM	2.5MG	A204800	001	Apr 29, 2019	Apr NEWA
	AB		5MG	A204800	002	Apr 29, 2019	Apr NEWA
	AB		10MG	A204800	003	Apr 29, 2019	Apr NEWA

FENOFIBRATE

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB	AUSTARPHARMA	67MG	A207805	001	Nov 16, 2017	Jan CAHN
AB		134MG	A207805	002	Nov 16, 2017	Jan CAHN
AB		200MG	A207805	003	Nov 16, 2017	Jan CAHN

## CAPSULE;ORAL

## FENOFIBRATE (MICRONIZED)

AB	INGENUS PHARMS LLC	67MG	A207564	001	Apr 19, 2019	Apr NEWA
AB		134MG	A207564	002	Apr 19, 2019	Apr NEWA
AB		200MG	A207564	003	Apr 19, 2019	Apr NEWA
>D> AB	NOVAST LABS	67MG	A207564	001	Apr 19, 2019	Oct DISC
>A> @		67MG	A207564	001	Apr 19, 2019	Oct DISC
AB		67MG	A207564	001	Apr 19, 2019	Sep CAHN
>D> AB		134MG	A207564	002	Apr 19, 2019	Oct DISC
>A> @		134MG	A207564	002	Apr 19, 2019	Oct DISC
AB		134MG	A207564	002	Apr 19, 2019	Sep CAHN
>D> AB		200MG	A207564	003	Apr 19, 2019	Oct DISC
>A> @		200MG	A207564	003	Apr 19, 2019	Oct DISC
AB		200MG	A207564	003	Apr 19, 2019	Sep CAHN

## TABLET;ORAL

## FENOFIBRATE

AB	ALEMBIC PHARMS LTD	48MG	A210476	001	Aug 09, 2019	Jul NEWA
AB		145MG	A210476	002	Aug 09, 2019	Jul NEWA
AB	APPCO PHARMA LLC	54MG	A210670	001	Sep 06, 2019	Aug NEWA
AB		160MG	A210670	002	Sep 06, 2019	Aug NEWA
AB	AUSTARPHARMA	54MG	A207803	001	Dec 19, 2017	Jan CAHN
AB		160MG	A207803	002	Dec 19, 2017	Jan CAHN
@	GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Feb DISC
@		160MG	A210606	002	Aug 17, 2018	Feb DISC
AB	NUVO PHARM	54MG	A210670	001	Sep 06, 2019	Sep CAHN
AB		160MG	A210670	002	Sep 06, 2019	Sep CAHN
AB	ORIT LABS LLC	54MG	A209660	001	Feb 11, 2019	Jan NEWA
AB		160MG	A209660	002	Feb 11, 2019	Jan NEWA

## FENOGLIDE

AB	+ SALIX	40MG	N022118	001	Aug 10, 2007	Mar CAHN
AB	+!	120MG	N022118	002	Aug 10, 2007	Mar CAHN

## TRIGLIDE

>D>	+ @ SKYEPHARMA AG	160MG	N021350	002	May 07, 2005	Oct CMFD
>A> BX	+	160MG	N021350	002	May 07, 2005	Oct CMFD
	+ @	160MG	N021350	002	May 07, 2005	Sep DISC

FENOFIBRIC ACID

## TABLET;ORAL

## FIBRICOR

+	ATHENA	35MG	N022418	001	Aug 14, 2009	Feb CAHN
+	!	105MG	N022418	002	Aug 14, 2009	Feb CAHN

FENOPROFEN CALCIUM

## TABLET;ORAL

## FENOPROFEN CALCIUM

@	ANI PHARMS INC	EQ 600MG BASE	A072274	001	May 02, 1988	May CAHN
---	----------------	---------------	---------	-----	--------------	----------

FENTANYL

## FILM, EXTENDED RELEASE;TRANSDERMAL

## FENTANYL-100

AB	MAYNE PHARMA	100MCG/HR	A077062	004	Aug 20, 2007	Aug CMFD
@		100MCG/HR	A077062	004	Aug 20, 2007	Jul DISC

## FENTANYL-25

AB	MAYNE PHARMA	25MCG/HR	A077062	001	Aug 20, 2007	Aug CMFD
@		25MCG/HR	A077062	001	Aug 20, 2007	Jul DISC

## FENTANYL-50

AB	MAYNE PHARMA	50MCG/HR	A077062	002	Aug 20, 2007	Aug CMFD
@		50MCG/HR	A077062	002	Aug 20, 2007	Jul DISC

## FENTANYL-75

AB	MAYNE PHARMA	75MCG/HR	A077062	003	Aug 20, 2007	Aug CMFD
@		75MCG/HR	A077062	003	Aug 20, 2007	Jul DISC

## SPRAY;SUBLINGUAL

## SUBSYS

+	BTCP PHARMA	0.1MG	N202788	001	Jan 04, 2012	Sep CAHN
+		0.2MG	N202788	002	Jan 04, 2012	Sep CAHN
+	!	0.4MG	N202788	003	Jan 04, 2012	Sep CAHN
+		0.6MG	N202788	004	Jan 04, 2012	Sep CAHN
+		0.8MG	N202788	005	Jan 04, 2012	Sep CAHN
+		1.2MG	N202788	006	Aug 30, 2012	Sep CAHN
+		1.6MG	N202788	007	Aug 30, 2012	Sep CAHN

FENTANYL CITRATE

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 0.05MG BASE/ML	A210762	001	May 03, 2019	Apr	NEWA
	SPRAY, METERED;NASAL						
	LAZANDA						
	+ BTCP PHARMA	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Sep	CAHN
	+ @	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep	DISC
	+ @	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Sep	CAHN
	+!	EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Sep	CAHN

&gt;D&gt; TABLET;SUBLINGUAL

&gt;D&gt; ABSTRAL

>D> AB	+ SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Oct	DISC
>A>	+ @	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Oct	DISC
>D> AB	+	EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Oct	DISC
>A>	+ @	EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Oct	DISC
>D> AB	+	EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Oct	DISC
>A>	+ @	EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Oct	DISC
>D> AB	+!	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Oct	DISC
>A>	+ @	EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Oct	DISC
>D> AB	+	EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Oct	DISC
>A>	+ @	EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Oct	DISC
>D> AB	+	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Oct	DISC
>A>	+ @	EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Oct	DISC

&gt;D&gt; FENTANYL CITRATE

>D> AB	ACTAVIS LABS FL INC	EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Oct	DISC
>A>	@	EQ 0.1MG BASE	A207338	001	Nov 17, 2017	Oct	DISC
>D> AB		EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Oct	DISC
>A>	@	EQ 0.2MG BASE	A207338	002	Nov 17, 2017	Oct	DISC
>D> AB		EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Oct	DISC
>A>	@	EQ 0.3MG BASE	A207338	003	Nov 17, 2017	Oct	DISC
>D> AB		EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Oct	DISC
>A>	@	EQ 0.4MG BASE	A207338	004	Nov 17, 2017	Oct	DISC
>D> AB		EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Oct	DISC
>A>	@	EQ 0.6MG BASE	A207338	005	Nov 17, 2017	Oct	DISC
>D> AB		EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Oct	DISC
>A>	@	EQ 0.8MG BASE	A207338	006	Nov 17, 2017	Oct	DISC

FERRIC CARBOXYMALTOSE

INJECTABLE;INTRAVENOUS

INJECTAFER

+!	AM REGENT	750MG IRON/15ML (50MG IRON/ML)	N203565	001	Jul 25, 2013	Jun	CAHN
----	-----------	--------------------------------	---------	-----	--------------	-----	------

FERRIC MALTOI

CAPSULE;ORAL

ACCRUFER

+!	SHIELD TX	30MG IRON	N212320	001	Jul 25, 2019	Jul	NEWA
----	-----------	-----------	---------	-----	--------------	-----	------

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

FESOTERODINE FUMARATE

AB	DR REDDYS LABS LTD	4MG	A204975	001	Aug 13, 2019	Jul	NEWA
AB		8MG	A204975	002	Aug 13, 2019	Jul	NEWA

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

FEXOFENADINE HYDROCHLORIDE

@ P AND L 30MG/5ML

A201311	001	Jul 25, 2012	Aug	CAHN
---------	-----	--------------	-----	------

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

@ MYLAN 30MG

A077081	002	Apr 11, 2008	Jul	DISC
---------	-----	--------------	-----	------

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

+ @	MERLION PHARMS GMBH	0.3%	N206307	001	Dec 17, 2014	Apr	DISC
-----	---------------------	------	---------	-----	--------------	-----	------

FINASTERIDE

TABLET; ORAL  
FINASTERIDE  
@ MYLAN

5MG

A077578 001 Dec 18, 2006 Jul DISC

FLOXURIDINE

INJECTABLE; INJECTION  
FLOXURIDINE  
@ LUITPOLD

500MG/VIAL

A203008 001 Nov 22, 2017 Mar DISC

FLUCONAZOLE

FOR SUSPENSION; ORAL  
FLUCONAZOLE

@ IVAX SUB TEVA PHARMS 50MG/5ML  
@ 200MG/5ML

A077523 001 Sep 12, 2007 Sep DISC

A077523 002 Sep 12, 2007 Sep DISC

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

&gt;D&gt; AP RENAISSANCE SSA LLC 200MG/100ML (2MG/ML)

A077988 001 May 26, 2010 Oct CAHN

&gt;D&gt; AP 400MG/200ML (2MG/ML)

A077988 002 May 26, 2010 Oct CAHN

&gt;A&gt; AP WOODWARD 200MG/100ML (2MG/ML)

A077988 001 May 26, 2010 Oct CAHN

&gt;A&gt; AP 400MG/200ML (2MG/ML)

A077988 002 May 26, 2010 Oct CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

@ DR REDDYS 200MG/100ML (2MG/ML)

A076653 001 Jul 29, 2004 May CAHN

@ 400MG/200ML (2MG/ML)

A076653 002 Jul 29, 2004 May CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ DR REDDYS 200MG/100ML (2MG/ML)

A076837 001 Jan 13, 2005 May CAHN

@ 400MG/200ML (2MG/ML)

A076837 002 Jan 13, 2005 May CAHN

&gt;D&gt; RENAISSANCE SSA LLC 100MG/50ML (2MG/ML)

A077909 003 Apr 20, 2015 Oct CAHN

&gt;D&gt; AP 200MG/100ML (2MG/ML)

A077909 001 May 26, 2010 Oct CAHN

&gt;D&gt; AP 400MG/200ML (2MG/ML)

A077909 002 May 26, 2010 Oct CAHN

&gt;A&gt; WOODWARD 100MG/50ML (2MG/ML)

A077909 003 Apr 20, 2015 Oct CAHN

&gt;A&gt; AP 200MG/100ML (2MG/ML)

A077909 001 May 26, 2010 Oct CAHN

&gt;A&gt; AP 400MG/200ML (2MG/ML)

A077909 002 May 26, 2010 Oct CAHN

TABLET; ORAL

FLUCONAZOLE

AB CHARTWELL 50MG

A076665 001 Jul 29, 2004 Jun CAHN

AB 100MG

A076665 002 Jul 29, 2004 Jun CAHN

AB 150MG

A076665 003 Jul 29, 2004 Jun CAHN

AB 200MG

A076665 004 Jul 29, 2004 Jun CAHN

FLUCYTOSINE

CAPSULE; ORAL  
ANCOBON

AB + BAUSCH 250MG

N017001 001 Feb CAHN

AB +! 500MG

N017001 002 Feb CAHN

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION  
FLUDARABINE PHOSPHATE

&gt;D&gt; AP MYLAN LABS LTD 50MG/2ML (25MG/ML)

A200647 001 Dec 21, 2011 Oct DISC

&gt;A&gt; @ 50MG/2ML (25MG/ML)

A200647 001 Dec 21, 2011 Oct DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS  
FLUDEOXYGLUCOSE F18

AP DECATUR 20-300mCi/ML

A204463 001 Oct 21, 2014 Apr CAHN

FLUMAZENIL

INJECTABLE; INJECTION  
FLUMAZENIL

@ DR REDDYS 0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004 May CAHN

@ 1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004 May CAHN

AP ! HIKMA FARMACEUTICA 1MG/10ML (0.1MG/ML)

A078527 002 Mar 23, 2009 Aug CHRS

@ MYLAN LABS LTD 1MG/10ML (0.1MG/ML)

A078595 002 May 13, 2008 Aug DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION  
AEROSPAN HFA

+ @ MYLAN SPECIALITY LP 0.078MG/INH

N021247 001 Jan 27, 2006 Jul DISC

SPRAY, METERED;NASAL							
FLUNISOLIDE							
	APOTEX	0.029MG/SPRAY		A077436	001	Aug 09, 2007	Jun CMFD
AB	APOTEX INC	0.029MG/SPRAY		A077436	001	Aug 09, 2007	Jun CMFD
<u>FLUOCINOLONE ACETONIDE</u>							
OIL/DROPS;OTIC							
FLAC							
AT	ANDA REPOSITORY	0.01%		A210736	001	Apr 11, 2018	Sep CAHN
SOLUTION;TOPICAL							
FLUOCINOLONE ACETONIDE							
	@ ACTAVIS LABS UT INC	0.01%		A208386	001	Oct 21, 2016	Mar DISC
AT	ENCUBE ETHICALS	0.01%		A209913	001	Feb 13, 2019	Jan NEWA
AT	GLASSHOUSE PHARMS	0.01%		A209596	001	Dec 26, 2017	Jan CMFD
AT	LUPIN	0.01%		A206422	001	Sep 02, 2015	Feb CAHN
<u>FLUOCINONIDE</u>							
CREAM;TOPICAL							
FLUOCINONIDE							
	@ AMNEAL PHARMS LLC	0.05%		A210554	001	Aug 21, 2018	Feb DISC
AB	TELIGENT PHARMA INC	0.1%		A211758	001	Apr 03, 2019	Mar NEWA
SOLUTION;TOPICAL							
FLUOCINONIDE							
AT	TELIGENT PHARMA INC	0.05%		A207554	001	Mar 18, 2019	Mar NEWA
>A> <u>FLUORODOPA F-18</u>							
SOLUTION;INTRAVENOUS							
FLUORODOPA F18							
>A> +! FEINSTEIN		0.42-8.33mCi/ML		N200655	001	Oct 10, 2019	Oct NEWA
<u>FLUOROMETHOLONE</u>							
SUSPENSION/DROPS;OPHTHALMIC							
FML FORTE							
	+! ALLERGAN	0.25%		N019216	001	Apr 23, 1986	Jun CHRS
	+	0.25%		N019216	001	Apr 23, 1986	Jun CRLD
<u>FLUOROMETHOLONE ACETATE</u>							
SUSPENSION/DROPS;OPHTHALMIC							
FLAREX							
	+! EYEVANCE	0.1%		N019079	001	Feb 11, 1986	Feb CAHN
<u>FLUOROMETHOLONE ACETATE; TOBRAMYCIN</u>							
SUSPENSION/DROPS;OPHTHALMIC							
TOBRASONE							
	@ EYEVANCE	0.1%;0.3%		N050628	001	Jul 21, 1989	May CAHN
<u>FLUOROURACIL</u>							
CREAM;TOPICAL							
EFUDEX							
AB	+! BAUSCH	5%		N016831	003		Aug CAHN
FLUOROPLEX							
	+! ALMIRALL	1%		N016988	001		Feb CAHN
INJECTABLE;INJECTION							
FLUOROURACIL							
	@ MYLAN LABS LTD	500MG/10ML (50MG/ML)		A202668	001	Jul 17, 2012	Sep DISC
	@	1GM/20ML (50MG/ML)		A202668	002	Jul 17, 2012	Sep DISC
SOLUTION;TOPICAL							
EFUDEX							
AT	+! BAUSCH	2%		N016831	001		Aug CAHN
AT	+!	5%		N016831	002		Aug CAHN
<u>FLUOXETINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
FLUOXETINE HYDROCHLORIDE							
AB1	APNAR PHARMA LP	EQ 10MG BASE		A075049	001	Aug 02, 2001	Jun CAHN
AB1		EQ 20MG BASE		A075049	002	Jan 29, 2002	Jun CAHN
AB		EQ 40MG BASE		A075049	003	Jan 29, 2002	Jun CAHN
	@ BEXIMCO PHARMS USA	EQ 10MG BASE		A075807	001	Jan 29, 2002	Feb CAHN
	@	EQ 20MG BASE		A075807	002	Jan 29, 2002	Feb CAHN
AB1	CADILA PHARMS LTD	EQ 10MG BASE		A206993	001	May 23, 2019	May NEWA
AB1		EQ 20MG BASE		A206993	002	May 23, 2019	May NEWA

## CAPSULE;ORAL

## FLUOXETINE HYDROCHLORIDE

AB		EQ 40MG BASE	A206993	003	May 23, 2019	May NEWA
	@ CELLTRION	EQ 10MG BASE	A078143	001	Jan 16, 2008	Aug CAHN
	@	EQ 20MG BASE	A078143	002	Jan 16, 2008	Aug CAHN
	@	EQ 40MG BASE	A078143	003	Jan 16, 2008	Aug CAHN
>D>	MYLAN	EQ 10MG BASE	A078045	001	Nov 17, 2008	Oct DISC
>A>	@	EQ 10MG BASE	A078045	001	Nov 17, 2008	Oct DISC
>D>	!	EQ 20MG BASE	A078045	002	Nov 17, 2008	Oct DISC
>A>	@	EQ 20MG BASE	A078045	002	Nov 17, 2008	Oct DISC
	@ PAR PHARM	EQ 40MG BASE	A076922	003	Dec 16, 2004	Mar DISC

## CAPSULE, DELAYED REL PELLETS;ORAL

## FLUOXETINE HYDROCHLORIDE

	@ BARR	EQ 90MG BASE	A076237	001	Mar 24, 2010	Apr DISC
	! DR REDDYS LABS LTD	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr CTEC
AB	!	EQ 90MG BASE	A078572	001	Mar 22, 2010	Apr CHRS

## SOLUTION;ORAL

## FLUOXETINE HYDROCHLORIDE

	@ NOSTRUM LABS INC	EQ 20MG BASE/5ML	A075292	001	Feb 07, 2002	May CAHN
--	--------------------	------------------	---------	-----	--------------	----------

## TABLET;ORAL

## FLUOXETINE HYDROCHLORIDE

AB	APPCO PHARMA LLC	EQ 10MG BASE	A211696	001	Jan 30, 2019	Jan NEWA
AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	Jan NEWA
AB	DR REDDYS LABS LTD	EQ 60MG BASE	A211721	001	Jan 25, 2019	Jan NEWA
AB	G AND W LABS INC	EQ 60MG BASE	A212191	001	Jul 05, 2019	Jun NEWA
AB	LUPIN LTD	EQ 10MG BASE	A211653	001	Apr 15, 2019	Apr NEWA
AB		EQ 20MG BASE	A211653	002	Apr 15, 2019	Apr NEWA
AB		EQ 60MG BASE	A211632	001	Feb 08, 2019	Feb NEWA
AB	SCIEGEN PHARMS INC	EQ 10MG BASE	A210935	001	Mar 20, 2019	Mar NEWA
AB		EQ 20MG BASE	A210935	002	Mar 20, 2019	Mar NEWA
AB	TARO	EQ 60MG BASE	A211477	001	Nov 21, 2018	Sep CAHN
AB	UPSHER SMITH LABS	EQ 10MG BASE	A211696	001	Jan 30, 2019	May CAHN
AB		EQ 20MG BASE	A211696	002	Jan 30, 2019	May CAHN

FLUOXYMESTERONE

## TABLET;ORAL

## FLUOXYMESTERONE

	! UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jul CAHN
--	---------------------	------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

## TABLET;ORAL

## FLUPHENAZINE HYDROCHLORIDE

AB	! LANNETT CO INC	10MG	A089743	001	Aug 25, 1988	May CHRS
AB	MYLAN	10MG	A089804	001	Aug 12, 1988	May CHRS

FLURANDRENOLIDE

## CREAM;TOPICAL

## CORDRAN SP

	+! ALMIRALL	0.025%	N012806	003		Feb CAHN
AT	+!	0.05%	N012806	002		Feb CAHN

## LOTION;TOPICAL

## CORDRAN

AT	+! ALMIRALL	0.05%	N013790	001		Feb CAHN
----	-------------	-------	---------	-----	--	----------

## OINTMENT;TOPICAL

## CORDRAN

	+ @ ALMIRALL	0.025%	N012806	004		Feb CAHN
AT	+!	0.05%	N012806	001		Feb CAHN

## TAPE;TOPICAL

## CORDRAN

	+! ALMIRALL	0.004MG/SQ CM	N016455	001		Feb CAHN
--	-------------	---------------	---------	-----	--	----------

FLURBIPROFEN

## TABLET;ORAL

## FLURBIPROFEN

>D>	AB	MYLAN	50MG	A074358	001	Jun 20, 1994	Oct CTEC
>A>			50MG	A074358	001	Jun 20, 1994	Oct CTEC
>D>	AB	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001	Oct DISC
>D>	AB		50MG	A075058	001	Apr 27, 2001	Oct DISC
>A>		@	50MG	A075058	001	Apr 27, 2001	Oct DISC
>D>	AB		100MG	A075058	002	Apr 27, 2001	Oct DISC
>A>		@	100MG	A075058	002	Apr 27, 2001	Oct DISC

FLUTAMIDECAPSULE; ORAL  
FLUTAMIDE

@ ACTAVIS LABS FL INC 125MG

A075820 001 Sep 18, 2001 Apr DISC

FLUTICASONE PROPIONATE

CREAM; TOPICAL

FLUTICASONE PROPIONATE

AB ! PERRIGO ISRAEL 0.05%

A076793 001 May 14, 2004 May CAHN

POWDER; INHALATION

ARMONAIR RESPICLICK

+ @ TEVA PHARM 0.055MG/INH

N208798 001 Jan 27, 2017 Sep DISC

+ @ 0.113MG/INH

N208798 002 Jan 27, 2017 Jul DISC

+ @ 0.232MG/INH

N208798 003 Jan 27, 2017 Sep DISC

FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE

POWDER; INHALATION

ADVAIR DISKUS 100/50

AB +! GLAXO GRP LTD 0.1MG/INH;EQ 0.05MG BASE/INH

N021077 001 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 250/50

AB +! GLAXO GRP LTD 0.25MG/INH;EQ 0.05MG BASE/INH

N021077 002 Aug 24, 2000 Jan CFTG

ADVAIR DISKUS 500/50

AB +! GLAXO GRP LTD 0.5MG/INH;EQ 0.05MG BASE/INH

N021077 003 Aug 24, 2000 Jan CFTG

AIRDUO DIGIHALER

+ TEVA PHARM 0.055MG/INH;EQ 0.014MG BASE/INH

N208799 004 Jul 12, 2019 Jul NEWA

+ 0.113MG/INH;EQ 0.014MG BASE/INH

N208799 005 Jul 12, 2019 Jul NEWA

+ 0.232MG/INH;EQ 0.014MG BASE/INH

N208799 006 Jul 12, 2019 Jul NEWA

AIRDUO RESPICLICK

+! TEVA PHARM 0.232MG/INH;EQ 0.014MG BASE/INH

N208799 003 Jan 27, 2017 Jul CMS1

WIXELA INHUB

AB MYLAN 0.1MG/INH;EQ 0.05MG BASE/INH

A208891 001 Jan 30, 2019 Jan NFTG

AB 0.25MG/INH;EQ 0.05MG BASE/INH

A208891 002 Jan 30, 2019 Jan NFTG

AB 0.5MG/INH;EQ 0.05MG BASE/INH

A208891 003 Jan 30, 2019 Jan NFTG

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

@ MYLAN EQ 80MG BASE

A202458 001 Sep 11, 2015 Jun DISC

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@ MYLAN 25MG

A075889 001 Nov 29, 2000 May DISC

@ 50MG

A075889 002 Nov 29, 2000 May DISC

@ 100MG

A075889 003 Nov 29, 2000 May DISC

FOLIC ACID

INJECTABLE; INJECTION

FOLIC ACID

&gt;A&gt; AP EXELA PHARMA SCS LLC 5MG/ML

A202522 001 Nov 06, 2019 Oct NEWA

&gt;D&gt; ! FRESENIUS KABI USA 5MG/ML

A089202 001 Feb 18, 1986 Oct CTEC

&gt;A&gt; AP ! 5MG/ML

A089202 001 Feb 18, 1986 Oct CTEC

TABLET; ORAL

FOLIC ACID

AA QINGDAO BAHEAL PHARM 1MG

A091145 001 Jul 12, 2013 May CAHN

FOMEPIZOLE

INJECTABLE; INJECTION

ANTIZOL

+ @ PAR PHARM INC 1.5GM/1.5ML (1GM/ML)

N020696 001 Dec 04, 1997 Jun DISC

FOMEPIZOLE

AP ! MYLAN INSTITUTIONAL 1.5GM/1.5ML (1GM/ML)

A078639 001 Mar 03, 2008 Jun CHRS

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+ MERCK SHARP DOHME 0.005MG/INH;0.05MG/INH

N022518 003 Aug 12, 2019 Aug NEWA

FOSAPREPITANTPOWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

>D>	TEVA PHARMS USA	150MG/VIAL	N210064	001	Sep 05, 2019	Oct CAIN
		150MG/VIAL	N210064	001	Sep 05, 2019	Sep NEWA

FOSAPREPITANT DIMEGLUMINEPOWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

AP	APOTEX	EQ 150MG BASE/VIAL	A205020	001	Sep 05, 2019	Aug NEWA
AP	BAXTER HLTHCARE CORP	EQ 150MG BASE/VIAL	A211860	001	Sep 05, 2019	Aug NEWA
AP	BE PHARMS	EQ 150MG BASE/VIAL	A212309	001	Sep 05, 2019	Aug NEWA
AP	LUPIN LTD	EQ 150MG BASE/VIAL	A210689	001	Sep 05, 2019	Aug NEWA
AP	MSN LABS PVT LTD	EQ 150MG BASE/VIAL	A209965	001	Sep 05, 2019	Aug NEWA
	MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Aug NFTG
AP		EQ 150MG BASE/VIAL	A204015	002	Sep 05, 2019	Aug NEWA
AP	SUNGEN PHARMA	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Aug NEWA
>A>	TEVA PHARMS USA	EQ 150MG BASE/VIAL	N210064	001	Sep 05, 2019	Oct CPOT
>A>		150MG/VIAL	N210064	001	Sep 05, 2019	Oct CAIN

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@ ANI PHARMS INC	10MG;12.5MG	A076608	001	Dec 03, 2004	May CAHN
@	20MG;12.5MG	A076608	002	Dec 03, 2004	May CAHN

FOSPHENYTOIN SODIUMINJECTABLE; INJECTION  
FOSPHENYTOIN SODIUM

@ DR REDDYS	EQ 50MG PHENYTOIN NA/ML	A076886	001	Aug 06, 2007	May CAHN
@ LUITPOLD	EQ 50MG PHENYTOIN NA/ML	A078277	001	Aug 06, 2007	Feb DISC
@	EQ 50MG PHENYTOIN NA/ML	A090099	001	May 13, 2010	Feb DISC

FROVATRIPTAN SUCCINATETABLET; ORAL  
FROVATRIPTAN SUCCINATE

AB	AMNEAL PHARMS CO	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	Aug CMFD
	@	EQ 2.5MG BASE	A211292	001	Nov 06, 2018	May DISC

FULVESTRANTINJECTABLE; INTRAMUSCULAR  
FASLODEX

AO	+! ASTRAZENECA	50MG/ML	N021344	001	Apr 25, 2002	Apr CMS1
AP	+!	50MG/ML	N021344	001	Apr 25, 2002	Feb CFTG

FULVESTRANT

AO	GLENMARK PHARMS INC	50MG/ML	A207754	001	Aug 22, 2019	Aug NEWA
AO	MYLAN INSTITUTIONAL	50MG/ML	A208811	001	Jul 23, 2019	Jul NEWA
AO	SAGENT PHARMS INC	50MG/ML	A205871	001	Aug 22, 2019	Aug NEWA
AO	SANDOZ INC	50MG/ML	A205935	001	May 14, 2019	Apr NEWA

SOLUTION; INTRAMUSCULAR  
FULVESTRANT

FRESENIUS KABI USA	250MG/5ML (50MG/ML)	N210326	001	May 20, 2019	May NEWA
TEVA PHARMS USA INC	250MG/5ML (50MG/ML)	N210063	001	Aug 19, 2019	Aug NEWA

FUROSEMIDEINJECTABLE; INJECTION  
FUROSEMIDE

AP	AUROBINDO PHARMA LTD	10MG/ML	A212174	001	May 03, 2019	Apr NEWA
----	----------------------	---------	---------	-----	--------------	----------

TABLET; ORAL  
FUROSEMIDE

	@ ANI PHARMS INC	20MG	A071379	001	Jan 02, 1987	Jul CAHN
	@	40MG	A070413	001	Feb 26, 1986	Sep CAHN
>A> AB	AVET	20MG	N018413	001	Nov 30, 1983	Oct CAHN
>A> AB		40MG	N018413	002	Nov 30, 1983	Oct CAHN
>D> AB	HERITAGE PHARMA	20MG	N018413	001	Nov 30, 1983	Oct CAHN
AB		20MG	N018413	001	Nov 30, 1983	Feb CAHN
>D> AB		40MG	N018413	002	Nov 30, 1983	Oct CAHN
AB		40MG	N018413	002	Nov 30, 1983	Feb CAHN

GABAPENTINCAPSULE;ORAL  
GABAPENTIN

AB	GRANULES INDIA LTD	100MG	A075360	001	Apr 06, 2005	Jun CAHN
AB		300MG	A075360	002	Apr 06, 2005	Jun CAHN
AB		400MG	A075360	003	Apr 06, 2005	Jun CAHN

TABLET;ORAL  
GABAPENTIN

	@ IVAX SUB TEVA PHARMS	600MG	A076017	004	Apr 29, 2005	Jul DISC
	@	800MG	A076017	005	Apr 29, 2005	Jul DISC
	@ LUPIN LTD	600MG	A209306	001	Aug 24, 2018	Mar DISC
	@	800MG	A209306	002	Aug 24, 2018	Mar DISC
AB	RUBICON	600MG	A077661	004	Sep 13, 2006	Aug CAHN
AB		800MG	A077661	005	Sep 13, 2006	Aug CAHN

GADOTERATE MEGLUMINESOLUTION;INTRAVENOUS  
CLARISCAN

>A>	GE HEALTHCARE	7.538GM/20ML (376.9MG/ML)	A210016	003	Nov 01, 2019	Oct NFTG
>A>		3.769GM/10ML (376.9MG/ML)	A210016	001	Nov 01, 2019	Oct NFTG
>A>		5.6535GM/15ML (376.9MG/ML)	A210016	002	Nov 01, 2019	Oct NFTG

DOTAREM

>D>	+! GUERBET	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Oct CFTG
>A>	+!	3.769GM/10ML (376.9MG/ML)	N204781	002	Mar 20, 2013	Oct CFTG
>D>	+!	5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Oct CFTG
>A>	+!	5.6535GM/15ML (376.9MG/ML)	N204781	003	Mar 20, 2013	Oct CFTG
>D>	+!	7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Oct CFTG
>A>	+!	7.538GM/20ML (376.9MG/ML)	N204781	004	Mar 20, 2013	Oct CFTG

GALANTAMINE HYDROBROMIDETABLET;ORAL  
GALANTAMINE HYDROBROMIDE

	@ HERITAGE PHARMA	EQ 4MG BASE	A077585	001	Sep 15, 2009	May CAHN
	@	EQ 4MG BASE	A077587	001	Jul 09, 2009	Sep DISC
AB		EQ 4MG BASE	A077587	001	Jul 09, 2009	May CAHN
	@	EQ 8MG BASE	A077585	002	Sep 15, 2009	May CAHN
	@	EQ 8MG BASE	A077587	002	Jul 09, 2009	Sep DISC
AB		EQ 8MG BASE	A077587	002	Jul 09, 2009	May CAHN
	@	EQ 12MG BASE	A077585	003	Sep 15, 2009	May CAHN
	@	EQ 12MG BASE	A077587	003	Jul 09, 2009	Sep DISC
AB		EQ 12MG BASE	A077587	003	Jul 09, 2009	May CAHN

GALLIUM CITRATE GA-67INJECTABLE;INJECTION  
GALLIUM CITRATE GA 67

BS	CURIUM	2mCi/ML	N018058	001		Jan CAHN
----	--------	---------	---------	-----	--	----------

GALLIUM DOTATOC GA-68SOLUTION;INTRAVENOUS  
GALLIUM DOTATOC GA 68

+!	UIHC PET IMAGING	0.5-4mCi/ML	N210828	001	Aug 21, 2019	Aug NEWA
----	------------------	-------------	---------	-----	--------------	----------

GALLIUM NITRATEINJECTABLE;INJECTION  
GANITE

@	CHEPLAPHARM	25MG/ML	N019961	002	Jan 17, 1991	Aug CAHN
---	-------------	---------	---------	-----	--------------	----------

GANCICLOVIRSOLUTION;INTRAVENOUS  
GANZYK-RTU

+!	EXELA PHARMA SCS LLC	500MG/250ML (2MG/ML)	N209347	001	Feb 17, 2017	Sep CTNA
----	----------------------	----------------------	---------	-----	--------------	----------

GANCICLOVIR SODIUMINJECTABLE;INJECTION  
CYTOVENE

AP	+! CHEPLAPHARM	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Aug CAHN
----	----------------	--------------------	---------	-----	--------------	----------

GANCICLOVIR SODIUM

AP	CUSTOPHARM INC	EQ 500MG BASE/VIAL	A212001	001	Jun 20, 2019	Jun NEWA
AP	FRESENIUS KABI USA	EQ 500MG BASE/VIAL	A090658	001	Jun 21, 2010	Jul CTNA
AP	HAINAN POLY PHARM	EQ 500MG BASE/VIAL	A204204	001	Nov 08, 2018	Jul CTNA
	@ LUITPOLD	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Jul CTNA

INJECTABLE;INJECTION  
GANCICLOVIR SODIUM

	@	EQ 500MG BASE/VIAL	A202624	001	Sep 18, 2013	Feb DISC
AP	MYLAN LABS LTD	EQ 500MG BASE/VIAL	A204560	001	Nov 17, 2017	Jul CTNA
AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	Jul CTNA

GANIRELIX ACETATE

INJECTABLE;INJECTION  
GANIRELIX ACETATE

AP	+!	ORGANON USA INC	250MCG/0.5ML	N021057	001	Jul 29, 1999	Mar CPOT
AP		SUN PHARM	250MCG/0.5ML	A204246	001	Nov 30, 2018	Mar CPOT

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION  
GEMCITABINE HYDROCHLORIDE

AP		FRESENIUS KABI USA	EQ 200MG BASE/VIAL	A090799	001	Jul 25, 2011	Jan CAHN
AP			EQ 1GM BASE/VIAL	A090799	002	Jul 25, 2011	Jan CAHN
AP			EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	Jan CAHN
>D>	AP	INGENUS PHARMS LLC	200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Oct DISC
>A>	@		200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Oct DISC
	AP		200MG/5.26ML (38MG/ML)	A210383	001	Feb 14, 2019	Feb NEWA
>D>	AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Oct DISC
>A>	@		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Oct DISC
	AP		1GM/26.3ML (38MG/ML)	A210383	002	Feb 14, 2019	Feb NEWA
>D>	AP		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Oct DISC
>A>	@		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Oct DISC
	AP		2GM/52.6ML (38MG/ML)	A210383	003	Feb 14, 2019	Feb NEWA
	@	LUITPOLD	EQ 200MG BASE/VIAL	A202031	001	May 07, 2013	Feb DISC
	@		EQ 1GM BASE/VIAL	A202031	002	May 07, 2013	Feb DISC
>D>	AP	SHILPA MEDICARE LTD	EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Oct DISC
>A>	@		EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Oct DISC
	AP		EQ 200MG BASE/VIAL	A207575	001	Feb 22, 2019	Feb NEWA
	AP		200MG/5.26ML (38MG/ML)	A210991	001	Oct 04, 2019	Sep NEWA
>D>	AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Oct DISC
>A>	@		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Oct DISC
	AP		EQ 1GM BASE/VIAL	A207575	002	Feb 22, 2019	Feb NEWA
	AP		1GM/26.3ML (38MG/ML)	A210991	002	Oct 04, 2019	Sep NEWA
	AP		2GM/52.6ML (38MG/ML)	A210991	003	Oct 04, 2019	Sep NEWA

GEMFIBROZIL

TABLET;ORAL  
GEMFIBROZIL

>D>	AB	SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Oct DISC
>A>	@		600MG	A079239	001	Dec 29, 2008	Oct DISC

GENTAMICIN SULFATE

CREAM;TOPICAL  
GENTAMICIN SULFATE

>A>	AT	TELIGENT PHARMA INC	EQ 0.1% BASE	A209304	001	Oct 18, 2019	Oct NEWA
-----	----	---------------------	--------------	---------	-----	--------------	----------

INJECTABLE;INJECTION  
GENTAMICIN SULFATE

AP	!	FRESENIUS KABI USA	EQ 10MG BASE/ML	A062366	002	Feb 06, 1986	Jul CHRS
----	---	--------------------	-----------------	---------	-----	--------------	----------

OINTMENT;OPHTHALMIC  
GENTAMICIN SULFATE

AT		FERA PHARMS LLC	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Sep CAHN
----	--	-----------------	--------------	---------	-----	--------------	----------

GLASDEGIB MALEATE

TABLET;ORAL  
DAURISMO

	+	PFIZER INC	EQ 25MG BASE	N210656	001	Nov 21, 2018	Feb CAIN
	+!		EQ 100MG BASE	N210656	002	Nov 21, 2018	Feb CAIN

GLIMEPIRIDE

TABLET;ORAL  
GLIMEPIRIDE

AB		MICRO LABS	1MG	A091220	001	Jun 29, 2012	Mar CAHN
AB			2MG	A091220	002	Jun 29, 2012	Mar CAHN
			3MG	A091220	003	Jun 29, 2012	Mar CAHN
AB			4MG	A091220	004	Jun 29, 2012	Mar CAHN
			6MG	A091220	005	Jun 29, 2012	Mar CAHN
AB			8MG	A091220	006	Jun 29, 2012	Mar CAHN
>D>	AB	TEVA	1MG	A076802	001	Oct 06, 2005	Oct DISC

TABLET;ORAL  
GLIMEPIRIDE

>A>	@	1MG	A076802	001	Oct 06, 2005	Oct DISC
>D> AB		2MG	A076802	002	Oct 06, 2005	Oct DISC
>A>	@	2MG	A076802	002	Oct 06, 2005	Oct DISC
>D> AB		4MG	A076802	003	Oct 06, 2005	Oct DISC
>A>	@	4MG	A076802	003	Oct 06, 2005	Oct DISC

GLIPIZIDE

TABLET;ORAL  
GLIPIZIDE

@ BEXIMCO PHARMS USA	5MG	A074542	001	Jun 20, 1995	Feb CAHN
@	10MG	A074542	002	Jun 20, 1995	Feb CAHN

## TABLET, EXTENDED RELEASE;ORAL

## GLIPIZIDE

@ MYLAN	2.5MG	A202298	001	May 19, 2015	Feb DISC
@	5MG	A202298	002	May 19, 2015	Feb DISC
@	10MG	A202298	003	May 19, 2015	Feb DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

## TABLET;ORAL

## GLIPIZIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN	2.5MG;250MG	A078083	001	Apr 12, 2007	Apr DISC	
>D> AB	SUN PHARM INDS INC	2.5MG;250MG	A077620	001	Jan 11, 2008	Oct DISC
>A>	@	2.5MG;250MG	A077620	001	Jan 11, 2008	Oct DISC
>D> AB		2.5MG;500MG	A077620	002	Jan 11, 2008	Oct DISC
>A>	@	2.5MG;500MG	A077620	002	Jan 11, 2008	Oct DISC
>D> AB		5MG;500MG	A077620	003	Jan 11, 2008	Oct DISC
>A>	@	5MG;500MG	A077620	003	Jan 11, 2008	Oct DISC

GLUCAGON

## POWDER;NASAL

## BAQSIMI

+! ELI LILLY AND CO	3MG	N210134	001	Jul 24, 2019	Jul NEWA
---------------------	-----	---------	-----	--------------	----------

## SOLUTION;SUBCUTANEOUS

## GVOKE HYOPEN

+! XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	003	Sep 10, 2019	Sep NEWA
+!	1MG/0.2ML (1MG/0.2ML)	N212097	004	Sep 10, 2019	Sep NEWA

## GVOKE PFS

+! XERIS	0.5MG/0.1ML (0.5MG/0.1ML)	N212097	001	Sep 10, 2019	Sep NEWA
+!	1MG/0.2ML (1MG/0.2ML)	N212097	002	Sep 10, 2019	Sep NEWA

GLYBURIDE

## TABLET;ORAL

## GLYBURIDE

@ ORIENT PHARMA CO LTD	1.25MG	A206483	001	Feb 22, 2019	Jul DISC
AB1	1.25MG	A206483	001	Feb 22, 2019	Feb NEWA
@	2.5MG	A206483	002	Feb 22, 2019	Jul DISC
AB1	2.5MG	A206483	002	Feb 22, 2019	Feb NEWA
@	5MG	A206483	003	Feb 22, 2019	Jul DISC
AB1	5MG	A206483	003	Feb 22, 2019	Feb NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

## TABLET;ORAL

## GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ HERITAGE PHARMS INC	1.25MG;250MG	A079009	001	Jun 03, 2009	Aug DISC
@	2.5MG;500MG	A079009	002	Jun 03, 2009	Aug DISC
@	5MG;500MG	A079009	003	Jun 03, 2009	Aug DISC

GLYCEROL PHENYLBUTYRATE

## LIQUID;ORAL

## RAVICTI

+! HORIZON THERAP	1.1GM/ML	N203284	001	Feb 01, 2013	Feb CAHN
-------------------	----------	---------	-----	--------------	----------

GLYCOPYRROLATE

## INJECTABLE;INJECTION

## GLYCOPYRROLATE

>A> AP	APOTEX	0.2MG/ML	A210246	001	Oct 29, 2019	Oct NEWA
AP	CAPLIN	0.2MG/ML	A211705	001	Mar 20, 2019	Mar NEWA
AP	GLAND PHARMA LTD	0.2MG/ML	A212612	001	Sep 30, 2019	Sep NEWA
AP	PIRAMAL CRITICAL	0.2MG/ML	A210842	001	Oct 25, 2018	Jun CAHN
AP	SANDOZ INC	0.2MG/ML	A211334	001	May 14, 2019	Apr NEWA

INJECTABLE; INJECTION							
ROBINUL							
	+ @ HIKMA	0.2MG/ML		N017558	001		Aug CAHN
TABLET; ORAL							
GLYCOPYRROLATE							
AA	AUROLIFE PHARMA LLC	2MG		A202675	002	Oct 30, 2018	May NEWA
AA	KENTON	1MG		A091182	001	Feb 03, 2014	Mar CAHN
AA		2MG		A091182	002	Feb 03, 2014	Mar CAHN
<u>GRANISETRON HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
GRANISETRON HYDROCHLORIDE							
AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A078863	001	Jun 30, 2008	Apr CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A078880	001	Jun 30, 2008	Apr CAHN
AP	! DR REDDYS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)		A078392	001	Dec 31, 2007	May CAHN
AP	! @ LUITPOLD	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)		A077297	001	Jun 30, 2008	May CAHN
		EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A091274	001	Sep 22, 2010	Feb DISC
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE							
AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A078863	002	Jun 30, 2008	Apr CAHN
	@ DR REDDYS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)		A077165	001	Dec 31, 2007	May CAHN
TABLET; ORAL							
GRANISETRON HYDROCHLORIDE							
	@ TEVA PHARMS	EQ 1MG BASE		A078080	001	Dec 31, 2007	Jan DISC
<u>GUAIFENESIN; HYDROCODONE BITARTRATE</u>							
SOLUTION; ORAL							
OBREDON							
	+ @ SOVEREIGN PHARMS	200MG/5ML; 2.5MG/5ML		N205474	001	Nov 14, 2014	Jun DISC
TABLET; ORAL							
XTRELUS							
	+ @ ECI PHARMS LLC	400MG; 5MG		N208085	001	Apr 25, 2018	Jun DISC
<u>GUANFACINE HYDROCHLORIDE</u>							
TABLET; ORAL							
GUANFACINE HYDROCHLORIDE							
AB	EPIC PHARMA LLC	EQ 1MG BASE		A074673	001	Feb 28, 1997	Apr CMFD
AB		EQ 2MG BASE		A074673	002	Feb 28, 1997	Apr CMFD
TABLET, EXTENDED RELEASE; ORAL							
GUANFACINE HYDROCHLORIDE							
	@ MYLAN	EQ 1MG BASE		A202578	001	Jun 02, 2015	May DISC
	@	EQ 2MG BASE		A202578	002	Jun 02, 2015	May DISC
	@	EQ 3MG BASE		A202578	003	Jun 02, 2015	May DISC
	@	EQ 4MG BASE		A202578	004	Jun 02, 2015	May DISC
<u>HALCINONIDE</u>							
CREAM; TOPICAL							
HALCINONIDE							
AB	MYLAN	0.1%		A211027	001	Aug 12, 2019	Jul NEWA
HALOG							
AB	+! SUN PHARM INDS INC	0.1%		N017556	001		Aug CFTG
<u>HALOBETASOL PROPIONATE</u>							
AEROSOL, FOAM; TOPICAL							
LEXETTE							
	+! MAYNE PHARMA	0.05%		N210566	001	May 24, 2018	Sep CTNA
LOTION; TOPICAL							
BRYHALI							
	+! BAUSCH	0.01%		N209355	001	Nov 06, 2018	Apr CAHN
	+! DOW PHARM	0.01%		N209355	001	Nov 06, 2018	Jan CHRS
	+	0.01%		N209355	001	Nov 06, 2018	Jan CRLD
<u>HALOBETASOL PROPIONATE; TAZAROTENE</u>							
LOTION; TOPICAL							
DUOBRII							
	+! BAUSCH	0.01%; 0.045%		N209354	001	Apr 25, 2019	Apr NEWA

HALOPERIDOL

## TABLET; ORAL

## HALOPERIDOL

>D>	@ INNOGENIX	0.5MG	A071173	002	Jan 02, 1987	Oct CMFD
>A>	AB	0.5MG	A071173	002	Jan 02, 1987	Oct CMFD
	@	0.5MG	A071173	002	Jan 02, 1987	May CMS1
>D>	@	1MG	A071173	003	Jan 02, 1987	Oct CMFD
>A>	AB	1MG	A071173	003	Jan 02, 1987	Oct CMFD
	@	1MG	A071173	003	Jan 02, 1987	May CMS1
>D>	@	2MG	A071173	004	Jan 02, 1987	Oct CMFD
>A>	AB	2MG	A071173	004	Jan 02, 1987	Oct CMFD
	@	2MG	A071173	004	Jan 02, 1987	May CMS1
>D>	@	5MG	A071173	005	Jan 07, 1988	Oct CMFD
>A>	AB	5MG	A071173	005	Jan 07, 1988	Oct CMFD
	@	5MG	A071173	005	Jan 07, 1988	May CMS1
>D>	@	10MG	A071173	001	Jan 07, 1988	Oct CMFD
>A>	AB	10MG	A071173	001	Jan 07, 1988	Oct CMFD
	@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
>D>	@	20MG	A071173	006	Jan 07, 1988	Oct CMFD
>A>	AB	20MG	A071173	006	Jan 07, 1988	Oct CMFD
	@	20MG	A071173	006	Jan 07, 1988	May CMS1
	! MYLAN	2MG	A070278	001	Jun 10, 1986	Jan CTEC
AB	!	2MG	A070278	001	Jun 10, 1986	Jan CHRS
	@ SANDOZ	2MG	A071208	001	Nov 17, 1986	Jan DISC

HALOPERIDOL DECANOATE

## INJECTABLE; INJECTION

## HALOPERIDOL DECANOATE

>A>	AO	ZYDUS PHARMS	EQ 50MG BASE/ML	A211180	001	Oct 22, 2019	Oct NEWA
>A>	AO		EQ 100MG BASE/ML	A211180	002	Oct 22, 2019	Oct NEWA

HALOPERIDOL LACTATE

## CONCENTRATE; ORAL

## HALOPERIDOL

AA	!	PHARM ASSOC	EQ 2MG BASE/ML	A073037	001	Feb 26, 1993	May CHRS
	@	TEVA PHARMS	EQ 2MG BASE/ML	A071617	001	Dec 01, 1988	May DISC
		HALOPERIDOL INTENSOL					
	@	HIKMA	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	Sep CAHN

## INJECTABLE; INJECTION

## HALOPERIDOL

AP		FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Jun NEWA
----	--	--------------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

## INJECTABLE; INJECTION

## HEPARIN SODIUM

		B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Aug CAHN
AP	+	HIKMA	1,000 UNITS/ML	N017037	001		Feb CAHN
AP	+		5,000 UNITS/ML	N017037	002		Feb CAHN
	@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Feb CAHN
AP	+		10,000 UNITS/ML	N017037	003		Feb CAHN
AP		NANJING KING-FRIEND	1,000 UNITS/ML	A211007	001	May 28, 2019	May NEWA
AP			5,000 UNITS/ML	A211007	002	May 28, 2019	May NEWA
AP			10,000 UNITS/ML	A211007	003	May 28, 2019	May NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

## SYRUP; ORAL

## HYCODAN

AA	+	GENUS LIFESCIENCES	1.5MG/5ML; 5MG/5ML	N005213	002	Jul 26, 1988	Jun CMFD
		HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE					
	@	BRECKENRIDGE	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	Jul DISC
AA		BRECKENRIDGE PHARM	1.5MG/5ML; 5MG/5ML	A210663	001	Jun 11, 2019	May NEWA

HYDRALAZINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## HYDRALAZINE HYDROCHLORIDE

@ LUITPOLD 20MG/ML

A040136 001 Jun 30, 1997 Feb DISC

## TABLET; ORAL

## HYDRALAZINE HYDROCHLORIDE

>A>	AA	STRIDES PHARMA	10MG	A200770	004	Jun 25, 2019	Oct NEWA
	AA	UPSHER SMITH LABS	10MG	A209251	001	Jul 09, 2018	Jun CAHN
	AA		25MG	A209251	002	Jul 09, 2018	Jun CAHN

## TABLET;ORAL

## HYDRALAZINE HYDROCHLORIDE

AA		50MG	A209251	003	Jul 09, 2018	Jun CAHN
AA		100MG	A209251	004	Jul 09, 2018	Jun CAHN

HYDROCHLOROTHIAZIDE

## TABLET;ORAL

## HYDROCHLOROTHIAZIDE

>D>	AB	SUN PHARM INDS INC	12.5MG	A040857	001	May 30, 2008	Oct DISC
>A>		@	12.5MG	A040857	001	May 30, 2008	Oct DISC
>D>	AB		25MG	A040810	001	Mar 27, 2007	Oct DISC
>A>		@	25MG	A040810	001	Mar 27, 2007	Oct DISC
>D>	AB		50MG	A040810	002	Mar 27, 2007	Oct DISC
>A>		@	50MG	A040810	002	Mar 27, 2007	Oct DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

## TABLET;ORAL

## IRBESARTAN AND HYDROCHLOROTHIAZIDE

	@	APOTEX INC	12.5MG;150MG	A201505	001	Oct 15, 2012	Jul DISC
	@		12.5MG;300MG	A201505	002	Oct 15, 2012	Jul DISC

HYDROCHLOROTHIAZIDE; LISINOPRIL

## TABLET;ORAL

## LISINOPRIL AND HYDROCHLOROTHIAZIDE

	@	HERITAGE PHARMA	12.5MG;10MG	A075776	001	Jul 01, 2002	Aug DISC
AB			12.5MG;10MG	A075776	001	Jul 01, 2002	Feb CAHN
	@		12.5MG;20MG	A075776	002	Jul 01, 2002	Aug DISC
AB			12.5MG;20MG	A075776	002	Jul 01, 2002	Feb CAHN
	@		25MG;20MG	A075776	003	Jul 01, 2002	Aug DISC
AB			25MG;20MG	A075776	003	Jul 01, 2002	Feb CAHN

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

	@	ACCORD HLTHCARE	12.5MG;20MG	A209281	001	Feb 07, 2019	Aug DISC
AB			12.5MG;20MG	A209281	001	Feb 07, 2019	Jan NEWA
	@		12.5MG;40MG	A209281	002	Feb 07, 2019	Aug DISC
AB			12.5MG;40MG	A209281	002	Feb 07, 2019	Jan NEWA
	@		25MG;40MG	A209281	003	Feb 07, 2019	Aug DISC
AB			25MG;40MG	A209281	003	Feb 07, 2019	Jan NEWA
	@	TEVA PHARMS USA	12.5MG;20MG	A200532	001	Apr 24, 2017	Jul DISC
	@		25MG;40MG	A200532	003	Apr 24, 2017	Jul DISC
AB		UMEDICA LABS PVT LTD	12.5MG;20MG	A208847	001	Sep 17, 2019	Sep NEWA
AB			12.5MG;40MG	A208847	003	Sep 17, 2019	Sep NEWA
AB			25MG;40MG	A208847	002	Sep 17, 2019	Sep NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

## TABLET;ORAL

## QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@	MYLAN	12.5MG;EQ 10MG BASE	A077093	001	Mar 28, 2005	May DISC
	@		12.5MG;EQ 20MG BASE	A077093	002	Mar 28, 2005	May DISC
	@		25MG;EQ 20MG BASE	A077093	003	Mar 28, 2005	May DISC
		QUINARETIC					
AB		LUPIN	12.5MG;EQ 10MG BASE	A076374	001	Mar 31, 2004	Feb CAHN
AB			12.5MG;EQ 20MG BASE	A076374	002	Mar 31, 2004	Feb CAHN
AB			25MG;EQ 20MG BASE	A076374	003	Mar 31, 2004	Feb CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

## TABLET;ORAL

## TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		GLENMARK PHARMS LTD	12.5MG;40MG	A202544	001	Mar 04, 2019	Feb NEWA
AB			12.5MG;80MG	A202544	002	Mar 04, 2019	Feb NEWA
AB			25MG;80MG	A202544	003	Mar 04, 2019	Feb NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

## CAPSULE;ORAL

## TRIAMTERENE AND HYDROCHLOROTHIAZIDE

	@	ANI PHARMS INC	25MG;50MG	A074259	001	Mar 30, 1995	Jun DISC
	@	CASI PHARMS INC	25MG;50MG	A073191	001	Jul 31, 1991	Jun DISC
AB		ZYDUS PHARMS	25MG;37.5MG	A208358	001	Feb 11, 2019	Jan NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL						
VALSARTAN AND HYDROCHLOROTHIAZIDE						
	@ ZYDUS PHARMS	12.5MG; 80MG	A203000	001	Mar 15, 2019	Aug DISC
AB		12.5MG; 80MG	A203000	001	Mar 15, 2019	Mar NEWA
	@	12.5MG; 160MG	A203000	002	Mar 15, 2019	Aug DISC
AB		12.5MG; 160MG	A203000	002	Mar 15, 2019	Mar NEWA
	@	12.5MG; 320MG	A203000	003	Mar 15, 2019	Aug DISC
AB		12.5MG; 320MG	A203000	003	Mar 15, 2019	Mar NEWA
	@	25MG; 160MG	A203000	004	Mar 15, 2019	Aug DISC
AB		25MG; 160MG	A203000	004	Mar 15, 2019	Mar NEWA
	@	25MG; 320MG	A203000	005	Mar 15, 2019	Aug DISC
AB		25MG; 320MG	A203000	005	Mar 15, 2019	Mar NEWA

HYDROCODONE BITARTRATECAPSULE, EXTENDED RELEASE; ORAL  
ZOHYDRO ER

+!	PERSION	10MG	N202880	001	Oct 25, 2013	Apr CAHN
+		15MG	N202880	002	Oct 25, 2013	Apr CAHN
+		20MG	N202880	003	Oct 25, 2013	Apr CAHN
+		30MG	N202880	004	Oct 25, 2013	Apr CAHN
+		40MG	N202880	005	Oct 25, 2013	Apr CAHN
+		50MG	N202880	006	Oct 25, 2013	Apr CAHN

TABLET, EXTENDED RELEASE; ORAL  
HYSINGLA ER

+!	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Jul CMS1
+		30MG	N206627	002	Nov 20, 2014	Jul CMS1
+		40MG	N206627	003	Nov 20, 2014	Jul CMS1
+		60MG	N206627	004	Nov 20, 2014	Jul CMS1
+		80MG	N206627	005	Nov 20, 2014	Jul CMS1
+		100MG	N206627	006	Nov 20, 2014	Jul CMS1
+		120MG	N206627	007	Nov 20, 2014	Jul CMS1

HYDROCODONE BITARTRATE; IBUPROFEN

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND IBUPROFEN

	@ ANI PHARMS INC	5MG; 200MG	A077454	001	Jun 23, 2010	May CAHN
>D> AB	SUN PHARM INDS INC	2.5MG; 200MG	A091633	001	May 28, 2013	Oct DISC
>A>	@	2.5MG; 200MG	A091633	001	May 28, 2013	Oct DISC
>D> AB		5MG; 200MG	A091633	002	May 28, 2013	Oct DISC
>A>	@	5MG; 200MG	A091633	002	May 28, 2013	Oct DISC
>D> AB		7.5MG; 200MG	A091633	003	May 28, 2013	Oct DISC
>A>	@	7.5MG; 200MG	A091633	003	May 28, 2013	Oct DISC
>D> AB		10MG; 200MG	A091633	004	May 28, 2013	Oct DISC
>A>	@	10MG; 200MG	A091633	004	May 28, 2013	Oct DISC
REPREXAIN						
>D> AB	AMNEAL PHARMS NY	2.5MG; 200MG	A076642	003	Oct 19, 2007	Oct CTEC
>A>		2.5MG; 200MG	A076642	003	Oct 19, 2007	Oct CTEC

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

## SOLUTION; ORAL

## HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	@ MAYNE PHARMA INC	5MG/5ML; 60MG/5ML	A205658	001	Nov 17, 2015	Jun DISC
	@ PADDOCK LLC	5MG/5ML; 60MG/5ML	A204658	001	Apr 29, 2014	Jun DISC
	@ TORRENT	5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Feb DISC
AA		5MG/5ML; 60MG/5ML	A206661	001	Jan 23, 2019	Jan NEWA
REZIRA						
+	@ PERSION	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Jun DISC
AA	+!	5MG/5ML; 60MG/5ML	N022442	001	Jun 08, 2011	Apr CAHN

HYDROCORTISONE

## CREAM; TOPICAL

## NUTRACORT

@	BAUSCH	0.5%	A080442	002		Feb CAHN
@		1%	A080442	003		Feb CAHN

## LOTION; TOPICAL

## CETACORT

@	BAUSCH	0.5%	A080426	002		Feb CAHN
@		1%	A080426	001		Feb CAHN

TABLET; ORAL									
HYDROCORTISONE									
AB	BRECKENRIDGE	5MG	A207029	001	Apr 27, 2017	Aug	CAHN		
AB		10MG	A207029	002	Apr 27, 2017	Aug	CAHN		
AB		20MG	A207029	003	Apr 27, 2017	Aug	CAHN		
<u>HYDROCORTISONE BUTYRATE</u>									
CREAM; TOPICAL									
LOCOID									
AB1	+! BAUSCH	0.1%	N018514	001	Mar 31, 1982	May	CAHN		
LOTION; TOPICAL									
LOCOID									
AB	+! BAUSCH	0.1%	N022076	001	May 18, 2007	May	CAHN		
SOLUTION; TOPICAL									
LOCOID									
AT	+! BAUSCH	0.1%	N019116	001	Feb 25, 1987	May	CAHN		
<u>HYDROCORTISONE VALERATE</u>									
CREAM; TOPICAL									
HYDROCORTISONE VALERATE									
AB	LUPIN LTD	0.2%	A210307	001	Aug 15, 2019	Aug	NEWA		
AB	PERRIGO ISRAEL	0.2%	A075666	001	May 24, 2000	May	CAHN		
<u>HYDROGEN PEROXIDE</u>									
SOLUTION; TOPICAL									
ESKATA									
	+ @ ACLARIS	40%	N209305	001	Dec 14, 2017	Aug	DISC		
<u>HYDROMORPHONE HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE; ORAL									
EXALGO									
	+ @ SPECGX LLC	8MG	N021217	001	Mar 01, 2010	Mar	DISC		
	+ @	12MG	N021217	002	Mar 01, 2010	Mar	DISC		
	+ @	16MG	N021217	003	Mar 01, 2010	Mar	DISC		
	+ @	32MG	N021217	004	Aug 24, 2012	Mar	DISC		
HYDROMORPHONE HYDROCHLORIDE									
AB	! OSMOTICA	32MG	A205629	004	Jul 07, 2016	Mar	CHRS		
<u>HYDROXYCHLOROQUINE SULFATE</u>									
TABLET; ORAL									
HYDROXYCHLOROQUINE SULFATE									
	@ LAURUS LABS LTD	200MG	A210959	001	Jan 15, 2019	Sep	DISC		
AB		200MG	A210959	001	Jan 15, 2019	Jan	CAHN		
	@ LUPIN LTD	200MG	A210543	001	Jul 06, 2018	Feb	DISC		
<u>HYDROXYPROGESTERONE CAPROATE</u>									
SOLUTION; INTRAMUSCULAR									
HYDROXYPROGESTERON CAPROATE									
AP1	AM REGENT	1250MG/5ML (250MG/ML)	A210724	001	Aug 09, 2019	Jul	NEWA		
HYDROXYPROGESTERONE CAPROATE									
AP	ASPEN	250MG/ML (250MG/ML)	A211777	001	Aug 08, 2019	Jul	NEWA		
AP2	! ASPEN GLOBAL INC	1250MG/5ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr	CPOT		
AP2	!	250MG/ML (250MG/ML)	A200271	001	Aug 24, 2015	Apr	CTEC		
AP	EUGIA PHARMA	250MG/ML (250MG/ML)	A211071	001	Apr 16, 2019	Apr	NEWA		
AP1		1250MG/5ML (250MG/ML)	A211070	001	Apr 16, 2019	Apr	NEWA		
AP	SLAYBACK PHARMA LLC	250MG/ML (250MG/ML)	A210877	001	Mar 22, 2019	Mar	NEWA		
AP1		1250MG/5ML (250MG/ML)	A210618	001	Dec 28, 2018	Apr	CTEC		
AP1	SUN PHARM	1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Apr	CTEC		
AP		1250MG/5ML (250MG/ML)	A208381	001	Apr 09, 2019	Mar	NEWA		
MAKENA									
AP1	+! AMAG PHARMA USA	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Apr	CTEC		
<u>HYDROXYPROPYL CELLULOSE</u>									
INSERT; OPHTHALMIC									
LACRISERT									
	+! VALEANT PHARMS INTL	5MG	N018771	001		Jan	CAHN		

HYDROXYZINE HYDROCHLORIDE

INJECTABLE;INJECTION  
HYDROXYZINE HYDROCHLORIDE

! LUITPOLD 50MG/ML  
@ 50MG/ML

A087408 002 Mar CMFD  
A087408 002 Feb DISC

SYRUP;ORAL

HYDROXYZINE HYDROCHLORIDE

@ ANIMA 10MG/5ML

A086880 001 Sep CAHN

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB EPIC PHARMA LLC 10MG  
AB 25MG  
AB 50MG  
AB KVK TECH 25MG  
AB 50MG  
@ MYLAN 10MG  
@ 25MG  
@ 50MG

A040604 002 Dec 28, 2004 Jan CAHN  
A040604 003 Dec 28, 2004 Jan CAHN  
A040604 001 Dec 28, 2004 Jan CAHN  
A040786 002 Mar 20, 2007 Feb CMS1  
A040786 003 Mar 20, 2007 Feb CMS1  
A091176 001 Jun 07, 2010 Aug DISC  
A091176 002 Jun 07, 2010 Aug DISC  
A091176 003 Jun 07, 2010 Aug DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

@ BEXIMCO PHARMS USA EQ 25MG HYDROCHLORIDE

A081127 001 Jun 28, 1991 Feb CAHN

IBANDRONATE SODIUM

TABLET;ORAL

IBANDRONATE SODIUM

>D> AB SUN PHARM INDUSTRIES EQ 150MG BASE  
>A> @ EQ 150MG BASE

A078996 001 Aug 15, 2012 Oct DISC  
A078996 001 Aug 15, 2012 Oct DISC

IBUPROFEN

SOLUTION;INTRAVENOUS  
CALDOLOR

+! CUMBERLAND PHARMS 800MG/200ML (4MG/ML)

N022348 003 Jan 25, 2019 Jan NEWA

SUSPENSION;ORAL

IBUPROFEN

AB L PERRIGO CO 100MG/5ML

A076925 001 Sep 23, 2004 May CAHN

TABLET;ORAL

IBUPROFEN

@ HEC PHARM 400MG  
@ 600MG  
@ 800MG  
AB PERRIGO PHARMS CO 400MG  
AB 600MG  
AB 800MG

A204062 001 Sep 10, 2018 Mar DISC  
A204062 002 Sep 10, 2018 Mar DISC  
A204062 003 Sep 10, 2018 Mar DISC  
A077114 001 Jul 18, 2005 May CAHN  
A077114 002 Jul 18, 2005 May CAHN  
A077114 003 Jul 18, 2005 May CAHN

IBUTILIDE FUMARATE

INJECTABLE;INJECTION

IBUTILIDE FUMARATE

@ LUITPOLD 0.1MG/ML

A090240 001 Jan 11, 2010 Feb DISC

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS  
FIRAZYR

AP +! SHIRE ORPHAN THERAP EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

N022150 001 Aug 25, 2011 Jul CFTG

ICATIBANT ACETATE

AP TEVA PHARMS USA EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A210118 001 Jul 15, 2019 Jul NFTG

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDARUBICIN HYDROCHLORIDE

>D> AP MYLAN LABS LTD 1MG/ML  
>A> @ 1MG/ML

A200144 001 Oct 11, 2012 Oct DISC  
A200144 001 Oct 11, 2012 Oct DISC

IFOSFAMIDE

INJECTABLE;INJECTION

IFOSFAMIDE

@ MYLAN LABS LTD 1GM/20ML (50MG/ML)  
@ 3GM/60ML (50MG/ML)

A201689 001 Nov 26, 2012 Sep DISC  
A201689 002 Nov 26, 2012 Sep DISC

ILOPERIDONE

## TABLET; ORAL

## FANAPT

+!	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Aug CTEC
+		2MG	N022192	002	May 06, 2009	Aug CTEC
+		4MG	N022192	003	May 06, 2009	Aug CTEC
+		6MG	N022192	004	May 06, 2009	Aug CTEC
+		8MG	N022192	005	May 06, 2009	Aug CTEC
+		10MG	N022192	006	May 06, 2009	Aug CTEC
+		12MG	N022192	007	May 06, 2009	Aug CTEC

## ILOPERIDONE

	@ INVENTIA	1MG	A207231	001	Nov 28, 2016	Aug CAHN
	@	2MG	A207231	002	Nov 28, 2016	Aug CAHN
	@	4MG	A207231	003	Nov 28, 2016	Aug CAHN
	@	6MG	A207231	004	Nov 28, 2016	Aug CAHN
	@	8MG	A207231	005	Nov 28, 2016	Aug CAHN
	@	10MG	A207231	006	Nov 28, 2016	Aug CAHN
	@	12MG	A207231	007	Nov 28, 2016	Aug CAHN
	@ INVENTIA HLTHCARE	1MG	A207231	001	Nov 28, 2016	Jul DISC
	@	2MG	A207231	002	Nov 28, 2016	Jul DISC
	@	4MG	A207231	003	Nov 28, 2016	Jul DISC
	@	6MG	A207231	004	Nov 28, 2016	Jul DISC
	@	8MG	A207231	005	Nov 28, 2016	Jul DISC
	@	10MG	A207231	006	Nov 28, 2016	Jul DISC
	@	12MG	A207231	007	Nov 28, 2016	Jul DISC
	@ TARO PHARM INDS LTD	1MG	A207098	001	Jul 22, 2019	Aug DISC
AB	@	1MG	A207098	001	Jul 22, 2019	Jul NEWA
	@	2MG	A207098	002	Jul 22, 2019	Aug DISC
AB	@	2MG	A207098	002	Jul 22, 2019	Jul NEWA
	@	4MG	A207098	003	Jul 22, 2019	Aug DISC
AB	@	4MG	A207098	003	Jul 22, 2019	Jul NEWA
	@	6MG	A207098	004	Jul 22, 2019	Aug DISC
AB	@	6MG	A207098	004	Jul 22, 2019	Jul NEWA
	@	8MG	A207098	005	Jul 22, 2019	Aug DISC
AB	@	8MG	A207098	005	Jul 22, 2019	Jul NEWA
	@	10MG	A207098	006	Jul 22, 2019	Aug DISC
AB	@	10MG	A207098	006	Jul 22, 2019	Jul NEWA
	@	12MG	A207098	007	Jul 22, 2019	Aug DISC
AB	@	12MG	A207098	007	Jul 22, 2019	Jul NEWA

IMATINIB MESYLATE

## TABLET; ORAL

## IMATINIB MESYLATE

	@ AMNEAL PHARMS	EQ 100MG BASE	A207495	001	Feb 08, 2019	Aug DISC
AB	@	EQ 100MG BASE	A207495	001	Feb 08, 2019	Feb NEWA
	@	EQ 400MG BASE	A207495	002	Feb 08, 2019	Aug DISC
AB		EQ 400MG BASE	A207495	002	Feb 08, 2019	Feb NEWA
AB	BRECKENRIDGE	EQ 100MG BASE	A205990	001	Feb 08, 2019	Feb NEWA
AB		EQ 400MG BASE	A205990	002	Feb 08, 2019	Feb NEWA
AB	NATCO PHARMA LTD	EQ 100MG BASE	A207818	001	Mar 01, 2019	Feb NEWA
AB		EQ 400MG BASE	A207818	002	Mar 01, 2019	Feb NEWA
AB	SHILPA MEDICARE LTD	EQ 100MG BASE	A208302	001	Jan 17, 2019	Jan NEWA
AB		EQ 400MG BASE	A208302	002	Jan 17, 2019	Jan NEWA
AB	WOCKHARDT BIO AG	EQ 100MG BASE	A208429	001	Jan 17, 2019	Jan NEWA
AB		EQ 400MG BASE	A208429	002	Jan 17, 2019	Jan NEWA

IMIPRAMINE HYDROCHLORIDE

## TABLET; ORAL

## IMIPRAMINE HYDROCHLORIDE

	@ OXFORD PHARMS	10MG	A040751	003	Feb 28, 2008	Mar DISC
	@	25MG	A040751	002	Feb 28, 2008	Mar DISC

IMIQUIMOD

## CREAM; TOPICAL

## ALDARA

AB	+! BAUSCH	5%	N020723	001	Feb 27, 1997	Aug CAHN
	ZYCLARA					
	+! BAUSCH	2.5%	N022483	002	Jul 15, 2011	Aug CAHN
	+!	3.75%	N022483	001	Mar 25, 2010	Aug CAHN

INDIUM IN-111 CHLORIDEINJECTABLE;INJECTION  
INDICLOR

+ @ GE HEALTHCARE	2mCi/0.2ML	N019862	001	Dec 29, 1992	Jun DISC
INDIUM IN 111 CHLORIDE					
+! CURIUM	5mCi/0.5ML	N019841	001	Sep 27, 1994	Jan CAHN

INDIUM IN-111 PENTETREOTIDE KITINJECTABLE;INJECTION  
OCTREOSCAN

+! CURIUM	3mCi/ML	N020314	001	Jun 02, 1994	Jan CAHN
-----------	---------	---------	-----	--------------	----------

INDOMETHACINCAPSULE;ORAL  
INDOCIN

+ @ EGALET	25MG	N016059	001		Feb CAHN
+ @	50MG	N016059	002		Feb CAHN

INDOMETHACIN

@ ANI PHARMS INC	25MG	A071148	001	Mar 18, 1987	May CAHN
@	50MG	A071149	001	Mar 18, 1987	May CAHN

AB	CADILA	25MG	A090403	001	Nov 15, 2010	May CAHN
----	--------	------	---------	-----	--------------	----------

AB		50MG	A090403	002	Nov 15, 2010	May CAHN
----	--	------	---------	-----	--------------	----------

AB	! GLENMARK GENERICS	50MG	A091276	002	Dec 22, 2010	Aug CHRS
----	---------------------	------	---------	-----	--------------	----------

AB	HERITAGE PHARMA	25MG	A070719	001	Feb 12, 1986	Feb CAHN
----	-----------------	------	---------	-----	--------------	----------

AB		50MG	A070756	001	Feb 12, 1986	Feb CAHN
----	--	------	---------	-----	--------------	----------

@ MYLAN	25MG	N018858	001	Apr 20, 1984	Aug DISC
---------	------	---------	-----	--------------	----------

@	50MG	A070624	001	Sep 04, 1985	Aug DISC
---	------	---------	-----	--------------	----------

>D> AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Oct DISC
--------	--------------------	------	---------	-----	--------------	----------

>A>	@	25MG	A091401	001	Mar 28, 2013	Oct DISC
-----	---	------	---------	-----	--------------	----------

>D> AB		50MG	A091401	002	Mar 28, 2013	Oct DISC
--------	--	------	---------	-----	--------------	----------

>A>	@	50MG	A091401	002	Mar 28, 2013	Oct DISC
-----	---	------	---------	-----	--------------	----------

TIVORBEX

+ EGALET	20MG	N204768	001	Feb 24, 2014	Feb CAHN
----------	------	---------	-----	--------------	----------

+!	40MG	N204768	002	Feb 24, 2014	Feb CAHN
----	------	---------	-----	--------------	----------

CAPSULE, EXTENDED RELEASE;ORAL

INDOCIN SR

+ @ EGALET	75MG	N018185	001	Feb 23, 1982	Feb CAHN
------------	------	---------	-----	--------------	----------

SUPPOSITORY;RECTAL

INDOCIN

+ @ EGALET	50MG	N017814	001	Aug 13, 1984	Feb CAHN
------------	------	---------	-----	--------------	----------

SUSPENSION;ORAL

INDOCIN

+! EGALET	25MG/5ML	N018332	001	Oct 10, 1985	Feb CAHN
-----------	----------	---------	-----	--------------	----------

INDOMETHACIN

@ HIKMA	25MG/5ML	A071412	001	Mar 18, 1987	Sep CAHN
---------	----------	---------	-----	--------------	----------

INSULIN ASPARTSOLUTION;SUBCUTANEOUS  
FIASP PENFILL

+! NOVO	300 UNITS/3ML (100 UNITS/ML)	N208751	003	Sep 24, 2018	Jun NEWA
---------	------------------------------	---------	-----	--------------	----------

INSULIN ASPART; INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS  
RYZODEG 70/30

+ @ NOVO	90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML)	N203313	001	Sep 25, 2015	Jun DISC
----------	--	---------	-----	--------------	----------

INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS  
TRESIBA

NOVO	1000 UNITS/10ML (100 UNITS/ML)	N203314	003	Nov 21, 2018	Jun NEWA
------	--------------------------------	---------	-----	--------------	----------

INSULIN HUMANSOLUTION;INTRAVENOUS  
MYXREDLIN

+! BAXTER HLTHCARE CORP	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jul CAHN
-------------------------	-----------------------------	---------	-----	--------------	----------

+! CELERITY PHARMS	100 UNITS/100ML (1 UNIT/ML)	N208157	001	Jun 20, 2019	Jun NEWA
--------------------	-----------------------------	---------	-----	--------------	----------

IOPROMIDE

INJECTABLE;INJECTION  
ULTRAVIST (PHARMACY BULK)

+ @ BAYER HLTHCARE	49.9%	N021425	003	Mar 12, 2004	Aug DISC
+!	49.9%	N021425	003	Mar 12, 2004	Apr CMFD
+ @	49.9%	N021425	003	Mar 12, 2004	Feb DISC
ULTRAVIST 240					
+ @ BAYER HLTHCARE	49.9%	N020220	003	May 10, 1995	Aug DISC
+!	49.9%	N020220	003	May 10, 1995	Apr CMFD
+ @	49.9%	N020220	003	May 10, 1995	Feb DISC

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION  
CONRAY 43

+ @ LIEBEL-FLARSHEIM	43%	N013295	002		Jun DISC
----------------------	-----	---------	-----	--	----------

IPRATROPIUM BROMIDE

SPRAY, METERED;NASAL  
IPRATROPIUM BROMIDE

@ MYLAN SPECIALITY LP	0.021MG/SPRAY	A075552	001	Mar 31, 2003	Mar DISC
@	0.042MG/SPRAY	A075553	001	Mar 31, 2003	Mar DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION  
IRINOTECAN HYDROCHLORIDE

>D> AP	FRESENIUS KABI USA	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Oct DISC
>A>	@	40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Oct DISC
AP		40MG/2ML (20MG/ML)	A078188	001	Feb 27, 2008	Jan CAHN
>D> AP		100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Oct DISC
>A>	@	100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Oct DISC
AP		100MG/5ML (20MG/ML)	A078188	002	Feb 27, 2008	Jan CAHN
AP	ZENNOVA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	Sep CAHN
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	Sep CAHN

IRON DEXTRAN

INJECTABLE;INJECTION  
DEXFERRUM

@ LUITPOLD	EQ 50MG IRON/ML	N040024	001	Feb 23, 1996	Mar DISC
PROFERDEX					
@ NEW RIVER	EQ 50MG IRON/ML	N017807	001		Mar DISC

IRON SUCROSE

INJECTABLE;INTRAVENOUS  
VENOFER

+ AM REGENT	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr CAHN
@	EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)	N021135	005	Mar 29, 2013	Apr CAHN
@	EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)	N021135	003	Mar 29, 2005	Apr CAHN
+!	EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N021135	001	Nov 06, 2000	Apr CAHN
+	EQ 200MG BASE/10ML (EQ 20MG BASE/ML)	N021135	004	Feb 09, 2007	Apr CAHN

ISONIAZID

TABLET;ORAL  
ISONIAZID

AA	!	BARR	100MG	A080936	001	Aug CHRS
AA	!		300MG	A080937	002	Aug CHRS
	+	@ SANDOZ	100MG	N008678	002	Aug DISC
	+	@	300MG	N008678	003	Aug DISC
>D>		LANIAZID				
>D> AA		LANNETT	300MG	A089776	001	Jun 13, 1988
>A>		@	300MG	A089776	001	Jun 13, 1988

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL  
ZURAGARD

+!	ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Apr NEWA
----	--------------	--------------	---------	-----	--------------	----------

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

AP	CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Jun NEWA
AP	+! BAUSCH	0.2MG/ML	N010515	001		Mar CAHN

ISOSORBIDE DINITRATE

TABLET; ORAL  
ISORDIL

AB	+ BAUSCH	5MG	N012093	007	Jul 29, 1988	Mar CAHN
	+ @	10MG	N012093	002	Jul 29, 1988	Mar CAHN
	+ @	20MG	N012093	006	Jul 29, 1988	Mar CAHN
	+ @	30MG	N012093	005	Jul 29, 1988	Mar CAHN
	+!	40MG	N012093	001	Jul 29, 1988	Mar CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL  
ISOSORBIDE MONONITRATE

AB	HIKMA INTL PHARMS	30MG	A076813	002	Mar 30, 2006	Mar CAHN
AB		60MG	A076813	001	Jan 07, 2005	Mar CAHN

ISOSULFAN BLUE

INJECTABLE; INJECTION  
ISOSULFAN BLUE

>D> AP	ANDA REPOSITORY	1%	A210558	001	Jul 12, 2019	Oct CAHN
AP		1%	A210558	001	Jul 12, 2019	Sep CAHN
	@ BELOTECA INC	1%	A210714	001	Jan 16, 2019	Jul DISC
>A> AP	SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	Oct CAHN
AP		1%	A210558	001	Jul 12, 2019	Jul NEWA

ISTRADEFYLLINE

TABLET; ORAL  
NOURIANZ

	+ KYOWA KIRIN	20MG	N022075	001	Aug 27, 2019	Aug NEWA
	+!	40MG	N022075	002	Aug 27, 2019	Aug NEWA

ITRACONAZOLE

CAPSULE; ORAL  
ITRACONAZOLE

AB	ANDA REPOSITORY	100MG	A206410	001	Jul 02, 2019	Aug CAHN
AB	PII	100MG	A206410	001	Jul 02, 2019	Jun NEWA

SOLUTION; ORAL  
ITRACONAZOLE

AA	APOTEX	10MG/ML	A208481	001	Aug 02, 2019	Jul NEWA
----	--------	---------	---------	-----	--------------	----------

IVABRADINE

SOLUTION; ORAL  
CORLANOR

	+! AMGEN INC	5MG/5ML (1MG/ML)	N209964	001	Apr 22, 2019	Apr NEWA
--	--------------	------------------	---------	-----	--------------	----------

IVACAFTOR

GRANULE; ORAL  
KALYDECO

	+ VERTEX PHARMS INC	25MG/PACKET	N207925	003	Apr 29, 2019	May NEWA
--	---------------------	-------------	---------	-----	--------------	----------

TABLET; ORAL  
KALYDECO

	+ VERTEX PHARMS	75MG	N203188	002	May 20, 2019	May NEWA
--	-----------------	------	---------	-----	--------------	----------

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET, TABLET; ORAL  
SYMDEKO (COPACKAGED)

	+! VERTEX PHARMS INC	75MG, N/A; 75MG, 50MG	N210491	002	Jun 21, 2019	Jul NEWA
--	----------------------	-----------------------	---------	-----	--------------	----------

IVERMECTIN

CREAM; TOPICAL  
IVERMECTIN

AB	TEVA PHARMS USA	1%	A210019	001	Sep 13, 2019	Sep NFTG
----	-----------------	----	---------	-----	--------------	----------

SOOLANTRA

AB	+! GALDERMA LABS LP	1%	N206255	001	Dec 19, 2014	Sep CFTG
----	---------------------	----	---------	-----	--------------	----------

KETOCONAZOLE

	GEL; TOPICAL						
	XOLEGEL						
	+! ALMIRALL	2%	N021946	001	Jul 28, 2006	Feb	CAHN
	SHAMPOO; TOPICAL						
	KETOCONAZOLE						
AB	PERRIGO ISRAEL	2%	A076419	001	Jan 07, 2004	May	CAHN
	TABLET; ORAL						
	KETOCONAZOLE						
	@ HERITAGE PHARMA	200MG	A074971	001	Jun 15, 1999	May	CAHN
	@	200MG	A075362	001	Jun 15, 1999	May	CAHN
AB	! TARO	200MG	A075319	001	Jun 15, 1999	Apr	CHRS
	@ TEVA	200MG	A075273	001	Jun 15, 1999	Apr	DISC

KETOROLAC TROMETHAMINE

	INJECTABLE; INJECTION						
	KETOROLAC TROMETHAMINE						
AP	WEST-WARD PHARMS INT	15MG/ML	A075772	001	Jul 21, 2004	Feb	CMFD
AP		30MG/ML	A075772	002	Jul 21, 2004	Feb	CMFD
	SOLUTION/DROPS; OPHTHALMIC						
	KETOROLAC TROMETHAMINE						
	@ AUROBINDO PHARMA LTD	0.4%	A205191	001	Nov 15, 2018	May	DISC
AT	MICRO LABS LTD INDIA	0.5%	A203410	001	Apr 05, 2019	Mar	NEWA
	@ SANDOZ INC	0.4%	A078721	001	Nov 05, 2009	May	DISC
	SPRAY, METERED; NASAL						
	SPRIX						
	+! ZYLA	15.75MG/SPRAY	N022382	001	May 14, 2010	Jul	CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

	SOLUTION; IRRIGATION						
	KETOROLAC TROMETHAMINE AND PHENYLEPHRINE HYDROCHLORIDE						
AT	LUPIN LTD	EQ 0.3% BASE; EQ 1% BASE	A210183	001	Jul 01, 2019	Jun	NFTG
	OMIDRIA						
AT	+! OMEROS	EQ 0.3% BASE; EQ 1% BASE	N205388	001	May 30, 2014	Jun	CFTG

L-GLUTAMINE

	FOR SOLUTION; ORAL						
	NUTRESTORE						
	+ @ EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	Jun	DISC

LABETALOL HYDROCHLORIDE

	INJECTABLE; INJECTION						
	LABETALOL HYDROCHLORIDE						
	@ MYLAN ASI	5MG/ML	A079134	001	Feb 03, 2010	Sep	DISC
	TABLET; ORAL						
	LABETALOL HYDROCHLORIDE						
AB	CADILA PHARMS LTD	100MG	A211325	001	May 13, 2019	Apr	NEWA
AB		200MG	A211325	002	May 13, 2019	Apr	NEWA
AB		300MG	A211325	003	May 13, 2019	Apr	NEWA
>D> AB	HERITAGE PHARMA	100MG	A074787	001	Aug 03, 1998	Oct	DISC
>A>	@	100MG	A074787	001	Aug 03, 1998	Oct	DISC
AB		100MG	A074787	001	Aug 03, 1998	Feb	CAHN
>D> AB		200MG	A074787	002	Aug 03, 1998	Oct	DISC
>A>	@	200MG	A074787	002	Aug 03, 1998	Oct	DISC
AB		200MG	A074787	002	Aug 03, 1998	Feb	CAHN
>D> AB		300MG	A074787	003	Aug 03, 1998	Oct	DISC
>A>	@	300MG	A074787	003	Aug 03, 1998	Oct	DISC
AB		300MG	A074787	003	Aug 03, 1998	Feb	CAHN
	TRANDATE						
AB	+ CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Jan	CRLD
AB	+	200MG	N018716	002	Aug 01, 1984	Jan	CRLD
AB	+	300MG	N018716	003	Aug 01, 1984	Jan	CRLD

LACTULOSE

	SOLUTION; ORAL						
	LACTULOSE						
	@ BAJAJ	10GM/15ML	A075911	001	Feb 21, 2002	Jan	CAHN
AA	XTTRIUM LABS INC	10GM/15ML	A075911	001	Feb 21, 2002	Aug	CMFD
	@	10GM/15ML	A075911	001	Feb 21, 2002	Mar	CAHN

SOLUTION;ORAL, RECTAL  
LACTULOSE

@ BAJAJ	10GM/15ML	A076645	001	Jul 28, 2003	Jan CAHN
---------	-----------	---------	-----	--------------	----------

LAMIVUDINE

## TABLET;ORAL

## LAMIVUDINE

AB	ANNORA	100MG	A211306	001	Mar 21, 2019	Mar NEWA
AB	MACLEODS PHARMS LTD	150MG	A090198	001	May 01, 2019	Apr NEWA
AB		300MG	A090198	002	May 01, 2019	Apr NEWA
>D> AB	MYLAN	100MG	A204002	001	Dec 31, 2014	Oct DISC
>A>	@	100MG	A204002	001	Dec 31, 2014	Oct DISC
	@	150MG	A204528	001	Mar 04, 2016	Apr DISC
	@	300MG	A204528	002	Mar 04, 2016	Apr DISC
AB	MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Feb NEWA
AB		300MG	A078545	002	Mar 05, 2019	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

## TABLET;ORAL

## LAMIVUDINE AND ZIDOVUDINE

AB	ANDA REPOSITORY	150MG;300MG	A206375	001	Apr 10, 2018	Sep CAHN
	@ MYLAN	150MG;300MG	A079079	001	Aug 12, 2019	Aug DISC
AB		150MG;300MG	A079079	001	Aug 12, 2019	Jul NEWA
	@	150MG;300MG	A204005	001	Aug 28, 2014	Jan DISC

LAMOTRIGINE

## TABLET;ORAL

## LAMOTRIGINE

	@ CELLTRION	25MG	A078982	001	Jan 27, 2009	Aug CAHN
	@	100MG	A078982	002	Jan 27, 2009	Aug CAHN
	@	150MG	A078982	003	Jan 27, 2009	Aug CAHN
	@	200MG	A078982	004	Jan 27, 2009	Aug CAHN
AB	RUBICON	25MG	A078625	001	Jan 27, 2009	Jul CAHN
AB		100MG	A078625	002	Jan 27, 2009	Jul CAHN
AB		150MG	A078625	003	Jan 27, 2009	Jul CAHN
AB		200MG	A078625	004	Jan 27, 2009	Jul CAHN

## TABLET, CHEWABLE;ORAL

## LAMOTRIGINE

@ TEVA	5MG	A076420	001	Jun 21, 2006	Jul DISC
@	25MG	A076420	002	Jun 21, 2006	Jul DISC

## TABLET, EXTENDED RELEASE;ORAL

## LAMOTRIGINE

@ RUBICON	25MG	A202887	001	Jun 17, 2013	Mar CAHN
@	50MG	A202887	002	Jun 17, 2013	Mar CAHN
AB	100MG	A202887	003	Jun 17, 2013	Mar CAHN
AB	200MG	A202887	004	Jun 17, 2013	Mar CAHN

LANSOPRAZOLE

## CAPSULE, DELAYED REL PELLETS;ORAL

## LANSOPRAZOLE

@ AJANTA PHARMA LTD	15MG	A203957	001	Oct 14, 2016	Sep DISC	
@	30MG	A203957	002	Oct 14, 2016	Sep DISC	
AB	ALKEM LABS LTD	15MG	A207394	001	Jan 18, 2019	Jan NEWA
AB		30MG	A207394	002	Jan 18, 2019	Jan NEWA
@ BRECKENRIDGE	15MG	A203964	001	Oct 17, 2018	May DISC	
@	30MG	A203964	002	Oct 17, 2018	May DISC	
AB	INVENTIA	15MG	A205868	001	Aug 30, 2017	Aug CAHN
AB		30MG	A205868	002	Aug 30, 2017	Aug CAHN
@ KRKA TOVARNA ZDRAVIL	15MG	A091212	001	Sep 16, 2013	Feb DISC	
@	30MG	A091212	002	Sep 16, 2013	Feb DISC	
AB	XIROMED	15MG	A203203	001	Jul 25, 2016	Aug CAHN
AB		30MG	A203203	002	Jul 25, 2016	Aug CAHN

LAROTRECTINIB

## CAPSULE;ORAL

## VITRAKVI

+ BAYER HLTHCARE	25MG	N210861	001	Nov 26, 2018	Feb CAHN
+!	100MG	N210861	002	Nov 26, 2018	Feb CAHN

## SOLUTION;ORAL

## VITRAKVI

+! BAYER HEALTHCARE	20MG/ML	N211710	001	Nov 26, 2018	Feb CAHN
---------------------	---------	---------	-----	--------------	----------

LAROTRECTINIB SULFATE

## CAPSULE; ORAL

## VITRAKVI

+	BAYER HLTHCARE	EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CAIN
+		EQ 25MG BASE	N210861	001	Nov 26, 2018	Jun CPOT
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CAIN
+	!	EQ 100MG BASE	N210861	002	Nov 26, 2018	Jun CPOT

## SOLUTION; ORAL

## VITRAKVI

+	!	BAYER HEALTHCARE	EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CAIN
+	!		EQ 20MG BASE/ML	N211710	001	Nov 26, 2018	Jun CPOT

LATANOPROST

## SOLUTION/DROPS; OPHTHALMIC

## LATANOPROST

AT		AUROBINDO PHARMA LTD	0.005%	A206519	001	Sep 03, 2019	Aug NEWA
>D> AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Oct CAHN
>A> AT		SOMERSET	0.005%	A201786	001	Mar 22, 2011	Oct CAHN

LATANOPROST; NETARSUDIL DIMESYLATE

## SOLUTION/DROPS; OPHTHALMIC

## ROCKLATAN

+	!	AERIE PHARMS INC	0.005%; EQ 0.02% BASE	N208259	001	Mar 12, 2019	Mar NEWA
---	---	------------------	-----------------------	---------	-----	--------------	----------

LEDIPASVIR; SOFOSBUVIR

## PELLETS; ORAL

## HARVONI

+		GILEAD SCIENCES INC	33.75MG; 150MG/PACKET	N212477	001	Aug 28, 2019	Aug NEWA
+	!		45MG; 200MG/PACKET	N212477	002	Aug 28, 2019	Aug NEWA

## TABLET; ORAL

## HARVONI

+		GILEAD SCIENCES INC	45MG; 200MG	N205834	002	Aug 28, 2019	Aug NEWA
---	--	---------------------	-------------	---------	-----	--------------	----------

LEFAMULIN ACETATE

## SOLUTION; INTRAVENOUS

## XENLETA

+	!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Aug NEWA
---	---	---------	--------------------------------------	---------	-----	--------------	----------

## TABLET; ORAL

## XENLETA

+	!	NABRIVA	EQ 600MG BASE	N211672	001	Aug 19, 2019	Aug NEWA
---	---	---------	---------------	---------	-----	--------------	----------

LEFLUNOMIDE

## TABLET; ORAL

## LEFLUNOMIDE

AB		ABHAI LLC	10MG	A212453	001	Jun 03, 2019	May NEWA
AB			20MG	A212453	002	Jun 03, 2019	May NEWA
AB		ZYDUS	10MG	A212308	001	Apr 24, 2019	Apr NEWA
AB			20MG	A212308	002	Apr 24, 2019	Apr NEWA

LESINURAD

## TABLET; ORAL

## ZURAMPIC

+	@	IRONWOOD PHARMS INC	200MG	N207988	001	Dec 22, 2015	Apr DISC
---	---	---------------------	-------	---------	-----	--------------	----------

LETROZOLE

## TABLET; ORAL

## LETROZOLE

AB		EUGIA PHARMA	2.5MG	A211717	001	Jan 11, 2019	Sep CMFD
	@		2.5MG	A211717	001	Jan 11, 2019	Jul DISC
>D> AB		FRESENIUS KABI USA	2.5MG	A090491	001	Jun 03, 2011	Oct DISC
>A>	@		2.5MG	A090491	001	Jun 03, 2011	Oct DISC
AB			2.5MG	A090491	001	Jun 03, 2011	Feb CAHN

LEUCOVORIN CALCIUM

## INJECTABLE; INJECTION

## LEUCOVORIN CALCIUM

>D> AP		INGENUS PHARMS LLC	EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Oct DISC
>A>	@		EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Oct DISC
AP			EQ 10MG BASE/ML	A210917	001	Nov 23, 2018	Feb CPOT

LEUPROLIDE ACETATEFOR SUSPENSION; INTRAMUSCULAR  
LUTRATE DEPOT KIT

+ @ GP-PHARM SA 22.5MG/VIAL N205054 001 Aug 28, 2018 Jun DISC

LEVALBUTEROL HYDROCHLORIDESOLUTION; INHALATION  
LEVALBUTEROL HYDROCHLORIDE

>D> AN	MYLAN SPECIALITY LP	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Oct DISC
>A>	@	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	Oct DISC
>D> AN		EQ 0.021% BASE	A077800	002	Mar 15, 2013	Oct DISC
>A>	@	EQ 0.021% BASE	A077800	002	Mar 15, 2013	Oct DISC
>D> AN		EQ 0.042% BASE	A077800	003	Mar 15, 2013	Oct DISC
>A>	@	EQ 0.042% BASE	A077800	003	Mar 15, 2013	Oct DISC

LEVETIRACETAMINJECTABLE; INTRAVENOUS  
KEPPRA

AP	+	UCB INC	500MG/5ML (100MG/ML)	N021872	001	Jul 31, 2006	Jun CDFR
		LEVETIRACETAM					
		@ AKORN	500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Aug DISC
AP			500MG/5ML (100MG/ML)	A209934	001	May 04, 2018	Jun CDFR
AP		AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jun CDFR
AP		FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090813	001	May 26, 2010	Jun CDFR
AP			500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jun CDFR
AP		HAINAN POLY PHARM	500MG/5ML (100MG/ML)	A209781	001	Mar 20, 2018	Jun CDFR
AP		HIKMA FARMACEUTICA	500MG/5ML (100MG/ML)	A090981	001	Oct 13, 2011	Jun CDFR
AP		HOSPIRA INC	500MG/5ML (100MG/ML)	A202869	001	Apr 06, 2012	Jun CDFR
AP		JUBILANT GENERICS	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	Jun CDFR
AP		MICRO LABS	500MG/5ML (100MG/ML)	A211954	001	Aug 09, 2019	Jul NEWA
AP		MYLAN LABS LTD	500MG/5ML (100MG/ML)	A203308	001	Sep 16, 2016	Jun CDFR
AP		SAGENT PHARMS	500MG/5ML (100MG/ML)	A091627	001	Jun 26, 2013	Jun CDFR
AP		SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	Jun CDFR
AP		X GEN PHARMS	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Jun CDFR
		LEVETIRACETAM IN SODIUM CHLORIDE					
AP		AUROBINDO PHARMA LTD	500MG/100ML (5MG/ML)	A207160	001	Jan 04, 2017	Jun CDFR
AP			1000MG/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Jun CDFR
AP			1500MG/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Jun CDFR
AP		GLAND PHARMA LTD	500MG/100ML (5MG/ML)	A206880	001	Oct 25, 2017	Jun CDFR
AP			1000MG/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Jun CDFR
AP			1500MG/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Jun CDFR
AP	+	HQ SPECIALITY PHARMA	500MG/100ML (5MG/ML)	N202543	001	Nov 09, 2011	Jun CDFR
AP	+		1000MG/100ML (10MG/ML)	N202543	002	Nov 09, 2011	Jun CDFR
AP	+		1500MG/100ML (15MG/ML)	N202543	003	Nov 09, 2011	Jun CDFR

SOLUTION; ORAL

LEVETIRACETAM

AA ANDA REPOSITORY 100MG/ML A079107 001 Jan 15, 2009 Aug CAHN

TABLET; ORAL

LEVETIRACETAM

>A>							
>A> AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Oct CTNA	
>A> AB		500MG	A090906	001	Nov 05, 2010	Oct CTNA	
>A> AB		750MG	A090906	003	Oct 31, 2016	Oct CTNA	
>A> AB		1GM	A090906	004	Oct 31, 2016	Oct CTNA	
>D>	ROWEEPPRA						
>D> AB	LOTUS PHARM CO LTD	250MG	A090906	002	Oct 31, 2016	Oct CTNA	
>D> AB		500MG	A090906	001	Nov 05, 2010	Oct CTNA	
>D> AB		750MG	A090906	003	Oct 31, 2016	Oct CTNA	
>D> AB		1GM	A090906	004	Oct 31, 2016	Oct CTNA	

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	ANDA REPOSITORY	500MG	A204511	001	Feb 23, 2016	Sep CAHN
AB		750MG	A204511	002	Feb 23, 2016	Sep CAHN
AB	HISUN PHARM HANGZHOU	500MG	A207175	001	Sep 28, 2017	Sep CAHN
AB		750MG	A207175	002	Sep 28, 2017	Sep CAHN
>D> AB	SUN PHARM INDUSTRIES	500MG	A091285	001	Sep 12, 2011	Oct DISC
>A>	@	500MG	A091285	001	Sep 12, 2011	Oct DISC
>D> AB		750MG	A091285	002	Sep 12, 2011	Oct DISC
>A>	@	750MG	A091285	002	Sep 12, 2011	Oct DISC

LEVOBUNOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 LEVOBUNOLOL HYDROCHLORIDE  
 @ SANDOZ INC 0.5%

A074850 001 Oct 28, 1996 May DISC

LEVOCARNITINE

SOLUTION;ORAL  
 LEVOCARNITINE

AA NOVITIUM PHARMA 1GM/10ML  
 LEVOCARNITINE SF  
 AA NOVITIUM PHARMA 1GM/10ML

A211676 001 Aug 14, 2019 Jul NEWA

A211676 002 Aug 14, 2019 Jul NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL  
 LEVOCETIRIZINE HYDROCHLORIDE

AA HETERO LABS LTD III 2.5MG/5ML

A210914 001 Apr 01, 2019 Mar NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION  
 LEVOFLOXACIN

>D> @ AKORN EQ 500MG/20ML (EQ 25MG/ML)  
 >A> AP EQ 500MG/20ML (EQ 25MG/ML)  
 >D> @ EQ 750MG/30ML (EQ 25MG/ML)  
 >A> AP EQ 750MG/30ML (EQ 25MG/ML)

A091644 001 Jun 20, 2011 Oct CMFD

A091644 001 Jun 20, 2011 Oct CMFD

A091644 002 Jun 20, 2011 Oct CMFD

A091644 002 Jun 20, 2011 Oct CMFD

SOLUTION/DROPS;OPHTHALMIC  
 LEVOFLOXACIN

MICRO LABS LTD INDIA 1.5%

A205600 001 Feb 27, 2019 Feb NEWA

TABLET;ORAL

LEVOFLOXACIN

AB CELLTRION 250MG  
 AB 500MG  
 AB 750MG  
 AB HEC PHARM 250MG  
 AB 500MG  
 AB 750MG

A090367 001 Jun 20, 2011 Aug CAHN

A090367 002 Jun 20, 2011 Aug CAHN

A090367 003 Jun 20, 2011 Aug CAHN

A204968 001 Feb 05, 2019 Jan NEWA

A204968 002 Feb 05, 2019 Jan NEWA

A204968 003 Feb 05, 2019 Jan NEWA

LEVOLEUCOVORIN

POWDER;INTRAVENOUS  
 KHAPZORY

+! ACROTECH 175MG/VIAL  
 +! 300MG/VIAL

N211226 001 Oct 19, 2018 Mar CAHN

N211226 002 Oct 19, 2018 Mar CAHN

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS  
 FUSILEV

AP +! ACROTECH EQ 50MG BASE/VIAL  
 LEVOLEUCOVORIN CALCIUM  
 + @ ACTAVIS LLC EQ 175MG BASE/VIAL  
 AP NANJING KING-FRIEND EQ 50MG BASE/VIAL

N020140 001 Mar 07, 2008 Mar CAHN

N208723 001 Sep 29, 2016 Jun DISC

A211003 001 Aug 22, 2019 Aug NEWA

SOLUTION;INTRAVENOUS  
 FUSILEV

+ @ ACROTECH EQ 175MG BASE/17.5ML (EQ 10MG  
 BASE/ML)  
 + @ EQ 250MG BASE/25ML (EQ 10MG  
 BASE/ML)

N020140 002 Apr 29, 2011 Mar CAHN

N020140 003 Apr 29, 2011 Mar CAHN

LEVOLEUCOVORIN CALCIUM

@ MYLAN TEORANTA EQ 175MG BASE/17.5ML (EQ 10MG  
 BASE/ML)

A203576 001 Oct 20, 2015 Aug DISC

@ EQ 250MG BASE/25ML (EQ 10MG  
 BASE/ML)

A203576 002 Oct 20, 2015 Aug DISC

AP NANJING KING-FRIEND EQ 175MG BASE/17.5ML (EQ 10MG  
 BASE/ML)

A211002 001 Aug 16, 2019 Aug NEWA

AP EQ 250MG BASE/25ML (EQ 10MG  
 BASE/ML)

A211002 002 Aug 16, 2019 Aug NEWA

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
 FETZIMA

+ ALLERGAN EQ 20MG BASE  
 + EQ 40MG BASE  
 + EQ 80MG BASE  
 +! EQ 120MG BASE

N204168 001 Jul 25, 2013 Jun CTEC

N204168 002 Jul 25, 2013 Jun CTEC

N204168 003 Jul 25, 2013 Jun CTEC

N204168 004 Jul 25, 2013 Jun CTEC

CAPSULE, EXTENDED RELEASE;ORAL  
FETZIMA

AB	+	ALLERGAN SALES LLC	EQ 20MG BASE	N204168	001	Jul 25, 2013	Jan CFTG
AB	+		EQ 40MG BASE	N204168	002	Jul 25, 2013	Jan CFTG
AB	+		EQ 80MG BASE	N204168	003	Jul 25, 2013	Jan CFTG
AB	+	!	EQ 120MG BASE	N204168	004	Jul 25, 2013	Jan CFTG
LEVOMILNACIPRAN HYDROCHLORIDE							
	@	AMNEAL PHARMS CO	EQ 20MG BASE	A210790	001	Feb 04, 2019	Jun DISC
AB			EQ 20MG BASE	A210790	001	Feb 04, 2019	Jan NFTG
	@		EQ 40MG BASE	A210790	002	Feb 04, 2019	Jun DISC
AB			EQ 40MG BASE	A210790	002	Feb 04, 2019	Jan NFTG
	@		EQ 80MG BASE	A210790	003	Feb 04, 2019	Jun DISC
AB			EQ 80MG BASE	A210790	003	Feb 04, 2019	Jan NFTG
	@		EQ 120MG BASE	A210790	004	Feb 04, 2019	Jun DISC
AB			EQ 120MG BASE	A210790	004	Feb 04, 2019	Jan NFTG

LEVONORGESTREL

## TABLET;ORAL

## LEVONORGESTREL

AB	!	L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May CAHN
----	---	--------------	--------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

## TABLET;ORAL

## LEVORPHANOL TARTRATE

	@	SENTYNL THERAPS INC	1MG	A074278	002	Jun 18, 2018	Feb DISC
!			3MG	A074278	003	Jun 18, 2018	May CMFD
	@		3MG	A074278	003	Jun 18, 2018	Feb DISC

LEVOTHYROXINE SODIUM

## POWDER;INTRAVENOUS

## LEVOTHYROXINE SODIUM

	@	PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	Apr DISC
--	---	----------------------	-------------	---------	-----	--------------	----------

## SOLUTION;INTRAVENOUS

## LEVOTHYROXINE SODIUM

+	!	FRESENIUS KABI USA	100MCG/5ML (20MCG/ML)	N210632	001	Apr 11, 2019	Apr NEWA
+	!		200MCG/5ML (40MCG/ML)	N210632	002	Apr 11, 2019	Apr NEWA
+	!		500MCG/5ML (100MCG/ML)	N210632	003	Apr 11, 2019	Apr NEWA

## SOLUTION;ORAL

## TIROSINT-SOL

+		INSTITUT BIOCHIMIQUE	13MCG/ML	N206977	001	Dec 15, 2016	Jan CMFD
+			25MCG/ML	N206977	002	Dec 15, 2016	Jan CMFD
+			50MCG/ML	N206977	003	Dec 15, 2016	Jan CMFD
+			75MCG/ML	N206977	004	Dec 15, 2016	Jan CMFD
+			88MCG/ML	N206977	005	Dec 15, 2016	Jan CMFD
+			100MCG/ML	N206977	006	Dec 15, 2016	Jan CMFD
+			112MCG/ML	N206977	007	Dec 15, 2016	Jan CMFD
+			125MCG/ML	N206977	008	Dec 15, 2016	Jan CMFD
+			137MCG/ML	N206977	009	Dec 15, 2016	Jan CMFD
+			150MCG/ML	N206977	010	Dec 15, 2016	Jan CMFD
+			175MCG/ML	N206977	011	Dec 15, 2016	Jan CMFD
+	!		200MCG/ML	N206977	012	Dec 15, 2016	Jan CMFD

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

## LEVOTHYROXINE SODIUM

	@	AMNEAL PHARMS LLC	0.025MG	A210831	001	Feb 19, 2019	Jun DISC
AB2			0.025MG	A210831	001	Feb 19, 2019	May CTEC
AB1, AB2			0.025MG	A210831	001	Feb 19, 2019	Feb NEWA
	@		0.05MG	A210831	002	Feb 19, 2019	Jun DISC
AB2			0.05MG	A210831	002	Feb 19, 2019	May CTEC
AB1, AB2			0.05MG	A210831	002	Feb 19, 2019	Feb NEWA
	@		0.075MG	A210831	003	Feb 19, 2019	Jun DISC
AB2			0.075MG	A210831	003	Feb 19, 2019	May CTEC
AB1, AB2			0.075MG	A210831	003	Feb 19, 2019	Feb NEWA
	@		0.088MG	A210831	004	Feb 19, 2019	Jun DISC
AB2			0.088MG	A210831	004	Feb 19, 2019	May CTEC
AB1, AB2			0.088MG	A210831	004	Feb 19, 2019	Feb NEWA
	@		0.1MG	A210831	005	Feb 19, 2019	Jun DISC

TABLET;ORAL						
LEVOTHYROXINE SODIUM						
AB2		0.1MG	A210831	005	Feb 19, 2019	May CTEC
AB1,		0.1MG	A210831	005	Feb 19, 2019	Feb NEWA
AB2	@	0.112MG	A210831	006	Feb 19, 2019	Jun DISC
AB2		0.112MG	A210831	006	Feb 19, 2019	May CTEC
AB1,		0.112MG	A210831	006	Feb 19, 2019	Feb NEWA
AB2	@	0.125MG	A210831	007	Feb 19, 2019	Jun DISC
AB2		0.125MG	A210831	007	Feb 19, 2019	May CTEC
AB1,		0.125MG	A210831	007	Feb 19, 2019	Feb NEWA
AB2	@	0.137MG	A210831	008	Feb 19, 2019	Jun DISC
AB2		0.137MG	A210831	008	Feb 19, 2019	May CTEC
AB1,		0.137MG	A210831	008	Feb 19, 2019	Feb NEWA
AB2	@	0.15MG	A210831	009	Feb 19, 2019	Jun DISC
AB2		0.15MG	A210831	009	Feb 19, 2019	May CTEC
AB1,		0.15MG	A210831	009	Feb 19, 2019	Feb NEWA
AB2	@	0.175MG	A210831	010	Feb 19, 2019	Jun DISC
AB2		0.175MG	A210831	010	Feb 19, 2019	May CTEC
AB1,		0.175MG	A210831	010	Feb 19, 2019	Feb NEWA
AB2	@	0.2MG	A210831	011	Feb 19, 2019	Jun DISC
AB2		0.2MG	A210831	011	Feb 19, 2019	May CTEC
AB1,		0.2MG	A210831	011	Feb 19, 2019	Feb NEWA
AB2	@	0.3MG	A210831	012	Feb 19, 2019	Jun DISC
AB2		0.3MG	A210831	012	Feb 19, 2019	May CTEC
AB1,		0.3MG	A210831	012	Feb 19, 2019	Feb NEWA
>D> AB1,	LUPIN ATLANTIS	0.025MG	A209713	001	Jan 18, 2019	Oct CTEC
AB2						
>A> AB1,		0.025MG	A209713	001	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.025MG	A209713	001	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.025MG	A209713	001	Jan 18, 2019	Jan NEWA
>D> AB1,		0.05MG	A209713	002	Jan 18, 2019	Oct CTEC
AB2						
>A> AB1,		0.05MG	A209713	002	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.05MG	A209713	002	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.05MG	A209713	002	Jan 18, 2019	Jan NEWA
>D> AB1,		0.075MG	A209713	003	Jan 18, 2019	Oct CTEC
AB2						
>A> AB1,		0.075MG	A209713	003	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.075MG	A209713	003	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.075MG	A209713	003	Jan 18, 2019	Jan NEWA
>D> AB1,		0.088MG	A209713	004	Jan 18, 2019	Oct CTEC
AB2						
>A> AB1,		0.088MG	A209713	004	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.088MG	A209713	004	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.088MG	A209713	004	Jan 18, 2019	Jan NEWA
>D> AB1,		0.1MG	A209713	005	Jan 18, 2019	Oct CTEC
AB2						
>A> AB1,		0.1MG	A209713	005	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.1MG	A209713	005	Jan 18, 2019	Sep CTEC
AB2						
AB2		0.1MG	A209713	005	Jan 18, 2019	Jan NEWA
>D> AB1,		0.112MG	A209713	006	Jan 18, 2019	Oct CTEC
AB2						
>A> AB1,		0.112MG	A209713	006	Jan 18, 2019	Oct CTEC
AB2,						
AB3						
AB1,		0.112MG	A209713	006	Jan 18, 2019	Sep CTEC
AB2						

TABLET;ORAL  
LEVOTHYROXINE SODIUM

	AB2	0.112MG	A209713	006	Jan 18, 2019	Jan NEWA
>D>	AB1, AB2	0.125MG	A209713	007	Jan 18, 2019	Oct CTEC
>A>	AB1, AB2, AB3	0.125MG	A209713	007	Jan 18, 2019	Oct CTEC
	AB1, AB2	0.125MG	A209713	007	Jan 18, 2019	Sep CTEC
	AB2	0.125MG	A209713	007	Jan 18, 2019	Jan NEWA
>D>	AB1, AB2	0.137MG	A209713	008	Jan 18, 2019	Oct CTEC
>A>	AB1, AB2, AB3	0.137MG	A209713	008	Jan 18, 2019	Oct CTEC
	AB1, AB2	0.137MG	A209713	008	Jan 18, 2019	Sep CTEC
	AB2	0.137MG	A209713	008	Jan 18, 2019	Jan NEWA
>D>	AB1, AB2	0.15MG	A209713	009	Jan 18, 2019	Oct CTEC
>A>	AB1, AB2, AB3	0.15MG	A209713	009	Jan 18, 2019	Oct CTEC
	AB1, AB2	0.15MG	A209713	009	Jan 18, 2019	Sep CTEC
	AB2	0.15MG	A209713	009	Jan 18, 2019	Jan NEWA
>D>	AB1, AB2	0.175MG	A209713	010	Jan 18, 2019	Oct CTEC
>A>	AB1, AB2, AB3	0.175MG	A209713	010	Jan 18, 2019	Oct CTEC
	AB1, AB2	0.175MG	A209713	010	Jan 18, 2019	Sep CTEC
	AB2	0.175MG	A209713	010	Jan 18, 2019	Jan NEWA
>D>	AB1, AB2	0.2MG	A209713	011	Jan 18, 2019	Oct CTEC
>A>	AB1, AB2, AB3	0.2MG	A209713	011	Jan 18, 2019	Oct CTEC
	AB1, AB2	0.2MG	A209713	011	Jan 18, 2019	Sep CTEC
	AB2	0.2MG	A209713	011	Jan 18, 2019	Jan NEWA
>D>	AB1, AB2	0.3MG	A209713	012	Jan 18, 2019	Oct CTEC
>A>	AB1, AB2, AB3	0.3MG	A209713	012	Jan 18, 2019	Oct CTEC
	AB1, AB2	0.3MG	A209713	012	Jan 18, 2019	Sep CTEC
	AB2	0.3MG	A209713	012	Jan 18, 2019	Jan NEWA
THYRO-TABS						
	AB2, + ALVOGEN	0.025MG	N021116	001	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.05MG	N021116	002	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.075MG	N021116	003	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.088MG	N021116	010	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.1MG	N021116	004	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.112MG	N021116	011	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.125MG	N021116	005	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.137MG	N021116	012	Dec 07, 2004	Mar CAHN
	AB4					
	AB2, +	0.15MG	N021116	006	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.175MG	N021116	007	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +	0.2MG	N021116	008	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, +!	0.3MG	N021116	009	Oct 24, 2002	Mar CAHN
	AB4					
	AB2, + LLOYD	0.025MG	N021116	001	Oct 24, 2002	Feb CMFD
	AB4					
	AB2, +	0.05MG	N021116	002	Oct 24, 2002	Feb CMFD
	AB4					
	AB2, +	0.075MG	N021116	003	Oct 24, 2002	Feb CMFD

TABLET;ORAL  
THYRO-TABS

AB4							
AB2, +	0.088MG	N021116	010	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +	0.1MG	N021116	004	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +	0.112MG	N021116	011	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +	0.125MG	N021116	005	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +	0.137MG	N021116	012	Dec 07, 2004	Feb	CMFD	
AB4							
AB2, +	0.15MG	N021116	006	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +	0.175MG	N021116	007	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +	0.2MG	N021116	008	Oct 24, 2002	Feb	CMFD	
AB4							
AB2, +!	0.3MG	N021116	009	Oct 24, 2002	Feb	CMFD	
AB4							

LIDOCAINE

OINTMENT;TOPICAL  
LIDOCAINE

AT	NOVAST LABS	5%	A208604	001	Sep 20, 2017	Sep	CAHN
>A> AT	SUNGEN PHARMA	5.0%	A212486	001	Oct 17, 2019	Oct	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A080404	002		Jun	CTNA
AP		2%	A080404	003		Jun	CTNA
AP	! HOSPIRA	1%	A083158	001		Sep	CHRS
AP	!	2%	A083158	002		Sep	CHRS
	@	20%	A083158	003		Sep	DISC
	@ LUITPOLD	1%	A080850	001		Mar	DISC
	@	1%	A091564	001	Aug 14, 2015	Feb	DISC
	XYLOCAINE PRESERVATIVE FREE						
+ @	FRESENIUS KABI USA	1%	N016801	005	Jan 19, 1988	Sep	DISC
+ @		2%	N016801	001		Sep	DISC
+ @		4%	N016801	002		Sep	DISC
+ @		20%	N016801	004		Sep	DISC

## JELLY;TOPICAL

## ANESTACON

@	BIONPHARMA INC	2%	A080429	001		Apr	CAHN
---	----------------	----	---------	-----	--	-----	------

## SOLUTION;ORAL

## XYLOCAINE VISCOUS

+ @	FRESENIUS KABI USA	2%	N009470	001		Aug	CRLD
-----	--------------------	----	---------	-----	--	-----	------

## SOLUTION;TOPICAL

## LIDOCAINE HYDROCHLORIDE

AT	LANNETT CO INC	4%	A040710	001	Feb 27, 2007	Sep	CMFD
----	----------------	----	---------	-----	--------------	-----	------

LIDOCAINE; PRILOCAINE

## CREAM;TOPICAL

## EMLA

AB	+! TEVA BRANDED PHARM	2.5%;2.5%	N019941	001	Dec 30, 1992	Apr	CAHN
----	-----------------------	-----------	---------	-----	--------------	-----	------

LIFITEGRAST

## SOLUTION/DROPS;OPHTHALMIC

## XIIDRA

+!	NOVARTIS	5%	N208073	001	Jul 11, 2016	Sep	CAHN
----	----------	----	---------	-----	--------------	-----	------

LINEZOLID

## TABLET;ORAL

## LINEZOLID

AB	CELLTRION	600MG	A210702	001	Apr 25, 2019	Apr	NEWA
	@ MYLAN	600MG	A078845	001	Dec 21, 2015	Jun	DISC

LIOETHYRONINE SODIUM

TABLET; ORAL

CYTOMEL

AB	+	KING PHARMS	EQ 0.05MG BASE	N010379	003		Jun	CHRS
		LIOETHYRONINE SODIUM						
	@	MYLAN	EQ 0.005MG BASE	A090326	001	Jul 14, 2009	Mar	DISC
	@		EQ 0.025MG BASE	A090326	002	Jul 14, 2009	Mar	DISC
	@		EQ 0.05MG BASE	A090326	003	Jul 14, 2009	Mar	DISC
AB	!	SIGMAPHARM LABS LLC	EQ 0.05MG BASE	A200295	003	Nov 29, 2012	Jun	CHRS
	@	SUN PHARM	EQ 0.005MG BASE	A091382	001	Apr 20, 2016	Jun	DISC
	@		EQ 0.025MG BASE	A091382	002	Apr 20, 2016	Jun	DISC
	@		EQ 0.05MG BASE	A091382	003	Apr 20, 2016	Jun	DISC
	@	TEVA PHARMS USA	EQ 0.005MG BASE	A211510	001	Oct 26, 2018	Apr	DISC
	@		EQ 0.025MG BASE	A211510	002	Oct 26, 2018	Apr	DISC
	@		EQ 0.05MG BASE	A211510	003	Oct 26, 2018	Apr	DISC

LISINOPRIL

TABLET; ORAL

LISINOPRIL

	@	HERITAGE PHARMA	2.5MG	A075752	001	Jul 01, 2002	Aug	DISC
AB			2.5MG	A075752	001	Jul 01, 2002	Feb	CAHN
	@		5MG	A075752	002	Jul 01, 2002	Aug	DISC
AB			5MG	A075752	002	Jul 01, 2002	Feb	CAHN
	@		10MG	A075752	003	Jul 01, 2002	Aug	DISC
AB			10MG	A075752	003	Jul 01, 2002	Feb	CAHN
	@		20MG	A075752	004	Jul 01, 2002	Aug	DISC
AB			20MG	A075752	004	Jul 01, 2002	Feb	CAHN
	@		30MG	A075752	005	Jul 01, 2002	Aug	DISC
AB			30MG	A075752	005	Jul 01, 2002	Feb	CAHN
	@		40MG	A075752	006	Jul 01, 2002	Aug	DISC
AB			40MG	A075752	006	Jul 01, 2002	Feb	CAHN
	@	MYLAN	2.5MG	A076071	001	Jul 01, 2002	Aug	DISC
	@		5MG	A076071	002	Jul 01, 2002	Aug	DISC
	@		10MG	A076071	003	Jul 01, 2002	Aug	DISC
	@		20MG	A076071	004	Jul 01, 2002	Aug	DISC
	@		30MG	A076071	005	Jul 01, 2002	Aug	DISC
	@		40MG	A076071	006	Jul 01, 2002	Aug	DISC
>D>		PRINIVIL						
>D>	AB	MERCK	10MG	N019558	002	Dec 29, 1987	Oct	DISC
>A>		@	10MG	N019558	002	Dec 29, 1987	Oct	DISC
>D>	AB		20MG	N019558	003	Dec 29, 1987	Oct	DISC
>A>		@	20MG	N019558	003	Dec 29, 1987	Oct	DISC

LITHIUM CARBONATE

CAPSULE; ORAL

LITHIUM CARBONATE

@ MYLAN

600MG

A078763 001 Apr 15, 2008 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

@ HERITAGE PHARMA

300MG

A076170 001 Jun 10, 2002 May CAHN

@

450MG

A076366 001 Aug 21, 2003 May CAHN

LORAZEPAM

CONCENTRATE; ORAL

LORAZEPAM

AA		LANNETT CO INC	2MG/ML	A079244	001	Apr 28, 2009	Jul	CAHN
AA		SAPTALIS PHARMS	2MG/ML	A079244	001	Apr 28, 2009	Feb	CAHN
		INJECTABLE; INJECTION						
		ATIVAN						
AP	+	HIKMA	2MG/ML	N018140	001		Mar	CAHN
AP	+		4MG/ML	N018140	002		Mar	CAHN
		TABLET; ORAL						
		ATIVAN						
AB	+	BAUSCH	0.5MG	N017794	001		Feb	CAHN
AB	+		1MG	N017794	002		Feb	CAHN
AB	+		2MG	N017794	003		Feb	CAHN

LOSARTAN POTASSIUM

## TABLET; ORAL

## LOSARTAN POTASSIUM

>D>	AB	HISUN PHARM HANGZHOU	25MG	A204795	001	Apr 04, 2019	Oct	DISC
>A>	@		25MG	A204795	001	Apr 04, 2019	Oct	DISC
	AB		25MG	A204795	001	Apr 04, 2019	Mar	NEWA
>D>	AB		50MG	A204795	002	Apr 04, 2019	Oct	DISC
>A>	@		50MG	A204795	002	Apr 04, 2019	Oct	DISC
	AB		50MG	A204795	002	Apr 04, 2019	Mar	NEWA
>D>	AB		100MG	A204795	003	Apr 04, 2019	Oct	DISC
>A>	@		100MG	A204795	003	Apr 04, 2019	Oct	DISC
	AB		100MG	A204795	003	Apr 04, 2019	Mar	NEWA
	AB	MICRO LABS	25MG	A091541	001	Sep 24, 2012	Mar	CAHN
	AB		50MG	A091541	002	Sep 24, 2012	Mar	CAHN
	AB		100MG	A091541	003	Sep 24, 2012	Mar	CAHN
	AB	STRIDES PHARMA	25MG	A090382	001	Oct 06, 2010	Apr	CAHN
	AB		50MG	A090382	002	Oct 06, 2010	Apr	CAHN
	AB		100MG	A090382	003	Oct 06, 2010	Apr	CAHN
	@	TEVA	25MG	A076958	001	Apr 06, 2010	Jul	DISC
	@		50MG	A076958	002	Apr 06, 2010	Jul	DISC
	@		100MG	A076958	003	Apr 06, 2010	Jul	DISC

LOTEPREDNOL ETABONATE

## GEL; OPHTHALMIC

## LOTEMAX SM

	+	BAUSCH AND LOMB INC	0.38%	N208219	001	Feb 22, 2019	Feb	NEWA
		SUSPENSION/DROPS; OPHTHALMIC						
		LOTEMAX						
AB	+	BAUSCH AND LOMB	0.5%	N020583	001	Mar 09, 1998	Apr	CFTG
		LOTEPREDNOL ETABONATE						
AB		HI TECH	0.5%	A207609	001	Apr 17, 2019	Apr	NFTG

LOVASTATIN

## TABLET; ORAL

## LOVASTATIN

AB		BEXIMCO PHARMS USA	10MG	A075300	001	Dec 17, 2001	Feb	CAHN
AB			20MG	A075300	002	Dec 17, 2001	Feb	CAHN
AB			40MG	A075300	003	Dec 17, 2001	Feb	CAHN
	@	MYLAN	10MG	A075451	001	Dec 17, 2001	Feb	DISC
	@		20MG	A075451	002	Dec 17, 2001	Feb	DISC
	@		40MG	A075451	003	Dec 17, 2001	Feb	DISC
>D>	AB	SUN PHARM INDUSTRIES	10MG	A077520	001	Apr 14, 2006	Oct	DISC
>A>	@		10MG	A077520	001	Apr 14, 2006	Oct	DISC
>D>	AB		20MG	A077520	002	Apr 14, 2006	Oct	DISC
>A>	@		20MG	A077520	002	Apr 14, 2006	Oct	DISC
>D>	AB		40MG	A077520	003	Apr 14, 2006	Oct	DISC
>A>	@		40MG	A077520	003	Apr 14, 2006	Oct	DISC

LOXAPINE

## POWDER; INHALATION

## ADASUVE

	+	ALEXZA PHARMS	10MG	N022549	001	Dec 21, 2012	Aug	CAHN
--	---	---------------	------	---------	-----	--------------	-----	------

LOXAPINE HYDROCHLORIDE

## CONCENTRATE; ORAL

## LOXITANE C

@	TEVA BRANDED PHARM	EQ 25MG BASE/ML	N017658	001			Feb	CAHN
---	--------------------	-----------------	---------	-----	--	--	-----	------

LOXAPINE SUCCINATE

## CAPSULE; ORAL

## LOXITANE

+	@	TEVA BRANDED PHARM	EQ 5MG BASE	N017525	001		Feb	CAHN
+	@		EQ 10MG BASE	N017525	002		Feb	CAHN
+	@		EQ 25MG BASE	N017525	003		Feb	CAHN
+	@		EQ 50MG BASE	N017525	004		Feb	CAHN

## TABLET; ORAL

## LOXITANE

+	@	TEVA BRANDED PHARM	EQ 10MG BASE	N017525	006		Feb	CAHN
+	@		EQ 25MG BASE	N017525	007		Feb	CAHN
+	@		EQ 50MG BASE	N017525	008		Feb	CAHN
+	@		EQ 50MG BASE	N017525	008		Feb	CAHN

LURASIDONE HYDROCHLORIDE

## TABLET; ORAL

## LURASIDONE HYDROCHLORIDE

	@ AMNEAL PHARMS CO	20MG	A208002	001	Jan 03, 2019	Jun	DISC
	@	40MG	A208002	002	Jan 03, 2019	Jun	DISC
	@	60MG	A208002	003	Jan 03, 2019	Jun	DISC
	@	80MG	A208002	004	Jan 03, 2019	Jun	DISC
	@	120MG	A208002	005	Jan 03, 2019	Jun	DISC
	@ EMCURE PHARMS LTD	20MG	A208058	001	Sep 04, 2019	Sep	DISC
AB		20MG	A208058	001	Sep 04, 2019	Aug	NEWA
	@	40MG	A208058	002	Sep 04, 2019	Sep	DISC
AB		40MG	A208058	002	Sep 04, 2019	Aug	NEWA
	@	60MG	A208058	003	Sep 04, 2019	Sep	DISC
AB		60MG	A208058	003	Sep 04, 2019	Aug	NEWA
	@	80MG	A208058	004	Sep 04, 2019	Sep	DISC
AB		80MG	A208058	004	Sep 04, 2019	Aug	NEWA
	@ INVAGEN PHARMS	20MG	A208028	001	Jan 03, 2019	Jul	DISC
	@	40MG	A208028	002	Jan 03, 2019	Jul	DISC
	@	60MG	A208028	003	Jan 03, 2019	Jul	DISC
	@	80MG	A208028	004	Jan 03, 2019	Jul	DISC
	@	120MG	A208028	005	Jan 03, 2019	Jul	DISC
	@ LUPIN LTD	20MG	A208031	001	Jan 03, 2019	Jul	DISC
	@	40MG	A208031	002	Jan 03, 2019	Jul	DISC
	@	60MG	A208031	003	Jan 03, 2019	Jul	DISC
	@	80MG	A208031	004	Jan 03, 2019	Jul	DISC
	@	120MG	A208031	005	Jan 03, 2019	Jul	DISC
	@ TORRENT	20MG	A208055	001	Jan 03, 2019	Feb	DISC
	@	40MG	A208055	002	Jan 03, 2019	Feb	DISC
	@	80MG	A208055	003	Jan 03, 2019	Feb	DISC
	@	120MG	A208055	004	Jan 03, 2019	Feb	DISC
	@ ZYDUS PHARMS	20MG	A208052	001	Mar 19, 2019	Aug	DISC
AB		20MG	A208052	001	Mar 19, 2019	Mar	NEWA
	@	40MG	A208052	002	Mar 19, 2019	Aug	DISC
AB		40MG	A208052	002	Mar 19, 2019	Mar	NEWA
	@	60MG	A208052	003	Mar 19, 2019	Aug	DISC
AB		60MG	A208052	003	Mar 19, 2019	Mar	NEWA
	@	80MG	A208052	004	Mar 19, 2019	Aug	DISC
AB		80MG	A208052	004	Mar 19, 2019	Mar	NEWA
	@	120MG	A208052	005	Mar 19, 2019	Aug	DISC
AB		120MG	A208052	005	Mar 19, 2019	Mar	NEWA

MAGNESIUM SULFATE

## SOLUTION; INTRAMUSCULAR, INTRAVENOUS

## MAGNESIUM SULFATE

AP	+! FRESSENIUS KABI USA	10GM/20ML (500MG/ML)	N019316	003	Jan 29, 2016	Jan	CTEC
AP	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Jan	CTEC

MALATHION

## LOTION; TOPICAL

## MALATHION

!	SUVEN LIFE	0.5%	A091559	001	May 23, 2012	Aug	CHRS
		0.5%	A091559	001	May 23, 2012	Aug	CTEC
	OVIDE						
+	@ TARO PHARM INDS LTD	0.5%	N018613	001	Aug 02, 1982	Aug	DISC

MANNITOL

## INJECTABLE; INJECTION

## MANNITOL 25%

@	LUITPOLD	12.5GM/50ML	A087409	001	Jan 21, 1982	Mar	DISC
---	----------	-------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

## TABLET; ORAL

## ANTIVERT

AA	+	CASPER PHARMA LLC	12.5MG	N010721	006		Feb	CMFD
	+	@	12.5MG	N010721	006		Jan	CRLD
AA	+		25MG	N010721	004		Feb	CMFD
	+	@	25MG	N010721	004		Jan	CRLD
AA	+		50MG	N010721	001	Jan 20, 1982	Feb	CMFD
	+	@	50MG	N010721	001	Jan 20, 1982	Jan	CRLD
		MECLIZINE HYDROCHLORIDE						
AA	!	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Jan	CHRS
AA	!		25MG	A201451	002	Feb 23, 2011	Jan	CHRS

TABLET; ORAL					
MECLIZINE HYDROCHLORIDE					
	@ ANI PHARMS INC	12.5MG	A084657	002	Sep CMS1
	@	12.5MG	A088732	001	Dec 11, 1985 May CAHN
>A> AA	AUREX	12.5MG	A087127	001	Oct CAHN
>A> AA		25MG	A087128	001	Oct CAHN
AA	INDICUS PHARMA	12.5MG	A205136	001	Feb 22, 2019 Feb NEWA
AA		25MG	A205136	002	Feb 22, 2019 Feb NEWA
		50MG	A205136	003	Feb 22, 2019 Feb NEWA
>D> AA	PAR PHARM	12.5MG	A087127	001	Oct CAHN
>D> AA		25MG	A087128	001	Oct CAHN
TABLET, CHEWABLE; ORAL					
ANTIVERT					
AA	+ CASPER PHARMA LLC	25MG	N010721	005	Feb CMFD
	+ @	25MG	N010721	005	Jan CRLD
<u>MEDROXYPROGESTERONE ACETATE</u>					
INJECTABLE; INJECTION					
MEDROXYPROGESTERONE ACETATE					
	@ CIPLA	150MG/ML	A210335	001	Jan 25, 2019 Jul DISC
AB		150MG/ML	A210335	001	Jan 25, 2019 Jan NEWA
AB	SUN PHARM	150MG/ML	A210760	001	May 01, 2019 Apr NEWA
AB		150MG/ML	A210761	001	Apr 24, 2019 Apr NEWA
TABLET; ORAL					
MEDROXYPROGESTERONE ACETATE					
	@ UPSHER SMITH LABS	10MG	A088484	001	Jul 26, 1984 Jul CAHN
<u>MEFENAMIC ACID</u>					
CAPSULE; ORAL					
MEFENAMIC ACID					
	@ BRECKENRIDGE	250MG	A090359	001	Feb 05, 2013 Feb DISC
<u>MELOXICAM</u>					
CAPSULE; ORAL					
VIVLODEX					
	+ EGALET	5MG	N207233	001	Oct 22, 2015 Feb CAHN
	+!	10MG	N207233	002	Oct 22, 2015 Feb CAHN
	+ ZYLA	5MG	N207233	001	Oct 22, 2015 Jul CAHN
	+!	10MG	N207233	002	Oct 22, 2015 Jul CAHN
SUSPENSION; ORAL					
MOBIC					
	+ @ AVONDALE PHARMS	7.5MG/5ML	N021530	001	Jun 01, 2004 Jun CAHN
TABLET; ORAL					
MELOXICAM					
	@ HERITAGE PHARMA	7.5MG	A077936	001	Jul 19, 2006 Sep DISC
AB		7.5MG	A077936	001	Jul 19, 2006 Feb CAHN
	@	15MG	A077936	002	Jul 19, 2006 Sep DISC
AB		15MG	A077936	002	Jul 19, 2006 Feb CAHN
<u>MELPHALAN HYDROCHLORIDE</u>					
INJECTABLE; INJECTION					
ALKERAN					
AP	+ APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992 Feb CMFD
MELPHALAN HYDROCHLORIDE					
AP	ALVOGEN INC	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019 May NEWA
AP	GLAND PHARMA LTD	EQ 50MG BASE/VIAL	A209826	001	May 28, 2019 May NEWA
AP	NORATECH	EQ 50MG BASE/VIAL	A211463	001	Sep 13, 2019 Sep NEWA
>D> AP	US WORLDMEDS LLC	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019 Oct DISC
>A>	@	EQ 50MG BASE/VIAL	A207032	001	May 03, 2019 Oct DISC
AP		EQ 50MG BASE/VIAL	A207032	001	May 03, 2019 Apr NEWA
POWDER; INTRAVENOUS					
EVOMELA					
	+! ACROTECH	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016 Mar CAHN
<u>MEMANTINE HYDROCHLORIDE</u>					
TABLET; ORAL					
MEMANTINE HYDROCHLORIDE					
	@ APOTEX INC	5MG	A090244	001	Jul 11, 2018 Jan DISC
	@	10MG	A090244	002	Jul 11, 2018 Jan DISC
AB	CADILA	5MG	A090961	001	Jul 10, 2017 Feb CAHN
AB		10MG	A090961	002	Jul 10, 2017 Feb CAHN
AB	CELLTRION	5MG	A090073	001	Sep 04, 2015 Aug CAHN

## TABLET;ORAL

## MEMANTINE HYDROCHLORIDE

AB		10MG	A090073	002	Sep 04, 2015	Aug CAHN	
>D>	AB	MYLAN	5MG	A079225	001	Jan 30, 2015	Oct DISC
>A>	@	5MG	A079225	001	Jan 30, 2015	Oct DISC	
>D>	AB	10MG	A079225	002	Jan 30, 2015	Oct DISC	
>A>	@	10MG	A079225	002	Jan 30, 2015	Oct DISC	

MEPERIDINE HYDROCHLORIDE

## TABLET;ORAL

## DEMEROL

+	@	US PHARM HOLDINGS	50MG	N005010	001		Aug DISC
+	@		100MG	N005010	004		Aug DISC

## MEPERIDINE HYDROCHLORIDE

	@	SPECGX LLC	50MG	A040352	001	Jun 13, 2000	Aug DISC
	@		100MG	A040352	002	Jun 13, 2000	Aug DISC
>D>	AA	SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002	Oct DISC
>A>	@		50MG	A040446	001	Aug 08, 2002	Oct DISC
>D>	AA		100MG	A040446	002	Aug 08, 2002	Oct DISC
>A>	@		100MG	A040446	002	Aug 08, 2002	Oct DISC

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## MEPERGAN

@	HIKMA	25MG/ML;25MG/ML	N011730	001		Jun CAHN
---	-------	-----------------	---------	-----	--	----------

MEQUINOL; TRETINOIN

## SOLUTION;TOPICAL

## SOLAGE

@	ALMIRALL	2%;0.01%	N020922	001	Dec 10, 1999	Feb CAHN
---	----------	----------	---------	-----	--------------	----------

MEROPENEM

## INJECTABLE;INJECTION

## MEROPENEM

@	HOSPIRA INC	500MG/VIAL	A090940	001	Jun 22, 2010	Sep DISC
@		1GM/VIAL	A090940	002	Jun 22, 2010	Sep DISC
AP	HQ SPCLT PHARMA	500MG/VIAL	A210773	001	Aug 16, 2019	Aug NEWA
AP		1GM/VIAL	A210773	002	Aug 16, 2019	Aug NEWA

MESALAMINE

## CAPSULE, DELAYED RELEASE;ORAL

## DELZICOL

AB	+!	APIL	400MG	N204412	001	Feb 01, 2013	Apr CFTG
AB		TEVA PHARMS USA	400MG	A207873	001	May 09, 2019	Apr NFTG

## SUPPOSITORY;RECTAL

## MESALAMINE

AB		AMRING PHARMS	1GM	A208362	001	Jun 21, 2019	Jun NEWA
AB		PHARM SOURCING	1GM	A207448	001	Apr 19, 2019	Apr NEWA
AB		SANDOZ INC	1GM	A202065	001	Jun 12, 2019	May NEWA

## TABLET, DELAYED RELEASE;ORAL

## MESALAMINE

@	SUN PHARM	1.2GM	A211858	001	Jan 25, 2019	Aug DISC
AB		1.2GM	A211858	001	Jan 25, 2019	Jan NEWA

MESTRANOL; NORETHINDRONE

## TABLET;ORAL-28

## NORINYL 1+50 28-DAY

+	@	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001		Jul DISC
---	---	---------------------	------------	---------	-----	--	----------

METAPROTERENOL SULFATE

## TABLET;ORAL

## METAPROTERENOL SULFATE

@	HERITAGE PHARMA	10MG	A072519	001	Mar 30, 1990	May CAHN
@		20MG	A072520	001	Mar 30, 1990	May CAHN
@	PAR PHARM	10MG	A072024	001	Jun 28, 1988	Jul DISC
@		20MG	A072025	001	Jun 28, 1988	Jul DISC

METAXALONETABLET;ORAL  
METAXALONE

AB	APPCO PHARMA LLC	800MG	A208774	001	Sep 24, 2018	Feb CAHN
----	------------------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDEFOR SUSPENSION, EXTENDED RELEASE;ORAL  
RIOMET ER

+! SUN PHARM 500MG/5ML

N212595	001	Aug 29, 2019	Aug NEWA
---------	-----	--------------	----------

TABLET;ORAL

GLUCOPHAGE

+ @ BRISTOL MYERS SQUIBB 500MG

N020357	001	Mar 03, 1995	Jun DISC
---------	-----	--------------	----------

+ @ 850MG

N020357	002	Mar 03, 1995	Jun DISC
---------	-----	--------------	----------

+ @ 1GM

N020357	005	Nov 05, 1998	Jun DISC
---------	-----	--------------	----------

+ @ EMD SERONO INC 500MG

N020357	001	Mar 03, 1995	Jul CAHN
---------	-----	--------------	----------

+ @ 625MG

N020357	003	Nov 05, 1998	Jul CAHN
---------	-----	--------------	----------

+ @ 750MG

N020357	004	Nov 05, 1998	Jul CAHN
---------	-----	--------------	----------

+ @ 850MG

N020357	002	Mar 03, 1995	Jul CAHN
---------	-----	--------------	----------

+ @ 1GM

N020357	005	Nov 05, 1998	Jul CAHN
---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

AB ! GRANULES INDIA 1GM

A090564	003	Apr 22, 2010	Jun CHRS
---------	-----	--------------	----------

AB HERITAGE PHARMA 500MG

A075978	001	Jan 25, 2002	Feb CAHN
---------	-----	--------------	----------

AB 850MG

A075978	002	Jan 25, 2002	Feb CAHN
---------	-----	--------------	----------

AB 1GM

A075978	003	Nov 05, 2002	Feb CAHN
---------	-----	--------------	----------

&gt;D&gt; AB SUN PHARM INDUSTRIES 500MG

A076038	001	Feb 21, 2002	Oct DISC
---------	-----	--------------	----------

&gt;A&gt; @ 500MG

A076038	001	Feb 21, 2002	Oct DISC
---------	-----	--------------	----------

&gt;D&gt; AB 850MG

A076038	002	Feb 21, 2002	Oct DISC
---------	-----	--------------	----------

&gt;A&gt; @ 850MG

A076038	002	Feb 21, 2002	Oct DISC
---------	-----	--------------	----------

&gt;D&gt; AB 1GM

A076038	003	Feb 21, 2002	Oct DISC
---------	-----	--------------	----------

&gt;A&gt; @ 1GM

A076038	003	Feb 21, 2002	Oct DISC
---------	-----	--------------	----------

@ SUNSHINE LAKE 500MG

A208999	001	Oct 12, 2018	Apr DISC
---------	-----	--------------	----------

@ 850MG

A208999	002	Oct 12, 2018	Apr DISC
---------	-----	--------------	----------

@ 1GM

A208999	003	Oct 12, 2018	Apr DISC
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

GLUCOPHAGE XR

+ @ BRISTOL MYERS SQUIBB 500MG

N021202	001	Oct 13, 2000	Jun DISC
---------	-----	--------------	----------

+ @ 750MG

N021202	004	Apr 11, 2003	Jun DISC
---------	-----	--------------	----------

+ @ EMD SERONO INC 500MG

N021202	001	Oct 13, 2000	Jul CAHN
---------	-----	--------------	----------

+ @ 750MG

N021202	004	Apr 11, 2003	Jul CAHN
---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

AB ! AMNEAL PHARMS NY 750MG

A078596	002	Jan 03, 2008	Jun CHRS
---------	-----	--------------	----------

AB1 CADILA 500MG

A077060	001	Apr 20, 2005	Feb CAHN
---------	-----	--------------	----------

AB 750MG

A077078	001	Apr 21, 2005	Feb CAHN
---------	-----	--------------	----------

AB1 INVENTIA 500MG

A201991	001	Jan 18, 2012	Aug CAHN
---------	-----	--------------	----------

AB2 ! LUPIN LTD 1GM

A090692	002	Jun 29, 2011	Apr CHRS
---------	-----	--------------	----------

AB1 SUN PHARM INDS (IN) 500MG

A077336	001	Feb 09, 2006	Sep CHRS
---------	-----	--------------	----------

AB1 ! 500MG

A077336	001	Feb 09, 2006	Jun CHRS
---------	-----	--------------	----------

@ YICHANG HUMANWELL 500MG

A211052	001	Sep 24, 2018	Mar DISC
---------	-----	--------------	----------

@ 750MG

A211052	002	Sep 24, 2018	Mar DISC
---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@ MYLAN 500MG;EQ 15MG BASE

A090406	001	Feb 25, 2011	Jul DISC
---------	-----	--------------	----------

@ 850MG;EQ 15MG BASE

A090406	002	Feb 25, 2011	Jul DISC
---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

+ @ TAKEDA PHARMS USA 1GM;EQ 15MG BASE

N022024	001	May 12, 2009	Mar DISC
---------	-----	--------------	----------

+ @ 1GM;EQ 30MG BASE

N022024	002	May 12, 2009	Mar DISC
---------	-----	--------------	----------

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA PHARM ASSOC 10MG/ML

A207368	001	Aug 22, 2019	Aug NEWA
---------	-----	--------------	----------

SOLUTION;ORAL

METHADONE HYDROCHLORIDE

AA PHARM ASSOC 5MG/5ML

A207537	001	Oct 02, 2019	Sep NEWA
---------	-----	--------------	----------

AA 10MG/5ML

A207537	002	Oct 01, 2019	Sep NEWA
---------	-----	--------------	----------

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

@ MICRO LABS

25MG

A207438 001 Oct 05, 2018 Mar DISC

@

50MG

A207438 002 Oct 05, 2018 Mar DISC

METHENAMINE HIPPURATE

TABLET; ORAL

METHENAMINE HIPPURATE

AB

MICRO LABS

1GM

A212172 001 Aug 01, 2019 Jul NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

&gt;D&gt; AB

SUN PHARM INDS INC

5MG

A040870 001 Sep 25, 2007 Oct DISC

&gt;A&gt;

@

5MG

A040870 001 Sep 25, 2007 Oct DISC

&gt;D&gt; AB

@

10MG

A040870 002 Sep 25, 2007 Oct DISC

&gt;A&gt;

@

10MG

A040870 002 Sep 25, 2007 Oct DISC

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP

SLATE

1GM/10ML (100MG/ML)

A208116 001 Jan 19, 2017 Feb CAHN

ROBAXIN

AP

+! HIKMA

1GM/10ML (100MG/ML)

N011790 001 Feb CAHN

TABLET; ORAL

METHOCARBAMOL

AA

ANI PHARMS INC

500MG

A084277 001 Sep CAHN

AA

! GRANULES INDIA LTD

500MG

A209312 001 May 07, 2018 Jul CHRS

ROBAXIN

+ @ AUXILIUM PHARMS LLC

500MG

N011011 004 Jul DISC

METHOTREXATE

SOLUTION; SUBCUTANEOUS

RASUVO

+! MEDEXUS

7.5MG/0.15ML (7.5MG/0.15ML)

N205776 001 Jul 10, 2014 Apr CAHN

+!

10MG/0.20ML (10MG/0.20ML)

N205776 002 Jul 10, 2014 Apr CAHN

+!

12.5MG/0.25ML (12.5MG/0.25ML)

N205776 003 Jul 10, 2014 Apr CAHN

+!

15MG/0.30ML (15MG/0.30ML)

N205776 004 Jul 10, 2014 Apr CAHN

+!

17.5MG/0.35ML (17.5MG/0.35ML)

N205776 005 Jul 10, 2014 Apr CAHN

+!

20MG/0.4ML (20MG/0.4ML)

N205776 006 Jul 10, 2014 Apr CAHN

+!

22.5MG/0.45ML (22.5MG/0.45ML)

N205776 007 Jul 10, 2014 Apr CAHN

+!

25MG/0.5ML (25MG/0.5ML)

N205776 008 Jul 10, 2014 Apr CAHN

+ @

27.5MG/0.55ML (27.5MG/0.55ML)

N205776 009 Jul 10, 2014 Apr CAHN

+!

30MG/0.6ML (30MG/0.6ML)

N205776 010 Jul 10, 2014 Apr CAHN

METHOXSALEN

CAPSULE; ORAL

OXSORALEN-ULTRA

AB

+! BAUSCH

10MG

N019600 001 Oct 30, 1986 Aug CAHN

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

&gt;D&gt; AA

BAYSHORE PHARMS LLC

2.5MG

A200602 001 Sep 24, 2012 Oct CTEC

&gt;A&gt;

2.5MG

A200602 001 Sep 24, 2012 Oct CTEC

&gt;D&gt; AA

@

5MG

A200602 002 Sep 24, 2012 Oct CTEC

&gt;A&gt;

!

5MG

A200602 002 Sep 24, 2012 Oct CHRS

&gt;A&gt;

@

5MG

A200602 002 Sep 24, 2012 Oct CTEC

@ BRECKENRIDGE PHARM

2.5MG

A040642 001 Dec 06, 2011 Jun DISC

@

5MG

A040642 002 Dec 06, 2011 Jun DISC

&gt;D&gt; AA

! VINTAGE PHARMS

2.5MG

A040624 001 Dec 28, 2006 Oct DISC

&gt;A&gt;

@

2.5MG

A040624 001 Dec 28, 2006 Oct DISC

&gt;D&gt; AA

!

5MG

A040624 002 Dec 28, 2006 Oct DISC

&gt;A&gt;

@

5MG

A040624 002 Dec 28, 2006 Oct DISC

METHYLDOPA

TABLET; ORAL  
METHYLDOPA

AB	HERITAGE PHARMA	250MG	A070098	001	Feb 20, 1986	Feb CAHN
AB		500MG	A070343	001	Feb 20, 1986	Feb CAHN

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION  
METHYLDOPATE HYDROCHLORIDE  
@ LUITPOLD

50MG/ML

A071279 001 Oct 02, 1987 Mar DISC

METHYLERGONOVINE MALEATE

TABLET; ORAL  
METHYLERGONOVINE MALEATE

AB	TEVA PHARMS USA	0.2MG
----	-----------------	-------

A211455 001 Mar 20, 2019 Mar NEWA

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
ADHANSIA XR

+	PURDUE PHARMA LP	25MG
		25MG
+		35MG
+		45MG
+		55MG
+		70MG
+		85MG

N212038	001	Feb 27, 2019	Mar CRLD
N212038	001	Feb 27, 2019	Feb NEWA
N212038	002	Feb 27, 2019	Feb NEWA
N212038	003	Feb 27, 2019	Feb NEWA
N212038	004	Feb 27, 2019	Feb NEWA
N212038	005	Feb 27, 2019	Feb NEWA
N212038	006	Feb 27, 2019	Feb NEWA

METHYLPHENIDATE HYDROCHLORIDE

AB1	GRANULES PHARMS	10MG
AB1		20MG
AB1		30MG
AB1		40MG
AB1		60MG
AB1	! MAYNE PHARMA	60MG

A211796	001	May 23, 2019	May NEWA
A211796	002	May 23, 2019	May NEWA
A211796	003	May 23, 2019	May NEWA
A211796	004	May 23, 2019	May NEWA
A211796	005	May 23, 2019	May NEWA
A078458	004	Jun 23, 2016	May CTEC

FOR SUSPENSION, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE  
@ ACTAVIS LABS FL INC 5MG/ML  
QUILLIVANT XR

+	! NEXTWAVE	5MG/ML
+	! NEXTWAVE PHARMS	5MG/ML

A206049	001	May 17, 2018	Jan DISC
N202100	001	Sep 27, 2012	Feb CAHN
N202100	001	Sep 27, 2012	Jan CTEC

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOVELGENIX THERAPS	5MG/5ML
AA		10MG/5ML

A210139	001	Oct 03, 2018	Sep CAHN
A210139	002	Oct 03, 2018	Sep CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ALKEM LABS LTD	5MG
AB		10MG
AB		20MG
	@ AUROLIFE PHARMA LLC	5MG
	@	10MG
	@	20MG
	@ CEDIPROF INC	5MG
AB		5MG
	@	10MG
AB		10MG
	@	20MG
AB		20MG
	@ LANNETT CO INC	5MG
	@	10MG
	@	20MG

A211779	001	Oct 04, 2019	Sep NEWA
A211779	002	Oct 04, 2019	Sep NEWA
A211779	003	Oct 04, 2019	Sep NEWA
A209276	001	Oct 25, 2018	Apr DISC
A209276	002	Oct 25, 2018	Apr DISC
A209276	003	Oct 25, 2018	Apr DISC
A208737	001	Feb 01, 2019	Aug DISC
A208737	001	Feb 01, 2019	Jan NEWA
A208737	002	Feb 01, 2019	Aug DISC
A208737	002	Feb 01, 2019	Jan NEWA
A208737	003	Feb 01, 2019	Aug DISC
A208737	003	Feb 01, 2019	Jan NEWA
A086429	001		Jan DISC
A085799	001		Jan DISC
A086428	001		Jan DISC

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@ LANNETT CO INC 20MG  
METHYLPHENIDATE HYDROCHLORIDE

AB	! ABHAI LLC	20MG
AB	ANDOR PHARMS	18MG
AB		27MG
AB		36MG
AB		54MG
AB	ASCENT PHARMS INC	18MG
AB		27MG

A089601	001	Jun 01, 1988	Jan DISC
A207488	002	Jun 09, 2015	Jan NEWA
A211918	001	Apr 24, 2019	Apr NEWA
A211918	002	Apr 24, 2019	Apr NEWA
A211918	003	Apr 24, 2019	Apr NEWA
A211918	004	Apr 24, 2019	Apr NEWA
A211009	001	Sep 03, 2019	Aug NEWA
A211009	002	Sep 03, 2019	Aug NEWA

TABLET, EXTENDED RELEASE;ORAL  
METHYLPHENIDATE HYDROCHLORIDE

AB		36MG	A211009	003	Sep 03, 2019	Aug NEWA
AB		54MG	A211009	004	Sep 03, 2019	Aug NEWA
	@ HERITAGE PHARMA	20MG	A075450	001	Dec 21, 2001	May CAHN

METHYLPREDNISOLONE

TABLET;ORAL  
MEDROL

AB	+	PHARMACIA AND UPJOHN	2MG	N011153	002		Mar CFTG
		METHYLPREDNISOLONE					
		@ LUPIN LTD	2MG	A209097	001	Feb 22, 2019	Sep DISC
AB			2MG	A209097	001	Feb 22, 2019	Mar NFTG
AB			2MG	A209097	001	Feb 22, 2019	Feb NEWA
		@	4MG	A209097	002	Feb 22, 2019	Sep DISC
AB			4MG	A209097	002	Feb 22, 2019	Feb NEWA
		@	8MG	A209097	003	Feb 22, 2019	Sep DISC
AB			8MG	A209097	003	Feb 22, 2019	Feb NEWA
		@	16MG	A209097	004	Feb 22, 2019	Sep DISC
AB			16MG	A209097	004	Feb 22, 2019	Feb NEWA
		@	32MG	A209097	005	Feb 22, 2019	Sep DISC
AB			32MG	A209097	005	Feb 22, 2019	Feb NEWA
>D> AB		NOVAST LABS	4MG	A210985	001	Jan 09, 2019	Oct DISC
>A>		@	4MG	A210985	001	Jan 09, 2019	Oct DISC
AB			4MG	A210985	001	Jan 09, 2019	Sep CAHN
AB		SUNGEN PHARMA	4MG	A212262	001	Jun 27, 2019	Jun NEWA
AB		TIANJIN TIANYAO	4MG	A204072	001	May 14, 2018	Apr CMFD

METHYLTESTOSTERONE

CAPSULE;ORAL  
VIRILON

	@ CHARTWELL	10MG	A087750	001	Nov 24, 1982	Jun CAHN
--	-------------	------	---------	-----	--------------	----------

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
METIPRANOLOL

	@ SANDOZ INC	0.3%	A075720	001	Aug 06, 2001	May DISC
	OPTIPRANOLOL					
+	@ BAUSCH AND LOMB	0.3%	N019907	001	Dec 29, 1989	Aug DISC
+	!	0.3%	N019907	001	Dec 29, 1989	May CTEC

METOLAZONE

TABLET;ORAL  
METOLAZONE

	@ ANI PHARMS INC	5MG	A076833	001	Mar 01, 2004	Sep CAHN
	@	10MG	A075543	003	Dec 24, 2003	Sep CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL  
TOPROL-XL

AB	+	TOPROL	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Mar CAHN
AB	+	!	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Mar CAHN
AB	+		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Mar CAHN
AB	+	!	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Mar CAHN

METOPROLOL TARTRATE

INJECTABLE;INJECTION  
LOPRESSOR

	+	@ NOVARTIS	1MG/ML	N018704	001	Mar 30, 1984	Jun DISC
		METOPROLOL TARTRATE					
AP	!	HOSPIRA	1MG/ML	A078085	001	Apr 29, 2008	Jun CHRS
		@ LUITPOLD	1MG/ML	A090386	001	Sep 30, 2009	Mar DISC
		@	1MG/ML	A091307	001	Dec 29, 2010	Feb DISC

TABLET;ORAL

METOPROLOL TARTRATE

AB		HERITAGE PHARMA	50MG	A074141	001	Jan 31, 1995	Apr CAHN
AB			100MG	A074141	002	Jan 31, 1995	Apr CAHN
>D>		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Oct CTEC
>A> AB			37.5MG	A076704	004	Mar 18, 2015	Oct CTEC
>D>			75MG	A076704	005	Mar 18, 2015	Oct CTEC
>A> AB			75MG	A076704	005	Mar 18, 2015	Oct CTEC
>A> AB		RUBICON	37.5MG	A200981	004	Aug 21, 2019	Oct NEWA

## TABLET;ORAL

## METOPROLOL TARTRATE

>A>	AB		75MG	A200981	005	Aug 21, 2019	Oct NEWA
>D>	AB	SUN PHARM INDUSTRIES	25MG	A073654	002	Jul 15, 2009	Oct DISC
>A>	@		25MG	A073654	002	Jul 15, 2009	Oct DISC
>D>	AB		50MG	A073654	003	Dec 21, 1993	Oct DISC
>A>	@		50MG	A073654	003	Dec 21, 1993	Oct DISC
>D>	AB		100MG	A073654	001	Dec 21, 1993	Oct DISC
>A>	@		100MG	A073654	001	Dec 21, 1993	Oct DISC
>D>	AB	WATSON LABS	50MG	A074217	001	May 27, 1994	Oct DISC
>A>	@		50MG	A074217	001	May 27, 1994	Oct DISC
>D>	AB		100MG	A074217	002	May 27, 1994	Oct DISC
>A>	@		100MG	A074217	002	May 27, 1994	Oct DISC

METRONIDAZOLE

## GEL;VAGINAL

## METROGEL-VAGINAL

AB	+	BAUSCH	0.75%	N020208	001	Aug 17, 1992	Mar CAHN
AB		GAGE DEVELOPMENT	0.75%	A211786	001	Jul 02, 2019	Jun NEWA
AB		PERRIGO UK FINCO	0.75%	A211786	001	Jul 02, 2019	Jul CAHN

## INJECTABLE;INJECTION

## METRONIDAZOLE IN PLASTIC CONTAINER

AP		INFORLIFE	500MG/100ML	A206191	001	Feb 25, 2019	Feb NEWA
----	--	-----------	-------------	---------	-----	--------------	----------

## TABLET;ORAL

## METRONIDAZOLE

AB		CADILA	250MG	A206560	001	Nov 16, 2016	Mar CAHN
AB			500MG	A206560	002	Nov 16, 2016	Mar CAHN
AB		STRIDES PHARMA	250MG	A070040	001	Jan 29, 1985	Apr CAHN
AB			500MG	A070039	001	Jan 29, 1985	Apr CAHN

METTYROSINE

## CAPSULE;ORAL

## DEMSEER

+	!	BAUSCH	250MG	N017871	001		Mar CAHN
---	---	--------	-------	---------	-----	--	----------

MICAFUNGIN SODIUM

## INJECTABLE;INTRAVENOUS

## MICAFUNGIN SODIUM

AP	FRESENIUS KABI USA	EQ 50MG BASE/VIAL	A207344	001	May 17, 2019	May NFTG
AP		EQ 100MG BASE/VIAL	A207344	002	May 17, 2019	May NFTG
	MYCAMINE					
AP	+! ASTELLAS	EQ 50MG BASE/VIAL	N021506	002	Mar 16, 2005	May CFTG
AP	+!	EQ 100MG BASE/VIAL	N021506	003	Jun 27, 2006	May CDFR

MICONAZOLE

## TABLET;BUCCAL

## ORAVIG

>A>	+	!	FORTOVIA	50MG	N022404	001	Apr 16, 2010	Oct CAHN
>D>	+	!	MIDATECH PHARMA US	50MG	N022404	001	Apr 16, 2010	Oct CAHN

MIDAZOLAM

## SPRAY;NASAL

## NAYZILAM

+	!	UCB INC	5MG/SPRAY	N211321	001	May 17, 2019	May NEWA
---	---	---------	-----------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

## INJECTABLE;INJECTION

## MIDOZALAM HYDROCHLORIDE

AP	@	MYLAN ASI	EQ 1MG BASE/ML	A090316	001	May 04, 2011	Sep DISC
AP			EQ 1MG BASE/ML	A090316	001	May 04, 2011	Apr CAHN
AP	@		EQ 5MG BASE/ML	A090316	002	May 04, 2011	Sep DISC
AP			EQ 5MG BASE/ML	A090316	002	May 04, 2011	Apr CAHN

MIDODRINE HYDROCHLORIDE

## TABLET;ORAL

## MIDODRINE HYDROCHLORIDE

AB	@	CASI PHARMS INC	2.5MG	A076514	001	Sep 11, 2003	May DISC
AB	@		5MG	A076514	002	Sep 11, 2003	May DISC
AB	@		10MG	A076514	003	Jul 02, 2004	May DISC
AB		MYLAN PHARMS INC	5MG	A076577	002	Sep 10, 2003	May CHRS
AB		RUBICON	2.5MG	A212543	001	Aug 19, 2019	Aug NEWA

TABLET;ORAL  
MIDODRINE HYDROCHLORIDE

AB		5MG	A212543	002	Aug 19, 2019	Aug NEWA
AB		10MG	A212543	003	Aug 19, 2019	Aug NEWA
ORVATEN						
AB	! UPSHER SMITH LABS	5MG	A076725	002	Nov 03, 2004	May CHRS

MIFEPRISTONE

TABLET;ORAL  
MIFEPREX

AB	+! DANCO LABS LLC	200MG	N020687	001	Sep 28, 2000	Mar CFTG
AB	GENBIOPRO	200MG	A091178	001	Apr 11, 2019	Mar NFTG

MILRINONE LACTATE

## INJECTABLE;INJECTION

## MILRINONE LACTATE IN DEXTROSE 5%

>D>	AP	RENAISSANCE SSA LLC	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Oct CAHN
>A>	AP	WOODWARD	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Oct CAHN
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER							
>D>	@	RENAISSANCE SSA LLC	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Oct CAHN
>A>	@	WOODWARD	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Oct CAHN

MINOCYCLINE HYDROCHLORIDE

&gt;A&gt; AEROSOL, FOAM;TOPICAL

&gt;A&gt; AMZEEQ

>A>	+!	FOAMIX	EQ 4% BASE	N212379	001	Oct 18, 2019	Oct NEWA
-----	----	--------	------------	---------	-----	--------------	----------

## CAPSULE;ORAL

## MINOCIN

AB	+	BAUSCH	EQ 50MG BASE	N050649	001	May 31, 1990	May CAHN
	+	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May CAHN
AB	+		EQ 100MG BASE	N050649	002	May 31, 1990	May CAHN

## CAPSULE, EXTENDED RELEASE;ORAL

## XIMINO

SUN PHARM INDS INC

		EQ 45MG BASE	N201922	001	Jul 11, 2012	Aug CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Aug CAHN
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Aug CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Aug CAHN
		EQ 135MG BASE	N201922	005	Jul 11, 2012	Aug CAHN

## SUSPENSION;ORAL

## MINOCIN

@ BAUSCH

		EQ 50MG BASE/5ML	N050445	001		May CAHN
--	--	------------------	---------	-----	--	----------

## TABLET;ORAL

## MINOCYCLINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDUSTRIES	EQ 50MG BASE	A090217	001	Jan 29, 2016	Oct DISC
>A>		@	EQ 50MG BASE	A090217	001	Jan 29, 2016	Oct DISC
>D>	AB		EQ 75MG BASE	A090217	002	Jan 29, 2016	Oct DISC
>A>		@	EQ 75MG BASE	A090217	002	Jan 29, 2016	Oct DISC
>D>	AB		EQ 100MG BASE	A090217	003	Jan 29, 2016	Oct DISC
>A>		@	EQ 100MG BASE	A090217	003	Jan 29, 2016	Oct DISC

## TABLET, EXTENDED RELEASE;ORAL

## MINOCYCLINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 55MG BASE	A202261	008	Aug 21, 2019	Aug NEWA
AB	BARR LABS INC	EQ 80MG BASE	A065485	007	Apr 26, 2017	Jan CMFD
AB		EQ 105MG BASE	A065485	008	Apr 26, 2017	Jan CMFD
	@ MYLAN	EQ 55MG BASE	A203443	001	Aug 21, 2019	Aug NEWA
	@ MYLAN LABS LTD	EQ 65MG BASE	A201467	001	Jul 30, 2019	Aug DISC
AB		EQ 65MG BASE	A201467	001	Jul 30, 2019	Jul NEWA
	@	EQ 115MG BASE	A201467	002	Jul 30, 2019	Aug DISC
AB		EQ 115MG BASE	A201467	002	Jul 30, 2019	Jul NEWA

MIRTAZAPINE

## TABLET;ORAL

## MIRTAZAPINE

@ WATSON LABS

		15MG	A076312	001	Jun 19, 2003	May DISC
	@	30MG	A076312	002	Jun 19, 2003	May DISC
	@	45MG	A076312	003	Jun 19, 2003	May DISC

MISOPROSTOL

TABLET; ORAL  
MISOPROSTOL

AB	ZYDUS PHARMS	0.1MG	A210201	001	Jul 02, 2019	Jun NEWA
AB		0.2MG	A210201	002	Jul 02, 2019	Jun NEWA

MITOMYCIN

INJECTABLE; INJECTION  
MITOMYCIN

AP	WEST-WARD PHARMS INT	20MG/VIAL	A064117	002	Apr 19, 1995	Jan CMFD
AP		40MG/VIAL	A064117	003	Jun 02, 1999	Jan CMFD

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION  
MITOXANTRONE HYDROCHLORIDE

	@ MYLAN INSTITUTIONAL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078980	001	Apr 13, 2009	Mar DISC
	@	EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078980	002	Apr 13, 2009	Mar DISC
	@ MYLAN LABS LTD	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Sep DISC
	NOVANTRONE					
+	@ EMD SERONO	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N019297	001	Dec 23, 1987	Sep CRLD

MODAFINIL

TABLET; ORAL  
MODAFINIL

AB	CADILA	100MG	A209966	001	Sep 14, 2017	Aug CMFD
	@	100MG	A209966	001	Sep 14, 2017	May CAHN
AB		200MG	A209966	002	Sep 14, 2017	Aug CMFD
	@	200MG	A209966	002	Sep 14, 2017	May CAHN
	@ HIKMA PHARMS	100MG	A090543	001	Sep 26, 2012	Aug DISC
	@	200MG	A090543	002	Sep 26, 2012	Aug DISC
	@ ZYDUS PHARMS	100MG	A209966	001	Sep 14, 2017	Apr DISC
	@	200MG	A209966	002	Sep 14, 2017	Apr DISC

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION  
ASMANEX HFA

+	MERCK SHARP DOHME	0.05MG/INH	N205641	003	Aug 12, 2019	Aug NEWA
	CREAM; TOPICAL					
	ELOCON					
+	@ MERCK SHARP DOHME	0.1%	N019625	002	Apr 19, 2013	Aug DISC
	MOMETASONE FUROATE					
AB	! GLENMARK GENERICS	0.1%	A078541	001	May 28, 2008	Aug CHRS
	OINTMENT; TOPICAL					
	ELOCON					
+	@ MERCK SHARP DOHME	0.1%	N019543	001	Apr 30, 1987	Jul DISC
	MOMETASONE FUROATE					
AB	! GLENMARK GENERICS	0.1%	A078571	001	May 28, 2008	Jul CHRS

MONTELUKAST SODIUM

GRANULE; ORAL  
MONTELUKAST SODIUM

	@ MYLAN PHARMS INC	EQ 4MG BASE/PACKET	A202776	001	Dec 18, 2012	Feb DISC
AB	TORRENT	EQ 4MG BASE/PACKET	A210431	001	Jul 31, 2018	Mar CAHN

TABLET; ORAL  
MONTELUKAST SODIUM

AB	L PERRIGO CO	EQ 10MG BASE	A206112	001	Apr 26, 2017	May CAHN
	@ MYLAN PHARMS INC	EQ 10MG BASE	A079103	001	Aug 03, 2012	Jul DISC
	@ VINTAGE PHARMS LLC	EQ 10MG BASE	A091576	001	Aug 03, 2012	Feb DISC

TABLET, CHEWABLE; ORAL  
MONTELUKAST SODIUM

	@ MYLAN PHARMS INC	EQ 4MG BASE	A079142	001	Aug 03, 2012	Apr DISC
	@	EQ 5MG BASE	A079142	002	Aug 03, 2012	Apr DISC
	@ VINTAGE PHARMS LLC	EQ 4MG BASE	A091588	001	Aug 03, 2012	Feb DISC
	@	EQ 5MG BASE	A091588	002	Aug 03, 2012	Feb DISC

MORPHINE SULFATE

INJECTABLE;INJECTION

ASTRAMORPH PF

@ FRESENIUS KABI USA

0.5MG/ML

A071050 001 Oct 07, 1986 Mar DISC

MITIGO

AP PIRAMAL CRITICAL

10MG/ML

A204393 001 Jul 16, 2018 Aug CAHN

AP 25MG/ML

A204393 002 Jul 16, 2018 Aug CAHN

MORPHINE SULFATE

+ @ ICU MEDICAL INC

5MG/ML

N019916 002 Oct 27, 2006 Sep DISC

SOLUTION;ORAL

MORPHINE SULFATE

@ LANNETT CO INC

10MG/5ML

A202309 001 Nov 25, 2015 Feb DISC

@

20MG/5ML

A202310 001 Oct 30, 2015 Jan DISC

@

100MG/5ML

N201517 001 Jun 23, 2011 Jan DISC

@ VISTAPHARM

10MG/5ML

A201947 001 Jan 05, 2012 Jul DISC

TABLET;ORAL

MORPHINE SULFATE

AB UPSHER SMITH LABS

15MG

A210610 001 Jul 22, 2019 Jul NFTG

AB 30MG

A210610 002 Jul 22, 2019 Jul NFTG

TABLET, EXTENDED RELEASE;ORAL

ARYMO ER

+ @ EGALET

15MG

N208603 001 Jan 09, 2017 Mar CAHN

+ @

30MG

N208603 002 Jan 09, 2017 Mar CAHN

+ @

60MG

N208603 003 Jan 09, 2017 Mar CAHN

+ @ ZYLA

15MG

N208603 001 Jan 09, 2017 Jul CAHN

+ @

30MG

N208603 002 Jan 09, 2017 Jul CAHN

+ @

60MG

N208603 003 Jan 09, 2017 Jul CAHN

MORPHINE SULFATE

@ MYLAN PHARMS INC

15MG

A200824 001 Oct 18, 2011 Aug DISC

@

30MG

A200824 002 Oct 18, 2011 Aug DISC

@

60MG

A200824 003 Oct 18, 2011 Aug DISC

@

100MG

A200824 004 Oct 18, 2011 Aug DISC

@

200MG

A200824 005 Oct 18, 2011 Feb DISC

&gt;D&gt; AB SUN PHARM INDUSTRIES

15MG

A205634 001 Aug 25, 2016 Oct DISC

&gt;A&gt; @

15MG

A205634 001 Aug 25, 2016 Oct DISC

&gt;D&gt; AB 30MG

A205634 002 Aug 25, 2016 Oct DISC

&gt;A&gt; @

30MG

A205634 002 Aug 25, 2016 Oct DISC

&gt;D&gt; AB 60MG

A205634 003 Aug 25, 2016 Oct DISC

&gt;A&gt; @

60MG

A205634 003 Aug 25, 2016 Oct DISC

&gt;D&gt; AB 100MG

A205634 004 Aug 25, 2016 Oct DISC

&gt;A&gt; @

100MG

A205634 004 Aug 25, 2016 Oct DISC

&gt;D&gt; AB 200MG

A205634 005 Aug 25, 2016 Oct DISC

&gt;A&gt; @

200MG

A205634 005 Aug 25, 2016 Oct DISC

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

MOXIFLOXACIN HYDROCHLORIDE

AT1 ALEMBIC PHARMS LTD EQ 0.5% BASE

A209469 001 Feb 13, 2019 Jan NEWA

TABLET;ORAL

MOXIFLOXACIN HYDROCHLORIDE

&gt;D&gt; AB MYLAN EQ 400MG BASE

A204635 001 Aug 31, 2015 Oct DISC

&gt;A&gt; @ EQ 400MG BASE

A204635 001 Aug 31, 2015 Oct DISC

@ SUNSHINE LAKE EQ 400MG BASE

A206295 001 Sep 28, 2018 Mar DISC

MUPIROCIN

OINTMENT;TOPICAL

MUPIROCIN

AB ! PERRIGO ISRAEL 2%

A065123 001 Nov 07, 2003 May CAHN

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB VISTAPHARM 200MG/ML

A210370 001 Feb 12, 2019 Jan NEWA

TABLET;ORAL

MYCOPHENOLATE MOFETIL

@ OXFORD PHARMS

500MG

A090606 001 Jul 16, 2010 Aug DISC

@ TEVA PHARMS

500MG

A065457 001 May 04, 2009 Sep DISC

NABUMETONETABLET; ORAL  
NABUMETONE

>D>	AB	APOTEX INC	500MG	A090427	001	Dec 30, 2011	Oct CAHN
>D>	AB		750MG	A090427	002	Dec 30, 2011	Oct CAHN
	AB	NEXGEN PHARMA INC	500MG	A203166	001	Aug 30, 2019	Aug NEWA
	AB		750MG	A203166	002	Aug 30, 2019	Aug NEWA
			1GM	A203166	003	Aug 30, 2019	Aug NEWA
>A>	AB	NOSTRUM LABS INC	500MG	A090427	001	Dec 30, 2011	Oct CAHN
>A>	AB		750MG	A090427	002	Dec 30, 2011	Oct CAHN
	AB	SCIEGEN PHARMS INC	500MG	A078420	001	Sep 24, 2008	Sep CMFD
	AB		750MG	A078420	002	Sep 24, 2008	Sep CMFD

NADOLOLTABLET; ORAL  
NADOLOL

	AB	HERITAGE PHARMA	20MG	A074229	001	Aug 30, 1996	Apr CAHN
	AB		40MG	A074229	002	Aug 30, 1996	Apr CAHN
	AB		80MG	A074255	001	Jan 24, 1996	Apr CAHN
		@	120MG	A074255	002	Jan 24, 1996	Apr CAHN
		@	160MG	A074255	003	Jan 24, 1996	Apr CAHN
	AB	VGYAAN	20MG	A212856	001	Sep 13, 2019	Sep NEWA
	AB		40MG	A212856	002	Sep 13, 2019	Sep NEWA
	AB		80MG	A212856	003	Sep 13, 2019	Sep NEWA

NAFCILLIN SODIUMINJECTABLE; INJECTION  
NAFCILLIN SODIUM

	@	MYLAN LABS LTD	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Sep DISC
	@		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Sep DISC

NAFTIFINE HYDROCHLORIDEGEL; TOPICAL  
NAFTIFINE HYDROCHLORIDE

	@	TARO	2%	A208201	001	Apr 10, 2019	May DISC
AB			2%	A208201	001	Apr 10, 2019	Mar NFTG
AB		TOLMAR	1%	A206165	001	Mar 20, 2019	Mar NFTG
		NAFTIN					
AB	+	SEBELA IRELAND LTD	1%	N019356	001	Jun 18, 1990	Mar CFTG
AB	+		2%	N204286	001	Jun 27, 2013	Mar CFTG

NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION  
NALBUPHINE HYDROCHLORIDE

	@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	May CAHN
	@		20MG/ML	A074471	002	Mar 19, 1998	May CAHN
AP		MYLAN LABS LTD	10MG/ML	A206506	001	Feb 06, 2019	Jan NEWA
AP			20MG/ML	A206506	002	Feb 06, 2019	Jan NEWA

NALDEMEDINE TOSYLATETABLET; ORAL  
SYMPROIC

	+!	BDSI	EQ 0.2MG BASE	N208854	001	Mar 23, 2017	Apr CAHN
--	----	------	---------------	---------	-----	--------------	----------

NALOXONE HYDROCHLORIDEINJECTABLE; INJECTION  
NALOXONE HYDROCHLORIDE

	AP	AUROBINDO PHARMA LTD	0.4MG/ML	A212455	001	Oct 15, 2019	Sep NEWA
>A>	AP		0.4MG/ML	A212456	001	Nov 04, 2019	Oct NEWA
>D>	AP	VIRTUS PHARMS	0.4MG/ML	A207846	001	Dec 17, 2018	Oct DISC
>A>	@		0.4MG/ML	A207846	001	Dec 17, 2018	Oct DISC
	AP		0.4MG/ML	A207846	001	Dec 17, 2018	Jul CAHN
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
		EVZIO (AUTOINJECTOR)					
	+	KALEO INC	2MG/0.4ML (2MG/0.4ML)	N209862	001	Oct 19, 2016	Feb CTNA
		SPRAY, METERED;NASAL					
		NALOXONE HYDROCHLORIDE					
		@ TEVA PHARMS USA	4MG/SPRAY	A209522	001	Apr 19, 2019	May DISC
	AB		4MG/SPRAY	A209522	001	Apr 19, 2019	Apr NFTG
		NARCAN					
	+	ADAPT	4MG/SPRAY	N208411	001	Nov 18, 2015	May CTEC

SPRAY, METERED;NASAL									
NARCAN									
AB	+	4MG/SPRAY		N208411	001	Nov 18, 2015	Apr	CFTG	
<u>NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE</u>									
TABLET;ORAL									
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE									
AB	LUPIN	EQ 0.5MG BASE;EQ 50MG BASE		A075735	001	Jul 11, 2001	Feb	CAHN	
<u>NANDROLONE DECANOATE</u>									
INJECTABLE;INJECTION									
NANDROLONE DECANOATE									
	@ LUITPOLD	200MG/ML		A091252	001	Aug 30, 2010	Feb	DISC	
<u>NAPROXEN</u>									
SUSPENSION;ORAL									
NAPROSYN									
AB	+	ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun	CHRS	
TABLET;ORAL									
NAPROXEN									
AB		PERRIGO PHARMS CO	250MG	A077339	001	Apr 27, 2005	Apr	CAHN	
AB			375MG	A077339	002	Apr 27, 2005	Apr	CAHN	
AB			500MG	A077339	003	Apr 27, 2005	Apr	CAHN	
<u>NAPROXEN SODIUM</u>									
TABLET;ORAL									
NAPROXEN SODIUM									
>A> AB		SCIEGEN PHARMS INC	EQ 250MG BASE	A212199	001	Oct 30, 2019	Oct	NEWA	
>A> AB			EQ 500MG BASE	A212199	002	Oct 30, 2019	Oct	NEWA	
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE</u>									
TABLET;ORAL									
TREXIMET									
	+	@ CURRAX	60MG;EQ 10MG BASE	N021926	002	May 14, 2015	Apr	CAHN	
AB	+	!	500MG;EQ 85MG BASE	N021926	001	Apr 15, 2008	Apr	CAHN	
<u>NARATRIPTAN HYDROCHLORIDE</u>									
TABLET;ORAL									
NARATRIPTAN									
AB		ANI PHARMS INC	EQ 1MG BASE	A078751	001	Jul 07, 2010	Sep	CAHN	
AB			EQ 2.5MG BASE	A078751	002	Jul 07, 2010	Sep	CAHN	
		@ CASI PHARMS INC	EQ 1MG BASE	A090288	001	Jul 07, 2010	Jun	DISC	
		@	EQ 2.5MG BASE	A090288	002	Jul 07, 2010	Jun	DISC	
>D> AB		MYLAN PHARMS INC	EQ 1MG BASE	A202431	001	May 31, 2012	Oct	DISC	
>A>		@	EQ 1MG BASE	A202431	001	May 31, 2012	Oct	DISC	
>D> AB			EQ 2.5MG BASE	A202431	002	May 31, 2012	Oct	DISC	
>A>		@	EQ 2.5MG BASE	A202431	002	May 31, 2012	Oct	DISC	
<u>NATEGLINIDE</u>									
TABLET;ORAL									
NATEGLINIDE									
AB		CADILA PHARMS LTD	60MG	A206432	001	Apr 19, 2019	Apr	NEWA	
AB			120MG	A206432	002	Apr 19, 2019	Apr	NEWA	
AB	!	ZYDUS PHARMS	120MG	A205248	002	Jul 06, 2016	Jul	CHRS	
STARLIX									
	+	@ NOVARTIS	60MG	N021204	001	Dec 22, 2000	Jul	DISC	
	+	@	120MG	N021204	002	Dec 22, 2000	Jul	DISC	
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>									
TABLET;ORAL									
BYVALSON									
	+	@ ALLERGAN	EQ 5MG BASE;80MG	N206302	001	Jun 03, 2016	Sep	DISC	
<u>NEOMYCIN SULFATE</u>									
TABLET;ORAL									
NEOMYCIN SULFATE									
	@	LANNETT CO INC	500MG	A204435	001	Jun 10, 2016	Jun	DISC	

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATE

@ WATSON LABS

EQ 40MG BASE/ML; 200,000 UNITS/ML

A062664 001 Apr 08, 1986 Jul DISC

NEOSTIGMINE METHYLSULFATE

SOLUTION; INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

AP AMRING PHARMS 5MG/10ML (0.5MG/ML)

A210989 001 Aug 22, 2018 Jan CAHN

AP 10MG/10ML (1MG/ML)

A210989 002 Aug 22, 2018 Jan CAHN

AP BE PHARMS 5MG/10ML (0.5MG/ML)

A212512 001 May 13, 2019 Apr NEWA

AP 10MG/10ML (1MG/ML)

A212512 002 May 13, 2019 Apr NEWA

AP GLAND PHARMA LTD 5MG/10ML (0.5MG/ML)

A212968 001 Oct 16, 2019 Sep NEWA

AP 10MG/10ML (1MG/ML)

A212968 002 Oct 16, 2019 Sep NEWA

NESIRITIDE RECOMBINANT

FOR SOLUTION; INTRAVENOUS

NATRECOR

+ @ SCIOS LLC

1.5MG/VIAL

N020920 001 Aug 10, 2001 Aug DISC

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

&gt;D&gt; AB MYLAN 100MG

A206271 001 Nov 09, 2015 Oct DISC

&gt;A&gt; @ 100MG

A206271 001 Nov 09, 2015 Oct DISC

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB JUBILANT GENERICS 500MG

A209156 001 May 14, 2018 Sep CMFD

@ 500MG

A209156 001 May 14, 2018 Apr DISC

AB 750MG

A209156 002 May 14, 2018 Sep CMFD

@ 750MG

A209156 002 May 14, 2018 Apr DISC

AB 1GM

A209156 003 May 14, 2018 Sep CMFD

@ 1GM

A209156 003 May 14, 2018 Apr DISC

AB MYLAN 500MG

A203742 001 Feb 22, 2019 Feb NEWA

AB 750MG

A203742 002 Feb 22, 2019 Feb NEWA

AB 1GM

A203742 003 Feb 22, 2019 Feb NEWA

AB YICHANG HUMANWELL 500MG

A212017 001 Jun 10, 2019 May NEWA

AB 750MG

A212017 002 Jun 10, 2019 May NEWA

AB 1GM

A212017 003 Jun 10, 2019 May NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

@ ANI PHARMS INC

20MG

A074670 001 Oct 28, 1996 Sep CAHN

@ 30MG

A074670 002 Oct 28, 1996 Sep CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB2 NOVAST LABS 30MG

A210614 001 Mar 12, 2019 Feb NEWA

AB2 60MG

A210614 002 Mar 12, 2019 Feb NEWA

AB2 90MG

A210614 003 Mar 12, 2019 Feb NEWA

AB2 OSMOTICA PHARM US 90MG

A077127 003 Oct 03, 2007 Apr CMS1

AB2 SPIL 30MG

A210838 001 Apr 16, 2019 Apr NEWA

AB2 60MG

A210838 002 Apr 16, 2019 Apr NEWA

AB2 90MG

A210838 003 Apr 16, 2019 Apr NEWA

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

&gt;D&gt; AB SUN PHARM INDS INC 30MG

A077067 001 Apr 17, 2007 Oct DISC

&gt;A&gt; @ 30MG

A077067 001 Apr 17, 2007 Oct DISC

NITISINONE

CAPSULE; ORAL

NITISINONE

AB NOVITIUM PHARMA 2MG

A211041 001 Aug 26, 2019 Aug NFTG

AB 5MG

A211041 002 Aug 26, 2019 Aug NFTG

AB 10MG

A211041 003 Aug 26, 2019 Aug NFTG

CAPSULE;ORAL  
ORFADIN

AB	+	SWEDISH ORPHAN	2MG	N021232	001	Jan 18, 2002	Aug CFTG
AB	+		5MG	N021232	002	Jan 18, 2002	Aug CFTG
AB	+		10MG	N021232	003	Jan 18, 2002	Aug CFTG

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL  
NITROFURANTOIN

	@	MYLAN	50MG	A074967	001	Jul 09, 1997	Jul DISC
	@		100MG	A077025	001	Aug 18, 2004	Jul DISC

NITROGLYCERINAEROSOL, METERED;SUBLINGUAL  
NITROMIST

+	!	EVUS	0.4MG/SPRAY	N021780	001	Nov 02, 2006	May CAHN
---	---	------	-------------	---------	-----	--------------	----------

FILM, EXTENDED RELEASE;TRANSDERMAL  
MINITRAN

	@	MEDICIS	0.4MG/HR	A089773	001	Aug 30, 1996	May DISC
	@	VALEANT PHARMS	0.1MG/HR	A089771	001	Aug 30, 1996	May DISC
	@		0.6MG/HR	A089774	001	Aug 30, 1996	Jun DISC
	@	VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May DISC

## NITRO-DUR

+	!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	May CTEC
+	!		0.2MG/HR	N020145	002	Apr 04, 1995	May CTEC
+	!		0.4MG/HR	N020145	004	Apr 04, 1995	May CTEC
+	!		0.6MG/HR	N020145	005	Apr 04, 1995	Jun CTEC

## NITROGLYCERIN

AB2		HERCON PHARM	0.1MG/HR	A089885	002	Oct 30, 2017	Feb NEWA
AB2	!	MYLAN TECHNOLOGIES	0.1MG/HR	A074559	004	Feb 06, 1998	Feb CTEC

TABLET;SUBLINGUAL  
NITROGLYCERIN

AB		ALVOGEN	0.3MG	A211604	001	Apr 30, 2019	Apr NEWA
AB			0.4MG	A211604	002	Apr 30, 2019	Apr NEWA
AB			0.6MG	A211604	003	Apr 30, 2019	Apr NEWA

NORETHINDRONETABLET;ORAL-28  
MICRONOR

	+	@	JANSSEN PHARMS	0.35MG	N016954	001	Mar	DISC
			NORETHINDRONE					
AB2	!		MYLAN LABS LTD	0.35MG	A200980	001	Jun 12, 2013	Mar CHRS

NORETHINDRONE ACETATETABLET;ORAL  
NORETHINDRONE ACETATE

	@	AUROBINDO PHARMA LTD	5MG	A204236	001	Jan 08, 2016	Sep DISC
AB		RISING	5MG	A206490	001	Nov 05, 2018	May CAHN

NYSTATINCREAM;TOPICAL  
NYSTATIN

AT		TORRENT	100,000 UNITS/GM	A212557	001	Jul 24, 2019	Jul NEWA
----	--	---------	------------------	---------	-----	--------------	----------

OINTMENT;TOPICAL  
NYSTATIN

>A>	AT	CADILA	100,000 UNITS/GM	A207767	001	May 25, 2018	Oct CAHN
	AT	TORRENT	100,000 UNITS/GM	A211838	001	Jan 28, 2019	Jan NEWA
>D>	AT	ZYDUS PHARMS	100,000 UNITS/GM	A207767	001	May 25, 2018	Oct CAHN

POWDER;TOPICAL  
NYSTATIN

AT		LUPIN	100,000 UNITS/GM	A065138	001	Jul 23, 2004	Feb CAHN
----	--	-------	------------------	---------	-----	--------------	----------

TABLET;ORAL  
NYSTATIN

	@	UPSHER SMITH LABS	500,000 UNITS	A062524	001	Nov 26, 1985	Jul CAHN
--	---	-------------------	---------------	---------	-----	--------------	----------

NYSTATIN; TRIAMCINOLONE ACETONIDEOINTMENT;TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

	@	CROWN LABS INC	100,000 UNITS/GM;0.1%	A207731	001	Dec 26, 2017	Sep DISC
	@	ZYDUS PHARMS	100,000 UNITS/GM;0.1%	A207764	001	Nov 08, 2018	Mar DISC

OCTREOTIDE ACETATE

## INJECTABLE; INJECTION

## OCTREOTIDE ACETATE

AP	HERITAGE PHARMS INC	EQ 0.05MG BASE/ML	A204669	001	Dec 27, 2018	Apr CAHN
AP		EQ 0.1MG BASE/ML	A204669	002	Dec 27, 2018	Apr CAHN
	@	EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Mar DISC
AP		EQ 0.2MG BASE/ML	A203765	001	Sep 07, 2018	Jan CAHN
AP		EQ 0.5MG BASE/ML	A204669	003	Dec 27, 2018	Apr CAHN
	@	EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Mar DISC
AP		EQ 1MG BASE/ML	A203765	002	Sep 07, 2018	Jan CAHN
	@ SUN PHARM INDS	EQ 0.05MG BASE/ML	A077372	001	Aug 14, 2007	Jul DISC
	@	EQ 0.1MG BASE/ML	A077372	002	Aug 14, 2007	Jul DISC
	@	EQ 0.2MG BASE/ML	A077373	001	Aug 14, 2007	Jul DISC
	@	EQ 0.5MG BASE/ML	A077372	003	Aug 14, 2007	Jul DISC
	@	EQ 1MG BASE/ML	A077373	002	Aug 14, 2007	Jul DISC

OFLOXACIN

## SOLUTION/DROPS; OPHTHALMIC

## OFLOXACIN

AT	APOTEX INC	0.3%	A076513	001	May 14, 2004	Feb CMFD
	@ SANDOZ INC	0.3%	A076231	001	May 14, 2004	Mar DISC

## SOLUTION/DROPS; OTIC

## OFLOXACIN

>D> AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Oct DISC
>A>	@	0.3%	A090395	001	Aug 11, 2009	Oct DISC
	@ SANDOZ INC	0.3%	A078222	001	Mar 17, 2008	Mar DISC

## TABLET; ORAL

## OFLOXACIN

@ LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Sep DISC
---------------	-------	---------	-----	--------------	----------

OLANZAPINE

## TABLET; ORAL

## OLANZAPINE

@ SUNSHINE LAKE	2.5MG	A206238	001	Nov 19, 2018	Apr DISC
@	5MG	A206238	002	Nov 19, 2018	Apr DISC
@	7.5MG	A206238	003	Nov 19, 2018	Apr DISC
@	10MG	A206238	004	Nov 19, 2018	Apr DISC
@	15MG	A206238	005	Nov 19, 2018	Apr DISC
@	20MG	A206238	006	Nov 19, 2018	Apr DISC

## TABLET, ORALLY DISINTEGRATING; ORAL

## OLANZAPINE

@ HEC PHARM	5MG	A208146	001	Jul 02, 2018	Feb DISC
@	10MG	A208146	002	Jul 02, 2018	Feb DISC
@	15MG	A208146	003	Jul 02, 2018	Feb DISC
@	20MG	A208146	004	Jul 02, 2018	Feb DISC

OLIVE OIL; SOYBEAN OIL

## EMULSION; INTRAVENOUS

## CLINOLIPID 20%

+! BAXTER HLTHCARE CORP	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Aug CMFD
+ @	16% (160GM/1000ML); 4% (40GM/1000ML)	N204508	001	Oct 03, 2013	Jun CDFR

OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL

AB	MICRO LABS	5MG	A206372	001	Sep 17, 2019	Sep NEWA
AB		20MG	A206372	002	Sep 17, 2019	Sep NEWA
AB		40MG	A206372	003	Sep 17, 2019	Sep NEWA
AB	SUNSHINE LAKE	5MG	A211049	001	Feb 22, 2019	Feb NEWA
AB		20MG	A211049	002	Feb 22, 2019	Feb NEWA
AB		40MG	A211049	003	Feb 22, 2019	Feb NEWA
AB	UMEDICA LABS PVT LTD	5MG	A207135	001	Jul 18, 2019	Jul NEWA
AB		20MG	A207135	002	Jul 18, 2019	Jul NEWA
AB		40MG	A207135	003	Jul 18, 2019	Jul NEWA

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

AT	ALEMBIC PHARMS LTD	EQ 0.2% BASE	A209420	001	Apr 29, 2019	Apr NEWA
AT	AUROBINDO PHARMA LTD	EQ 0.2% BASE	A209995	001	Apr 04, 2019	Mar NEWA
AT	FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019	Sep NEWA
AT	GLAND PHARMA LTD	EQ 0.1% BASE	A209619	001	Aug 02, 2019	Jul NEWA
AT	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Jun CAHN

OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET;ORAL  
TECHNIVIE

+	@ ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Apr DISC
---	--------------	------------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL  
OMEGA-3-ACID ETHYL ESTERS

AB	ASCENT PHARMS INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A207420	001	Feb 25, 2019	Feb NEWA
AB	BIONPHARMA INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Jul NEWA
	@ PAR PHARM INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091018	001	Jun 24, 2014	Jun DISC
AB	SOFGEN PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A211355	001	Jul 10, 2019	Jun NEWA
AB	ZYDUS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A210107	001	Jun 14, 2019	Jun NEWA

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL  
OMEPRAZOLE

AB	HETERO LABS LTD III	10MG	A204012	001	Sep 26, 2019	Sep NEWA
AB		20MG	A204012	002	Sep 26, 2019	Sep NEWA
	@ MYLAN	10MG	A075876	001	May 29, 2003	Jun DISC
	@	40MG	A075876	003	Jan 21, 2009	Sep DISC

OMEPRAZOLE; SODIUM BICARBONATECAPSULE;ORAL  
ZEGERID

AB	+	SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Sep CAHN
AB	+	!	40MG;1.1GM	N021849	002	Feb 27, 2006	Sep CAHN
		FOR SUSPENSION;ORAL					
		ZEGERID					
AB	+	SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Apr CAHN
AB	+	!	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Apr CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION  
ONDANSETRON HYDROCHLORIDE

	@ LUITPOLD	EQ 2MG BASE/ML	A079039	001	Nov 18, 2008	Feb DISC
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE				
	@ HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076780	001	Dec 26, 2006	Feb DISC
	@ LUITPOLD	EQ 2MG BASE/ML	A079032	001	Nov 18, 2008	Feb DISC
	@ TEVA	EQ 2MG BASE/ML	A076759	001	Nov 22, 2006	Aug DISC

TABLET;ORAL

		ONDANSETRON HYDROCHLORIDE					
	@ MYLAN	EQ 24MG BASE	A076930	004	Jun 25, 2007	Feb DISC	

ORPHENADRINE CITRATEINJECTABLE;INJECTION  
NORFLEX

+	@ TELIGENT	30MG/ML	N013055	001		Jan CRLD	
---	------------	---------	---------	-----	--	----------	--

TABLET, EXTENDED RELEASE;ORAL

		ORPHENADRINE CITRATE					
AB	LUPIN	100MG	A040284	001	Jun 19, 1998	Feb CAHN	

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	ALEMBIC PHARMS LTD	EQ 30MG BASE	A211823	001	Jun 24, 2019	Jun NEWA
AB		EQ 45MG BASE	A211823	002	Jun 24, 2019	Jun NEWA
AB		EQ 75MG BASE	A211823	003	Jun 24, 2019	Jun NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB	TEVA PHARMS USA	EQ 6MG BASE/ML	A211125	001	Feb 27, 2019	Feb NEWA
----	-----------------	----------------	---------	-----	--------------	----------

OXACILLIN SODIUM

INJECTABLE;INJECTION

OXACILLIN SODIUM

>D>	AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015	Oct DISC
>A>		@	EQ 1GM BASE/VIAL	A203950	001	Dec 11, 2015	Oct DISC
>D>	AP		EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015	Oct DISC
>A>		@	EQ 2GM BASE/VIAL	A203950	002	Dec 11, 2015	Oct DISC
	AP	PIRAMAL CRITICAL	EQ 1GM BASE/VIAL	A206681	001	Sep 11, 2017	Jul CAHN
	AP		EQ 2GM BASE/VIAL	A206681	002	Sep 11, 2017	Jul CAHN
	AP		EQ 10GM BASE/VIAL	A206760	001	Oct 26, 2017	Jul CAHN

OXALIPLATIN

INJECTABLE;INTRAVENOUS

ELOXATIN

		+ @ SANOFI AVENTIS US	50MG/VIAL	N021492	001	Aug 09, 2002	Feb CDFR
AP		+	50MG/10ML (5MG/ML)	N021759	001	Jan 31, 2005	Feb CDFR
		+ @	100MG/VIAL	N021492	002	Aug 09, 2002	Feb CDFR
AP		+	100MG/20ML (5MG/ML)	N021759	002	Jan 31, 2005	Feb CDFR
		+ @	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Feb CDFR

OXALIPLATIN

	AP	ACCORD HLTHCARE	50MG/10ML (5MG/ML)	A207474	001	Mar 21, 2017	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A207474	002	Mar 21, 2017	Feb CDFR
	AP		200MG/40ML (5MG/ML)	A207474	003	Mar 21, 2017	Feb CDFR
	AP	ACTAVIS LLC	50MG/10ML (5MG/ML)	A204880	001	Mar 05, 2018	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A204880	002	Mar 05, 2018	Feb CDFR
	AP	! ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Jul CHRS
	AP		50MG/VIAL	A078803	001	Aug 08, 2012	Feb CDFR
	AP	!	100MG/VIAL	A078803	002	Aug 08, 2012	Jul CHRS
	AP		100MG/VIAL	A078803	002	Aug 08, 2012	Feb CDFR
	AP	CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	Feb CDFR
	AP	EUGIA PHARMA	50MG/10ML (5MG/ML)	A205529	001	Sep 06, 2017	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A205529	002	Sep 06, 2017	Feb CDFR
	AP	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	A078811	001	Jun 10, 2010	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A078811	002	Jun 10, 2010	Feb CDFR
	AP		50MG/VIAL	A078819	001	Jun 02, 2010	Feb CDFR
	AP		50MG/10ML (5MG/ML)	A090030	001	Jan 31, 2017	Feb CDFR
	AP		100MG/VIAL	A078819	002	Jun 02, 2010	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A090030	002	Jan 31, 2017	Feb CDFR
	AP		200MG/40ML (5MG/ML)	A090030	003	Jan 31, 2017	Feb CDFR
	AP	GLAND PHARMA LTD	50MG/10ML (5MG/ML)	A207325	001	Feb 10, 2017	Feb CDFR
	AP		50MG/VIAL	A207385	001	May 23, 2017	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A207325	002	Feb 10, 2017	Feb CDFR
	AP		100MG/VIAL	A207385	002	May 23, 2017	Feb CDFR
	AP		200MG/40ML (5MG/ML)	A207325	003	Oct 18, 2017	Feb CDFR
	AP	HOSPIRA WORLDWIDE	50MG/10ML (5MG/ML)	A078813	001	Aug 07, 2009	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A078813	002	Aug 07, 2009	Feb CDFR
	AP	INGENUS PHARMS LLC	50MG/10ML (5MG/ML)	A207562	001	Oct 16, 2018	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A207562	002	Oct 16, 2018	Feb CDFR
	AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Feb CDFR
	AP	MYLAN LABS LTD	50MG/10ML (5MG/ML)	A091358	001	Aug 07, 2012	Feb CDFR
>D>	AP		50MG/VIAL	A200979	001	Aug 08, 2012	Oct DISC
>A>		@	50MG/VIAL	A200979	001	Aug 08, 2012	Oct DISC
	AP		50MG/VIAL	A200979	001	Aug 08, 2012	Feb CDFR
	AP		100MG/20ML (5MG/ML)	A091358	002	Aug 07, 2012	Feb CDFR
>D>	AP		100MG/VIAL	A200979	002	Aug 08, 2012	Oct DISC
>A>		@	100MG/VIAL	A200979	002	Aug 08, 2012	Oct DISC
	AP		100MG/VIAL	A200979	002	Aug 08, 2012	Feb CDFR
		@	200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Sep DISC
	AP		200MG/40ML (5MG/ML)	A091358	003	Nov 14, 2017	Feb CDFR
	AP	QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	Feb CDFR

INJECTABLE; INTRAVENOUS  
OXALIPLATIN

AP		50MG/VIAL	A204616	001	May 11, 2016	Feb CDFR
AP		100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	Feb CDFR
AP		100MG/VIAL	A204616	002	May 11, 2016	Feb CDFR
AP	!	200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Feb CDFR
AP		50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Feb CDFR
	@	50MG/VIAL	A090849	001	Apr 28, 2011	Feb CDFR
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Feb CDFR
	@	100MG/VIAL	A090849	002	Apr 28, 2011	Feb CDFR
	@ SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Feb CDFR
	@	100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Feb CDFR
	@ SUN PHARM	50MG/VIAL	A078818	001	Aug 07, 2009	Jul DISC
	@	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Jul DISC
	@	100MG/VIAL	A078818	002	Aug 07, 2009	Jul DISC
	@	100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Jul DISC
	@	200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Jul DISC
AP		200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Apr CDFR
AP	!	SUN PHARMA GLOBAL 50MG/VIAL	A078818	001	Aug 07, 2009	Feb CDFR
AP		50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Feb CDFR
AP	!	100MG/VIAL	A078818	002	Aug 07, 2009	Feb CDFR
AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Feb CDFR
AP	+	TEVA PHARMS 50MG/10ML (5MG/ML)	N022160	001	Aug 07, 2009	Feb CDFR
AP	+	100MG/20ML (5MG/ML)	N022160	002	Aug 07, 2009	Feb CDFR

INJECTABLE; IV (INFUSION)  
OXALIPLATIN

AP		SUN PHARMA GLOBAL 200MG/40ML (5MG/ML)	A202922	003	Feb 15, 2019	Feb NEWA
----	--	---------------------------------------	---------	-----	--------------	----------

OXAPROZIN

TABLET; ORAL  
OXAPROZIN

	@	BEXIMCO PHARMS USA 600MG	A075842	001	Apr 12, 2001	Mar CAHN
>D> AB		SUN PHARM INDS INC 600MG	A075844	001	Jan 03, 2002	Oct DISC
>A>	@	600MG	A075844	001	Jan 03, 2002	Oct DISC

OXYBUTYNIN CHLORIDE

SYRUP; ORAL  
OXYBUTYNIN CHLORIDE

@	LANNETT CO INC	5MG/5ML	A076682	001	Dec 28, 2004	Sep DISC
---	----------------	---------	---------	-----	--------------	----------

TABLET; ORAL  
OXYBUTYNIN CHLORIDE

AB		ARISE 5MG	A209025	001	Dec 21, 2017	Sep CAHN
AB		EMCURE PHARMS LTD 5MG	A211682	001	May 10, 2019	Apr NEWA
>A> AB		NOVAST LABS 5MG	A210611	001	Oct 30, 2019	Oct NEWA

TABLET, EXTENDED RELEASE; ORAL  
OXYBUTYNIN CHLORIDE

AB	!	ACCORD HLTHCARE 15MG	A207138	003	Feb 29, 2016	Aug CHRS
AB		AJANTA PHARMA LTD 5MG	A211655	001	Feb 28, 2019	Feb NEWA
AB		10MG	A211655	002	Feb 28, 2019	Feb NEWA
AB		15MG	A211655	003	Feb 28, 2019	Feb NEWA
AB		MYLAN PHARMS INC 15MG	A076644	002	May 10, 2007	Aug CHRS

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL  
OXYCODONE HYDROCHLORIDE

AA		ALKEM LABS LTD 5MG/5ML	A211748	001	Feb 07, 2019	Feb NEWA
AA		100MG/5ML	A211749	001	Feb 04, 2019	Jan NEWA
AA		EYWA 5MG/5ML	A207511	001	Nov 23, 2016	Sep CAHN
AA		100MG/5ML	A209897	001	Sep 06, 2017	Sep CAHN
	@	LANNETT CO INC 100MG/5ML	A204085	001	Sep 09, 2014	Jan DISC
AA		PHARM ASSOC 5MG/5ML	A206914	001	Feb 01, 2019	May CPOT
AA		5MG/ML	A206914	001	Feb 01, 2019	Jan NEWA

TABLET; ORAL  
OXAYDO

	ZYLA	5MG	N202080	001	Jun 17, 2011	Jul CAHN
		7.5MG	N202080	002	Jun 17, 2011	Jul CAHN

OXYCODONE HYDROCHLORIDE

@	VINTAGE PHARMS	5MG	A077712	003	Mar 02, 2009	Apr DISC
@		10MG	A077712	004	Apr 13, 2015	Apr DISC
@		15MG	A077712	001	Jan 31, 2007	Apr DISC
@		20MG	A077712	005	Apr 13, 2015	Apr DISC
@		30MG	A077712	002	Jan 31, 2007	Apr DISC

## TABLET; ORAL

## ROXYBOND

@ INSPIRION DELIVERY

5MG

N209777 001 Apr 20, 2017 Sep CAHN

@

15MG

N209777 002 Apr 20, 2017 Sep CAHN

@

30MG

N209777 003 Apr 20, 2017 Sep CAHN

OXYMETAZOLINE HYDROCHLORIDE

## CREAM; TOPICAL

## RHOFADÉ

&gt;D&gt;

+! ACLARIS

1%

N208552 001 Jan 18, 2017 Oct CAHN

&gt;A&gt;

+! EPI HLTH

1%

N208552 001 Jan 18, 2017 Oct CAHN

OXYTOCIN

## INJECTABLE; INJECTION

## OXYTOCIN

@ DR REDDYS

10USP UNITS/ML (10USP UNITS/ML)

A077453 001 Jan 24, 2008 May CAHN

@

100USP UNITS/10ML (10USP UNITS/ML)

A077453 002 Jan 24, 2008 May CAHN

PACLITAXEL

## INJECTABLE; INJECTION

## PACLITAXEL

@ ACCORD HLTHCARE

6MG/ML

A205720 001 Aug 17, 2018 Mar DISC

PALIPERIDONE

## TABLET, EXTENDED RELEASE; ORAL

## PALIPERIDONE

AB AMNEAL PHARMS

1.5MG

A204707 001 Sep 23, 2019 Sep NEWA

AB

3MG

A204707 002 Sep 23, 2019 Sep NEWA

AB

6MG

A204707 003 Sep 23, 2019 Sep NEWA

AB

9MG

A204707 004 Sep 23, 2019 Sep NEWA

AB

INVENTIA

1.5MG

A204452 001 Jun 12, 2019 Aug CAHN

AB

3MG

A204452 002 Jun 12, 2019 Aug CAHN

AB

6MG

A204452 003 Jun 12, 2019 Aug CAHN

AB

9MG

A204452 004 Jun 12, 2019 Aug CAHN

AB

INVENTIA HLTHCARE

1.5MG

A204452 001 Jun 12, 2019 May NEWA

AB

3MG

A204452 002 Jun 12, 2019 May NEWA

AB

6MG

A204452 003 Jun 12, 2019 May NEWA

AB

9MG

A204452 004 Jun 12, 2019 May NEWA

PALONOSETRON HYDROCHLORIDE

## INJECTABLE; INTRAVENOUS

## PALONOSETRON HYDROCHLORIDE

@ DR REDDYS LABS LTD

EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

A201533 001 Apr 21, 2016 Mar DISC

## SOLUTION; INTRAVENOUS

## PALONOSETRON HYDROCHLORIDE

HIKMA

EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML)

N207963 001 Aug 22, 2016 Jul CAHN

PAMIDRONATE DISODIUM

## INJECTABLE; INJECTION

## PAMIDRONATE DISODIUM

AP DR REDDYS

30MG/10ML (3MG/ML)

A078156 001 Aug 19, 2008 May CAHN

AP

60MG/10ML (6MG/ML)

A078156 002 Aug 19, 2008 May CAHN

AP

90MG/10ML (9MG/ML)

A078156 003 Aug 19, 2008 May CAHN

@ LUITPOLD

30MG/10ML (3MG/ML)

A078942 001 Jul 25, 2008 Mar DISC

@

90MG/10ML (9MG/ML)

A078942 002 Jul 25, 2008 Mar DISC

PANCURONIUM BROMIDE

## INJECTABLE; INJECTION

## PANCURONIUM BROMIDE

AP ! DR REDDYS

1MG/ML

A072759 001 Jul 31, 1990 May CAHN

!

2MG/ML

A072760 001 Jul 31, 1990 May CAHN

PANOBINOSTAT LACTATE

## CAPSULE; ORAL

## FARYDAK

+ SECURA

EQ 10MG BASE

N205353 001 Feb 23, 2015 Jun CAHN

+

EQ 15MG BASE

N205353 002 Feb 23, 2015 Jun CAHN

+!

EQ 20MG BASE

N205353 003 Feb 23, 2015 Jun CAHN

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)  
PANTOPRAZOLE SODIUM

>D>	AP	MYLAN LABS LTD	EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Oct DISC
>A>	@		EQ 40MG BASE/VIAL	A208580	001	May 04, 2018	Oct DISC
	AP	SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Aug NEWA
		POWDER;IV (INFUSION)					
		PANTOPRAZOLE SODIUM					
		+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Sep CRLD
		!	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Sep CHRS
			EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Jul CAHN
		TABLET, DELAYED RELEASE;ORAL					
		PANTOPRAZOLE SODIUM					
	AB	INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Feb NEWA
	AB	L PERRIGO CO	EQ 20MG BASE	A203024	001	May 07, 2014	May CAHN
	AB	RUBICON	EQ 20MG BASE	A090807	001	May 02, 2012	Aug CAHN
	AB		EQ 40MG BASE	A090807	002	May 02, 2012	Aug CAHN

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Oct DISC
>A>	@		EQ 10MG BASE	A078194	001	Jun 29, 2007	Oct DISC
>D>	AB		EQ 20MG BASE	A078194	002	Jun 29, 2007	Oct DISC
>A>	@		EQ 20MG BASE	A078194	002	Jun 29, 2007	Oct DISC
>D>	AB		EQ 30MG BASE	A078194	003	Jun 29, 2007	Oct DISC
>A>	@		EQ 30MG BASE	A078194	003	Jun 29, 2007	Oct DISC
>D>	AB		EQ 40MG BASE	A078194	004	Jun 29, 2007	Oct DISC
>A>	@		EQ 40MG BASE	A078194	004	Jun 29, 2007	Oct DISC

>D> PEGADEMASE BOVINE

>D> INJECTABLE;INJECTION

>D> ADAGEN

>D>	+!	LEADIANT BIOSCI INC	250 UNITS/ML	N019818	001	Mar 21, 1990	Oct DISC
>A>	+ @		250 UNITS/ML	N019818	001	Mar 21, 1990	Oct DISC

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

	@	VALEANT PHARMS INTL	125MG	N019853	002		Jan CAHN
AB	+!		250MG	N019853	001		Apr CFTG
	+!		250MG	N019853	001		Jan CAHN
		PENICILLAMINE					
AB		AMERIGEN PHARMS LTD	250MG	A209921	001	May 07, 2019	Apr NFTG
AB		WATSON LABS INC	250MG	A210976	001	Jun 24, 2019	Jun NEWA

PENTAMIDINE ISETHIONATE

FOR SOLUTION;INHALATION

NEBUPENT

AN	+!	FRESENIUS KABI USA	300MG/VIAL	N019887	001	Jun 15, 1989	Apr CFTG
		PENTAMIDINE ISETHIONATE					
AN		SETON PHARMS	300MG/VIAL	A206667	001	Apr 24, 2019	Apr NFTG

PENTOBARBITAL SODIUM

INJECTABLE;INJECTION

PENTOBARBITAL SODIUM

AP		ATHENEX	50MG/ML	A206677	001	Nov 27, 2017	Sep CAHN
----	--	---------	---------	---------	-----	--------------	----------

PENTOSTATIN

INJECTABLE;INJECTION

PENTOSTATIN

@	MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Mar DISC
---	---------------------	-----------	---------	-----	--------------	----------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

@	ANI PHARMS INC	400MG	A074878	001	Jul 09, 1997	May CAHN
@		400MG	A075107	001	Sep 04, 1998	Sep CAHN
@	MYLAN	400MG	A074425	001	Jul 08, 1997	Jun DISC



SOLUTION/DROPS;OPHTHALMIC PHENYLEPHRINE HYDROCHLORIDE						
AT	+	!	10%	N203510	002	Mar 21, 2013 Jan CTEC
<u>PHENYTOIN SODIUM</u>						
CAPSULE;ORAL EXTENDED PHENYTOIN SODIUM						
AB			LUPIN LTD 100MG EXTENDED	A211633	001	Sep 30, 2019 Sep NEWA
			@ SUN PHARM INDS (IN) 100MG EXTENDED	A040621	001	Dec 11, 2006 Jul DISC
INJECTABLE;INJECTION PHENYTOIN SODIUM						
			@ LUITPOLD 50MG/ML	A040781	001	Dec 04, 2007 Feb DISC
<u>PHYTONADIONE</u>						
INJECTABLE;INJECTION PHYTONADIONE						
AB			DR REDDYS LABS LTD 10MG/ML	A207719	001	May 22, 2019 May NEWA
VITAMIN K1						
AB	!		HOSPIRA 10MG/ML	A087955	001	Jul 25, 1983 May CTEC
TABLET;ORAL MEPHYTON						
AB	+	!	BAUSCH 5MG	N010104	003	Feb CAHN
AB	+	!	VALEANT PHARMS INTL 5MG	N010104	003	Jan CAHN
PHYTONADIONE						
AB			ZYDUS 5MG	A210189	001	Feb 20, 2019 Feb NEWA
<u>PILOCARPINE HYDROCHLORIDE</u>						
TABLET;ORAL PILOCARPINE HYDROCHLORIDE						
AB			AUROBINDO PHARMA LTD 5MG	A212377	001	Aug 13, 2019 Jul NEWA
AB			7.5MG	A212377	002	Aug 13, 2019 Jul NEWA
SALAGEN						
AB	+		CONCORDIA 5MG	N020237	001	Mar 22, 1994 Jul CAHN
AB	+	!	7.5MG	N020237	002	Apr 18, 2003 Jul CAHN
<u>PIMAVANSERIN TARTRATE</u>						
TABLET;ORAL NUPLAZID						
	+	@	ACADIA PHARMS INC EQ 17MG BASE	N207318	001	Apr 29, 2016 Jan DISC
<u>PIMECROLIMUS</u>						
CREAM;TOPICAL ELIDEL						
AB	+	!	BAUSCH 1%	N021302	001	Dec 13, 2001 Aug CAHN
PIMECROLIMUS						
AB			GLENMARK PHARMS LTD 1%	A211769	001	Aug 29, 2019 Aug NEWA
<u>PIMOZIDE</u>						
TABLET;ORAL ORAP						
	+	@	TEVA 1MG	N017473	003	Aug 27, 1997 Sep DISC
	+	@	2MG	N017473	001	Jul 31, 1984 Sep DISC
PIMOZIDE						
			PAR PHARM 1MG	A204521	001	Sep 28, 2015 Sep CTEC
	!		2MG	A204521	002	Sep 28, 2015 Sep CHRS
			2MG	A204521	002	Sep 28, 2015 Sep CTEC
<u>PINDOLOL</u>						
TABLET;ORAL PINDOLOL						
AB			BAYSHORE PHARMS LLC 5MG	A211712	001	Aug 01, 2019 Jul NEWA
AB			10MG	A211712	002	Aug 01, 2019 Jul NEWA
		@	ZYDUS PHARMS 5MG	A209866	001	Aug 18, 2017 Jun DISC
		@	10MG	A209866	002	Aug 18, 2017 Jun DISC
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</u>						
INJECTABLE;INJECTION PIPERACILLIN AND TAZOBACTAM						
AP			ASTRAL EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019 Jul NEWA
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019 Jul NEWA

INJECTABLE; INJECTION  
PIPERACILLIN AND TAZOBACTAM

AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Jul NEWA
>D>	AP	HOSPIRA INC EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Oct DISC
>A>	@	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Oct DISC
>D>	AP	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Oct DISC
>A>	@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Oct DISC
>D>	AP	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Oct DISC
>A>	@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Oct DISC
>D>	AP	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Oct DISC
>A>	@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Oct DISC

PIROXICAM

CAPSULE; ORAL  
PIROXICAM

AB		BRECKENRIDGE	10MG	A206136	001	Jun 20, 2017	Aug CAHN
AB			20MG	A206136	002	Jun 20, 2017	Aug CAHN
AB		CADILA	10MG	A205585	001	Jul 17, 2018	Feb CAHN
AB			20MG	A205585	002	Jul 17, 2018	Feb CAHN
>D>	AB	SUN PHARM INDUSTRIES	10MG	A073536	002	Jan 23, 2008	Oct DISC
>A>	@		10MG	A073536	002	Jan 23, 2008	Oct DISC
>D>	AB		20MG	A073536	001	Mar 12, 1993	Oct DISC
>A>	@		20MG	A073536	001	Mar 12, 1993	Oct DISC

PITAVASTATIN CALCIUM

TABLET; ORAL  
PITAVASTATIN CALCIUM

	@	MYLAN	EQ 1MG BASE	A206070	001	Apr 04, 2019	Apr DISC
	@		EQ 2MG BASE	A206070	002	Apr 04, 2019	Apr DISC
	@		EQ 4MG BASE	A206070	003	Apr 04, 2019	Apr DISC
AB		MYLAN PHARMS INC	EQ 1MG BASE	A206070	001	Apr 04, 2019	Mar NEWA
AB			EQ 2MG BASE	A206070	002	Apr 04, 2019	Mar NEWA
AB			EQ 4MG BASE	A206070	003	Apr 04, 2019	Mar NEWA

PITAVASTATIN MAGNESIUM

TABLET; ORAL  
ZYPITAMAG

	+ @	MEDICURE	EQ 1MG BASE	N208379	001	Jul 14, 2017	Sep DISC
>A>	+		EQ 2MG BASE	N208379	002	Jul 14, 2017	Oct CAHN
>A>	+		EQ 4MG BASE	N208379	003	Jul 14, 2017	Oct CAHN
>D>	+	ZYDUS PHARMS	EQ 2MG BASE	N208379	002	Jul 14, 2017	Oct CAHN
>D>	+		EQ 4MG BASE	N208379	003	Jul 14, 2017	Oct CAHN

PITOLISANT HYDROCHLORIDE

TABLET; ORAL  
WAKIX

	+	BIOPROJET PHARMA	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Aug NEWA
	+		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Aug NEWA
	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Sep CAHN
	+		EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Sep CAHN

PLAZOMICIN SULFATE

SOLUTION; INTRAVENOUS  
ZEMDRI

	+	CIPLA USA	EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	N210303	001	Jun 25, 2018	Jul CAHN
--	---	-----------	---	---------	-----	--------------	----------

PLECANATIDE

TABLET; ORAL  
TRULANCE

	+	BAUSCH	3MG	N208745	001	Jan 19, 2017	Mar CAHN
	+	SALIX	3MG	N208745	001	Jan 19, 2017	Apr CAHN

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL  
GLYCOLAX

@ LANNETT CO INC	17GM/SCOOPFUL	A076652	001	Jul 02, 2004	May DISC
POLYETHYLENE GLYCOL 3350					
@ NEXGEN PHARMA INC	17GM/SCOOPFUL	A077706	001	Sep 27, 2006	May DISC
@ PADDOCK LLC	17GM/SCOOPFUL	A077893	001	May 26, 2006	May DISC

POLYMYXIN B SULFATEINJECTABLE;INJECTION  
POLYMYXIN B SULFATE

>D> AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Oct CHRS
>A> AP	!	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Oct CHRS
>D> AP	!	WEST-WARD PHARMS INT	A060716	001		Oct DISC
>A>	@	EQ 500,000 UNITS BASE/VIAL	A060716	001		Oct DISC

PORFIMER SODIUMINJECTABLE;INJECTION  
PHOTOFRIN

>D>	CONCORDIA LABS INC	75MG/VIAL	N020451	001	Dec 27, 1995	Oct CAHN
>A>	PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995	Oct CAHN

POSACONAZOLETABLET, DELAYED RELEASE;ORAL  
NOXAFIL

AB	+!	MERCK SHARP DOHME	100MG	N205053	001	Nov 25, 2013	Aug CFTG
POSACONAZOLE							
AB		SINOTHERAPEUTICS INC	100MG	A212411	001	Aug 21, 2019	Aug NFTG

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB		ANDA REPOSITORY	8MEQ	A205549	001	Dec 08, 2015	Aug CAHN
AB			10MEQ	A205549	002	Dec 08, 2015	Aug CAHN
AB		PRINSTON INC	8MEQ	A209026	001	Jun 11, 2019	May NEWA
AB			10MEQ	A209026	002	Jun 11, 2019	May NEWA
AB		ZYDUS PHARMS	8MEQ	A208445	001	Mar 11, 2019	Feb NEWA
AB			10MEQ	A208445	002	Mar 11, 2019	Feb NEWA

FOR SOLUTION;ORAL  
POTASSIUM CHLORIDE

AA		AMNEAL PHARMS LLC	20MEQ	A210902	001	May 23, 2019	May NEWA
AA		BELCHER PHARMS LLC	20MEQ	A212183	001	May 06, 2019	Apr NEWA

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA		PHARM ASSOC	20MEQ/15ML	A210766	001	Mar 29, 2019	Mar NEWA
AA			40MEQ/15ML	A210766	002	Mar 29, 2019	Mar NEWA

TABLET, EXTENDED RELEASE;ORAL  
K-TAB

AB3	+!	ABBVIE	20MEQ	N018279	003	Nov 25, 2013	Sep CTEC
KLOR-CON M15							
AB1		UPSHER SMITH LABS	15MEQ	A074726	003	Jun 06, 2003	Mar CTEC
POTASSIUM CHLORIDE							
AB1		ADARE PHARMS INC	10MEQ	A076368	002	Jun 05, 2019	Jun NEWA
	@	ANDA REPOSITORY	8MEQ	A206881	001	Jan 22, 2019	Aug CAHN
	@		10MEQ	A206881	002	Jan 22, 2019	Aug CAHN
AB1		BRECKENRIDGE	10MEQ	A206630	001	Mar 29, 2019	Aug CAHN
AB3			10MEQ	A210097	001	Jun 17, 2019	Aug CAHN
AB1			15MEQ	A206630	002	Mar 29, 2019	Aug CAHN
AB1			20MEQ	A206630	003	Mar 29, 2019	Aug CAHN
AB3			20MEQ	A210098	001	Apr 26, 2019	Sep CTEC
AB2			20MEQ	A210098	001	Apr 26, 2019	Aug CAHN
	@	PII	8MEQ	A206881	001	Jan 22, 2019	Jul DISC
AB2			8MEQ	A206881	001	Jan 22, 2019	Jan NEWA
AB1			10MEQ	A206630	001	Mar 29, 2019	Mar NEWA
	@		10MEQ	A206881	002	Jan 22, 2019	Jul DISC
AB2			10MEQ	A206881	002	Jan 22, 2019	Jan NEWA
AB3			10MEQ	A210097	001	Jun 17, 2019	Jun NEWA
AB1			15MEQ	A206630	002	Mar 29, 2019	Mar NEWA
AB1			20MEQ	A206630	003	Mar 29, 2019	Mar NEWA
AB2			20MEQ	A210098	001	Apr 26, 2019	Apr NEWA
AB1		PRINSTON INC	10MEQ	A209922	001	Apr 30, 2019	Apr NEWA

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

AB1		15MEQ	A209922	002	Apr 30, 2019	Apr NEWA
AB1		20MEQ	A209922	003	Apr 30, 2019	Apr NEWA
AB3	VITRUVIAS THERAP	20MEQ	A209688	002	Jan 12, 2018	Sep CTEC
AB3	YICHANG HUMANWELL	10MEQ	A212561	001	Sep 30, 2019	Sep NEWA
AB3		20MEQ	A212561	002	Sep 30, 2019	Sep NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS  
POTASSIUM PHOSPHATES

+!	CMP DEV LLC	4500MG/15ML (300MG/ML);2650MG/15ML (175MG/ML)	N212121	001	Sep 19, 2019	Sep NEWA
----	-------------	---	---------	-----	--------------	----------

PRALATREXATE

SOLUTION;INTRAVENOUS  
FOLOTYN

+	ACROTECH	20MG/ML (20MG/ML)	N022468	001	Sep 24, 2009	Mar CAHN
+		40MG/2ML (20MG/ML)	N022468	002	Sep 24, 2009	Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

AB	HERITAGE PHARMA	0.125MG	A077724	001	Feb 19, 2008	May CAHN
AB		0.125MG	A090241	001	Oct 08, 2010	Sep CAHN
	@	0.125MG	A091254	001	Nov 30, 2010	May CAHN
AB		0.25MG	A077724	002	Feb 19, 2008	May CAHN
AB		0.25MG	A090241	002	Oct 08, 2010	Sep CAHN
	@	0.25MG	A091254	002	Nov 30, 2010	May CAHN
AB		0.5MG	A077724	003	Feb 19, 2008	May CAHN
AB		0.5MG	A090241	003	Oct 08, 2010	Sep CAHN
	@	0.5MG	A091254	003	Nov 30, 2010	May CAHN
AB		0.75MG	A090241	004	Oct 08, 2010	Sep CAHN
	@	0.75MG	A091254	004	Nov 30, 2010	May CAHN
AB		1MG	A077724	004	Feb 19, 2008	May CAHN
AB		1MG	A090241	005	Oct 08, 2010	Sep CAHN
	@	1MG	A091254	005	Nov 30, 2010	May CAHN
AB		1.5MG	A077724	005	Feb 19, 2008	May CAHN
AB		1.5MG	A090241	006	Oct 08, 2010	Sep CAHN
	@	1.5MG	A091254	006	Nov 30, 2010	May CAHN
>D> AB	SUN PHARM INDS INC	0.125MG	A091683	001	Mar 27, 2013	Oct DISC
>A>	@	0.125MG	A091683	001	Mar 27, 2013	Oct DISC
>D> AB		0.25MG	A091683	002	Mar 27, 2013	Oct DISC
>A>	@	0.25MG	A091683	002	Mar 27, 2013	Oct DISC
>D> AB		0.5MG	A091683	003	Mar 27, 2013	Oct DISC
>A>	@	0.5MG	A091683	003	Mar 27, 2013	Oct DISC
>D> AB		0.75MG	A091683	004	Mar 27, 2013	Oct DISC
>A>	@	0.75MG	A091683	004	Mar 27, 2013	Oct DISC
>D> AB		1MG	A091683	005	Mar 27, 2013	Oct DISC
>A>	@	1MG	A091683	005	Mar 27, 2013	Oct DISC
>D> AB		1.5MG	A091683	006	Mar 27, 2013	Oct DISC
>A>	@	1.5MG	A091683	006	Mar 27, 2013	Oct DISC

PRAVASTATIN SODIUM

TABLET;ORAL  
PRAVASTATIN SODIUM

AB	APNAR PHARMA LP	10MG	A076397	003	Oct 23, 2006	Jun CAHN
AB		20MG	A076397	002	Oct 23, 2006	Jun CAHN
AB		40MG	A076397	001	Oct 23, 2006	Jun CAHN
AB		80MG	A077491	001	Feb 11, 2008	Jun CAHN

PREDNISOLONE ACETATE

SUSPENSION/DROPS;OPHTHALMIC  
ECONOPRED

@	EYEVANCE	0.125%	N017468	001		May CAHN
---	----------	--------	---------	-----	--	----------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC  
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

!	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	May CTEC
@	SANDOZ INC	EQ 0.23% PHOSPHATE;10%	A073630	001	May 27, 1993	May DISC

PREDNISONTABLET; ORAL  
PREDNISON

AB	GENEYORK PHARMS	1MG	A211496	001	Dec 28, 2018	Jul CMFD
	@	1MG	A211496	001	Dec 28, 2018	May DISC
AB		2.5MG	A211495	001	Dec 07, 2018	Jul CMFD
	@	2.5MG	A211495	001	Dec 07, 2018	May DISC
AB		5MG	A211495	002	Dec 07, 2018	Jul CMFD
	@	5MG	A211495	002	Dec 07, 2018	May DISC
AB		10MG	A210525	001	Dec 04, 2018	Jul CMFD
	@	10MG	A210525	001	Dec 04, 2018	May DISC
AB		20MG	A210525	002	Dec 04, 2018	Jul CMFD
	@	20MG	A210525	002	Dec 04, 2018	May DISC
AB		50MG	A210525	003	Dec 04, 2018	Jul CMFD
	@	50MG	A210525	003	Dec 04, 2018	May DISC
AB	SUN PHARM INDUSTRIES	5MG	A089247	002	Dec 04, 1985	Jan CMS1
AB		10MG	A089247	003	Dec 04, 1985	Jan CMS1

PREGABALINCAPSULE; ORAL  
LYRICA

AB	+	PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Jul CFTG
AB	+		50MG	N021446	002	Dec 30, 2004	Jul CFTG
AB	+		75MG	N021446	003	Dec 30, 2004	Jul CFTG
AB	+		100MG	N021446	004	Dec 30, 2004	Jul CFTG
AB	+		150MG	N021446	005	Dec 30, 2004	Jul CFTG
AB	+		200MG	N021446	006	Dec 30, 2004	Jul CFTG
AB	+		225MG	N021446	007	Dec 30, 2004	Jul CFTG
AB	+		300MG	N021446	008	Dec 30, 2004	Jul CFTG

## PREGABALIN

AB	ALEMBIC PHARMS LTD	25MG	A203459	001	Jul 19, 2019	Jul NFTG
AB		50MG	A203459	002	Jul 19, 2019	Jul NFTG
AB		75MG	A203459	003	Jul 19, 2019	Jul NFTG
AB		100MG	A203459	004	Jul 19, 2019	Jul NFTG
AB		150MG	A203459	005	Jul 19, 2019	Jul NFTG
AB		200MG	A203459	006	Jul 19, 2019	Jul NFTG
AB		225MG	A203459	007	Jul 19, 2019	Jul NFTG
AB		300MG	A203459	008	Jul 19, 2019	Jul NFTG
AB	ALKEM LABS LTD	25MG	A211177	001	Sep 30, 2019	Sep NEWA
AB		50MG	A211177	002	Sep 30, 2019	Sep NEWA
AB		75MG	A207799	001	Jul 19, 2019	Jul NFTG
AB		100MG	A207799	002	Jul 19, 2019	Jul NFTG
AB		150MG	A207799	003	Jul 19, 2019	Jul NFTG
AB		200MG	A207799	004	Jul 19, 2019	Jul NFTG
AB		225MG	A207799	005	Jul 19, 2019	Jul NFTG
AB		300MG	A207799	006	Jul 19, 2019	Jul NFTG
AB	AMNEAL PHARMS CO	25MG	A209743	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209743	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209743	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209743	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209743	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209743	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209743	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209743	008	Jul 19, 2019	Jul NFTG
AB	DR REDDYS	25MG	A209664	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209664	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209664	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209664	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209664	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209664	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209664	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209664	008	Jul 19, 2019	Jul NFTG
AB	HAINAN	75MG	A210891	001	Sep 30, 2019	Sep NEWA
AB		300MG	A210891	002	Sep 30, 2019	Sep NEWA
AB	HETERO LABS LTD III	25MG	A206912	001	Oct 08, 2019	Sep NEWA
AB		50MG	A206912	002	Oct 08, 2019	Sep NEWA
AB		75MG	A206912	003	Oct 08, 2019	Sep NEWA
AB		100MG	A206912	004	Oct 08, 2019	Sep NEWA
AB		150MG	A206912	005	Oct 08, 2019	Sep NEWA
AB		200MG	A206912	006	Oct 08, 2019	Sep NEWA
AB		225MG	A206912	007	Oct 08, 2019	Sep NEWA
AB		300MG	A206912	008	Oct 08, 2019	Sep NEWA
AB	INVAGEN PHARMS	25MG	A211384	001	Jul 19, 2019	Jul NFTG

CAPSULE;ORAL  
PREGABALIN

AB		50MG	A211384	002	Jul 19, 2019	Jul NFTG
AB		75MG	A211384	003	Jul 19, 2019	Jul NFTG
AB		100MG	A211384	004	Jul 19, 2019	Jul NFTG
AB		150MG	A211384	005	Jul 19, 2019	Jul NFTG
AB		200MG	A211384	006	Jul 19, 2019	Jul NFTG
AB		225MG	A211384	007	Jul 19, 2019	Jul NFTG
AB		300MG	A211384	008	Jul 19, 2019	Jul NFTG
AB	MSN LABS PVT LTD	25MG	A209357	001	Jul 19, 2019	Jul NFTG
AB		50MG	A209357	002	Jul 19, 2019	Jul NFTG
AB		75MG	A209357	003	Jul 19, 2019	Jul NFTG
AB		100MG	A209357	004	Jul 19, 2019	Jul NFTG
AB		150MG	A209357	005	Jul 19, 2019	Jul NFTG
AB		200MG	A209357	006	Jul 19, 2019	Jul NFTG
AB		225MG	A209357	007	Jul 19, 2019	Jul NFTG
AB		300MG	A209357	008	Jul 19, 2019	Jul NFTG
AB	MYLAN	25MG	A091228	001	Sep 20, 2019	Sep NEWA
AB		50MG	A091228	002	Sep 20, 2019	Sep NEWA
AB		75MG	A091228	003	Sep 20, 2019	Sep NEWA
AB		100MG	A091228	004	Sep 20, 2019	Sep NEWA
AB		150MG	A091228	005	Sep 20, 2019	Sep NEWA
AB		200MG	A091228	006	Sep 20, 2019	Sep NEWA
AB		225MG	A091228	007	Sep 20, 2019	Sep NEWA
AB		300MG	A091228	008	Sep 20, 2019	Sep NEWA
AB	RISING	25MG	A210432	001	Jul 19, 2019	Jul NFTG
AB		50MG	A210432	002	Jul 19, 2019	Jul NFTG
AB		75MG	A210432	003	Jul 19, 2019	Jul NFTG
AB		100MG	A210432	004	Jul 19, 2019	Jul NFTG
AB		150MG	A210432	005	Jul 19, 2019	Jul NFTG
AB		200MG	A210432	006	Jul 19, 2019	Jul NFTG
AB		225MG	A210432	007	Jul 19, 2019	Jul NFTG
AB		300MG	A210432	008	Jul 19, 2019	Jul NFTG
AB	SCIEGEN PHARMS INC	25MG	A208677	001	Jul 19, 2019	Jul NFTG
AB		50MG	A208677	002	Jul 19, 2019	Jul NFTG
AB		75MG	A208677	003	Jul 19, 2019	Jul NFTG
AB		100MG	A208677	004	Jul 19, 2019	Jul NFTG
AB		150MG	A208677	005	Jul 19, 2019	Jul NFTG
AB		200MG	A208677	006	Jul 19, 2019	Jul NFTG
AB		225MG	A208677	007	Jul 19, 2019	Jul NFTG
AB		300MG	A208677	008	Jul 19, 2019	Jul NFTG
AB	TEVA PHARMS	25MG	A091219	001	Jul 19, 2019	Jul NFTG
AB		50MG	A091219	002	Jul 19, 2019	Jul NFTG
AB		75MG	A091224	001	Jul 19, 2019	Jul NFTG
AB		100MG	A091224	002	Jul 19, 2019	Jul NFTG
AB		150MG	A091224	003	Jul 19, 2019	Jul NFTG
AB		200MG	A091224	004	Jul 19, 2019	Jul NFTG
AB		225MG	A091224	005	Jul 19, 2019	Jul NFTG
AB		300MG	A091224	006	Jul 19, 2019	Jul NFTG

SOLUTION;ORAL  
LYRICA

AA	+! PF PRISM CV	20MG/ML	N022488	001	Jan 04, 2010	Jul CFTG
AA	ALKEM LABS LTD	20MG/ML	A207623	001	Jul 19, 2019	Jul NFTG

PRETOMANIDTABLET;ORAL  
PRETOMANID

>A>	+! MYLAN IRELAND LTD	200MG	N212862	001	Aug 14, 2019	Oct CAHN
>D>	+! TB ALLIANCE	200MG	N212862	001	Aug 14, 2019	Oct CAHN
	+!	200MG	N212862	001	Aug 14, 2019	Aug NEWA

PROBENECIDTABLET;ORAL  
PROBENECID

AB	MYLAN	500MG	A084211	002		Sep CHRS
	! WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Sep CHRS

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION  
PROCHLORPERAZINE EDISYLATE

AP	NEXUS PHARMS	EQ 5MG BASE/ML	A204860	001	Feb 15, 2019	Feb NEWA
----	--------------	----------------	---------	-----	--------------	----------

PROCHLORPERAZINE MALEATE

TABLET; ORAL  
PROCHLORPERAZINE MALEATE

@	TEVA PHARMS	EQ 5MG BASE	A040120	001	Jul 11, 1996	Jul DISC
@		EQ 10MG BASE	A040120	002	Jul 11, 1996	Jul DISC

PROGESTERONE

INJECTABLE; INJECTION  
PROGESTERONE

@	LUITPOLD	50MG/ML	A090845	001	Jun 22, 2009	Mar DISC
---	----------	---------	---------	-----	--------------	----------

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL  
PROMETHAZINE HYDROCHLORIDE

AB	PERRIGO ISRAEL	12.5MG	A040500	001	Jun 30, 2003	May CAHN
AB		25MG	A040500	002	Jun 30, 2003	May CAHN

TABLET; ORAL  
PROMETHAZINE HYDROCHLORIDE

@	IMPAX LABS	12.5MG	A040791	002	Feb 12, 2008	Mar DISC
@		25MG	A040791	003	Feb 12, 2008	Mar DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
INNOPRAN XL

BX	+	ANI PHARMS INC	80MG	N021438	001	Mar 12, 2003	Jul CRLD
BX	+	!	120MG	N021438	002	Mar 12, 2003	Jul CHRS
BX	+		120MG	N021438	002	Mar 12, 2003	Jul CRLD

PROPRANOLOL HYDROCHLORIDE

AB		ADARE PHARMS INC	60MG	A078703	001	Jul 15, 2011	Sep CAHN
AB			80MG	A078703	002	Jul 15, 2011	Sep CAHN
AB			120MG	A078703	003	Jul 15, 2011	Sep CAHN
AB			160MG	A078703	004	Jul 15, 2011	Sep CAHN

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE

	@	ANI PHARMS INC	60MG	A071791	001	Jul 15, 1987	Sep CAHN
>D>	@	INNOGENIX	10MG	A070322	002	Oct 22, 1985	Oct CMFD
>A>	AB		10MG	A070322	002	Oct 22, 1985	Oct CMFD
	@		10MG	A070322	002	Oct 22, 1985	May CMS1
>D>	@		20MG	A070322	003	Oct 22, 1985	Oct CMFD
>A>	AB		20MG	A070322	003	Oct 22, 1985	Oct CMFD
	@		20MG	A070322	003	Oct 22, 1985	May CMS1
>D>	@		40MG	A070322	004	Oct 22, 1985	Oct CMFD
>A>	AB		40MG	A070322	004	Oct 22, 1985	Oct CMFD
	@		40MG	A070322	004	Oct 22, 1985	May CMS1
>D>	@		60MG	A070322	005	Sep 24, 1986	Oct CMFD
>A>	AB		60MG	A070322	005	Sep 24, 1986	Oct CMFD
	@		60MG	A070322	005	Sep 24, 1986	May CMS1
>D>	@		80MG	A070322	001	Aug 04, 1986	Oct CMFD
>A>	AB		80MG	A070322	001	Aug 04, 1986	Oct CMFD
	@		80MG	A070322	001	Aug 04, 1986	Mar CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL  
VIVACTIL

AB		HERITAGE PHARMA	5MG	A073644	001	Aug 24, 1995	May CAHN
AB	!		10MG	A073645	001	Aug 24, 1995	May CAHN

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION  
MESTINON

AP	+	!	BAUSCH	5MG/ML	N009830	001	Feb CAHN
----	---	---	--------	--------	---------	-----	----------

SYRUP; ORAL  
MESTINON

AA	+	!	BAUSCH	60MG/5ML	N015193	001	Feb CFTG
	+	!		60MG/5ML	N015193	001	Feb CAHN

SYRUP;ORAL					
PYRIDOSTIGMINE BROMIDE					
AA	NOVITIUM PHARMA	60MG/5ML	A211694	001	Mar 08, 2019 Feb NFTG
TABLET;ORAL					
MESTINON					
AB	+! BAUSCH	60MG	N009829	002	Feb CAHN
PYRIDOSTIGMINE BROMIDE					
APNAR PHARMA LP		30MG	A211181	002	May 14, 2019 May NEWA
ELYSIUM		30MG	A211181	002	May 14, 2019 Sep CAHN
AB		60MG	A211181	001	Jul 20, 2018 Sep CAHN
TABLET, EXTENDED RELEASE;ORAL					
MESTINON					
AB	+! BAUSCH	180MG	N011665	001	Feb CAHN
<u>PYRIDOXINE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
PYRIDOXINE HYDROCHLORIDE					
@ DR REDDYS		100MG/ML	A080572	001	May CAHN
<u>QUETIAPINE FUMARATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
QUETIAPINE FUMARATE					
@ AMNEAL PHARMS		EQ 400MG BASE	A211405	001	Oct 26, 2018 Apr DISC
<u>QUINIDINE GLUCONATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
QUINAGLUTE					
+ @ BAYER HLTHCARE		324MG	N016647	001	Sep CRLD
QUINIDINE GLUCONATE					
! SUN PHARM INDUSTRIES		324MG	A089338	001	Feb 11, 1987 Sep CTEC
<u>QUINIDINE SULFATE</u>					
TABLET;ORAL					
QUINIDINE SULFATE					
>D> AB	SUN PHARM INDUSTRIES	200MG	A081030	001	Apr 14, 1989 Oct DISC
>A>	@	200MG	A081030	001	Apr 14, 1989 Oct DISC
>D> AB		300MG	A081031	001	Apr 14, 1989 Oct DISC
>A>	@	300MG	A081031	001	Apr 14, 1989 Oct DISC
<u>QUININE SULFATE</u>					
CAPSULE;ORAL					
QUININE SULFATE					
@ MYLAN PHARMS INC		324MG	A202581	001	Dec 14, 2012 Mar DISC
<u>RABEPRAZOLE SODIUM</u>					
TABLET, DELAYED RELEASE;ORAL					
RABEPRAZOLE SODIUM					
@ MYLAN		20MG	A076885	001	Nov 08, 2013 Jul DISC
AB	RUBICON	20MG	A204237	001	Nov 18, 2015 Feb CAHN
<u>RAMELTEON</u>					
TABLET;ORAL					
RAMELTEON					
AB	ZYDUS PHARMS	8MG	A211567	001	Jul 22, 2019 Jul NEWA
<u>RANITIDINE HYDROCHLORIDE</u>					
CAPSULE;ORAL					
RANITIDINE HYDROCHLORIDE					
AB	APPCO PHARMA LLC	EQ 150MG BASE	A211893	001	Apr 05, 2019 Mar NEWA
AB		EQ 300MG BASE	A211893	002	Apr 05, 2019 Mar NEWA
SYRUP;ORAL					
RANITIDINE HYDROCHLORIDE					
@ TORRENT		EQ 15MG BASE/ML	A090102	001	May 26, 2009 Jul DISC
AA		EQ 15MG BASE/ML	A090102	001	May 26, 2009 Jan CAHN
TABLET;ORAL					
RANITIDINE HYDROCHLORIDE					
>D> AB	ANI PHARMS INC	EQ 150MG BASE	A074488	001	Jul 31, 1997 Oct DISC
>A>	@	EQ 150MG BASE	A074488	001	Jul 31, 1997 Oct DISC
>D> AB		EQ 300MG BASE	A074488	002	Jul 31, 1997 Oct DISC
>A>	@	EQ 300MG BASE	A074488	002	Jul 31, 1997 Oct DISC
AB	HERITAGE PHARMA	EQ 150MG BASE	A075165	001	Sep 30, 1998 Feb CAHN

## TABLET;ORAL

## RANITIDINE HYDROCHLORIDE

AB		EQ 300MG BASE	A075165	002	Sep 30, 1998	Feb CAHN
AB	STRIDES PHARMA	EQ 150MG BASE	A210010	001	Aug 01, 2018	Apr CAHN
AB		EQ 300MG BASE	A210010	002	Aug 01, 2018	Apr CAHN
AB	VKT PHARMA PVT LTD	EQ 150MG BASE	A211289	001	Jan 31, 2019	Jan NEWA
AB		EQ 300MG BASE	A211289	002	Jan 31, 2019	Jan NEWA

RANOLAZINE

## TABLET, EXTENDED RELEASE;ORAL

## RANEXA

AB	+ GILEAD	500MG	N021526	002	Jan 27, 2006	Feb CTEC
AB	+!	1GM	N021526	001	Feb 12, 2007	Feb CTEC

## RANOLAZINE

AB	ACTAVIS ELIZABETH	500MG	A208862	001	May 28, 2019	May NEWA
AB		1GM	A208862	002	May 28, 2019	May NEWA
AB	AJANTA PHARMA LTD	500MG	A210054	001	May 28, 2019	May NEWA
AB		1GM	A210054	002	May 28, 2019	May NEWA
>A> AB	AMERIGEN PHARMS LTD	500MG	A210482	001	Oct 29, 2019	Oct NEWA
>A> AB		1GM	A210482	002	Oct 29, 2019	Oct NEWA
AB	CADILA	500MG	A210188	001	Aug 19, 2019	Aug NEWA
AB		1GM	A210188	002	Aug 19, 2019	Aug NEWA
AB	CIPLA	500MG	A211291	001	May 28, 2019	May NEWA
AB		1GM	A211291	002	May 28, 2019	May NEWA
AB	GLENMARK PHARMS LTD	500MG	A211082	001	Jul 05, 2019	Jun NEWA
AB		1GM	A211082	002	Jul 05, 2019	Jun NEWA
AB	LUPIN LTD	500MG	A201046	001	Jul 29, 2013	Feb CMFD
AB		1GM	A201046	002	Jul 29, 2013	Feb CMFD
AB	SCIEGEN PHARMS INC	500MG	A211829	001	Jun 04, 2019	May NEWA
AB		1GM	A211829	002	Jun 04, 2019	May NEWA
AB	SUN PHARM	500MG	A211707	001	May 28, 2019	May NEWA
AB		1GM	A211707	002	May 28, 2019	May NEWA

RASAGILINE

## TABLET;ORAL

## RASAGILINE

AB	INDOCO REMEDIES	EQ 0.5MG BASE	A206153	001	Oct 04, 2019	Sep NEWA
AB		EQ 1MG BASE	A206153	002	Oct 04, 2019	Sep NEWA

RASAGILINE MESYLATE

## TABLET;ORAL

## RASAGILINE MESYLATE

AB	MICRO LABS	EQ 0.5MG BASE	A207004	001	Mar 29, 2019	Mar NEWA
AB		EQ 1MG BASE	A207004	002	Mar 29, 2019	Mar NEWA

REPAGLINIDE

## TABLET;ORAL

## PRANDIN

	+ @ GEMINI LABS LLC	0.5MG	N020741	001	Dec 22, 1997	Mar DISC
	+ @	1MG	N020741	002	Dec 22, 1997	Mar DISC
	+ @	2MG	N020741	003	Dec 22, 1997	Mar DISC

## REPAGLINIDE

AB	! AUROBINDO PHARMA LTD	2MG	A203820	003	Jan 22, 2014	Mar CHRS
	@ MYLAN	0.5MG	A090252	001	Aug 23, 2013	Feb DISC
	@	1MG	A090252	002	Jan 22, 2014	Jul DISC
	@	2MG	A090252	003	Jan 22, 2014	Jul DISC

RETAPAMULIN

## OINTMENT;TOPICAL

## ALTABAX

	+! ALMIRALL	1%	N022055	001	Apr 12, 2007	Mar CAHN
--	-------------	----	---------	-----	--------------	----------

RIBAVIRIN

## CAPSULE;ORAL

## RIBAVIRIN

	@ CASI PHARMS INC	200MG	A076192	001	Apr 06, 2004	Jun DISC
--	-------------------	-------	---------	-----	--------------	----------

## SOLUTION;ORAL

## REBETOL

	+ @ SCHERING	40MG/ML	N021546	001	Jul 29, 2003	Jun DISC
--	--------------	---------	---------	-----	--------------	----------

## TABLET;ORAL

## RIBAVIRIN

AB	BEXIMCO PHARMS USA	200MG	A202546	001	Aug 12, 2014	Feb CAHN
----	--------------------	-------	---------	-----	--------------	----------

TABLET;ORAL  
RIBAVIRIN

AB		400MG	A202546	002	Aug 12, 2014	Feb CAHN	
AB		500MG	A202546	003	Aug 12, 2014	Feb CAHN	
AB		600MG	A202546	004	Aug 12, 2014	Feb CAHN	
>D>	AB	HERITAGE PHARMA	200MG	A077053	001	Dec 05, 2005	Oct DISC
>A>	@	200MG	A077053	001	Dec 05, 2005	Oct DISC	
AB		200MG	A077053	001	Dec 05, 2005	May CAHN	

RIFAMYCIN

TABLET, DELAYED RELEASE;ORAL  
AEMCOLO

>D>	+	COSMO TECHNOLOGIES	194MG	N210910	001	Nov 16, 2018	Oct CAIN
-----	---	--------------------	-------	---------	-----	--------------	----------

RIFAMYCIN SODIUM

TABLET, DELAYED RELEASE;ORAL  
AEMCOLO

>A>	+	COSMO TECHNOLOGIES	EQ 194MG BASE	N210910	001	Nov 16, 2018	Oct CPOT
>A>	+		194MG	N210910	001	Nov 16, 2018	Oct CAIN

RILUZOLE

TABLET;ORAL  
RILUZOLE

@	DAITO PHARMS CO LTD	50MG	A204430	001	Oct 16, 2018	Mar DISC
---	---------------------	------	---------	-----	--------------	----------

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

@	HERITAGE PHARMA	100MG	A076375	001	Jan 14, 2003	May CAHN
---	-----------------	-------	---------	-----	--------------	----------

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC  
VEXOL

@	EYEVANCE	1%	N020474	001	Dec 30, 1994	May CAHN
---	----------	----	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

RISEDRONATE SODIUM

@	HANGZHOU BINJIANG	35MG	A207516	001	Feb 15, 2019	Aug DISC
AB		35MG	A207516	001	Feb 15, 2019	Feb NEWA
@	MYLAN	5MG	A200477	001	Nov 30, 2015	May DISC
@		30MG	A200477	002	Nov 30, 2015	May DISC
@		35MG	A200477	003	Nov 30, 2015	May DISC
@		75MG	A200477	004	Jun 10, 2014	May DISC
@		150MG	A200477	005	Jun 10, 2014	May DISC
AB	ORCHID HLTHCARE	30MG	A205280	001	May 13, 2019	Apr NEWA
AB		35MG	A205280	002	May 13, 2019	Apr NEWA

TABLET, DELAYED RELEASE;ORAL  
RISEDRONATE SODIUM

AB	SUN PHARM	35MG	A203925	001	Jul 09, 2019	Jun NEWA
@	ZYDUS PHARMS	35MG	A203822	001	Sep 11, 2018	Feb DISC

RISPERIDONE

SOLUTION;ORAL  
RISPERIDONE

>D>	AA	APOTEX INC	1MG/ML	A077719	001	Jul 29, 2009	Oct CAHN
>A>	AA	PHARM ASSOC	1MG/ML	A077719	001	Jul 29, 2009	Oct CAHN
>D>	AA	TORRENT	1MG/ML	A078909	001	Jul 29, 2009	Oct DISC
>A>	@	1MG/ML	A078909	001	Jul 29, 2009	Oct DISC	
AA		1MG/ML	A078909	001	Jul 29, 2009	Jan CAHN	

TABLET;ORAL

RISPERIDONE

AB	CELLTRION	0.25MG	A078871	001	Oct 09, 2008	Aug CAHN
AB		0.5MG	A078871	002	Oct 09, 2008	Aug CAHN
AB		1MG	A078871	003	Oct 09, 2008	Aug CAHN
AB		2MG	A078871	004	Oct 09, 2008	Aug CAHN
AB		3MG	A078871	005	Oct 09, 2008	Aug CAHN
AB		4MG	A078871	006	Oct 09, 2008	Aug CAHN
@	HERITAGE PHARMA	0.25MG	A076228	001	Jun 30, 2008	Aug DISC
AB		0.25MG	A076228	001	Jun 30, 2008	May CAHN
AB		0.25MG	A077769	001	Oct 16, 2008	May CAHN
@		0.5MG	A076228	002	Jun 30, 2008	Aug DISC

TABLET;ORAL  
RISPERIDONE

AB		0.5MG	A076228	002	Jun 30, 2008	May CAHN
AB		0.5MG	A077769	002	Oct 16, 2008	May CAHN
	@	1MG	A076228	003	Jun 30, 2008	Aug DISC
AB		1MG	A076228	003	Jun 30, 2008	May CAHN
AB		1MG	A077769	003	Oct 16, 2008	May CAHN
	@	2MG	A076228	004	Jun 30, 2008	Aug DISC
AB		2MG	A076228	004	Jun 30, 2008	May CAHN
AB		2MG	A077769	004	Oct 16, 2008	May CAHN
	@	3MG	A076228	005	Jun 30, 2008	Aug DISC
AB		3MG	A076228	005	Jun 30, 2008	May CAHN
AB		3MG	A077769	005	Oct 16, 2008	May CAHN
	@	4MG	A076228	006	Jun 30, 2008	Aug DISC
AB		4MG	A076228	006	Jun 30, 2008	May CAHN
AB		4MG	A077769	006	Oct 16, 2008	May CAHN
AB	RISING	0.25MG	A078269	001	Oct 08, 2008	Sep CAHN
AB		0.5MG	A078269	002	Oct 08, 2008	Sep CAHN
AB		1MG	A078269	003	Oct 08, 2008	Sep CAHN
AB		2MG	A078269	004	Oct 08, 2008	Sep CAHN
AB		3MG	A078269	005	Oct 08, 2008	Sep CAHN
AB		4MG	A078269	006	Oct 08, 2008	Sep CAHN
>D> AB	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Oct DISC
>A>	@	0.25MG	A078036	001	Mar 10, 2014	Oct DISC
>D> AB		0.5MG	A078036	002	Mar 10, 2014	Oct DISC
>A>	@	0.5MG	A078036	002	Mar 10, 2014	Oct DISC
>D> AB		1MG	A078036	003	Mar 10, 2014	Oct DISC
>A>	@	1MG	A078036	003	Mar 10, 2014	Oct DISC
>D> AB		2MG	A078036	004	Mar 10, 2014	Oct DISC
>A>	@	2MG	A078036	004	Mar 10, 2014	Oct DISC
>D> AB		3MG	A078036	005	Mar 10, 2014	Oct DISC
>A>	@	3MG	A078036	005	Mar 10, 2014	Oct DISC
>D> AB		4MG	A078036	006	Mar 10, 2014	Oct DISC
>A>	@	4MG	A078036	006	Mar 10, 2014	Oct DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
RISPERIDONE

AB	HERITAGE PHARMA	0.5MG	A076908	001	Mar 12, 2012	May CAHN
AB		1MG	A076908	002	Mar 12, 2012	May CAHN
AB		2MG	A076908	003	Mar 12, 2012	May CAHN

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
RIVASTIGMINE

AB	ZYDUS NOVELTECH INC	4.6MG/24HR	A206318	001	Mar 04, 2019	Feb NEWA
AB		9.5MG/24HR	A206318	002	Mar 04, 2019	Feb NEWA
AB		13.3MG/24HR	A206318	003	Mar 04, 2019	Feb NEWA

RIVASTIGMINE TARTRATE

CAPSULE;ORAL  
EXELON

+	@ NOVARTIS	EQ 1.5MG BASE	N020823	003	Apr 21, 2000	Aug DISC
+	@	EQ 3MG BASE	N020823	004	Apr 21, 2000	Aug DISC
+	@	EQ 4.5MG BASE	N020823	005	Apr 21, 2000	Aug DISC
+	@	EQ 6MG BASE	N020823	006	Apr 21, 2000	Aug DISC

RIVASTIGMINE TARTRATE

AB	! DR REDDYS LABS INC	EQ 1.5MG BASE	A077130	001	Oct 31, 2007	Aug CHRS
AB	!	EQ 6MG BASE	A077130	004	Oct 31, 2007	Aug CHRS

ROCURONIUM BROMIDE

INJECTABLE;INJECTION  
ROCURONIUM BROMIDE

AP	CAMARGO PHARM	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Jul NEWA
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Jul NEWA
AP	SANOVEL ILAC	50MG/5ML (10MG/ML)	A210437	001	Aug 13, 2019	Aug CAHN
AP		100MG/10ML (10MG/ML)	A210437	002	Aug 13, 2019	Aug CAHN

ROFLUMILAST

TABLET;ORAL  
ROFLUMILAST

AB	MICRO LABS	500MCG	A208180	001	Mar 22, 2019	Mar NEWA
----	------------	--------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

## TABLET; ORAL

## ROPINIROLE HYDROCHLORIDE

AB	CADILA	EQ 0.25MG BASE	A090411	001	Jun 01, 2009	Feb CAHN
AB		EQ 0.5MG BASE	A090411	002	Jun 01, 2009	Feb CAHN
AB		EQ 1MG BASE	A090411	003	Jun 01, 2009	Feb CAHN
AB		EQ 2MG BASE	A090411	004	Jun 01, 2009	Feb CAHN
AB		EQ 3MG BASE	A090411	005	Jun 01, 2009	Feb CAHN
AB		EQ 4MG BASE	A090411	006	Jun 01, 2009	Feb CAHN
AB		EQ 5MG BASE	A090411	007	Jun 01, 2009	Feb CAHN
AB	CELLTRION	EQ 0.25MG BASE	A079050	001	May 29, 2008	Jul CAHN
AB		EQ 0.5MG BASE	A079050	002	May 29, 2008	Jul CAHN
AB		EQ 1MG BASE	A079050	003	May 29, 2008	Jul CAHN
AB		EQ 2MG BASE	A079050	004	May 29, 2008	Jul CAHN
AB		EQ 3MG BASE	A079050	005	May 29, 2008	Jul CAHN
AB		EQ 4MG BASE	A079050	006	May 29, 2008	Jul CAHN
AB		EQ 5MG BASE	A079050	007	May 29, 2008	Jul CAHN
AB	LAX	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Mar CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Mar CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Mar CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Mar CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Mar CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Mar CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Mar CAHN
AB	MLV	EQ 0.25MG BASE	A079165	001	Feb 07, 2012	Sep CAHN
AB		EQ 0.5MG BASE	A079165	002	Feb 07, 2012	Sep CAHN
AB		EQ 1MG BASE	A079165	003	Feb 07, 2012	Sep CAHN
AB		EQ 2MG BASE	A079165	004	Feb 07, 2012	Sep CAHN
AB		EQ 3MG BASE	A079165	005	Feb 07, 2012	Sep CAHN
AB		EQ 4MG BASE	A079165	006	Feb 07, 2012	Sep CAHN
AB		EQ 5MG BASE	A079165	007	Feb 07, 2012	Sep CAHN

## TABLET, EXTENDED RELEASE; ORAL

## ROPINIROLE HYDROCHLORIDE

AB	CELLTRION	EQ 2MG BASE	A091395	001	Aug 27, 2012	Aug CAHN
AB		EQ 4MG BASE	A091395	002	Aug 27, 2012	Aug CAHN
AB		EQ 6MG BASE	A091395	003	Aug 27, 2012	Aug CAHN
AB		EQ 8MG BASE	A091395	004	Aug 27, 2012	Aug CAHN
AB		EQ 12MG BASE	A091395	005	Aug 27, 2012	Aug CAHN

ROSIGLITAZONE MALEATE

## TABLET; ORAL

## ROSIGLITAZONE MALEATE

@	ANI PHARMS INC	EQ 2MG BASE	A076747	001	Jan 25, 2013	Sep CAHN
@		EQ 4MG BASE	A076747	002	Jan 25, 2013	Sep CAHN
@		EQ 8MG BASE	A076747	003	Jan 25, 2013	Sep CAHN

ROSUVASTATIN CALCIUM

## TABLET; ORAL

## ROSUVASTATIN CALCIUM

@	AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr DISC
@		10MG	A208850	002	Oct 16, 2018	Apr DISC
@		20MG	A208850	003	Oct 16, 2018	Apr DISC
@		40MG	A208850	004	Oct 16, 2018	Apr DISC
@	MYLAN	5MG	A079161	001	Jul 19, 2016	Jul DISC
@		10MG	A079161	002	Jul 19, 2016	Jul DISC
@		20MG	A079161	003	Jul 19, 2016	Jul DISC
@		40MG	A079161	004	Jul 19, 2016	Jul DISC
AB	SHANDONG	5MG	A207375	001	May 07, 2019	Apr NEWA
AB		10MG	A207375	002	May 07, 2019	Apr NEWA
AB		20MG	A207375	003	May 07, 2019	Apr NEWA
AB		40MG	A207375	004	May 07, 2019	Apr NEWA
@	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Jul DISC
@		10MG	A079166	002	Jul 19, 2016	Jul DISC
@		20MG	A079166	003	Jul 19, 2016	Jul DISC
@		40MG	A079166	004	Jul 19, 2016	Jul DISC
>D> AB	UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Oct DISC
>A>	@	5MG	A207626	001	Apr 09, 2019	Oct DISC
AB		5MG	A207626	001	Apr 09, 2019	Mar NEWA
>D> AB		10MG	A207626	002	Apr 09, 2019	Oct DISC
>A>	@	10MG	A207626	002	Apr 09, 2019	Oct DISC
AB		10MG	A207626	002	Apr 09, 2019	Mar NEWA
>D> AB		20MG	A207626	003	Apr 09, 2019	Oct DISC

## TABLET;ORAL

## ROSUVASTATIN CALCIUM

>A>	@	20MG	A207626	003	Apr 09, 2019	Oct	DISC	
AB		20MG	A207626	003	Apr 09, 2019	Mar	NEWA	
>D>	AB	40MG	A207626	004	Apr 09, 2019	Oct	DISC	
>A>	@	40MG	A207626	004	Apr 09, 2019	Oct	DISC	
AB		40MG	A207626	004	Apr 09, 2019	Mar	NEWA	
>A>	AB	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Oct	NEWA
>A>	AB		10MG	A212059	002	Nov 04, 2019	Oct	NEWA
>A>	AB		20MG	A212059	003	Nov 04, 2019	Oct	NEWA
>A>	AB		40MG	A212059	004	Nov 04, 2019	Oct	NEWA
	@	ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Aug	DISC
AB			5MG	A206513	001	Mar 01, 2019	Feb	NEWA
	@		10MG	A206513	002	Mar 01, 2019	Aug	DISC
AB			10MG	A206513	002	Mar 01, 2019	Feb	NEWA
	@		20MG	A206513	003	Mar 01, 2019	Aug	DISC
AB			20MG	A206513	003	Mar 01, 2019	Feb	NEWA
	@		40MG	A206513	004	Mar 01, 2019	Aug	DISC
AB			40MG	A206513	004	Mar 01, 2019	Feb	NEWA

RUFINAMIDE

## SUSPENSION;ORAL

## BANZEL

AB	+!	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Apr	CFTG
		RUFINAMIDE						
AB		BIONPHARMA INC	40MG/ML	A211388	001	Apr 23, 2019	Apr	NFTG
AB		HIKMA	40MG/ML	A207363	001	Apr 23, 2019	Apr	NFTG

## TABLET;ORAL

## RUFINAMIDE

## @ MYLAN

## @

200MG

400MG

A205095 001 May 16, 2016 Feb DISC  
A205095 002 May 16, 2016 Feb DISC

SAPROPTERIN DIHYDROCHLORIDE

## POWDER;ORAL

## KUVAN

AB	+!	BIOMARIN PHARM	100MG/PACKET	N205065	001	Dec 19, 2013	Aug	CFTG
	+		500MG/PACKET	N205065	002	Oct 27, 2015	Sep	CTEC
AB	+		500MG/PACKET	N205065	002	Oct 27, 2015	Aug	CFTG
		SAPROPTERIN DIHYDROCHLORIDE						
AB		PAR PHARM INC	100MG/PACKET	A207207	001	Aug 20, 2019	Aug	NFTG
	@		500MG/PACKET	A210027	001	Aug 20, 2019	Sep	DISC
AB			500MG/PACKET	A210027	001	Aug 20, 2019	Aug	NFTG

## TABLET;ORAL

## KUVAN

	+!	BIOMARIN PHARM	100MG	N022181	001	Dec 13, 2007	May	CTEC
AB	+!		100MG	N022181	001	Dec 13, 2007	Apr	CFTG
		SAPROPTERIN DIHYDROCHLORIDE						
	@	PAR PHARM INC	100MG	A207200	001	May 10, 2019	May	DISC
AB			100MG	A207200	001	May 10, 2019	Apr	NFTG

SCOPOLAMINE

## FILM, EXTENDED RELEASE;TRANSDERMAL

## SCOPOLAMINE

AB		MYLAN TECHNOLOGIES	1MG/72HR	A203753	001	Jun 19, 2019	Jun	NEWA
----	--	--------------------	----------	---------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

## TABLET;ORAL

## SELEGILINE HYDROCHLORIDE

AB		BOSCOGEN	5MG	A074912	001	Apr 30, 1998	Jun	CAHN
AB		KENTON	5MG	A074912	001	Apr 30, 1998	Mar	CAHN
	@	MYLAN	5MG	A074866	001	Nov 26, 1997	Aug	DISC

## TABLET, ORALLY DISINTEGRATING;ORAL

## ZELAPAR

+!	BAUSCH	1.25MG	N021479	001	Jun 14, 2006	Mar	CAHN
----	--------	--------	---------	-----	--------------	-----	------

SELENIOS ACID

## SOLUTION;INTRAVENOUS

## SELENIOS ACID

+!	AM REGENT	EQ 600MCG BASE/10ML (EQ 60MCG BASE/ML)	N209379	001	Apr 30, 2019	Apr	NEWA
----	-----------	--	---------	-----	--------------	-----	------

SELINEXORTABLET;ORAL  
XPOVIO

+! KARYOPHARM THERAPS 20MG N212306 001 Jul 03, 2019 Jul NEWA

SEMAGLUTIDETABLET;ORAL  
RYBELSUS

+	NOVO	3MG	N213051	001	Sep 20, 2019	Sep NEWA
+		7MG	N213051	002	Sep 20, 2019	Sep NEWA
+		14MG	N213051	003	Sep 20, 2019	Sep NEWA

SERTACONAZOLE NITRATECREAM;TOPICAL  
ERTACZO

+! BAUSCH 2% N021385 001 Dec 10, 2003 Jun CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@ CADILA	EQ 25MG BASE	A077106	001	Feb 06, 2007	Jun DISC
AB		EQ 25MG BASE	A077106	001	Feb 06, 2007	Feb CAHN
	@	EQ 50MG BASE	A077106	002	Feb 06, 2007	Jun DISC
AB		EQ 50MG BASE	A077106	002	Feb 06, 2007	Feb CAHN
	@	EQ 100MG BASE	A077106	003	Feb 06, 2007	Jun DISC
AB		EQ 100MG BASE	A077106	003	Feb 06, 2007	Feb CAHN
>D> AB	HERITAGE PHARMA	EQ 25MG BASE	A076465	001	Aug 11, 2006	Oct DISC
>A>	@	EQ 25MG BASE	A076465	001	Aug 11, 2006	Oct DISC
AB		EQ 25MG BASE	A076465	001	Aug 11, 2006	May CAHN
	@	EQ 25MG BASE	A077299	001	Feb 06, 2007	May CAHN
	@	EQ 25MG BASE	A077345	001	Feb 06, 2007	May CAHN
>D> AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	Oct DISC
>A>	@	EQ 50MG BASE	A076465	002	Aug 11, 2006	Oct DISC
AB		EQ 50MG BASE	A076465	002	Aug 11, 2006	May CAHN
	@	EQ 50MG BASE	A077299	002	Feb 06, 2007	May CAHN
	@	EQ 50MG BASE	A077345	002	Feb 06, 2007	May CAHN
>D> AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	Oct DISC
>A>	@	EQ 100MG BASE	A076465	003	Aug 11, 2006	Oct DISC
AB		EQ 100MG BASE	A076465	003	Aug 11, 2006	May CAHN
	@	EQ 100MG BASE	A077299	003	Feb 06, 2007	May CAHN
	@	EQ 100MG BASE	A077345	003	Feb 06, 2007	May CAHN
	@ MYLAN PHARMS INC	EQ 25MG BASE	A078626	001	Jan 31, 2008	May DISC
	@	EQ 50MG BASE	A078626	002	Jan 31, 2008	May DISC

SEVELAMER HYDROCHLORIDE

TABLET;ORAL

RENAGEL

AB	+	GENZYME	400MG	N021179	001	Jul 12, 2000	Feb CFTG
AB	+		800MG	N021179	002	Jul 12, 2000	Feb CFTG

SEVELAMER HYDROCHLORIDE

AB		GLENMARK PHARMS LTD	400MG	A204724	001	Feb 08, 2019	Feb NFTG
AB			800MG	A204724	002	Feb 08, 2019	Feb NFTG

SILDENAFIL CITRATEFOR SUSPENSION;ORAL  
REVATIO

AB +! PFIZER EQ 10MG BASE/ML N203109 001 Aug 30, 2012 May CFTG

SILDENAFIL CITRATE

AB NOVITIUM PHARMA EQ 10MG BASE/ML A212260 001 May 31, 2019 May NFTG

TABLET;ORAL

SILDENAFIL CITRATE

AB		LUPIN LTD	EQ 25MG BASE	A212051	001	Mar 22, 2019	Mar NEWA
AB			EQ 50MG BASE	A212051	002	Mar 22, 2019	Mar NEWA
AB			EQ 100MG BASE	A212051	003	Mar 22, 2019	Mar NEWA
AB		MYLAN	EQ 25MG BASE	A201171	001	Mar 25, 2019	Mar NEWA
AB			EQ 50MG BASE	A201171	002	Mar 25, 2019	Mar NEWA
AB			EQ 100MG BASE	A201171	003	Mar 25, 2019	Mar NEWA

SIMVASTATINTABLET;ORAL  
SIMVASTATIN

AB	MICRO LABS	5MG	A090383	001	Sep 16, 2011	Mar CAHN
AB		10MG	A090383	002	Sep 16, 2011	Mar CAHN
AB		20MG	A090383	003	Sep 16, 2011	Mar CAHN
AB		40MG	A090383	004	Sep 16, 2011	Mar CAHN
AB		80MG	A090383	005	Sep 16, 2011	Mar CAHN

SIPONIMODTABLET;ORAL  
MAYZENT

+	NOVARTIS PHARMS CORP	0.25MG	N209884	001	Mar 26, 2019	Mar NEWA
+	!	2MG	N209884	002	Mar 26, 2019	Mar NEWA

SIPONIMOD FUMARIC ACIDTABLET;ORAL  
MAYZENT

+	NOVARTIS	EQ 0.25MG BASE	N209884	001	Mar 26, 2019	Apr CAIN
+	!	EQ 2MG BASE	N209884	002	Mar 26, 2019	Apr CAIN

SIROLIMUSSOLUTION;ORAL  
RAPAMUNE

AA	+	PF PRISM CV	1MG/ML	N021083	001	Sep 15, 1999	Jan CFTG
		SIROLIMUS					
>A>	AA	AMNEAL PHARMS LLC	1MG/ML	A211212	001	Oct 18, 2019	Oct NEWA
>A>	AA	APOTEX	1MG/ML	A211406	001	Oct 22, 2019	Oct NEWA
	AA	NOVITIUM PHARMA	1MG/ML	A211040	001	Jan 28, 2019	Jan NFTG

SODIUM BICARBONATEINJECTABLE;INJECTION  
SODIUM BICARBONATE

>D>		EXELA PHARMA SCS LLC	0.5MEQ/ML	A211091	001	Jun 20, 2019	Oct CTEC
>A>	AP		0.5MEQ/ML	A211091	001	Jun 20, 2019	Oct CTEC
			0.5MEQ/ML	A211091	001	Jun 20, 2019	Jun NEWA
	AP		0.9MEQ/ML	A211091	002	Jun 20, 2019	Jun NEWA
	AP		1MEQ/ML	A211091	003	Jun 20, 2019	Jun NEWA
>D>		@ HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Oct CMFD
>A>	AP		0.5MEQ/ML	A202981	001	Mar 04, 2016	Oct CMFD

SODIUM CHLORIDEINJECTABLE;INJECTION  
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP		JUBILANT CADISTA	9MG/ML	A203352	001	May 18, 2016	Sep CAHN
	+	@ LIEBEL-FLARSHEIM	405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Aug DISC
		SODIUM CHLORIDE 3% IN PLASTIC CONTAINER					
AP		FRESENIUS KABI USA	3GM/100ML	A209476	001	Mar 13, 2019	Feb NEWA

SODIUM CHROMATE CR-51INJECTABLE;INJECTION  
SODIUM CHROMATE CR 51

@	CURIUM	100uCi/ML	N016708	001		Jan CAHN
---	--------	-----------	---------	-----	--	----------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS  
SODIUM FLUORIDE F-18

AP		DECATUR	10-200mCi/ML	A204464	001	Oct 21, 2014	Apr CAHN
----	--	---------	--------------	---------	-----	--------------	----------

SODIUM IODIDE I-131CAPSULE;ORAL  
SODIUM IODIDE I 131

@	CURIUM	0.8-100mCi	N016515	002		Jan CAHN
+	@	0.8-100mCi	N016517	001		Jan CAHN
@		15-100uCi	N016517	002		Jan CAHN

SOLUTION;ORAL

SODIUM IODIDE I 131

+	@	CURIUM	3.5-150mCi/VIAL	N016515	001	Jan CAHN
---	---	--------	-----------------	---------	-----	----------

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION  
SODIUM NITROPRUSSIDE

AP	DR REDDYS LABS LTD	25MG/ML	A210114	001	Apr 10, 2019	Mar	NEWA
AP	SAGENT PHARMS INC	25MG/ML	A207426	001	Dec 08, 2016	Sep	CAHN
	@ SUN PHARM	25MG/ML	A210467	001	Nov 26, 2018	Jul	DISC
>D> AP	VIRTUS PHARM	25MG/ML	A209834	001	Jun 26, 2018	Oct	DISC
>A>	@	25MG/ML	A209834	001	Jun 26, 2018	Oct	DISC
AP		25MG/ML	A209834	001	Jun 26, 2018	Jul	CAHN

SOLUTION; INTRAVENOUS

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

+	@ EXELA PHARMA SCS LLC	10MG/50ML (0.2MG/ML)	N209387	002	Dec 07, 2017	Jul	DISC
---	------------------------	----------------------	---------	-----	--------------	-----	------

SODIUM PHENYLBUTYRATE

POWDER; ORAL  
BUPHENYL

AB	+! HORIZON THERAP	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Feb	CAHN
----	-------------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL  
BUPHENYL

AB	+! HORIZON THERAP	500MG	N020572	001	May 13, 1996	Feb	CAHN
----	-------------------	-------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	NOVELGENIX THERAPS	454GM/BOT	A206815	001	Feb 18, 2016	Sep	CAHN
----	--------------------	-----------	---------	-----	--------------	-----	------

SOFOSBUVIR

PELLETS; ORAL

SOVALDI

+	GILEAD SCIENCES INC	150MG/PACKET	N212480	001	Aug 28, 2019	Aug	NEWA
+!		200MG/PACKET	N212480	002	Aug 28, 2019	Aug	NEWA

TABLET; ORAL

SOVALDI

+	GILEAD SCIENCES INC	200MG	N204671	002	Aug 28, 2019	Aug	NEWA
---	---------------------	-------	---------	-----	--------------	-----	------

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	May	NEWA
AB		10MG	A205483	002	May 20, 2019	May	NEWA
AB	ALEMBIC PHARMS LTD	5MG	A205575	001	May 20, 2019	May	NEWA
AB		10MG	A205575	002	May 20, 2019	May	NEWA
AB	ALKEM LABS LTD	5MG	A210224	001	May 20, 2019	May	NEWA
AB		10MG	A210224	002	May 20, 2019	May	NEWA
AB	AMNEAL PHARMS CO	5MG	A209719	001	May 20, 2019	May	NEWA
AB		10MG	A209719	002	May 20, 2019	May	NEWA
AB	BRECKENRIDGE	5MG	A209818	001	May 20, 2019	May	NEWA
AB		10MG	A209818	002	May 20, 2019	May	NEWA
AB	CELLTRION	5MG	A210582	001	May 20, 2019	May	NEWA
AB		10MG	A210582	002	May 20, 2019	May	NEWA
AB	CIPLA	5MG	A209839	001	May 20, 2019	May	NEWA
AB		10MG	A209839	002	May 20, 2019	May	NEWA
AB	GLENMARK PHARMS INC	5MG	A209239	001	May 20, 2019	May	NEWA
AB		10MG	A209239	002	May 20, 2019	May	NEWA
AB	JIANGXI BOYA SEEHOT	5MG	A210281	001	May 20, 2019	May	NEWA
AB		10MG	A210281	002	May 20, 2019	May	NEWA
AB	MSN LABS PVT LTD	5MG	A210688	001	May 20, 2019	May	NEWA
AB		10MG	A210688	002	May 20, 2019	May	NEWA
AB	QILU PHARM CO LTD	5MG	A209333	001	May 20, 2019	May	NEWA
AB		10MG	A209333	002	May 20, 2019	May	NEWA
AB	SCIEGEN PHARMS INC	5MG	A211657	001	May 20, 2019	May	NEWA
AB		10MG	A211657	002	May 20, 2019	May	NEWA
AB	STRIDES PHARMA	5MG	A212214	001	Sep 26, 2019	Sep	NEWA
AB		10MG	A212214	002	Sep 26, 2019	Sep	NEWA
AB	UNICHEM LABS LTD	5MG	A211701	001	Aug 27, 2019	Aug	NEWA
AB		10MG	A211701	002	Aug 27, 2019	Aug	NEWA
AB	WATSON LABS INC	5MG	A202551	001	May 20, 2019	May	NEWA
AB		10MG	A202551	002	May 20, 2019	May	NEWA

SOLRIAMFETOL

TABLET; ORAL

SUNOSI

+	JAZZ	75MG	N211230	001	Jun 17, 2019	Jun NEWA
+		150MG	N211230	002	Jun 17, 2019	Jun NEWA

SOMATROPIN

INJECTABLE; INJECTION

GENOTROPIN

BX	+	PHARMACIA AND UPJOHN	5.8MG/VIAL	N020280	006	Aug 24, 1995	Aug CAIN
	+		13.8MG/VIAL	N020280	007	Oct 23, 1996	Aug CAIN

GENOTROPIN PRESERVATIVE FREE

	+	PHARMACIA AND UPJOHN	0.2MG/VIAL	N020280	001	Jan 27, 1998	Aug CAIN
	+		0.4MG/VIAL	N020280	002	Jan 27, 1998	Aug CAIN
	+		0.6MG/VIAL	N020280	003	Jan 27, 1998	Aug CAIN
	+		0.8MG/VIAL	N020280	005	Jan 27, 1998	Aug CAIN
	+		1MG/VIAL	N020280	008	Jan 27, 1998	Aug CAIN
	+		1.2MG/VIAL	N020280	009	Jan 27, 1998	Aug CAIN
	+		1.4MG/VIAL	N020280	010	Jan 27, 1998	Aug CAIN
	+	@	1.5MG/VIAL	N020280	004	Aug 24, 1995	Aug CAIN
	+		1.6MG/VIAL	N020280	011	Jan 27, 1998	Aug CAIN
	+		1.8MG/VIAL	N020280	012	Jan 27, 1998	Aug CAIN
	+	!	2MG/VIAL	N020280	013	Jan 27, 1998	Aug CAIN

NORDITROPIN

	@	NOVO NORDISK INC	5MG/1.5ML	N021148	001	Jun 20, 2000	Aug CAIN
	@		10MG/1.5ML	N021148	002	Jun 20, 2000	Aug CAIN
	@		15MG/1.5ML	N021148	003	Jun 20, 2000	Aug CAIN

NORDITROPIN FLEXPOR

BX		NOVO NORDISK INC	5MG/1.5ML	N021148	008	Mar 01, 2010	Aug CAIN
BX			10MG/1.5ML	N021148	009	Mar 01, 2010	Aug CAIN
			15MG/1.5ML	N021148	010	Mar 01, 2010	Aug CAIN
			30MG/3ML	N021148	011	Jan 23, 2015	Aug CAIN

NORDITROPIN NORDIFLEX

	@	NOVO NORDISK INC	5MG/1.5ML	N021148	004	Oct 01, 2004	Aug CAIN
	@		10MG/1.5ML	N021148	005	Oct 01, 2004	Aug CAIN
	@		15MG/1.5ML	N021148	006	Oct 01, 2004	Aug CAIN
	@		30MG/3ML	N021148	007	Mar 10, 2009	Aug CAIN

NUTROPIN

	@	GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Aug CAIN
	@		10MG/VIAL	N020168	002	Nov 17, 1993	Aug CAIN

NUTROPIN AQ

	@	GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Aug CAIN
--	---	-----------	-------------------	---------	-----	--------------	----------

NUTROPIN AQ NUSPIN

	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Aug CAIN
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Aug CAIN
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Aug CAIN

NUTROPIN AQ PEN

	+	@ GENENTECH	10MG/2ML (5MG/ML)	N020522	002	Apr 22, 2002	Aug CAIN
	+	@	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Aug CAIN

OMNITROPE

BX		SANDOZ	1.5MG/VIAL	N021426	002	May 30, 2006	Aug CAIN
BX			5MG/1.5ML	N021426	003	Jan 16, 2008	Aug CAIN
BX			5.8MG/VIAL	N021426	001	May 30, 2006	Aug CAIN
BX			10MG/1.5ML	N021426	004	Aug 25, 2008	Aug CAIN

SAIZEN

	@	EMD SERONO	4MG/VIAL	N019764	005	Jan 16, 2007	Aug CAIN
BX	+		5MG/VIAL	N019764	002	Oct 08, 1996	Aug CAIN
	@		6MG/VIAL	N019764	001	Oct 08, 1996	Aug CAIN
	+	!	8.8MG/VIAL	N019764	003	Aug 29, 2000	Aug CAIN

SEROSTIM

		EMD SERONO	4MG/VIAL	N020604	003	Jul 25, 1997	Aug CAIN
BX			5MG/VIAL	N020604	002	Aug 23, 1996	Aug CAIN
BX			6MG/VIAL	N020604	001	Aug 23, 1996	Aug CAIN
	@		8.8MG/VIAL	N020604	004	Sep 06, 2001	Aug CAIN

INJECTABLE; SUBCUTANEOUS

SEROSTIM LQ

	@	EMD SERONO	6MG/0.5ML (6MG/0.5ML)	N020604	005	Feb 11, 2005	Aug CAIN
--	---	------------	-----------------------	---------	-----	--------------	----------

SOTALOL HYDROCHLORIDE

## TABLET; ORAL

## BETAPACE

AB	+	COVIS PHARMA BV	80MG	N019865	001	Oct 30, 1992	May CTEC
AB	+		120MG	N019865	005	Apr 20, 1994	May CTEC
AB	+	!	160MG	N019865	002	Oct 30, 1992	May CTEC
AB	+		240MG	N019865	003	Oct 30, 1992	May CTEC

## BETAPACE AF

AB	+	COVIS PHARMA BV	80MG	N021151	001	Feb 22, 2000	May CTEC
AB	+		120MG	N021151	002	Feb 22, 2000	May CTEC
AB	+	!	160MG	N021151	003	Feb 22, 2000	May CTEC

## SORINE

AB		UPSHER SMITH LABS	80MG	A075500	001	Apr 27, 2001	May CTEC
AB			120MG	A075500	004	Apr 27, 2001	May CTEC
AB			160MG	A075500	002	Apr 27, 2001	May CTEC
AB			240MG	A075500	003	Apr 27, 2001	May CTEC

## SOTALOL HYDROCHLORIDE

AB		APOTEX	80MG	A076140	001	Sep 26, 2002	May CTEC
AB			80MG	A076214	001	Aug 27, 2003	May CTEC
AB			120MG	A076140	002	Sep 26, 2002	May CTEC
AB			120MG	A076214	002	Aug 27, 2003	May CTEC
AB			160MG	A076140	003	Sep 26, 2002	May CTEC
AB			160MG	A076214	003	Aug 27, 2003	May CTEC
AB			240MG	A076140	004	Sep 26, 2002	May CTEC
AB		BEXIMCO PHARMS USA	80MG	A207428	001	Oct 21, 2016	May CTEC
AB			80MG	A207429	001	Nov 02, 2018	May CTEC
AB			120MG	A207428	002	Oct 21, 2016	May CTEC
AB			120MG	A207429	002	Nov 02, 2018	May CTEC
AB			160MG	A207428	003	Oct 21, 2016	May CTEC
AB			160MG	A207429	003	Nov 02, 2018	May CTEC
AB		EPIC PHARMA INC	80MG	A077070	001	Nov 04, 2005	May CTEC
AB			120MG	A077070	002	Nov 04, 2005	May CTEC
AB			160MG	A077070	003	Nov 04, 2005	May CTEC
AB		MYLAN	80MG	A077616	001	Feb 07, 2007	May CTEC
AB			120MG	A077616	002	Feb 07, 2007	May CTEC
AB			160MG	A077616	003	Feb 07, 2007	May CTEC
AB		OXFORD PHARMS	80MG	A075563	001	Nov 07, 2003	May CTEC
AB			120MG	A075563	002	Nov 07, 2003	May CTEC
AB			160MG	A075563	003	Nov 07, 2003	May CTEC
AB			240MG	A075563	004	Nov 07, 2003	May CTEC
AB		TEVA	80MG	A075429	001	May 01, 2000	May CTEC
AB			120MG	A075429	002	May 01, 2000	May CTEC
AB			160MG	A075429	003	May 01, 2000	May CTEC
AB			240MG	A075429	004	May 01, 2000	May CTEC
AB		@ UPSHER SMITH LABS	80MG	A075366	001	May 01, 2000	Jun DISC
AB			80MG	A075366	001	May 01, 2000	May CTEC
		@	120MG	A075366	002	May 01, 2000	Jun DISC
AB			120MG	A075366	002	May 01, 2000	May CTEC
		@	160MG	A075366	003	May 01, 2000	Jun DISC
AB			160MG	A075366	003	May 01, 2000	May CTEC
		@	240MG	A075366	004	May 01, 2000	Jun DISC
AB			240MG	A075366	004	May 01, 2000	May CTEC

SPIRONOLACTONE

## TABLET; ORAL

## SPIRONOLACTONE

	@	ACTAVIS ELIZABETH	25MG	A040353	003	Mar 15, 2006	Jun DISC
	@		50MG	A040353	001	Jul 29, 1999	Jun DISC
	@		100MG	A040353	002	Jul 29, 1999	Jun DISC
	@	CASI PHARMS INC	25MG	A086809	001		Jun DISC

STAVUDINE

## CAPSULE; ORAL

## STAVUDINE

>D>	AB	MYLAN	15MG	A079069	001	Dec 29, 2008	Oct DISC
>A>		@	15MG	A079069	001	Dec 29, 2008	Oct DISC
>D>	AB		20MG	A079069	002	Dec 29, 2008	Oct DISC
>A>		@	20MG	A079069	002	Dec 29, 2008	Oct DISC
>D>	AB		30MG	A079069	003	Dec 29, 2008	Oct DISC
>A>		@	30MG	A079069	003	Dec 29, 2008	Oct DISC
>D>	AB		40MG	A079069	004	Dec 29, 2008	Oct DISC
>A>		@	40MG	A079069	004	Dec 29, 2008	Oct DISC

FOR SOLUTION;ORAL  
ZERIT

+ @ BRISTOL-MYERS SQUIBB 1MG/ML N020413 001 Sep 06, 1996 Mar DISC

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION  
STERILE WATER

>D> AT BAXTER HLTHCARE 100% N017428 001 Oct CRLD  
>A> AT + 100% N017428 001 Oct CRLD

STRONTIUM CHLORIDE SR-89

INJECTABLE;INJECTION  
METASTRON

AP +! Q BIOMED 1mCi/ML N020134 001 Jun 18, 1993 Jan CAHN  
STRONTIUM CHLORIDE SR-89  
>D> AP BIO NUCLEONICS 1mCi/ML A075941 001 Jan 06, 2003 Oct CAHN  
>A> AP Q BIOMED 1mCi/ML A075941 001 Jan 06, 2003 Oct CAHN

SUCCINYLCHOLINE CHLORIDE

INJECTABLE;INJECTION  
SUCCINYLCHOLINE CHLORIDE

AP AMRING PHARMS 20MG/ML A210231 001 Jun 04, 2018 Jan CAHN  
AP DR REDDYS 20MG/ML A210698 001 Aug 02, 2019 Jul NEWA

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE;INJECTION  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D> AP ANDA REPOSITORY 80MG/ML;16MG/ML A212231 001 Jun 26, 2019 Oct CAHN  
AP 80MG/ML;16MG/ML A212231 001 Jun 26, 2019 Sep CAHN  
AP ! MYLAN LABS LTD 80MG/ML;16MG/ML A206607 001 Aug 30, 2017 Aug CHRS  
>A> AP SOMERSET 80MG/ML;16MG/ML A212231 001 Jun 26, 2019 Oct CAHN  
AP SOMERSET THERAPS LLC 80MG/ML;16MG/ML A212231 001 Jun 26, 2019 Jun NEWA  
@ TEVA PHARMS USA 80MG/ML;16MG/ML A073303 001 Oct 31, 1991 Aug DISC

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D> @ ANI PHARMS INC 200MG/5ML;40MG/5ML A077612 001 Nov 13, 2006 Oct CMFD  
>A> AB 200MG/5ML;40MG/5ML A077612 001 Nov 13, 2006 Oct CMFD

TABLET;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH

AB HERITAGE PHARMA 800MG;160MG A070037 001 Jun 02, 1987 May CAHN  
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH  
AB HERITAGE PHARMA 400MG;80MG A070030 001 Jun 02, 1987 May CAHN

SUMATRIPTAN

SPRAY;NASAL  
TOSYMRA

+! DR REDDYS LABS LTD 10MG/SPRAY N210884 001 Jan 25, 2019 Jan NEWA  
+! UPSHER SMITH LABS 10MG/SPRAY N210884 001 Jan 25, 2019 Sep CAHN  
+! 10MG/SPRAY N210884 001 Jan 25, 2019 Jul CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE

@ MYLAN LABS LTD EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML)  
@ PAR STERILE PRODUCTS EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML)  
@ ZYDUS EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML)

A203322 001 Apr 14, 2014 Sep DISC  
A077871 001 Jul 09, 2009 Apr DISC  
A090310 001 Aug 11, 2010 Apr CAHN

POWDER;NASAL

ONZETRA XSAIL

+! AVANIR PHARMS EQ 11MG BASE N206099 001 Jan 27, 2016 Sep CDFR  
+! CURRAX EQ 11MG BASE N206099 001 Jan 27, 2016 Sep CAHN

SOLUTION;SUBCUTANEOUS  
ZEMBRACE SYMTOUCH

+ UPSHER SMITH LABS EQ 3MG BASE/0.5ML (EQ 3MG  
BASE/0.5ML) N208223 001 Jan 28, 2016 Jul CAHN

TACROLIMUSOINTMENT; TOPICAL  
TACROLIMUS

AB	ACCORD HLTHCARE	0.03%	A211688	001	Jan 31, 2019	Jan NEWA
AB		0.1%	A211688	002	Jan 31, 2019	Jan NEWA

TADALAFILTABLET; ORAL  
ALYQ

AB2	TEVA PHARMS USA	20MG	A209942	001	Feb 05, 2019	Jan NEWA
	TADALAFIL					
AB	ACCORD HLTHCARE	2.5MG	A209167	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209167	002	Mar 26, 2019	Mar NEWA
AB1		20MG	A209167	004	Mar 26, 2019	Mar NEWA
AB	AJANTA PHARMA LTD	2.5MG	A209654	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209654	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209654	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209654	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210392	001	Feb 05, 2019	Jan NEWA
AB	ALEMBIC PHARMS LTD	2.5MG	A204809	001	Mar 26, 2019	Mar NEWA
AB		5MG	A204809	002	Mar 26, 2019	Mar NEWA
AB		10MG	A204809	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A204809	004	Mar 26, 2019	Mar NEWA
AB	AMNEAL PHARMS CO	2.5MG	A209744	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209744	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209744	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209744	004	Mar 26, 2019	Mar NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A206285	001	Mar 26, 2019	Mar NEWA
AB		5MG	A206285	002	Mar 26, 2019	Mar NEWA
AB		10MG	A206285	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A206285	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A206286	001	Feb 05, 2019	Jan NEWA
AB	CIPLA	2.5MG	A209539	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209539	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209539	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A209539	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210255	001	Feb 05, 2019	Jan NEWA
AB	DR REDDYS LABS LTD	2.5MG	A210069	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210069	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210069	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210069	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210145	001	Feb 05, 2019	Jan NEWA
AB	HETERO LABS LTD III	2.5MG	A209908	001	Mar 26, 2019	Mar NEWA
AB		5MG	A209908	002	Mar 26, 2019	Mar NEWA
AB		10MG	A209908	003	Mar 26, 2019	Mar NEWA
AB2		20MG	A209907	001	Feb 05, 2019	Jan NEWA
AB1		20MG	A209908	004	Mar 26, 2019	Mar NEWA
AB	LUPIN LTD	2.5MG	A210567	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210567	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210567	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210567	004	Mar 26, 2019	Mar NEWA
AB2		20MG	A210572	001	Feb 05, 2019	Jan NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A207244	001	Oct 07, 2019	Sep NEWA
AB		5MG	A207244	002	Oct 07, 2019	Sep NEWA
AB		10MG	A207244	003	Oct 07, 2019	Sep NEWA
AB1		20MG	A207244	004	Oct 07, 2019	Sep NEWA
AB2		20MG	A207290	001	Oct 16, 2019	Sep NEWA
AB	MYLAN	2.5MG	A206956	001	Apr 29, 2019	Apr NEWA
AB		5MG	A206957	001	Apr 29, 2019	Apr NEWA
AB		10MG	A206956	002	Apr 29, 2019	Apr NEWA
AB1		20MG	A206956	003	Apr 29, 2019	Apr NEWA
AB	QILU PHARM CO LTD	2.5MG	A210420	001	Mar 26, 2019	Mar NEWA
AB		5MG	A210420	002	Mar 26, 2019	Mar NEWA
AB		10MG	A210420	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A210420	004	Mar 26, 2019	Mar NEWA
AB	SUN PHARM	2.5MG	A208934	001	Mar 26, 2019	Mar NEWA
AB		5MG	A208934	002	Mar 26, 2019	Mar NEWA
AB		10MG	A208934	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A208934	004	Mar 26, 2019	Mar NEWA
AB	SUNSHINE LAKE	2.5MG	A211335	001	Mar 26, 2019	Mar NEWA
AB		5MG	A211335	002	Mar 26, 2019	Mar NEWA
AB		10MG	A211335	003	Mar 26, 2019	Mar NEWA
AB1		20MG	A211335	004	Mar 26, 2019	Mar NEWA

## TABLET;ORAL

## TADALAFIL

AB	TORRENT	2.5MG	A211839	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A211839	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A211839	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A211839	004	Mar 26, 2019	Mar	NEWA
AB2		20MG	A212062	001	Mar 26, 2019	Mar	NEWA
AB	UNICHEM LABS LTD	2.5MG	A209250	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A209250	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A209250	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A209250	004	Mar 26, 2019	Mar	NEWA
	@ WATSON LABS INC	2.5MG	A205885	001	Mar 29, 2019	Sep	DISC
AB		2.5MG	A205885	001	Mar 29, 2019	Mar	NEWA
	@	5MG	A205885	002	Mar 29, 2019	Sep	DISC
AB		5MG	A205885	002	Mar 29, 2019	Mar	NEWA
	@	10MG	A205885	003	Mar 29, 2019	Sep	DISC
AB		10MG	A205885	003	Mar 29, 2019	Mar	NEWA
	@	20MG	A205885	004	Mar 29, 2019	Sep	DISC
AB1		20MG	A205885	004	Mar 29, 2019	Mar	NEWA
AB	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Mar	NEWA
AB		5MG	A206693	002	Mar 26, 2019	Mar	NEWA
AB		10MG	A206693	003	Mar 26, 2019	Mar	NEWA
AB1		20MG	A206693	004	Mar 26, 2019	Mar	NEWA

TAFAMIDIS

## CAPSULE;ORAL

## VYNDAMAX

+	!	FOLDRX PHARMS	61MG	N212161	001	May 03, 2019	May	NEWA
---	---	---------------	------	---------	-----	--------------	-----	------

TAFAMIDIS MEGLUMINE

## CAPSULE;ORAL

## VYNDAQEL

+	!	FOLDRX PHARMS	20MG	N211996	001	May 03, 2019	May	NEWA
---	---	---------------	------	---------	-----	--------------	-----	------

TAFLUPROST

## SOLUTION/DROPS;OPHTHALMIC

## TAFLUPROST

AT		MICRO LABS	0.0015%	A209051	001	Aug 19, 2019	Aug	NFTG	
		ZIOPTAN							
AT	+	!	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Aug	CFTG

TAMOXIFEN CITRATE

## SOLUTION;ORAL

## SOLTAMOX

		FORTOVIA	EQ 20MG BASE/10ML	N021807	001	Oct 29, 2005	Aug	CAHN
--	--	----------	-------------------	---------	-----	--------------	-----	------

TAMSULOSIN HYDROCHLORIDE

## CAPSULE;ORAL

## TAMSULOSIN HYDROCHLORIDE

>A>	AB	ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Oct	NEWA
-----	----	-------------	-------	---------	-----	--------------	-----	------

TAZAROTENE

## CREAM;TOPICAL

## TAZAROTENE

		@ FOUGERA PHARMS INC	0.1%	A211175	001	Jan 28, 2019	Aug	DISC
AB			0.1%	A211175	001	Jan 28, 2019	May	CPOT
AB			1%	A211175	001	Jan 28, 2019	Jan	NEWA

TECHNETIUM TC-99M DISOFENIN KIT

## INJECTABLE;INJECTION

## HEPATOLITE

		@ PHARMALUCENCE	N/A	N018467	001	Mar 16, 1982	Aug	DISC
--	--	-----------------	-----	---------	-----	--------------	-----	------

TECHNETIUM TC-99M MERTIATIDE KIT

## INJECTABLE;INJECTION

## TECHNISCAN MAG3

AP	+	!	CURIUM	N/A	N019882	001	Jun 15, 1990	Jul	CFTG
	+	!		N/A	N019882	001	Jun 15, 1990	Jan	CAHN
			TECHNETIUM TC99M MERTIATIDE KIT						
AP			PHARMALUCENCE	N/A	A208994	001	Jul 12, 2019	Jul	NFTG

TECHNETIUM TC-99M OXIDRONATE KITINJECTABLE; INJECTION  
TECHNISCAN

+! CURIUM N/A N018321 001 Jan CAHN

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION  
DRAXIMAGE DTPA

+! JUBILANT DRAXIMAGE N/A N018511 001 Dec 29, 1989 Sep CTNA

TECHNETIUM TC-99M PYROPHOSPHATE KITINJECTABLE; INJECTION  
TECHNISCAN PYP KIT

AP CURIUM N/A N017538 001 Jan CAHN

TECHNETIUM TC-99M RED BLOOD CELL KITINJECTABLE; INJECTION  
ULTRATAG

+! CURIUM N/A N019981 001 Jun 10, 1991 Jan CAHN

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION; INTRAVENOUS  
ULTRA-TECHNEKOW FM+! CURIUM 1-19 CI/GENERATOR N017243 003 Feb 18, 2014 Jan CAHN  
@ 0.25-3 CI/GENERATOR N017243 002 Jan CAHNSOLUTION; INTRAVENOUS, ORAL  
TECHNETIUM TC 99M GENERATOR

+ @ GE HEALTHCARE 68-2703mCi/GENERATOR N017693 002 Dec 13, 2013 Feb DISC

TEGASEROD MALEATETABLET; ORAL  
ZELNORM+ @ ALFASIGMA EQ 2MG BASE N021200 001 Jul 24, 2002 Aug CAHN  
+! EQ 6MG BASE N021200 002 Jul 24, 2002 Sep CMFD  
+ @ EQ 6MG BASE N021200 002 Jul 24, 2002 Aug CAHN  
+ @ US WORLDMEDS LLC EQ 2MG BASE N021200 001 Jul 24, 2002 Jul CRLD  
+ @ EQ 6MG BASE N021200 002 Jul 24, 2002 Jul CRLDTELMISARTANTABLET; ORAL  
TELMISARTAN

	@ CIPLA	20MG	A078710	001	Jan 08, 2014	Jun DISC
AB		20MG	A078710	001	Jan 08, 2014	Feb CAHN
	@	40MG	A078710	002	Jan 08, 2014	Feb CAHN
	@	80MG	A078710	003	Jan 08, 2014	Feb CAHN
	@ HISUN PHARM HANGZHOU	20MG	A207843	001	Feb 19, 2019	Aug DISC
AB		20MG	A207843	001	Feb 19, 2019	Feb NEWA
	@	40MG	A207843	002	Feb 19, 2019	Aug DISC
AB		40MG	A207843	002	Feb 19, 2019	Feb NEWA
	@	80MG	A207843	003	Feb 19, 2019	Aug DISC
AB		80MG	A207843	003	Feb 19, 2019	Feb NEWA
AB	INVENTIA	20MG	A205150	001	Oct 30, 2015	Aug CAHN
AB		40MG	A205150	002	Oct 30, 2015	Aug CAHN
AB		80MG	A205150	003	Oct 30, 2015	Aug CAHN
	@ MICRO LABS	20MG	A207016	001	Oct 03, 2017	Mar DISC
	@	40MG	A207016	002	Oct 03, 2017	Mar DISC
	@	80MG	A207016	003	Oct 03, 2017	Mar DISC
	@ WATSON LABS	80MG	A078710	003	Jan 08, 2014	Feb DISC

TEMOZOLOMIDECAPSULE; ORAL  
TEMOZOLOMIDE

	@ APOTEX INC	5MG	A204159	001	Jul 05, 2018	Jan DISC
	@	20MG	A204159	002	Jul 05, 2018	Jan DISC
	@	100MG	A204159	003	Jul 05, 2018	Jan DISC
	@	140MG	A204159	004	Jul 05, 2018	Jan DISC
	@	180MG	A204159	005	Jul 05, 2018	Jan DISC
	@	250MG	A204159	006	Jul 05, 2018	Jan DISC
>D> AB	LANNETT CO INC	5MG	A203898	001	Feb 10, 2016	Oct DISC
>A>	@	5MG	A203898	001	Feb 10, 2016	Oct DISC
>D> AB		20MG	A203898	002	Feb 10, 2016	Oct DISC

CAPSULE;ORAL  
TEMOZOLOMIDE

>A>	@	20MG	A203898	002	Feb 10, 2016	Oct DISC
>D> AB		100MG	A203898	003	Feb 10, 2016	Oct DISC
>A>	@	100MG	A203898	003	Feb 10, 2016	Oct DISC
>D> AB		140MG	A203898	004	Feb 10, 2016	Oct DISC
>A>	@	140MG	A203898	004	Feb 10, 2016	Oct DISC
>D> AB		180MG	A203898	005	Feb 10, 2016	Oct DISC
>A>	@	180MG	A203898	005	Feb 10, 2016	Oct DISC
>D> AB		250MG	A203898	006	Feb 10, 2016	Oct DISC
>A>	@	250MG	A203898	006	Feb 10, 2016	Oct DISC

TEMSIROLIMUSSOLUTION;INTRAVENOUS  
TEMSIROLIMUS

AP	GLAND PHARMA LTD	25MG/ML (25MG/ML)	A207383	001	Aug 16, 2019	Aug NEWA
----	------------------	-------------------	---------	-----	--------------	----------

TENAPANOR HYDROCHLORIDETABLET;ORAL  
IBSRELA

+	ARDELYX INC	EQ 50MG BASE	N211801	001	Sep 12, 2019	Sep NEWA
---	-------------	--------------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDECAPSULE;ORAL  
TERAZOSIN HYDROCHLORIDE

AB	APNAR PHARMA LP	EQ 1MG BASE	A074823	001	Mar 30, 1998	Jun CAHN
AB	!	EQ 2MG BASE	A074823	002	Mar 30, 1998	Jun CAHN
AB		EQ 5MG BASE	A074823	003	Mar 30, 1998	Jun CAHN
AB		EQ 10MG BASE	A074823	004	Mar 30, 1998	Jun CAHN
	@ BEXIMCO PHARMS USA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Feb CAHN
	@	EQ 2MG BASE	A075667	002	Jul 28, 2000	Feb CAHN
	@	EQ 5MG BASE	A075667	003	Jul 28, 2000	Feb CAHN
	@	EQ 10MG BASE	A075667	004	Jul 28, 2000	Feb CAHN
AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	Mar CAHN
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	Mar CAHN
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	Mar CAHN
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	Mar CAHN
AB	HIKMA	EQ 1MG BASE	A075498	001	Apr 12, 2001	Jun CAHN
AB		EQ 2MG BASE	A075498	002	Apr 12, 2001	Jun CAHN
AB		EQ 5MG BASE	A075498	003	Apr 12, 2001	Jun CAHN
AB		EQ 10MG BASE	A075498	004	Apr 12, 2001	Jun CAHN

TERBINAFINE HYDROCHLORIDETABLET;ORAL  
TERBINAFINE HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 250MG BASE	A076377	001	Jul 02, 2007	May CAHN
----	-----------------	---------------	---------	-----	--------------	----------

TERBUTALINE SULFATEINJECTABLE;INJECTION  
TERBUTALINE SULFATE

@	DR REDDYS	1MG/ML	A076853	001	Jul 20, 2004	May CAHN
---	-----------	--------	---------	-----	--------------	----------

TERCONAZOLECREAM;VAGINAL  
TERCONAZOLE

BX	+	FOUGERA PHARMS INC	0.8%	N021735	001	Oct 01, 2004	May CAHN
----	---	--------------------	------	---------	-----	--------------	----------

SUPPOSITORY;VAGINAL  
TERCONAZOLE

AB	!	PERRIGO ISRAEL	80MG	A077149	001	Mar 17, 2006	May CAHN
----	---	----------------	------	---------	-----	--------------	----------

TERIFLUNOMIDETABLET;ORAL  
TERIFLUNOMIDE

AB		ALEMBIC PHARMS LTD	7MG	A209572	001	Apr 19, 2019	Apr NEWA
AB			14MG	A209572	002	Apr 19, 2019	Apr NEWA
	@	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	Feb DISC
	@		14MG	A209613	002	Sep 28, 2018	Feb DISC
	@	APOTEX	7MG	A209601	001	Nov 02, 2018	Jan DISC
	@		14MG	A209601	002	Nov 02, 2018	Jan DISC
	@	AUROBINDO PHARMA LTD	7MG	A209638	001	Oct 26, 2018	Feb DISC
	@		14MG	A209638	002	Oct 26, 2018	Feb DISC
>D> AB		MSN LABS PVT LTD	7MG	A209623	001	Apr 24, 2019	Oct DISC

## TABLET;ORAL

## TERIFLUNOMIDE

>A>	@	7MG	A209623	001	Apr 24, 2019	Oct DISC
AB		7MG	A209623	001	Apr 24, 2019	Apr NEWA
>D> AB		14MG	A209623	002	Apr 24, 2019	Oct DISC
>A>	@	14MG	A209623	002	Apr 24, 2019	Oct DISC
AB		14MG	A209623	002	Apr 24, 2019	Apr NEWA
	@ TEVA PHARMS USA	7MG	A209700	001	Sep 04, 2018	Mar DISC
	@	14MG	A209700	002	Sep 04, 2018	Mar DISC
	@ WATSON LABS TEVA	7MG	A209549	001	Jul 27, 2018	Feb DISC
	@	14MG	A209549	002	Jul 27, 2018	Feb DISC
	@ ZYDUS PHARMS	7MG	A209668	001	Nov 30, 2018	May DISC
	@	14MG	A209668	002	Nov 30, 2018	May DISC

TERIPARATIDE RECOMBINANT HUMAN

## SOLUTION;SUBCUTANEOUS

>A>	BONSITY					
>A>	PFENEX INC	0.62MG/2.48ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Oct NEWA

TESTOSTERONE

## GEL;TRANSDERMAL

## TESTOSTERONE

	@ PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Mar DISC
	GEL, METERED;TRANSDERMAL					
	TESTOSTERONE					
AB	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM ACTUATION)	A204570	001	Apr 10, 2019	Mar NEWA
AB	AMNEAL PHARMS LLC	1.62% (20.25MG/1.25GM ACTUATION)	A207373	001	Apr 10, 2019	Mar NEWA
AB	DR REDDYS	1.62% (20.25MG/1.25GM ACTUATION)	A208620	001	Apr 10, 2019	Mar NEWA
AB	LUPIN ATLANTIS	1.62% (20.25MG/1.25GM ACTUATION)	A208560	001	Apr 10, 2019	Mar NEWA
AB	TWI PHARMS	1.62% (20.25MG/1.25GM ACTUATION)	A209390	001	Sep 23, 2019	Sep NEWA

## TABLET, EXTENDED RELEASE;BUCCAL

## STRIANT

	+ @ AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Jul DISC
--	-------------------------	------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

## INJECTABLE;INJECTION

## TESTOSTERONE CYPIONATE

	@ MYLAN INSTITUTIONAL	200MG/ML	A040652	001	Dec 11, 2006	Mar DISC
AO	WILSHIRE PHARMS INC	200MG/ML	A206368	001	Apr 24, 2019	Apr NEWA

TESTOSTERONE UNDECANOATE

## CAPSULE;ORAL

## JATENZO

	+ CLARUS	158MG	N206089	001	Mar 27, 2019	Mar NEWA
	+	198MG	N206089	002	Mar 27, 2019	Mar NEWA
	+!	237MG	N206089	003	Mar 27, 2019	Mar NEWA

TETRABENAZINE

## TABLET;ORAL

## TETRABENAZINE

	@ LUPIN LTD	12.5MG	A210544	001	Apr 20, 2018	Feb DISC
	@	25MG	A210544	002	Apr 20, 2018	Feb DISC
AB	MYLAN	12.5MG	A207682	001	Jan 31, 2017	Jul CAHN
AB		25MG	A207682	002	Jan 31, 2017	Jul CAHN

TETRACAINE HYDROCHLORIDE

## SOLUTION;OPHTHALMIC

## TETRACAINE HYDROCHLORIDE

	BAUSCH	0.5%	N210821	001	Mar 12, 2019	Apr CAHN
	VALEANT PHARMS	0.5%	N210821	001	Mar 12, 2019	Mar NEWA

TETRACYCLINE HYDROCHLORIDE

## CAPSULE;ORAL

## ACHROMYCIN V

>A> AB	+	AVET	250MG	N050278	003	Oct CAHN
>A> AB	+	!	500MG	N050278	001	Oct CAHN
>D> AB	+	HERITAGE PHARMS INC	250MG	N050278	003	Oct CAHN
>D> AB	+	!	500MG	N050278	001	Oct CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION  
THALLOUS CHLORIDE TL 201

AP	+	!	CURIUM	1mCi/ML	N018150	001			Jan CAHN
----	---	---	--------	---------	---------	-----	--	--	----------

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL  
THEOPHYLLINE

AB	!	HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Feb CAHN
AB	!		200MG	A089808	001	Apr 30, 1990	Feb CAHN
AB			300MG	A089763	001	Apr 30, 1990	Feb CAHN
	@		450MG	A081236	001	Nov 09, 1992	Feb CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL  
THIORIDAZINE HYDROCHLORIDE

>D>	AB	MYLAN	10MG	A088004	002	Mar 15, 1983	Oct CTEC
>A>			10MG	A088004	002	Mar 15, 1983	Oct CTEC
>D>	AB		25MG	A088004	003	Mar 15, 1983	Oct CTEC
>A>			25MG	A088004	003	Mar 15, 1983	Oct CTEC
>D>	AB		50MG	A088004	004	Mar 15, 1983	Oct CTEC
>A>			50MG	A088004	004	Mar 15, 1983	Oct CTEC
>D>	AB	!	100MG	A088004	001	Nov 18, 1983	Oct CTEC
>A>		!	100MG	A088004	001	Nov 18, 1983	Oct CTEC
>D>	AB	SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Oct DISC
>A>		@	10MG	A089953	004	Aug 01, 1986	Oct DISC
>D>	AB		25MG	A089953	003	Aug 01, 1986	Oct DISC
>A>		@	25MG	A089953	003	Aug 01, 1986	Oct DISC
>D>	AB		50MG	A089953	002	Aug 01, 1986	Oct DISC
>A>		@	50MG	A089953	002	Aug 01, 1986	Oct DISC
>D>	AB		100MG	A089953	001	Oct 07, 1988	Oct DISC
>A>		@	100MG	A089953	001	Oct 07, 1988	Oct DISC

THIOTHIXENE

CAPSULE;ORAL  
THIOTHIXENE

AB	MYLAN	1MG	A071093	002	Jun 23, 1987	Mar CTEC
AB		2MG	A071093	003	Jun 23, 1987	Mar CTEC
AB		5MG	A071093	004	Jun 23, 1987	Jul CHRS
AB	!	5MG	A071093	004	Jun 23, 1987	Mar CTEC
AB		10MG	A071093	001	Jun 23, 1987	Mar CTEC
AB	NOVITIUM PHARMA	1MG	A211642	001	Apr 05, 2019	Mar NEWA
AB		2MG	A211642	002	Apr 05, 2019	Mar NEWA
AB	!	5MG	A211642	003	Apr 05, 2019	Jul CHRS
AB		5MG	A211642	003	Apr 05, 2019	Mar NEWA
AB		10MG	A211642	004	Apr 05, 2019	Mar NEWA

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE;ORAL  
THIOTHIXENE HYDROCHLORIDE INTENSOL  
@ HIKMA EQ 5MG BASE/ML

A073494	001	Jun 30, 1992	Sep CAHN
---------	-----	--------------	----------

TICAGRELOR

TABLET;ORAL  
BRILINTA

+	ASTRAZENECA PHARMS	60MG	N022433	002	Sep 03, 2015	Jun CTEC
	TICAGRELOR					
	@ AMNEAL PHARMS CO	90MG	A208531	001	Jan 23, 2019	Jun DISC
AB		90MG	A208531	001	Jan 23, 2019	Jan NEWA
AB	HISUN PHARM HANGZHOU	90MG	A208575	001	Jan 23, 2019	Jan NEWA
	@ WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Feb DISC
	@	90MG	A208390	002	Sep 04, 2018	Feb DISC

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL  
TICLOPIDINE HYDROCHLORIDE

>D>	AB	SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002	Oct DISC
>A>		@	250MG	A075526	001	Sep 26, 2002	Oct DISC

TIGECYCLINEPOWDER; INTRAVENOUS  
TIGECYCLINE

AP	AMNEAL PHARMS LLC	50MG/VIAL	N211158	001	Aug 02, 2018	Jul CMFD
	@	50MG/VIAL	N211158	001	Aug 02, 2018	Feb DISC
AP	AUROBINDO PHARMA LTD	50MG/VIAL	A206335	001	Jun 11, 2019	May NEWA
>A> AP	XELLIA PHARMS APS	50MG/VIAL	A205722	001	Oct 18, 2019	Oct NEWA

TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC  
TIMOPTIC

AT	+ VALEANT PHARMS INTL	EQ 0.25% BASE	N018086	001		Jan CAHN
AT1	+ VALEANT PHARMS INTL	EQ 0.5% BASE	N018086	002		Jan CAHN
	TIMOPTIC IN OCUDOSE					
	+! VALEANT PHARMS INTL	EQ 0.25% BASE	N019463	001	Nov 05, 1986	Jan CAHN
	+! VALEANT PHARMS INTL	EQ 0.5% BASE	N019463	002	Nov 05, 1986	Jan CAHN

## TABLET; ORAL

## BLOCADREN

	+ @ MERCK	5MG	N018017	001		Apr CRLD
	+ @	10MG	N018017	002		Apr CRLD
	+ @	20MG	N018017	004		Apr CRLD

## TIMOLOL MALEATE

	@ ANI PHARMS INC	5MG	A072917	001	Jul 31, 1991	Sep CAHN
	@	10MG	A072918	001	Jul 31, 1991	Sep CAHN
	@	20MG	A072919	001	Jul 31, 1991	Sep CAHN
AB	ELYSIUM	5MG	A207556	001	May 02, 2019	Sep CAHN
AB		10MG	A207556	002	May 02, 2019	Sep CAHN
AB		20MG	A207556	003	May 02, 2019	Sep CAHN
AB	INVATECH PHARMA	5MG	A207556	001	May 02, 2019	Apr NEWA
AB		10MG	A207556	002	May 02, 2019	Apr NEWA
AB		20MG	A207556	003	May 02, 2019	Apr NEWA
AB	MYLAN	5MG	A072668	002	Jun 08, 1990	Apr CTEC
AB		10MG	A072668	003	Jun 08, 1990	Apr CTEC
AB	!	20MG	A072668	001	Jun 08, 1990	Apr CTEC

TIOPRONINTABLET, DELAYED RELEASE; ORAL  
THIOLA EC

	+ MISSION PHARMACAL CO	100MG	N211843	001	Jun 28, 2019	Jun NEWA
	+! MISSION PHARMACAL CO	300MG	N211843	002	Jun 28, 2019	Jun NEWA

TIZANIDINE HYDROCHLORIDE

## CAPSULE; ORAL

## TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A212196	001	Mar 27, 2019	Mar NEWA
AB		EQ 4MG BASE	A212196	002	Mar 27, 2019	Mar NEWA
AB		EQ 6MG BASE	A212196	003	Mar 27, 2019	Mar NEWA
AB	CADILA PHARMS LTD	EQ 2MG BASE	A210021	001	Mar 26, 2019	Mar NEWA
AB		EQ 4MG BASE	A210021	002	Mar 26, 2019	Mar NEWA
AB		EQ 6MG BASE	A210021	003	Mar 26, 2019	Mar NEWA
AB	NOVAST LABS	EQ 2MG BASE	A210267	001	Mar 12, 2019	Sep CAHN
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Sep CAHN
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Sep CAHN
AB	RICONPHARMA LLC	EQ 2MG BASE	A210267	001	Mar 12, 2019	Feb NEWA
AB		EQ 4MG BASE	A210267	002	Mar 12, 2019	Feb NEWA
AB		EQ 6MG BASE	A210267	003	Mar 12, 2019	Feb NEWA

## TABLET; ORAL

## TIZANIDINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE	A211798	001	Jan 25, 2019	Jan NEWA
AB		EQ 4MG BASE	A211798	002	Jan 25, 2019	Jan NEWA
	@ ANI PHARMS INC	EQ 2MG BASE	A076283	001	Jul 12, 2002	May CAHN
AB		EQ 2MG BASE	A076284	001	Jul 03, 2002	Sep CAHN
	@	EQ 2MG BASE	A076371	001	Apr 09, 2003	May CAHN
	@	EQ 4MG BASE	A076283	002	Jul 12, 2002	May CAHN
AB		EQ 4MG BASE	A076284	002	Jul 03, 2002	Sep CAHN
	@	EQ 4MG BASE	A076371	002	Apr 09, 2003	May CAHN
	@ PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	Mar DISC
	@	EQ 4MG BASE	A207170	002	Jan 26, 2017	Mar DISC

TOBRAMYCIN

SOLUTION; INHALATION							
BETHKIS							
	+!	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Jul CTEC
AN	+!		300MG/4ML	N201820	001	Oct 12, 2012	Jun CFTG
TOBRAMYCIN							
AN		DR REDDYS LABS SA	300MG/5ML	A207080	001	Jul 09, 2018	Mar CMFD
	@		300MG/5ML	A207080	001	Jul 09, 2018	Jan DISC
	@	TEVA PHARMS USA	300MG/4ML	A210915	001	Jun 26, 2019	Jul DISC
AN			300MG/4ML	A210915	001	Jun 26, 2019	Jun NFTG
SOLUTION/DROPS; OPHTHALMIC							
TOBRAMYCIN							
AT		ALEMBIC PHARMS LTD	0.3%	A211847	001	Apr 19, 2019	Apr NEWA

TOFACITINIB CITRATE

TABLET; ORAL							
XELJANZ							
	+	PF PRISM CV	EQ 5MG BASE	N203214	001	Nov 06, 2012	May CHRS

TOLAZAMIDE

TABLET; ORAL							
TOLAZAMIDE							
	@	COSETTE	100MG	N018894	001	Nov 02, 1984	Jun CAHN
	@		250MG	N018894	002	Nov 02, 1984	Jun CAHN
	@		500MG	N018894	003	Nov 02, 1984	Jun CAHN

TOLCAPONE

TABLET; ORAL							
TASMAR							
AB	+!	BAUSCH	100MG	N020697	001	Jan 29, 1998	Mar CAHN
	@		200MG	N020697	002	Jan 29, 1998	Mar CAHN
TOLCAPONE							
AB		KINEDEXE UK	100MG	A210095	001	Aug 01, 2019	Jul NEWA
AB		MAYNE PHARMA	100MG	A210095	001	Aug 01, 2019	Sep CAHN
AB		NOVAST LABS	100MG	A208937	001	Aug 07, 2018	Sep CAHN

TOLMETIN SODIUM

CAPSULE; ORAL							
TOLMETIN SODIUM							
	@	ANI PHARMS INC	EQ 400MG BASE	A073308	001	Jan 24, 1992	May CAHN
	@		EQ 400MG BASE	A073519	001	May 29, 1992	Sep CAHN
TABLET; ORAL							
TOLMETIN SODIUM							
	@	ANI PHARMS INC	EQ 600MG BASE	A073527	001	Jun 30, 1992	May CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL							
TOLTERODINE TARTRATE							
AB		INVENTIA HLTHCARE	2MG	A204562	001	Aug 19, 2019	Aug NEWA
AB			4MG	A204562	002	Aug 19, 2019	Aug NEWA

TOLVAPTAN

TABLET; ORAL							
JYNARQUE							
	+!	OTSUKA PHARM CO LTD	45MG	N204441	003	Apr 23, 2018	Jun CHRS
	+		90MG	N204441	005	Apr 23, 2018	Jun CHRS

TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL							
QUDEXY XR							
BC	+	UPSHER SMITH LABS	25MG	N205122	001	Mar 11, 2014	Feb CTEC
BC	+		50MG	N205122	002	Mar 11, 2014	Feb CTEC
BC	+		100MG	N205122	003	Mar 11, 2014	Feb CTEC
BC	+!		200MG	N205122	005	Mar 11, 2014	Feb CTEC
TROKENDI XR							
BC	+!	SUPERNUS PHARMS	200MG	N201635	004	Aug 16, 2013	Apr CTEC

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

>D>	@	FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010	Oct CAHN
>A>	@	FRESENIUS KABI USA	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010	Oct CAHN
>D>	AP	MYLAN LABS LTD	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Oct DISC
>A>	@		EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Oct DISC

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB		POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Jun NEWA
AB		RUBICON	50MG	A208708	001	Jun 28, 2019	Jun NEWA
AB			100MG	A208708	002	Jun 28, 2019	Jun NEWA
>D>	AB	SUN PHARM INDUSTRIES	50MG	A076100	001	Jun 20, 2002	Oct DISC
>A>	@		50MG	A076100	001	Jun 20, 2002	Oct DISC
AB		UNICHEM LABS LTD	50MG	A211825	001	Aug 09, 2019	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL

TRAMADOL HYDROCHLORIDE

@	AUROBINDO PHARMA LTD	100MG
@		200MG
@		300MG

A204421	001	Oct 20, 2015	Sep DISC
A204421	002	Oct 20, 2015	Sep DISC
A204421	003	Oct 20, 2015	Sep DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

TARKA

+ @ ABBVIE 1MG;240MG

N020591 003 Oct 22, 1996 Aug DISC

TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE

GLENMARK GENERICS 1MG;240MG

A079135 004 Aug 30, 2010 Aug CTEC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP		APOLLO PHARMS INC	100MG/ML
AP		CAPLIN	100MG/ML
+	!	EXELA PHARMA SCS LLC	10MG/ML
AP		MICRO LABS	100MG/ML

A212676	001	Jul 17, 2019	Jul NEWA
A212360	001	Jul 17, 2019	Jul NEWA
N212020	001	Apr 15, 2019	Apr NEWA
A206713	001	Jun 27, 2017	Mar CAHN

SOLUTION;INTRAVENOUS

TRANEXAMIC ACID

+! EXELA PHARMA SCS LLC 1GM/100ML (10MG/ML)

N212020 001 Apr 15, 2019 May CPOT

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS

TREPROSTINIL

AP		PAR STERILE PRODUCTS	1MG/ML
AP			2.5MG/ML
AP			5MG/ML
AP			10MG/ML
AP		TEVA PHARMS USA	1MG/ML
AP			2.5MG/ML
AP			5MG/ML
AP			10MG/ML

A209382	001	Sep 24, 2019	Sep NEWA
A209382	002	Sep 24, 2019	Sep NEWA
A209382	003	Sep 24, 2019	Sep NEWA
A209382	004	Sep 24, 2019	Sep NEWA
A206648	001	Sep 26, 2019	Sep NEWA
A206648	002	Sep 26, 2019	Sep NEWA
A206648	003	Sep 26, 2019	Sep NEWA
A206648	004	Sep 26, 2019	Sep NEWA

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE;ORAL

ORENITRAM

+	!	UNITED THERAP	EQ 1MG BASE
+			EQ 2.5MG BASE

N203496	003	Dec 20, 2013	Feb CHRS
N203496	004	Dec 20, 2013	Feb CHRS

TRETINOIN

CREAM;TOPICAL

TRETINOIN

AB1		TARO PHARMS	0.05%
AB			0.1%

A211644	001	Jan 25, 2019	Jan NEWA
A211645	001	Jan 22, 2019	Jan NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		MLV	0.025%
AT			0.1%
AT		SAPTALIS PHARMS	0.025%

A040671	001	Jun 09, 2006	Sep CAHN
A040671	002	Jun 09, 2006	Sep CAHN
A040671	001	Jun 09, 2006	May CAHN

CREAM; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		0.1%		A040671	002	Jun 09, 2006	May	CAHN	
AT	STRIDES PHARMA	0.025%		A210346	001	Feb 11, 2019	Jan	NEWA	
AT		0.1%		A210346	002	Feb 11, 2019	Jan	NEWA	
AT		0.5%		A210346	003	Feb 11, 2019	Jan	NEWA	
INJECTABLE; INJECTION									
KENALOG-80									
+	APOTHECON	80MG/ML		N014901	002	Apr 12, 2019	Apr	NEWA	
TRIAMCINOLONE ACETONIDE									
AB	TEVA PHARMS USA	40MG/ML		A209852	001	Oct 05, 2018	Jul	CMFD	
@		40MG/ML		A209852	001	Oct 05, 2018	Mar	DISC	
LOTION; TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT	ALLIED	0.1%		A040672	002	Dec 13, 2006	Sep	CAHN	
AT	SAPTALIS PHARMS	0.1%		A040672	002	Dec 13, 2006	May	CAHN	
<u>TRIAMTERENE</u>									
CAPSULE; ORAL									
DYRENIUM									
AB	+ CONCORDIA	50MG		N013174	001		Aug	CFTG	
AB	+	100MG		N013174	002		Aug	CFTG	
TRIAMTERENE									
AB	AGNITIO	50MG		A211581	001	Aug 19, 2019	Aug	NFTG	
AB		100MG		A211581	002	Aug 19, 2019	Aug	NFTG	
<u>TRICLABENDAZOLE</u>									
TABLET; ORAL									
EGATEN									
+	NOVARTIS	250MG		N208711	001	Feb 13, 2019	Feb	NEWA	
<u>TRIENTINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
SYPRINE									
AB	+	BAUSCH	250MG	N019194	001	Nov 08, 1985	Sep	CAHN	
TRIENTINE HYDROCHLORIDE									
AB	AMNEAL PHARMS LLC	250MG		A210619	001	Feb 08, 2019	Feb	NEWA	
AB	DR REDDYS LABS LTD	250MG		A211076	001	Jul 03, 2019	Jun	NEWA	
AB	KADMON PHARMS LLC	250MG		A209415	001	Sep 16, 2019	Sep	NEWA	
>A>	AB	250MG		A209731	001	Oct 21, 2019	Oct	NEWA	
AB	MSN LABS PVT LTD	250MG		A211134	001	May 22, 2019	May	NEWA	
AB	PAR PHARM INC	250MG		A210096	001	Sep 25, 2019	Sep	NEWA	
AB	ZYDUS PHARMS	250MG		A211554	001	Apr 26, 2019	Apr	NEWA	
>A>	<u>TRIFAROTENE</u>								
>A>	CREAM; TOPICAL								
>A>	AKLIEF								
>A>	+	GALDERMA R AND D	0.005%	N211527	001	Oct 04, 2019	Oct	NEWA	
<u>TRIMETHADIONE</u>									
TABLET; ORAL									
TRIDIONE									
+	@ ABBVIE	150MG		N005856	009		Jul	DISC	
<u>TRIMETHOBENZAMIDE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
TRIMETHOBENZAMIDE HYDROCHLORIDE									
AB	LUPIN	300MG		A076546	001	Aug 20, 2003	Feb	CAHN	
INJECTABLE; INJECTION									
TIGAN									
+	PAR STERILE PRODUCTS	100MG/ML		N017530	001		May	CTEC	
<u>TRIMIPRAMINE MALEATE</u>									
CAPSULE; ORAL									
SURMONTIL									
+	@ ODYSSEY PHARMS	EQ 25MG BASE		N016792	001		Jul	DISC	
+	@	EQ 50MG BASE		N016792	002		Jul	DISC	
+	@	EQ 100MG BASE		N016792	003	Sep 15, 1982	Jul	DISC	
TRIMIPRAMINE MALEATE									
AB	!	CROSSMEDIKA SA	EQ 50MG BASE	A208127	002	Apr 15, 2016	Jul	CHRS	

UPADACITINIB

TABLET, EXTENDED RELEASE;ORAL  
RINVOQ

+! ABBVIE INC EQ 15MG BASE N211675 001 Aug 16, 2019 Aug NEWA

URSODIOL

CAPSULE;ORAL  
URSODIOL

AB AMNEAL PHARMS CO 300MG A211301 001 Oct 16, 2018 Jun CMFD  
@ 300MG A211301 001 Oct 16, 2018 Apr DISC  
>A> AB EYWA PHARMA 300MG A212452 001 Oct 30, 2019 Oct NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL  
VALACYCLOVIR HYDROCHLORIDE

@ WATSON LABS INC EQ 500MG BASE A090370 001 Mar 16, 2011 Apr DISC  
@ EQ 1GM BASE A090370 002 Mar 16, 2011 Apr DISC

VALPROATE SODIUM

INJECTABLE;INJECTION  
DEPACON

+ @ ABBVIE EQ 100MG BASE/ML N020593 001 Dec 30, 1996 Apr DISC  
VALPROATE SODIUM  
AP ! HIKMA FARMACEUTICA EQ 100MG BASE/ML A078523 001 Feb 17, 2010 Apr CHRS

VALPROIC ACID

CAPSULE;ORAL  
DEPAKENE

>D> AB +! ABBVIE 250MG N018081 001 Oct DISC  
>A> + @ 250MG N018081 001 Oct DISC  
VALPROIC ACID  
>D> AB BIONPHARMA INC 250MG A073484 001 Jun 29, 1993 Oct CHRS  
>A> AB ! 250MG A073484 001 Jun 29, 1993 Oct CHRS  
AB NOVELGENIX THERAPS 250MG A207611 001 Aug 05, 2019 Jul NEWA  
@ UPSHER SMITH LABS 250MG A070631 001 Jun 11, 1987 Jul CAHN  
SYRUP;ORAL  
DEPAKENE  
+ @ ABBVIE 250MG/5ML N018082 001 Aug DISC  
VALPROIC ACID  
>A> @ APOTEX 250MG/5ML A077105 001 Jul 29, 2005 Oct CAHN  
@ PD PARTNERS 250MG/5ML A077105 001 Jul 29, 2005 May CAHN  
AA ! PHARM ASSOC 250MG/5ML A075379 001 Dec 15, 2000 Aug CHRS  
>D> @ 250MG/5ML A077105 001 Jul 29, 2005 Oct CAHN

VALRUBICIN

SOLUTION;INTRAVESICAL  
VALRUBICIN

AO CUSTOPHARM INC 40MG/ML A206430 001 Apr 19, 2019 Apr NFTG  
VALSTAR PRESERVATIVE FREE  
AO +! ENDO PHARM 40MG/ML N020892 001 Sep 25, 1998 Apr CFTG

VALSARTAN

TABLET;ORAL  
VALSARTAN

AB ALKEM LABS LTD 40MG A205536 001 Mar 12, 2019 Feb NEWA  
AB 80MG A205536 002 Mar 12, 2019 Feb NEWA  
AB 160MG A205536 003 Mar 12, 2019 Feb NEWA  
AB 320MG A205536 004 Mar 12, 2019 Feb NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL  
VANCOMYCIN HYDROCHLORIDE

AB ORIENT PHARMA CO LTD EQ 125MG BASE A210729 001 Apr 29, 2019 Apr NEWA  
AB EQ 250MG BASE A210729 002 Apr 29, 2019 Apr NEWA

FOR SOLUTION;ORAL  
VANCOCIN HYDROCHLORIDE

ANI PHARMS INC EQ 250MG BASE/5ML A061667 002 Jul 13, 1983 Jul CMFD

INJECTABLE;INJECTION  
VANCOMYCIN HYDROCHLORIDE

AP HAINAN POLY PHARM EQ 500MG BASE/VIAL A212332 001 Jun 12, 2019 May NEWA

INJECTABLE; INJECTION  
VANCOMYCIN HYDROCHLORIDE

AP		EQ 1GM BASE/VIAL	A212332	002	Jun 12, 2019	May NEWA
	SOLUTION; INTRAVENOUS					
	VANCOMYCIN HYDROCHLORIDE					
	+! XELLIA PHARMS APS	EQ 500MG BASE/100ML	N211962	001	Feb 15, 2019	Feb NEWA
	+!	EQ 1GM BASE/200ML	N211962	002	Feb 15, 2019	Feb NEWA
	+!	EQ 1.5GM BASE/300ML	N211962	003	Feb 15, 2019	Feb NEWA
	+!	EQ 2GM BASE/400ML	N211962	004	Feb 15, 2019	Feb NEWA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL  
VARDENAFIL HYDROCHLORIDE

	@ AMNEAL PHARMS CO	5MG	A210738	001	Oct 31, 2018	Apr DISC
	@	10MG	A210738	002	Oct 31, 2018	Apr DISC
	@	20MG	A210738	003	Oct 31, 2018	Apr DISC
>A> AB	MACLEODS PHARMS LTD	2.5MG	A204632	001	Oct 22, 2019	Oct NEWA
>A> AB		5MG	A204632	002	Oct 22, 2019	Oct NEWA
>A> AB		10MG	A204632	003	Oct 22, 2019	Oct NEWA
>A> AB		20MG	A204632	004	Oct 22, 2019	Oct NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS  
VASOSTRICT

	+! PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Mar CDFR
	+!	200UNITS/10ML (20UNITS/ML)	N204485	002	Dec 17, 2016	Mar CDFR

VECURONIUM BROMIDE

INJECTABLE; INJECTION  
VECURONIUM BROMIDE

AP	HIKMA	10MG/VIAL	A203725	001	Jul 30, 2019	Jul NEWA
AP		20MG/VIAL	A203725	002	Jul 30, 2019	Jul NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
VENLAFAXINE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 37.5MG BASE	A212277	001	Jul 08, 2019	Jun NEWA
AB		EQ 75MG BASE	A212277	002	Jul 08, 2019	Jun NEWA
AB		EQ 150MG BASE	A212277	003	Jul 08, 2019	Jun NEWA

TABLET; ORAL  
VENLAFAXINE HYDROCHLORIDE

>D> AB	PRINSTON INC	EQ 25MG BASE	A090027	001	Aug 04, 2010	Oct DISC
>A>	@	EQ 25MG BASE	A090027	001	Aug 04, 2010	Oct DISC
>D> AB		EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Oct DISC
>A>	@	EQ 37.5MG BASE	A090027	002	Aug 04, 2010	Oct DISC
>D> AB		EQ 50MG BASE	A090027	003	Aug 04, 2010	Oct DISC
>A>	@	EQ 50MG BASE	A090027	003	Aug 04, 2010	Oct DISC
>D> AB		EQ 75MG BASE	A090027	004	Aug 04, 2010	Oct DISC
>A>	@	EQ 75MG BASE	A090027	004	Aug 04, 2010	Oct DISC
>D> AB		EQ 100MG BASE	A090027	005	Aug 04, 2010	Oct DISC
>A>	@	EQ 100MG BASE	A090027	005	Aug 04, 2010	Oct DISC

TABLET, EXTENDED RELEASE; ORAL  
VENLAFAXINE HYDROCHLORIDE

AB	CADILA PHARMS LTD	EQ 75MG BASE	A211323	001	Aug 29, 2019	Aug NEWA
AB		EQ 150MG BASE	A211323	002	Aug 29, 2019	Aug NEWA
AB		EQ 225MG BASE	A211323	003	Aug 29, 2019	Aug NEWA
>A> AB	DEXCEL PHARMA	EQ 150MG BASE	A209193	001	Oct 31, 2019	Oct NEWA
>A> AB		EQ 225MG BASE	A209193	002	Oct 31, 2019	Oct NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
VERAPAMIL HYDROCHLORIDE

	@ MYLAN	300MG	A078306	003	Aug 09, 2007	May DISC
	VERELAN PM					
	+! RECRO GAINESVILLE	300MG	N020943	003	Nov 25, 1998	May CTEC

SOLUTION; INTRAVENOUS  
VERAPAMIL HYDROCHLORIDE

>D> AP	ANDA REPOSITORY	5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Oct CAHN
AP		5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Sep CAHN
>D> AP		10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Oct CAHN
AP		10MG/4ML (2.5MG/ML)	A211035	002	Jun 18, 2018	Sep CAHN
>A> AP	SOMERSET	5MG/2ML (2.5MG/ML)	A211035	001	Jun 18, 2018	Oct CAHN

		SOLUTION; INTRAVENOUS																	
		VERAPAMIL HYDROCHLORIDE																	
>A>	AP		10MG/4ML (2.5MG/ML)			A211035	002	Jun 18, 2018	Oct	CAHN									
		TABLET; ORAL																	
		CALAN																	
		+ @ GD SEARLE LLC		80MG		N018817	001	Sep 10, 1984	May	DISC									
		VERAPAMIL HYDROCHLORIDE																	
AB	!	HERITAGE PHARMS INC	120MG			A071881	001	Apr 05, 1988	May	CHRS									
<u>VIGABATRIN</u>																			
		FOR SOLUTION; ORAL																	
		VIGADRONE																	
AA		AUCTA	500MG/PACKET			A210196	001	Jun 21, 2018	Jun	CAHN									
AA		SHANGHAI	500MG/PACKET			A210196	001	Jun 21, 2018	Mar	CAHN									
<u>VILAZODONE HYDROCHLORIDE</u>																			
		TABLET; ORAL																	
		VIIBRYD																	
AB	+	ALLERGAN	10MG			N022567	001	Jan 21, 2011	Sep	CFTG									
AB	+		20MG			N022567	002	Jan 21, 2011	Sep	CFTG									
AB	+		40MG			N022567	003	Jan 21, 2011	Sep	CFTG									
		VILAZODONE HYDROCHLORIDE																	
AB		TEVA PHARMS USA	10MG			A208212	001	Sep 30, 2019	Sep	NFTG									
AB			20MG			A208212	002	Sep 30, 2019	Sep	NFTG									
AB			40MG			A208212	003	Sep 30, 2019	Sep	NFTG									
<u>VINCRISTINE SULFATE</u>																			
		INJECTABLE; INJECTION																	
		VINCRISTINE SULFATE PFS																	
>D>	AP	!	HOSPIRA	1MG/ML		A071484	001	Apr 19, 1988	Oct	CTEC									
>A>		!		1MG/ML		A071484	001	Apr 19, 1988	Oct	CTEC									
>D>	AP		TEVA PHARMS USA	1MG/ML		A075493	001	Sep 01, 1999	Oct	DISC									
>A>		@		1MG/ML		A075493	001	Sep 01, 1999	Oct	DISC									
		INJECTABLE, LIPOSOMAL; INTRAVENOUS																	
		MARQIBO KIT																	
	+	!	ACROTECH	5MG/5ML (1MG/ML)		N202497	001	Aug 09, 2012	Mar	CAHN									
<u>VINORELBINE TARTRATE</u>																			
		INJECTABLE; INJECTION																	
		NAVELBINE																	
		+ @ PIERRE FABRE		EQ 10MG BASE/ML		N020388	001	Dec 23, 1994	Jun	DISC									
		VINORELBINE TARTRATE																	
AP		INGENUS PHARMS LLC	EQ 10MG BASE/ML			A208997	001	Aug 05, 2019	Jul	NEWA									
>D>	AP		NOVAST LABS	EQ 10MG BASE/ML		A208997	001	Aug 05, 2019	Oct	DISC									
>A>		@		EQ 10MG BASE/ML		A208997	001	Aug 05, 2019	Oct	DISC									
AP				EQ 10MG BASE/ML		A208997	001	Aug 05, 2019	Sep	CAHN									
<u>VORAPAXAR SULFATE</u>																			
		TABLET; ORAL																	
		ZONTIVITY																	
	+	!	TOPROL	EQ 2.08MG BASE		N204886	001	May 08, 2014	May	CAHN									
<u>VORICONAZOLE</u>																			
		INJECTABLE; INTRAVENOUS																	
		VFEND																	
AP	+	!	PF PRISM CV	200MG/VIAL		N021267	001	May 24, 2002	May	CDFR									
		VORICONAZOLE																	
AP		ALVOGEN	200MG/VIAL			A206398	001	Mar 23, 2016	Sep	CAHN									
AP		ALVOGEN INC	200MG/VIAL			A206398	001	Mar 23, 2016	May	CDFR									
AP		HAINAN POLY PHARM	200MG/VIAL			A211661	001	Nov 30, 2018	May	CDFR									
AP		SANDOZ INC	200MG/VIAL			A090862	001	May 30, 2012	May	CDFR									
AP		ZYDUS PHARMS	200MG/VIAL			A208983	001	Jul 16, 2018	May	CDFR									
		POWDER; INTRAVENOUS																	
		VORICONAZOLE																	
AP		XELLIA PHARMS APS	200MG/VIAL			N208562	001	Mar 09, 2017	May	CDFR									
		POWDER; IV (INFUSION)																	
		VORICONAZOLE																	
AP		XELLIA PHARMS APS	200MG/VIAL			N208562	001	Mar 09, 2017	Feb	CTEC									
		TABLET; ORAL																	
		VORICONAZOLE																	
AB		APPCO PHARMA LLC	50MG			A206762	001	May 24, 2016	Feb	CAHN									

TABLET;ORAL  
VORICONAZOLE

AB		200MG	A206762	002	May 24, 2016	Feb CAHN
AB	CADILA	50MG	A206747	001	May 24, 2016	Apr CAHN
AB		200MG	A206747	002	May 24, 2016	Apr CAHN

WARFARIN SODIUM

TABLET;ORAL  
JANTOVEN

AB	UPSHER SMITH LABS	1MG	A040416	001	Oct 02, 2003	Jul CAHN
AB		2MG	A040416	002	Oct 02, 2003	Jul CAHN
AB		2.5MG	A040416	003	Oct 02, 2003	Jul CAHN
AB		3MG	A040416	004	Oct 02, 2003	Jul CAHN
AB		4MG	A040416	005	Oct 02, 2003	Jul CAHN
AB		5MG	A040416	006	Oct 02, 2003	Jul CAHN
AB		6MG	A040416	007	Oct 02, 2003	Jul CAHN
AB		7.5MG	A040416	008	Oct 02, 2003	Jul CAHN
AB		10MG	A040416	009	Oct 02, 2003	Jul CAHN

XENON XE-133

GAS; INHALATION  
XENON XE 133  
CURIUM

	10mCi/VIAL	N018327	001	Mar 09, 1982	May CAHN
	20mCi/VIAL	N018327	002	Mar 09, 1982	May CAHN

ZIDOVUDINE

INJECTABLE; INJECTION  
ZIDOVUDINE

@ LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb DISC
------------	---------	---------	-----	--------------	----------

ZILEUTON

TABLET, EXTENDED RELEASE;ORAL  
ZILEUTON

>A> AB	LUPIN LTD	600MG	A211972	001	Nov 05, 2019	Oct NEWA
--------	-----------	-------	---------	-----	--------------	----------

ZINC SULFATE

SOLUTION; INTRAVENOUS  
ZINC SULFATE

>D>	+	AM REGENT	EQ 25MG BASE/5ML (EQ 5 BASE/ML)	N209377	002	Jul 18, 2019	Oct CMS1
>A>	+		EQ 25MG BASE/5ML (EQ 5MG BASE/ML)	N209377	002	Jul 18, 2019	Oct CMS1
	+		EQ 25MG BASE/5ML (EQ 5 BASE/ML)	N209377	002	Jul 18, 2019	Jul NEWA
	+		EQ 30MG BASE/10ML (EQ 3MG BASE/ML)	N209377	001	Jul 18, 2019	Jul NEWA

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL  
ZIPRASIDONE HYDROCHLORIDE

	@ CADILA	EQ 20MG BASE	A208988	001	Aug 22, 2017	Jun DISC
AB		EQ 20MG BASE	A208988	001	Aug 22, 2017	Feb CAHN
	@	EQ 40MG BASE	A208988	002	Aug 22, 2017	Jun DISC
AB		EQ 40MG BASE	A208988	002	Aug 22, 2017	Feb CAHN
	@	EQ 60MG BASE	A208988	003	Aug 22, 2017	Jun DISC
AB		EQ 60MG BASE	A208988	003	Aug 22, 2017	Feb CAHN
	@	EQ 80MG BASE	A208988	004	Aug 22, 2017	Jun DISC
AB		EQ 80MG BASE	A208988	004	Aug 22, 2017	Feb CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
RECLAST

AP	+	NOVARTIS	EQ 5MG BASE/100ML	N021817	001	Apr 16, 2007	Mar CDFR
		ZOLEDRONIC					
AP		GLAND PHARMA LTD	EQ 4MG BASE/100ML	A205749	001	Jun 29, 2018	Mar CDFR
		ZOLEDRONIC ACID					
AP		ACCORD HLTHCARE	EQ 4MG BASE/5ML	A205279	001	Nov 28, 2016	Mar CDFR
	@	ACTAVIS INC	EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Jul DISC
AP			EQ 4MG BASE/5ML	A202472	001	Mar 04, 2013	Mar CDFR
AP		AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Mar CDFR
AP		AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	Mar CDFR
AP		APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar CDFR
AP		AUROBINDO PHARMA LTD	EQ 4MG BASE/5ML	A207751	001	Sep 26, 2016	Mar CDFR
AP			EQ 5MG BASE/100ML	A209125	001	Dec 08, 2017	Mar CDFR
AP		BPI LABS LLC	EQ 4MG BASE/5ML	A207341	001	Dec 29, 2017	Mar CDFR
AP		BRECKENRIDGE	EQ 4MG BASE/5ML	A091170	001	Mar 04, 2013	Mar CDFR

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

AP		EQ 4MG BASE/5ML	A202571	001	May 07, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202163	001	Aug 05, 2013	Mar CDFR
AP	CIPLA	EQ 4MG BASE/100ML	A210174	001	Oct 27, 2017	Mar CDFR
AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	May CDFR
>D> AP		EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Oct DISC
>A>	@	EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Oct DISC
AP		EQ 4MG BASE/100ML	A204344	001	Nov 19, 2018	Mar CDFR
AP		EQ 5MG BASE/100ML	A091363	001	Mar 29, 2013	Mar CDFR
AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML	A201783	001	Mar 12, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A201801	001	Mar 29, 2013	Mar CDFR
AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Mar CDFR
AP	GLAND PHARMA LTD	EQ 4MG BASE/5ML	A202930	001	Aug 05, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A204217	001	Aug 18, 2016	Mar CDFR
AP		EQ 5MG BASE/100ML	A209578	001	Aug 08, 2019	Jul NEWA
AP	HIKMA FARMACEUTICA	EQ 4MG BASE/5ML	A202182	001	Jun 03, 2013	Mar CDFR
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar CDFR
AP		EQ 5MG BASE/100ML	A202837	001	Apr 05, 2013	Mar CDFR
AP	INFORLIFE	EQ 4MG BASE/100ML	N203231	001	Aug 02, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A202828	001	Sep 23, 2013	Mar CDFR
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Mar CDFR
AP		EQ 5MG BASE/100ML	A203841	001	Feb 14, 2017	Mar CDFR
AP		EQ 5MG BASE/100ML	A205254	001	Oct 27, 2017	Mar CDFR
AP	SAGENT PHARMS INC	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Mar CDFR
>D> AP	SHILPA MEDICARE LTD	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Oct DISC
>A>	@	EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Oct DISC
AP		EQ 4MG BASE/5ML	A208513	001	May 15, 2019	Apr NEWA
	@ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Mar CDFR
	@	EQ 4MG BASE/5ML	A202746	001	Mar 04, 2013	Mar CDFR
AP	USV	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Jun CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CDFR
	ZOMETA					
	+ @ NOVARTIS	EQ 4MG BASE/VIAL	N021223	001	Aug 20, 2001	Mar CDFR
AP	+	EQ 4MG BASE/5ML	N021223	002	Mar 07, 2003	Mar CDFR
AP	+	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Mar CDFR

INJECTABLE; IV (INFUSION)  
ZOLEDRONIC ACID

AP	DR REDDYS LABS LTD	EQ 4MG BASE/5ML	A091186	001	Mar 04, 2013	Mar CDFR
----	--------------------	-----------------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS  
ZOLEDRONIC ACID

	HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Mar CDFR
--	-------------	---------------------------------------	---------	-----	--------------	----------

ZOLMITRIPTAN

## TABLET; ORAL

## ZOLMITRIPTAN

>D> AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Oct DISC
>A>	@	2.5MG	A203772	001	Sep 30, 2015	Oct DISC
>D> AB		5MG	A203772	002	Sep 30, 2015	Oct DISC
>A>	@	5MG	A203772	002	Sep 30, 2015	Oct DISC
>A> AB	ORCHID HLTHCARE	2.5MG	A203726	001	Oct 21, 2019	Oct NEWA
>A> AB		5MG	A203726	002	Oct 21, 2019	Oct NEWA

## TABLET, ORALLY DISINTEGRATING; ORAL

## ZOLMITRIPTAN

>D> AB	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct DISC
>A>	@	2.5MG	A204336	001	Oct 22, 2015	Oct DISC
>D> AB		5MG	A204336	002	Oct 22, 2015	Oct DISC
>A>	@	5MG	A204336	002	Oct 22, 2015	Oct DISC
AB	MYLAN	2.5MG	A202855	001	Sep 20, 2019	Sep NEWA
AB		5MG	A202855	002	Sep 20, 2019	Sep NEWA

ZOLPIDEM TARTRATE

## SPRAY, METERED; ORAL

## ZOLPIMIST

+	AYTU	5MG/SPRAY	N022196	001	Dec 19, 2008	Feb CAHN
---	------	-----------	---------	-----	--------------	----------

## TABLET; ORAL

## ZOLPIDEM TARTRATE

	@ STRIDES PHARMA	5MG	A076062	001	Apr 23, 2007	Apr CAHN
	@	10MG	A076062	002	Apr 23, 2007	Apr CAHN
>D> AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Oct DISC
>A>	@	5MG	A077359	001	Apr 23, 2007	Oct DISC
>D> AB		10MG	A077359	002	Apr 23, 2007	Oct DISC

TABLET;ORAL							
ZOLPIDEM TARTRATE							
>A>	@	10MG	A077359	002	Apr 23, 2007	Oct	DISC
	@ WOCKHARDT	5MG	A078426	001	May 15, 2007	Aug	DISC
	@	10MG	A078426	002	May 15, 2007	Aug	DISC
TABLET;SUBLINGUAL							
ZOLPIDEM TARTRATE							
AB	! NOVEL LABS INC	3.5MG	A204299	002	Jun 03, 2015	Mar	CHRS
<u>ZONISAMIDE</u>							
CAPSULE;ORAL							
ZONISAMIDE							
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Apr	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Apr	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Apr	CAHN
AB	CELLTRION	25MG	A077636	003	Jul 27, 2006	Aug	CAHN
AB		50MG	A077636	002	Jul 27, 2006	Aug	CAHN
AB		100MG	A077636	001	Dec 22, 2005	Aug	CAHN

ACETAMINOPHEN

## SUPPOSITORY;RECTAL

## ACEPHEN

ACP NIMBLE	120MG	N018060	001		Feb CAHN
@	325MG	N018060	003	Dec 18, 1986	Feb CAHN
@	650MG	N018060	002		Feb CAHN

## TABLET, EXTENDED RELEASE;ORAL

## ACETAMINOPHEN

GRANULES INDIA LTD	650MG	A211544	001	Apr 16, 2019	Apr NEWA
HERITAGE PHARMA	650MG	A207035	001	May 31, 2018	Sep CMFD
@	650MG	A207035	001	May 31, 2018	Mar DISC

ADAPALENE

## GEL;TOPICAL

## ADAPALENE

GLENMARK GENERICS	0.1%	A091314	002	Jul 09, 2019	Jul NEWA
-------------------	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

## SOLUTION;ORAL

## CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

QUAGEN	5MG/5ML	A212266	001	May 16, 2019	May NEWA
--------	---------	---------	-----	--------------	----------

## SYRUP;ORAL

## CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

ATHEM	5MG/5ML	A091327	001	Oct 17, 2011	Sep CAHN
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb NEWA
TORRENT	5MG/5ML	A090474	002	Mar 30, 2009	Jan CAHN

## CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

ATHEM	5MG/5ML	A091327	002	Oct 17, 2011	Sep CAHN
TORRENT	5MG/5ML	A090474	001	Mar 30, 2009	Jan CAHN

## TABLET;ORAL

## CETIRIZINE HYDROCHLORIDE ALLERGY

@ HERITAGE PHARMA	5MG	A078615	003	Dec 28, 2007	May CAHN
@	10MG	A078615	004	Dec 28, 2007	May CAHN
>D> SUN PHARM INDS INC	5MG	A077499	001	Dec 27, 2007	Oct DISC
>A> @	5MG	A077499	001	Dec 27, 2007	Oct DISC
>D>	10MG	A077499	002	Dec 27, 2007	Oct DISC
>A> @	10MG	A077499	002	Dec 27, 2007	Oct DISC

## CETIRIZINE HYDROCHLORIDE HIVES

>D> SUN PHARM INDS INC	5MG	A077499	003	Dec 27, 2007	Oct DISC
>A> @	5MG	A077499	003	Dec 27, 2007	Oct DISC
>D>	10MG	A077499	004	Dec 27, 2007	Oct DISC
>A> @	10MG	A077499	004	Dec 27, 2007	Oct DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

@ PERRIGO R AND D	5MG;120MG	A210719	001	Nov 16, 2018	May DISC
-------------------	-----------	---------	-----	--------------	----------

CHLORHEXIDINE GLUCONATE

## SOLUTION;TOPICAL

## CHLORHEXIDINE GLUCONATE

BAJAJ	0.75%	N020111	001	Sep 11, 1997	Apr CTNA
	0.75%	N020111	001	Sep 11, 1997	Jan CMFD

CHLORPHENIRAMINE MALEATE

## TABLET, EXTENDED RELEASE;ORAL

## CHLORPHENIRAMINE MALEATE

! AVANTHI INC	12MG	A040829	001	May 13, 2009	Jan CHRS
---------------	------	---------	-----	--------------	----------

CLOTRIMAZOLE

## CREAM;VAGINAL

## CLOTRIMAZOLE

! P AND L	1%	A074165	001	Jul 16, 1993	Aug CAHN
-----------	----	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

AUROBINDO PHARMA LTD 25MG;EQ 200MG FREE ACID AND  
POTASSIUM SALT

A210676 001 Feb 14, 2019 Jan NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE

@ ACTAVIS ELIZABETH 25MG;220MG

A207597 001 Jan 25, 2019 Jul DISC

25MG;220MG

A207597 001 Jan 25, 2019 Jan NEWA

APOTEX 25MG;220MG

A211830 001 Aug 22, 2019 Aug NEWA

@ P AND L 25MG;220MG

A207597 001 Jan 25, 2019 Aug CAHN

PERRIGO R AND D 25MG;220MG

A208499 001 May 10, 2019 Apr NEWA

DOCOSANOL

CREAM; TOPICAL

DOCOSANOL

P AND L 10%

A208754 001 Nov 19, 2018 Aug CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AMNEAL PHARMS NY EQ 20MG BASE

A209716 001 Jun 05, 2019 May NEWA

MYLAN EQ 20MG BASE

A212376 001 Oct 16, 2019 Sep NEWA

TABLET, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

@ ACTAVIS ELIZABETH EQ 20MG BASE

A209202 001 Mar 05, 2019 Apr DISC

EQ 20MG BASE

A209202 001 Mar 05, 2019 Feb NEWA

@ P AND L EQ 20MG BASE

A209202 001 Mar 05, 2019 Aug CAHN

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

P AND L 10MG

A075512 001 Jul 26, 2001 Aug CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

P AND L 30MG/5ML

A203330 001 Nov 18, 2014 Aug CAHN

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

! P AND L 30MG/5ML

A203330 002 Nov 18, 2014 Aug CAHN

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

@ MYLAN 30MG

A077081 004 Jul 21, 2011 Jul DISC

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

@ MYLAN 30MG

A077081 005 Jul 21, 2011 Jul DISC

FEXOFENADINE HYDROCHLORIDE ALLERGY

&gt;A&gt; GRANULES INDIA LTD 60MG

A211075 001 Oct 18, 2019 Oct NEWA

&gt;A&gt; 180MG

A211075 002 Oct 18, 2019 Oct NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLUTICASONE PROPIONATE

HI TECH 0.05MG/SPRAY

A208024 001 Apr 17, 2019 Apr NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

&gt;A&gt; AUROBINDO PHARMA LTD 600MG

A210453 001 Oct 21, 2019 Oct NEWA

&gt;A&gt; 1.2GM

A210453 002 Oct 21, 2019 Oct NEWA

@ OHM LABS INC 600MG

A209254 001 Jul 16, 2018 Mar DISC

@ 1.2GM

A209254 002 Jul 16, 2018 Mar DISC

IBUPROFEN

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

@ MOBERG PHARMA NORTH 100MG/5ML

N021604 001 Jan 07, 2004 Sep DISC

IBUPROFEN

@ GUARDIAN DRUG 100MG/5ML

A210149 001 Aug 17, 2018 Feb DISC

P AND L 100MG/5ML

A074916 001 Apr 30, 1999 Aug CAHN

SUSPENSION/DROPS;ORAL  
INFANT'S ADVIL

+!	PFIZER	50MG/1.25ML	N020812	002	Jan 12, 2000	Aug	NEWA
	PEDIATRIC ADVIL						
+ @	PFIZER	100MG/2.5ML	N020812	001	Jan 30, 1998	Aug	DISC
	TABLET;ORAL						
	IBUPROFEN						
!	PERRIGO R AND D	200MG	A077349	001	Jun 21, 2005	Jun	CHRS
	IBUPROHM						
>D>	OHM LABS	200MG	A071214	001	Dec 01, 1986	Oct	DISC
>A>	@	200MG	A071214	001	Dec 01, 1986	Oct	DISC
	MOTRIN IB						
+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	May	CHRS

ISOPROPYL ALCOHOLSOLUTION;TOPICAL  
ZURAGARD

+	@ ZUREX PHARMA	70% (10.5ML)	N210872	001	Apr 26, 2019	Sep	DISC
+	!	70% (10.5ML)	N210872	001	Apr 26, 2019	May	CMS2

KETOCONAZOLESHAMPOO;TOPICAL  
NIZORAL A-D

+	!	KRAMER	1%	N020310	001	Oct 10, 1997	Jan	CAHN
---	---	--------	----	---------	-----	--------------	-----	------

KETOTIFEN FUMARATESOLUTION/DROPS;OPHTHALMIC  
KETOTIFEN FUMARATE

>D>	@	APOTEX INC	EQ 0.025% BASE	A077354	001	May 09, 2006	Oct	CMFD
>A>			EQ 0.025% BASE	A077354	001	May 09, 2006	Oct	CMFD
		ZADITOR						
!		ALCON PHARMS LTD	EQ 0.025% BASE	A077200	001	Sep 02, 2008	Feb	CTNA

LEVOCETIRIZINE DIHYDROCHLORIDETABLET;ORAL  
LEVOCETIRIZINE DIHYDROCHLORIDE  
PERRIGO R AND D

		5MG	A211983	001	Mar 28, 2019	Jul	CMS1
		5MG	A211983	001	Mar 26, 2019	Mar	NEWA

LEVONORGESTRELTABLET;ORAL  
LEVONORGESTREL

		ACCORD HLTHCARE	1.5MG	A207660	001	May 02, 2019	Apr	NEWA
		ALVOGEN	1.5MG	A202246	001	Jun 05, 2015	Jul	CAHN
	@	APOTEX	1.5MG	A205329	001	Sep 18, 2018	Jan	DISC
	@	FDN CONSUMER	1.5MG	A200670	001	Jul 12, 2012	Jun	DISC
!		L PERRIGO CO	0.75MG	A090740	001	Dec 30, 2010	May	CAHN
		NAARI PTE LTD	1.5MG	A202380	001	May 29, 2015	Sep	CAHN

LORATADINECAPSULE;ORAL  
LORATADINE

	@	BIONPHARMA INC	10MG	A202538	001	Dec 21, 2018	Mar	DISC
--	---	----------------	------	---------	-----	--------------	-----	------

TABLET;ORAL  
LORATADINE

		GUARDIAN DRUG	10MG	A207569	001	Mar 12, 2019	Mar	CAHN
		NEWGEN PHARMS LLC	10MG	A207569	001	Mar 12, 2019	Feb	NEWA

TABLET, CHEWABLE;ORAL  
LORATADINE

		PERRIGO PHARMA INTL	5MG	A210033	001	Jun 12, 2019	May	NEWA
		SUN PHARM	5MG	A210088	001	Apr 16, 2018	Mar	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATETABLET, EXTENDED RELEASE;ORAL  
LORATADINE AND PSEUDOEPHEDRINE SULFATE

	@	HERITAGE PHARMA	5MG;120MG	A076208	001	Jan 28, 2004	May	CAHN
		P AND L	10MG;240MG	A075706	001	Feb 21, 2003	Aug	CAHN

MICONAZOLE NITRATECREAM;VAGINAL  
MICONAZOLE 7

P AND L	2%	A074164	001	Mar 29, 1996	Aug CAHN
---------	----	---------	-----	--------------	----------

CREAM, SUPPOSITORY;TOPICAL, VAGINAL  
M-ZOLE 3 COMBINATION PACK

P AND L	2%,200MG	A074926	001	Apr 16, 1999	Aug CAHN
---------	----------	---------	-----	--------------	----------

SUPPOSITORY;VAGINAL  
MICONAZOLE NITRATE

P AND L	100MG	A073507	001	Nov 19, 1993	Aug CAHN
---------	-------	---------	-----	--------------	----------

MINOXIDILAEROSOL, FOAM;TOPICAL  
MINOXIDIL (FOR MEN)

P AND L	5%	A208092	001	Feb 17, 2017	Aug CAHN
---------	----	---------	-----	--------------	----------

MINOXIDIL (FOR WOMEN)

P AND L	5%	A208092	002	Jul 27, 2017	Aug CAHN
TARO	5%	A209074	002	Apr 22, 2019	Apr NEWA

SOLUTION;TOPICAL

MINOXIDIL (FOR MEN)

P AND L	2%	A074588	001	Apr 05, 1996	Aug CAHN
---------	----	---------	-----	--------------	----------

MINOXIDIL EXTRA STRENGTH (FOR MEN)

P AND L	5%	A075518	001	Nov 17, 2000	Aug CAHN
---------	----	---------	-----	--------------	----------

NAPROXEN SODIUMCAPSULE;ORAL  
NAPROXEN SODIUM

@ CATALENT	EQ 200MG BASE	A202807	001	Jan 04, 2019	Jul DISC
------------	---------------	---------	-----	--------------	----------

TABLET;ORAL

ALEVE

+! BAYER	220MG	N020204	002	Jan 11, 1994	Sep CPOT
----------	-------	---------	-----	--------------	----------

NAPROXEN SODIUM

AMNEAL PHARMS NY	220MG	A079096	001	Dec 16, 2008	Sep CPOT
AUROBINDO PHARMA LTD	220MG	A205497	001	Mar 18, 2016	Sep CPOT
CONTRACT PHARMACAL	220MG	A074635	001	Jan 13, 1997	Sep CPOT
@	220MG	A074789	001	Feb 27, 1997	Sep CPOT
DR REDDYS LABS INC	220MG	A075168	001	Jul 28, 1998	Sep CPOT
GRANULES INDIA	220MG	A091353	001	Sep 20, 2011	Sep CPOT
LNK INTL INC	220MG	A204872	001	Jan 23, 2017	Sep CPOT
MARKSANS PHARMA	220MG	A090545	001	Mar 16, 2011	Sep CPOT
NOVELGENIX THERAPS	220MG	A207612	001	Nov 16, 2018	Sep CPOT
PERRIGO	220MG	A074661	001	Jan 13, 1997	Sep CPOT
@ PLD ACQUISITIONS LLC	220MG	A074646	001	Jan 13, 1997	Sep CPOT
SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011	Sep CPOT
YICHANG HUMANWELL	EQ 200MG BASE	A212033	001	Aug 30, 2019	Aug NEWA
	220MG	A212033	001	Aug 30, 2019	Sep CPOT

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALEVE-D SINUS &amp; COLD

+! BAYER	EQ 200MG BASE;120MG	N021076	001	Nov 29, 1999	Mar CPOT
+!	220MG;120MG	N021076	001	Nov 29, 1999	Sep CPOT

NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS INC	220MG;120MG	A077381	001	Sep 27, 2006	Sep CPOT
PERRIGO	220MG;120MG	A076518	001	Mar 17, 2004	Sep CPOT

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

P AND L	EQ 2MG BASE	A074507	001	Mar 15, 1999	Aug CAHN
	EQ 2MG BASE	A076569	001	Jul 29, 2004	Aug CAHN
	EQ 2MG BASE	A078699	001	Dec 29, 2008	Aug CAHN
	EQ 2MG BASE	A079044	001	Jul 08, 2009	Aug CAHN
	EQ 2MG BASE	A079216	001	Jul 08, 2009	Aug CAHN
	EQ 2MG BASE	A204794	001	May 10, 2016	Aug CAHN
	EQ 4MG BASE	A074707	001	Mar 19, 1999	Aug CAHN
	EQ 4MG BASE	A076568	002	Jul 29, 2004	Aug CAHN
	EQ 4MG BASE	A078697	001	Dec 29, 2008	Aug CAHN
	EQ 4MG BASE	A079038	001	Jul 08, 2009	Aug CAHN
	EQ 4MG BASE	A079219	001	Jul 08, 2009	Aug CAHN
	EQ 4MG BASE	A204833	001	Feb 26, 2016	Aug CAHN

TROPHE/LOZENGE;ORAL  
NICOTINE POLACRILEX

>A>	P AND L	EQ 2MG BASE	A208875	001	Oct 31, 2019	Oct NEWA
	@	EQ 2MG BASE	A209206	001	Jun 26, 2018	Aug CAHN
	@	EQ 2MG BASE	A209519	001	Jul 02, 2018	Aug CAHN
>A>		EQ 2MG BASE	A209520	001	Oct 31, 2019	Oct NEWA
>A>		EQ 2MG BASE	A210711	001	Oct 31, 2019	Oct NEWA
		EQ 2MG BASE	A210712	001	Sep 06, 2019	Aug NEWA
		EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul CAHN
>A>		EQ 4MG BASE	A208875	002	Oct 31, 2019	Oct NEWA
	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Aug CAHN
	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Aug CAHN
>A>		EQ 4MG BASE	A209520	002	Oct 31, 2019	Oct NEWA
>A>		EQ 4MG BASE	A210711	002	Oct 31, 2019	Oct NEWA
		EQ 4MG BASE	A210712	002	Sep 06, 2019	Aug NEWA
		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul CAHN
	PLD ACQUISITIONS	EQ 2MG BASE	A207868	001	Feb 07, 2019	Feb NEWA
		EQ 4MG BASE	A207868	002	Feb 07, 2019	Feb NEWA
	TEVA PHARMS USA INC	EQ 2MG BASE	A212056	001	Jul 26, 2019	Jul NEWA
		EQ 4MG BASE	A212056	002	Jul 26, 2019	Jul NEWA
	@ WATSON LABS INC	EQ 2MG BASE	A209206	001	Jun 26, 2018	Feb DISC
	@	EQ 4MG BASE	A209206	002	Jun 26, 2018	Feb DISC
	@ WATSON LABS TEVA	EQ 2MG BASE	A209519	001	Jul 02, 2018	Feb DISC
	@	EQ 4MG BASE	A209519	002	Jul 02, 2018	Feb DISC

OMEPRAZOLETABLET, DELAYED RELEASE;ORAL  
OMEPRAZOLE

@ APOTEX	20MG	A210070	001	Feb 11, 2019	Aug DISC
APOTEX INC	20MG	A210070	001	Feb 11, 2019	Apr CTEC

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL  
GLYCOLAX

@ LANNETT CO INC	17GM/PACKET	A090600	001	Oct 06, 2009	Jun DISC
@	17GM/SCOOPFUL	A090600	002	Oct 06, 2009	Jun DISC
POLYETHYLENE GLYCOL 3350					
NOVELGENIX THERAPS	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Sep CAHN

RANITIDINE HYDROCHLORIDE

## TABLET;ORAL

## RANITIDINE HYDROCHLORIDE

>D>	ANI PHARMS INC	EQ 75MG BASE	A075296	001	Jan 14, 2000	Oct DISC
>A>	@	EQ 75MG BASE	A075296	001	Jan 14, 2000	Oct DISC
>D>	MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Oct DISC
>A>	@	EQ 75MG BASE	A075497	001	Jan 14, 2000	Oct DISC
	STRIDES PHARMA	EQ 75MG BASE	A209160	001	Mar 05, 2018	Apr CAHN
		EQ 150MG BASE	A209161	001	Feb 22, 2018	Apr CAHN
	UNIQUE PHARM LABS	EQ 75MG BASE	A210250	001	Aug 30, 2019	Aug NEWA
		EQ 150MG BASE	A210228	001	Aug 30, 2019	Aug NEWA

SODIUM FLUORIDE; TRICLOSANPASTE;DENTAL  
COLGATE TOTAL

+ @ COLGATE PALMOLIVE	0.24%;0.3%	N020231	001	Jul 11, 1997	Mar DISC
-----------------------	------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2019**

NO OCTOBER 2019 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2019 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABIRATERONE ACETATE - ABIRATERONE ACETATE</u>						
A 208327 001					PC	Apr 29, 2019
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 002	8822438	Aug 24, 2027	U-1579	Y		
	8822438	Aug 24, 2027	U-1580	Y		
	8822438	Aug 24, 2027	U-2235	Y		
<u>ABIRATERONE ACETATE - YONSA</u>						
N 210308 001	10292990	May 20, 2034	U-2535			
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145			
	10272083	Jan 21, 2035	U-2519			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	10383834	Nov 13, 2028	U-2262			
	10383834	Nov 13, 2028	U-2621			
<u>ACETAMINOPHEN - ACETAMINOPHEN</u>						
N 204767 001	8741959	Apr 19, 2030	DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 002	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE - APADAZ</u>						
N 208653 003	8461137	Feb 22, 2031	DS DP			
	8748413	Jul 10, 2030	DS DP			
	8828978	Jul 01, 2030	DP			
	9132125	Jul 01, 2030	DS DP U-2249			
	9549923	Jul 01, 2030	DS DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	10034867	Jul 07, 2020	DP U-2513			
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	7078412	Jul 07, 2020	DS DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</u>						
N 210595 001	10034867	Jul 07, 2020	DP U-2513		NC	Mar 29, 2022
	10034867	Jul 07, 2020	DP U-2514			
	10085974	Mar 13, 2029	DP U-2513			
	6681768	Aug 07, 2022	DP			
	7078412	Jul 07, 2020	DS DP U-2513			
	7750023	Jul 07, 2020	DP U-2513			
	8051851	Apr 22, 2027	DP			
	8129405	Jul 07, 2020	DP U-2513			
	9056100	Jul 07, 2020	DP U-2513			
	9333195	Jul 07, 2020	DP U-2513			
	RE46417	Feb 10, 2025	DS DP U-2513			
<u>ACYCLOVIR - AVACLYR</u>						
N 202408 001					ODE-235	Mar 29, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AFAMELANOTIDE - SCENESSE</u>						
N 210797 001					>A> NCE	Oct 08, 2024
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 001					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 002					ODE-230	Jan 12, 2025
<u>AFATINIB DIMALEATE - GILOTRIF</u>						
N 201292 003					ODE-230	Jan 12, 2025
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	10124131	May 18, 2031	DP			
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 001	10183012	Nov 26, 2028	U-2104			
<u>ALLOPURINOL; LESINURAD - DUZALLO</u>						
N 209203 002	10183012	Nov 26, 2028	U-2104			
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Sep 28, 2030	DS DP U-2539		NCE	May 24, 2024
	8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	10213393	Feb 15, 2038	U-20			
	10213394	Feb 15, 2038	U-2497			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMIFAMPRIDINE - RUZURGI</u>						
N 209321 001					ODE-244	May 06, 2026
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	10251900	May 15, 2035	U-2414		ODE-214 GAIN	Sep 28, 2025 Sep 28, 2030
<u>AMINOCAPROIC ACID - AMINOCAPROIC ACID</u>						
A 212780 001					CGT	Feb 26, 2020
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-804			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10350171	Jun 14, 2038	DP			
	9662315	May 22, 2029	DP U-2410			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 001	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			
<u>ANGIOTENSIN II ACETATE - GIAPREZA</u>						
N 209360 002	10335451	Dec 16, 2029	U-2581			
	9572856	Nov 20, 2030	U-2221			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	8445507	Sep 15, 2030	DS DP U-2237		I-808	Sep 17, 2022
	8445507	Sep 15, 2030	DS DP U-2624			
	8802689	Mar 27, 2027	U-2237			
	8802689	Mar 27, 2027	U-2624			
	9481663	Jun 04, 2033	DS DP U-2237			
	9481663	Jun 04, 2033	DS DP U-2624			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					I-803 ODE-248	Jul 19, 2022 Jul 19, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437	002				I-803 ODE-248	Jul 19, 2022 Jul 19, 2026
<u>APREMILAST - OTEZLA</u>						
N 205437	003				I-803 ODE-248	Jul 19, 2022 Jul 19, 2026
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	001 >A>	10441194 8114021	May 12, 2029 Jun 21, 2030	DP DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	002 >A>	10441194 8114021	May 12, 2029 Jun 21, 2030	DP DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	003 >A>	10441194 8114021	May 12, 2029 Jun 21, 2030	DP DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	004 >A>	10441194 8114021	May 12, 2029 Jun 21, 2030	DP DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	005 >A>	10441194 8114021	May 12, 2029 Jun 21, 2030	DP DP		
<u>ARIPIPRAZOLE - ABILIFY MYCITE KIT</u>						
N 207202	006 >A>	10441194 8114021	May 12, 2029 Jun 21, 2030	DP DP		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	001	10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	002	10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	003	10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402		
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533	004	10226458 10238651	Mar 19, 2032 Mar 19, 2035	U-543 U-2402		
<u>ASENAPINE - SECUADO</u>						
N 212268	001 >A>	10022445 >A> 9687474	Jul 25, 2033 Jul 25, 2033	DP DP	>A> NP	Oct 11, 2022
<u>ASENAPINE - SECUADO</u>						
N 212268	002 >A>	10022445 >A> 9687474	Jul 25, 2033 Jul 25, 2033	DP DP	>A> NP	Oct 11, 2022
<u>ASENAPINE - SECUADO</u>						
N 212268	003 >A>	10022445 >A> 9687474	Jul 25, 2033 Jul 25, 2033	DP DP	>A> NP	Oct 11, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	8338429	Jun 30, 2023	U-2577		I-802	Jun 26, 2022
	8765764	Jan 15, 2023	U-2314		ODE-246	Jun 26, 2026
	8765764	Jan 15, 2023	U-2578			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-2244			
	7112592	Feb 24, 2022	DS DP U-2508			
	7112592	Feb 24, 2022	DS DP U-282			
	8178554	Jul 24, 2021	DS DP U-2245			
	8178554	Jul 24, 2021	DS DP U-2509			
	8178554	Jul 24, 2021	DS DP U-282			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	10322085	Oct 24, 2023	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9387249	Jul 01, 2031	U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9387249	Jul 01, 2031	U-3			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001	10392406	Apr 27, 2036	DS		>A> I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002	10392406	Apr 27, 2036	DS		>A> I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	6479535	May 06, 2024	DP U-594			
	6479535	May 06, 2024	DP U-904			
<u>BECLOMETHASONE DIPROPIONATE - ONASI</u>						
N 202813 001	10188811	Oct 21, 2031	DP			
<u>BECLOMETHASONE DIPROPIONATE - ONASI</u>						
N 202813 002	10188811	Oct 21, 2031	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001					NPP ODE-251	Aug 09, 2022 Aug 09, 2026
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE</u>						
A 205128 001					PC	Aug 18, 2019
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	10220049	Jun 03, 2029	DP U-916			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002	10220049	Jun 03, 2029	DP U-916			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	10179137	Aug 31, 2030	DP U-1858			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-1761		NPP	Jul 25, 2022
	6753013	Jan 27, 2020	DP U-193		PED	Jan 25, 2023
	6753013	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-193			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - TACLONEX</u>						
N 022185 001	6787529	Jan 27, 2020	DP U-88			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	10130640	Jun 10, 2031	DP		NPP	Jul 30, 2022
	10130640*PED	Dec 10, 2031			PED	Jan 30, 2023
	6753013	Jan 27, 2020	DP U-1761			
	6753013	Jan 27, 2020	DP U-2627			
	9119781	Jun 10, 2031	DP U-1761			
	9119781	Jun 10, 2031	DP U-2627			
	9119781*PED	Dec 10, 2031				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	10385067	Jun 19, 2035	U-257		NPP	Jun 18, 2022
					ODE-256	Jun 18, 2026
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N 203341 003	7417148	Dec 11, 2025	U-1283			
<u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u>						
N 210557 001	10286034	Nov 05, 2033	U-2568		NCE	Jun 21, 2024
	6579968	Jun 28, 2020	DS DP			
	6794489	Jun 28, 2020	DS DP			
	9352013	Nov 05, 2033	U-2568			
	9700592	Nov 05, 2033	U-2568			
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10117951	Mar 13, 2029	DP		NCE	Jun 17, 2024
	10251894	Nov 27, 2033	U-2552			
	10322139	Jan 23, 2033	DP			
	7635773	Mar 13, 2029	DP			
	8410077	Mar 13, 2029	DP			
	9200088	Mar 13, 2029	DP			
	9750822	Mar 13, 2029	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	10307419	Oct 12, 2032	DP			
	7888362	Apr 12, 2026	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Apr 12, 2026	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 001	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 002	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIGATINIB - ALUNBRIG</u>						
N 208772 003	10385078	Nov 10, 2035	DS DP U-1927			
	9012462	Jul 31, 2030	DS			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	10307368	Jul 10, 2021	DP			
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	10201517	Jun 13, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	10307375	Sep 07, 2031	DP			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 001	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE - ORTIKOS</u>						
N 211929 002	10172802	Sep 09, 2036	U-2554			
	9707182	Sep 09, 2036	DP U-2554			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	10166247	Jan 29, 2023	DP U-2001			
	10166247	Jan 29, 2023	DP U-2002			
	10166247	Jan 29, 2023	DP U-2122			
	10166247*PED	Jul 29, 2023				
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002	10198218	Jun 06, 2031	U-2489			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 001	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 002	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 003	10285910	Oct 11, 2022	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N 022410 004	10285910	Oct 11, 2022	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	10231964	Jul 02, 2034	U-1583			
	10307376	Nov 08, 2027	U-1585			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	8927592	Oct 27, 2030	U-1630			
	8927592*PED	Apr 27, 2031				
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	10034873	Jul 18, 2031	U-2488		I-792	Jan 14, 2022
	8497284	Sep 24, 2024	U-1220		ODE-227	Jan 14, 2026
	8497284	Sep 24, 2024	U-1480			
	8497284	Sep 24, 2024	U-2488			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	10213442	Feb 02, 2027	DP			
	10300078	Mar 14, 2034	DP			
	10357502	Mar 14, 2034	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 001	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE</u>						
N 210906 002	10130646	Jul 25, 2037	DP			
	10342813	Jul 25, 2037	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001	7943582	Feb 26, 2029	DS DP U-2441		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002	7943582	Feb 26, 2029	DS DP U-2441		I-809	Sep 27, 2022
	7943582	Feb 26, 2029	DS DP U-2632			
	7943582	Feb 26, 2029	DS DP U-493			
	8222219	Apr 11, 2025	U-2441			
	8222219	Apr 11, 2025	U-2632			
	8222219	Apr 11, 2025	U-493			
	>A> 8513202	Dec 03, 2027	DS DP U-2441			
	>A> 8513202	Dec 03, 2027	DS DP U-2632			
	>A> 8513202	Dec 03, 2027	DS DP U-493			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10195159	May 07, 2022	DS			
<u>CARBOPROST TROMETHAMINE - CARBOPROST TROMETHAMINE</u>						
A 211941 001					CGT	Dec 29, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
	RE47350	Jul 16, 2029	U-1750			
	RE47350	Jul 16, 2029	U-2543			
	RE47350	Jul 16, 2029	U-2544			
	RE47350	Jul 16, 2029	U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
	7737142	Mar 27, 2027	DS DP U-2545			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		I-798	May 24, 2022
	7737142	Mar 27, 2027	DS DP U-2543			
	7737142	Mar 27, 2027	DS DP U-2544			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10028963	Sep 07, 2032	U-2565			
	10028963	Sep 07, 2032	U-2566			
	10376496	Sep 09, 2034	U-2610			
	10376496	Sep 09, 2034	U-2611			
>A>	10420841	Mar 14, 2034	U-1672			
>A>	10420841	Mar 14, 2034	U-2631			
	9724353	Sep 07, 2032	U-2565			
	9724353	Sep 07, 2032	U-2566			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP			
	7964592	Jan 13, 2027	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8188276	Jan 31, 2023	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8399450	Nov 20, 2027	DS DP			
	8703787	Feb 02, 2032	U-1179			
	8835430	Jan 31, 2023	DS DP			
	9018204	Jan 31, 2023	DS DP			
	9309229	Jan 18, 2032	DS DP			
	9416112	Jan 31, 2023	DS DP			
<u>CETIRIZINE HYDROCHLORIDE - QUZYTIR</u>						
N 211415 001	>A> 8263581	Feb 28, 2030	U-2635		>A> NP	Oct 04, 2022
	>A> 8314083	Feb 28, 2030	U-2634			
	>A> 8513259	Feb 11, 2030	U-2636			
	>A> 9119771	Feb 11, 2030	U-2635			
	>A> 9180090	Feb 11, 2030	U-2635			
<u>CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL</u>						
N 208791 001	8969412	Sep 05, 2026	DP U-2609			
	9504666	Dec 11, 2033	DP			
<u>CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S ADVIL ALLERGY SINUS</u>						
N 021587 001	10238640	May 25, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819 001	8487093	Nov 19, 2029	DS DP U-2586			
	8487093	Nov 19, 2029	DS DP U-2587			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589 001	9827231	Jun 26, 2034	DP U-2162			
<u>CLADRIBINE - MAVENCLAD</u>						
N 022561 001	7713947	Oct 16, 2026	U-2520		NP	Mar 29, 2022
	7888328	Apr 11, 2024	DP U-2521			
	8377903	May 31, 2026	U-2522			
	8785415	Apr 11, 2024	DP U-2523			
<u>COBICISTAT - TYBOST</u>						
N 203094 001					>A> NPP	Aug 22, 2022
					>A> ODE-260	Aug 22, 2026
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10231961	Feb 07, 2037	DP			
	10413505	Feb 07, 2037	U-2479			
	>A> 10420760	Feb 07, 2037	U-2478			
<u>COLCHICINE - GLOPERBA</u>						
N 210942 001	10226423	Dec 20, 2037	DP			
	9907751	Nov 22, 2036	DP			
<u>COLESEVELAM HYDROCHLORIDE - WELCHOL</u>						
N 210895 001	7229613	Apr 17, 2022	U-2516			
<u>COPANLISIB DIHYDROCHLORIDE - ALIQOPA</u>						
N 209936 001	10383876	Mar 29, 2032	DS DP			
<u>CROFELEMER - MYTESI</u>						
N 202292 001	7341744	Jun 02, 2022	DP U-1319			
	9585868	Oct 31, 2031	U-1319			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	10328037	Aug 16, 2036	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	10328037	Aug 16, 2036	U-1399			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	10166184	Oct 15, 2032	DP U-2341			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					>A> M-246	Oct 06, 2022
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					>A> M-246	Oct 06, 2022
<u>DALFAMPRIDINE - DALFAMPRIDINE</u>						
A 206863 001					PC	Mar 09, 2019
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	>A> 8007826	May 26, 2027	U-1030	Y		
	>A> 8354437	Dec 22, 2026	U-1030	Y		
	>A> 8440703	Apr 08, 2025	U-1030	Y		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	001				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	002				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	003				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	004				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	005				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	006				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	007				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	008				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	009				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	010				NPP	May 16, 2022
<u>DALTEPARIN SODIUM - FRAGMIN</u>						
N 020287	011				NPP	May 16, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002				M-238	Feb 22, 2022
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	001	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874	002	6414126	Oct 04, 2020	DS DP U-493	NP	May 02, 2022
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8628799	Jul 13, 2025	DP		
		8716251	Mar 21, 2028	DP		
		9198925	Oct 04, 2020	U-493		
		9616028	Nov 12, 2030	DP		
		RE44186	Jul 31, 2023	DS DP U-493		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 002	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 003	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - QTERNMET XR</u>						
N 210874 004	6414126	Oct 04, 2020	DS DP U-493		NP	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	9616028	Nov 12, 2030	DP			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 001	6414126	Oct 04, 2020	DS DP U-493		I-804	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-1976			
	6936590	Oct 04, 2020	U-1977			
	6936590	Oct 04, 2020	U-493			
	8361972	Mar 21, 2028	U-1976			
	8361972	Mar 21, 2028	U-1977			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-1976			
	8501698	Jun 20, 2027	DP U-1977			
	8501698	Jun 20, 2027	DP U-493			
	9198925	Oct 04, 2020	U-1976			
	9198925	Oct 04, 2020	U-1977			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			
<u>DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE - QTERN</u>						
N 209091 002	6414126	Oct 04, 2020	DS DP U-493		NS	May 02, 2022
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8628799	Jul 13, 2025	DP			
	8716251	Mar 21, 2028	DP			
	9198925	Oct 04, 2020	U-493			
	RE44186	Jul 31, 2023	DS DP U-493			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPSONE - ACZONE</u>						
N 207154 001					>A> NPP	Sep 10, 2022
<u>DAPTOMYCIN - DAPTOMYCIN</u>						
A 212667 001					CGT	Jan 12, 2020
<u>DAROLUTAMIDE - NUBEQA</u>						
N 212099 001	10010530	Jan 28, 2036	DS		NCE	Jul 30, 2024
	10383853	Jan 28, 2036	DS			
	8975254	Oct 27, 2030	DS DP U-2605			
	9657003	Oct 27, 2030	DS DP U-2605			
<u>DARUNAVIR - PREZISTA</u>						
N 021976 002	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 004	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 005	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 021976 006	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DARUNAVIR - PREZISTA</u>						
N 202895 001	9889115	Jun 23, 2019	U-1305			
	9889115*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	10201542	Oct 18, 2033	DP U-1753			
<u>DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR</u>						
N 208624 001	10201541	May 17, 2032	DP			
	10201584	May 17, 2032	U-1889			
<u>DASATINIB - SPRYCEL</u>						
N 021986 001					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 002					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 003					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 004					ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DASATINIB - SPRYCEL</u>						
N 021986 005					ODE-225 PED	Dec 21, 2025 Jun 21, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASATINIB - SPRYCEL</u>						
N 021986	006				ODE-225 PED	Dec 21, 2025 Jun 21, 2026
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	001				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	002				PC	Apr 05, 2019
<u>DEFERASIROX - DEFERASIROX</u>						
A 203560	003				PC	Apr 05, 2019
<u>DEFERASIROX - EXJADE</u>						
N 021882	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - EXJADE</u>						
N 021882	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU</u>						
N 206910	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	001				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	002				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERASIROX - JADENU SPRINKLE</u>						
N 207968	003				M-239 M-241	Dec 12, 2021 Jul 24, 2022
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030	002	7049328 8703156	Jun 28, 2021 Oct 29, 2029	U-735 DP U-735		
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	001				ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684	002				ODE-252	Jun 07, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 003					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208684 004					ODE-252	Jun 07, 2026
<u>DEFLAZACORT - EMFLAZA</u>						
N 208685 001					ODE-252	Jun 07, 2026
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	10307459	May 07, 2023	DP			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	10307459	May 07, 2023	DP			
<u>DESONIDE - VERDESO</u>						
N 021978 001	8460641	Aug 13, 2027	DP U-1412			
<u>DEXAMETHASONE - DEXTENZA</u>						
N 208742 001	8409606	May 14, 2030	DP		I-800	Jun 20, 2022
	8563027	Feb 12, 2030	U-2487		NP	Nov 30, 2021
	9254267	Sep 11, 2024	DP			
<u>DEXAMETHASONE - DEXYCU KIT</u>						
N 208912 001	10159683	May 23, 2034	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - DEXMEDETOMIDINE HYDROCHLORIDE</u>						
A 208129 001					PC	Nov 30, 2019
<u>DIGOXIN - DIGOXIN</u>						
A 213000 001					CGT	Apr 01, 2020
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9763880	Sep 30, 2033	U-2558			
	9763880	Sep 30, 2033	U-2559			
	9763880	Sep 30, 2033	U-2560			
	9763880	Sep 30, 2033	U-2561			
	9763880	Sep 30, 2033	U-2562			
	9763880	Sep 30, 2033	U-2563			
	9763880	Sep 30, 2033	U-2564			
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
	9242986	Dec 08, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001	8129385	Oct 05, 2027	DS DP		NC	Apr 08, 2022
	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA</u>						
N 210192 001 >A>	10426780	Jan 24, 2031	DS DP U-257			
<u>DORAVIRINE - PIFELTRO</u>						
N 210806 001 >A>	8486975	Oct 07, 2031	DS DP U-2394			
	>A> 8486975	Oct 07, 2031	DS DP U-2630			
<u>DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE - DELSTRIGO</u>						
N 210807 001	8486975	Oct 07, 2031	DS DP U-2395		I-806	Sep 19, 2022
	8486975	Oct 07, 2031	DS DP U-2629			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 001	10238620	May 18, 2027	U-620			
<u>DOXEPIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	10238620	May 18, 2027	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	10058564	Apr 05, 2022	U-1063			
<u>DRONABINOL - SYNDROS</u>						
N 205525 001	10265293	Aug 06, 2028	DS DP			
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	10179140	Jun 28, 2031	U-2553		NP	May 23, 2022
	9603860	Jun 28, 2031	U-2553			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10413525	Apr 13, 2037	DP			
	9839626	Apr 13, 2037	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-243	Aug 09, 2022
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003					M-243	Aug 09, 2022
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001					>A> NCE	Feb 12, 2023
					>A> NCE	Oct 21, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-2451			
	8052993	Aug 01, 2027	DP U-930			
	8052993*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-2451			
	8052994	Aug 01, 2027	DP U-930			
	8052994*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293	May 21, 2023	U-930			
	7795293*PED	Nov 21, 2023				
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-2451			
	8062665	Aug 01, 2027	DP U-930			
	8062665*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-2451			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-2451			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-2451			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-2451			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-2451			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-2451			
	7795293*PED	Nov 21, 2023				
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-2451			
	8071129	Aug 01, 2027	DP U-930			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-2451			
	8828430*PED	Feb 01, 2028				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 001	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-1736	
	7332481*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-1736	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-1736	
	7795293*PED	Nov 24, 2023				
<u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u>						
N 207027 002	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1736			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021			U-1306	
	7332481	May 24, 2021			U-1736	
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1736			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1736			
	7547719	Jul 13, 2025	DS DP U-2452			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021			U-1306	
	7790704	May 24, 2021			U-1736	
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023			U-1306	
	7795293	May 21, 2023			U-1736	
	7795293*PED	Nov 21, 2023				
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	10188632	Mar 14, 2033		DP		
	10213415	Mar 14, 2025	DS		U-2152	
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	10188632	Mar 14, 2033		DP		
	10213415	Mar 14, 2025	DS		U-2152	
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	10258637	Apr 03, 2034			U-2290	
	10406172	Jun 15, 2030			U-1652	
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	10258637	Apr 03, 2034			U-2290	
	10406172	Jun 15, 2030			U-1652	
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034			U-2290	
	10406172	Jun 15, 2030			U-1652	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	10258637	Apr 03, 2034	U-2290			
	10406172	Jun 15, 2030	U-1652			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	10258637	Apr 03, 2034	U-2290			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	10258637	Apr 03, 2034	U-2290			
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001					>A> I-812	Oct 03, 2022
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 001	10294215	Jan 07, 2033	DP U-2087			
<u>ENASIDENIB MESYLATE - IDHIFA</u>						
N 209606 002	10294215	Jan 07, 2033	DP U-2087			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 001	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		>A> ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			
	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	10231965	Feb 17, 2035	U-2617		NCE	Aug 15, 2024
	10231965	Feb 17, 2035	U-2618		>A> ODE-265	Aug 15, 2026
	10398693	Jul 18, 2038	DP			
	8299057	Mar 01, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTRECTINIB - ROZLYTREK</u>						
N 212725 002	8673893	Jul 08, 2028	U-2617			
	8673893	Jul 08, 2028	U-2618			
	9029356	Jul 08, 2028	DS DP			
	9085558	Jul 08, 2028	DP			
	9085565	May 22, 2033	DS DP			
	9255087	Jul 08, 2028	U-2617			
	9255087	Jul 08, 2028	U-2618			
	9616059	Jul 08, 2028	U-2618			
	9649306	May 22, 2033	U-2617			
	9649306	May 22, 2033	U-2618			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 003	10314977	Nov 23, 2024	DP			
	10335549	Apr 30, 2025	DP			
<u>ERAVACYCLINE DIHYDROCHLORIDE - XERAVA</u>						
N 211109 001	8796245	Aug 07, 2029	U-2380			
	8906887	Dec 28, 2030	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	8895601	May 22, 2031	DS DP		NCE	Apr 12, 2024
	9464071	Apr 28, 2031	U-2518			
	9902714	Mar 26, 2035	DP			
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 001					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 002					PC	Nov 05, 2019
<u>ERLOTINIB HYDROCHLORIDE - ERLOTINIB HYDROCHLORIDE</u>						
A 091002 003					PC	Nov 05, 2019
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	8785500	Jul 09, 2031	U-2502		NCE*	Mar 05, 2024
	9592207	Mar 20, 2027	U-2502			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10258630	Dec 20, 2033	U-2316			
	10258630	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2317			
	10398708	Dec 20, 2033	U-2614			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	10206932	Nov 21, 2032	U-2439			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002	10344765	Jun 27, 2034	DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003	10344765	Jun 27, 2034	DP			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	10337003	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1918			
	10364431	Mar 14, 2034	U-1919			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	6414126	Oct 04, 2020	U-2588			
	6515117	Oct 04, 2020	U-2588			
	6872700	Jan 14, 2020	U-2589		Y	
	6872700	Jan 14, 2020	U-2590		Y	
	6872700	Jan 14, 2020	U-2591		Y	
	6936590	Oct 04, 2020	U-2588			
	7456254	Jun 30, 2025	DP U-2588		Y	
	7456254	Jun 30, 2025	DP U-2589		Y	
	7456254	Jun 30, 2025	DP U-2590		Y	
	7456254	Jun 30, 2025	DP U-2592		Y	
	7612176	Apr 13, 2025	DP U-2589		Y	
	7612176	Apr 13, 2025	DP U-2590		Y	
	7612176	Apr 13, 2025	DP U-2592		Y	
	8329648	Aug 18, 2026	U-2588		Y	
	8329648	Aug 18, 2026	U-2589		Y	
	8329648	Aug 18, 2026	U-2590		Y	
	8329648	Aug 18, 2026	U-2593		Y	
	8329648	Aug 18, 2026	U-2594		Y	
	8329648	Aug 18, 2026	U-2595		Y	
	8329648	Aug 18, 2026	U-2596		Y	
	8361972	Mar 21, 2028	U-2588			
	8431685	Apr 13, 2025	DP U-2589		Y	
	8431685	Apr 13, 2025	DP U-2590		Y	
	8431685	Apr 13, 2025	DP U-2597		Y	
	8431685	Apr 13, 2025	DP U-2598		Y	
	8461105	Apr 13, 2025	DP U-2589		Y	
	8461105	Apr 13, 2025	DP U-2590		Y	
	8461105	Apr 13, 2025	DP U-2597		Y	
	8461105	Apr 13, 2025	DP U-2598		Y	
	8501698	Jun 20, 2027	U-2588			
	8895033	Oct 04, 2030	DP U-2589		Y	
	8895033	Oct 04, 2030	DP U-2590		Y	
	8895033	Oct 04, 2030	DP U-2597		Y	
	8895033	Oct 04, 2030	DP U-2600		Y	
	8895033	Oct 04, 2030	DP U-2601		Y	
	8895033	Oct 04, 2030	DP U-2602		Y	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	8906851	Aug 18, 2026	U-2589	Y		
	8906851	Aug 18, 2026	U-2590	Y		
	8906851	Aug 18, 2026	U-2593	Y		
	8906851	Aug 18, 2026	U-2597	Y		
	9198925	Oct 04, 2020	U-2588			
	9238076	Apr 15, 2024	DP U-2589	Y		
	9238076	Apr 15, 2024	DP U-2590	Y		
	9238076	Apr 15, 2024	DP U-2597	Y		
	9238076	Apr 15, 2024	DP U-2599	Y		
	9884092	Aug 18, 2026	U-2589	Y		
	9884092	Aug 18, 2026	U-2590	Y		
	9884092	Aug 18, 2026	U-2593	Y		
	9884092	Aug 18, 2026	U-2594	Y		
	9884092	Aug 18, 2026	U-2595	Y		
	9884092	Aug 18, 2026	U-2596	Y		
	9884092	Aug 18, 2026	U-2597	Y		
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 001					PC	Dec 28, 2019
<u>FEBUXOSTAT - FEBUXOSTAT</u>						
A 205385 002					PC	Dec 28, 2019
<u>FEDRATINIB HYDROCHLORIDE - INREBIC</u>						
N 212327 001	10391094	May 29, 2032	DP U-2607		NCE	Aug 16, 2024
	7528143	Dec 16, 2026	DS		>A> ODE-259	Aug 16, 2026
	7825246	Dec 16, 2026	DS			
	8138199	Jun 30, 2028	U-2607			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	DP U-1432			
	7754702	Feb 15, 2028	DP U-2555			
	7754702	Feb 15, 2028	DP U-2556			
	7754702	Feb 15, 2028	DP U-2557			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	10300039	Jul 21, 2030	U-2549		I-790	Nov 06, 2020
	5753706	Feb 03, 2020	DP U-1577			
<u>FERRIC MALTOL - ACCRUFER</u>						
N 212320 001	10179120	Jan 06, 2035	U-2603		NCE	Jul 25, 2024
	9248148	Mar 29, 2031	U-2603			
	9802973	Oct 23, 2035	DS DP U-2603			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 208551 001	7816404	Apr 17, 2029	U-1656			
	7857977	Sep 08, 2027	U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 02, 2030	DP			
<u>FINGOLIMOD HYDROCHLORIDE - GILENYA</u>						
N 022527 001	9187405	Jun 25, 2027	U-2613			
	9187405*PED	Dec 25, 2027				
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 001	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FISH OIL TRIGLYCERIDES - OMEGAVEN</u>						
N 210589 002	10350186	Nov 05, 2024	U-2585			
	9566260	Jul 11, 2025	DP U-2366			
	9629821	Jul 11, 2025	DP U-2367			
<u>FLUORODOPA F-18 - FLUORODOPA F18</u>						
N 200655 001					>A> NCE	Oct 10, 2024
					>A> W	Oct 10, 2024
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022 001	10179216	Jul 08, 2033	DP U-2133			
	10252010	Feb 07, 2031	DP			
	10300229	Jul 07, 2035	DP U-2133			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 001	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10195375	Feb 14, 2031	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9415008	Oct 06, 2034	DP U-645			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10022510	May 18, 2031	DP			
	10124131	May 18, 2031	DP			
	10195375	Feb 14, 2031	DP			
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9066957	Oct 06, 2034	DP U-645			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
	9782550	Aug 28, 2035	DP			
	9782551	Aug 28, 2035	DP			
	9987229	Sep 01, 2024	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-2546			
	8703806	May 28, 2030	U-2546			
	8808713	May 28, 2030	DP U-2546			
	8815258	Mar 17, 2031	U-2546			
	9415009	May 28, 2030	U-2546			
	9463161	May 28, 2030	DP U-2546			
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 001	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA</u>						
N 022518 002	7067502	May 21, 2020	DP U-1068		M-214	Dec 20, 2020
	7067502*PED	Nov 21, 2020			PED	Jun 20, 2021
	7566705	May 21, 2020	DP U-1068			
	7566705*PED	Nov 21, 2020				
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	10208073	May 23, 2032	U-2301			
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122	Jan 09, 2021	U-1826			
	6774122	Jan 09, 2021	U-2108			
	6774122	Jan 09, 2021	U-2163			
	6774122	Jan 09, 2021	U-2504			
	6774122	Jan 09, 2021	U-596			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	6774122*PED	Jul 09, 2021				
	7456160	Jan 09, 2021	U-1826			
	7456160	Jan 09, 2021	U-2108			
	7456160	Jan 09, 2021	U-2163			
	7456160	Jan 09, 2021	U-2504			
	7456160	Jan 09, 2021	U-596			
	7456160*PED	Jul 09, 2021				
	8329680	Jan 09, 2021	U-1826			
	8329680	Jan 09, 2021	U-2108			
	8329680	Jan 09, 2021	U-2163			
	8329680	Jan 09, 2021	U-2504			
	8329680	Jan 09, 2021	U-596			
	8329680*PED	Jul 09, 2021				
	8466139	Jan 09, 2021	U-1826			
	8466139	Jan 09, 2021	U-2108			
	8466139	Jan 09, 2021	U-2163			
	8466139	Jan 09, 2021	U-2504			
	8466139	Jan 09, 2021	U-596			
	8466139*PED	Jul 09, 2021				
<u>FULVESTRANT - FULVESTRANT</u>						
N 210326 001	10188663	Feb 14, 2034	DP U-2540			
	9271990	May 17, 2034	DP U-2540			
	9833459	Feb 14, 2034	DP U-2540			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	6818787	Apr 06, 2025	DS DP			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	6818787	Apr 06, 2025	DS DP			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-801	Jul 12, 2022
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-801	Jul 12, 2022
<u>GALLIUM DOTATOC GA-68 - GALLIUM DOTATOC GA 68</u>						
N 210828 001					NCE W	Aug 21, 2024 Aug 21, 2024
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349 001					NCE	Nov 28, 2023
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 001	10414748	Apr 13, 2036	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656 002	10414748	Apr 13, 2036	DS DP			
<u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u>						
N 209394 001	10028937	Jun 10, 2030	U-2141		D-175	Sep 26, 2022
	10028937	Jun 10, 2030	U-2532		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2141		ODE-232	Apr 30, 2026
	10039754	Jun 10, 2030	U-2532		ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532			
	8648037	Jan 19, 2032	DS DP U-2141			
	8648037	Jan 19, 2032	DS DP U-2532			
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10213487	Feb 16, 2036	DP U-2604		NP	Jul 24, 2022
	6938798	Jan 03, 2022	DP			
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 001					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE PFS</u>						
N 212097 002					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 003					NP	Sep 10, 2022
<u>GLUCAGON - GVOKE HYOPEN</u>						
N 212097 004					NP	Sep 10, 2022
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	10183002	Sep 22, 2030	U-1816			
	10183003	Sep 22, 2030	U-1816			
	10183004	Sep 22, 2030	U-1816			
	10183005	Sep 22, 2030	U-1816			
	10183006	Sep 22, 2030	U-1816			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10376661	Sep 14, 2035	DP			
<u>GRANISETRON - SUSTOL</u>						
N 022445 001	10357570	Sep 28, 2024	U-2253			
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355 001	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354 001	10251895	Jun 06, 2036	DP		NP	Apr 25, 2022
	10426787	Jun 06, 2036	U-2625			
	6517847	Aug 03, 2020	DP			
	8809307	Nov 02, 2031	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	10322120	Jul 25, 2033	DP			
	>A> 10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	10322120	Jul 25, 2033	DP			
	>A> 10456393	Jul 25, 2033	U-1810			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	10322120	Jul 25, 2033	DP			
>A>	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	10322120	Jul 25, 2033	DP			
>A>	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	10322120	Jul 25, 2033	DP			
>A>	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	10322120	Jul 25, 2033	DP			
>A>	10456393	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 001	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 002	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 003	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 004	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 005	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 006	10369109	Jun 16, 2023	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA ER</u>						
N 206627 007	10369109	Jun 16, 2023	DP			
<u>HYDROCORTISONE VALERATE - HYDROCORTISONE VALERATE</u>						
A 211750 001					CGT	Jul 16, 2019
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	10294231	Jun 03, 2033	DP		M-236	Jan 25, 2022
	10294232	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004	10213386	Mar 03, 2036	DP		M-236	Jan 25, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBUPROFEN - CHILDREN'S ADVIL-FLAVORED</u>						
N 020589 002	10238640	May 25, 2024	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002 >A>	8871810	Sep 30, 2029	U-981			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003	8735452	Sep 30, 2029	U-981			
	8871810	Sep 30, 2029	U-981			
	9012508	Sep 14, 2030	U-981			
	9072661	Mar 16, 2032	U-2264			
	9072710	Mar 16, 2032	U-2266			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10238644	Dec 11, 2029	U-68			
	10238645	Aug 18, 2029	U-1455			
	10238645	Aug 18, 2029	U-172			
<u>INSULIN ASPART - FIASP</u>						
N 208751 001				>A> M-247		Oct 21, 2022
<u>INSULIN ASPART - FIASP FLEXTOUCH</u>						
N 208751 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG PENFILL</u>						
N 020986 002	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 003	10376652	Jan 20, 2026	DP			
	7615532	Jun 28, 2029	DS DP			
<u>INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6</u>						
N 208583 001	10220155	Jul 17, 2026	DP		M-242	Aug 08, 2022
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 02, 2022	DP			
	7615532	Jun 28, 2029	DS DP			
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DS DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8937042	May 05, 2029	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
	9457154	Sep 27, 2027	DP			
	9486588	Jan 02, 2022	DP			
	9616180	Jan 20, 2026	DP			
	9687611	Feb 27, 2027	DP			
	9775953	Jul 17, 2026	DP			
	9861757	Jan 20, 2026	DP			
	RE46363	Aug 03, 2026	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33</u>						
N 208673 001	10029011	Nov 11, 2030	DP			
	9011391	Mar 26, 2024		U-1923		
	9011391	Mar 26, 2024		U-2496		
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	10201672	Aug 02, 2030	DP			
	10342938	Jun 12, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872	001				NP	Apr 26, 2022
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075	001	7541363	Nov 13, 2024	DS DP	NCE	Aug 27, 2024
		7727993	Jan 28, 2023	U-2623		
		7727994	Jan 18, 2023	U-2623		
		8318201	Sep 05, 2027	DP		
<u>ISTRADEFYLLINE - NOURIANZ</u>						
N 022075	002	7541363	Nov 13, 2024	DS DP	NCE	Aug 27, 2024
		7727993	Jan 28, 2023	U-2623		
		7727994	Jan 18, 2023	U-2623		
		8318201	Sep 05, 2027	DP		
<u>IVABRADINE - CORLANOR</u>						
N 209964	001	7361649	Feb 22, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361650	Feb 22, 2026	DS DP U-1694	NP	Apr 22, 2022
		7867996	Feb 22, 2026	DS DP U-1694	ODE-234	Apr 22, 2026
		7879842	Feb 22, 2026	DS DP U-1694	PED	Oct 15, 2020
					PED	Oct 22, 2022
					PED	Oct 22, 2026
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	001	7361649	Feb 22, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361649*PED	Aug 22, 2026		PED	Oct 15, 2020
		7361650	Feb 22, 2026	DS DP U-1694		
		7361650*PED	Aug 22, 2026			
		7867996	Feb 22, 2026	DS DP U-1694		
		7867996*PED	Aug 22, 2026			
		7879842	Feb 22, 2026	DS DP U-1694		
		7879842*PED	Aug 22, 2026			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143	002	7361649	Feb 22, 2026	DS DP U-1694	NCE	Apr 15, 2020
		7361649*PED	Aug 22, 2026		PED	Oct 15, 2020
		7361650	Feb 22, 2026	DS DP U-1694		
		7361650*PED	Aug 22, 2026			
		7867996	Feb 22, 2026	DS DP U-1694		
		7867996*PED	Aug 22, 2026			
		7879842	Feb 22, 2026	DS DP U-1694		
		7879842*PED	Aug 22, 2026			
<u>IVACAFITOR - KALYDECO</u>						
N 203188	002				NPP	Jul 31, 2020
					ODE-186	Feb 21, 2021
					ODE-187	Dec 29, 2021
					ODE-189	Jul 31, 2024
					ODE-190	May 17, 2024
					ODE-199	Aug 15, 2025
<u>IVACAFITOR - KALYDECO</u>						
N 207925	001	10272046	Feb 27, 2033	DP U-2531	NPP	Apr 29, 2022
		8324242	Aug 05, 2027	U-1311	ODE-236	Apr 29, 2026
		8324242	Aug 05, 2027	U-1906		
		8324242	Aug 05, 2027	U-2527		
		8354427	Jul 06, 2026	U-1311		
		8354427	Jul 06, 2026	U-1905		
		8354427	Jul 06, 2026	U-2528		
		8629162	Jun 24, 2025	U-2234		
		8629162	Jun 24, 2025	U-2529		
		9670163	Dec 28, 2026	DP U-1311		
		9670163	Dec 28, 2026	DP U-2530		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFITOR - KALYDECO</u>						
N 207925 002	10272046	Feb 27, 2033	DP U-2531		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-236	Apr 29, 2026
	8324242	Aug 05, 2027	U-1906			
	8324242	Aug 05, 2027	U-2527			
	8354427	Jul 06, 2026	U-1311			
	8354427	Jul 06, 2026	U-1905			
	8354427	Jul 06, 2026	U-2528			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR - KALYDECO</u>						
N 207925 003	10272046	Feb 27, 2033	DP U-2531		NPP	Jul 31, 2020
	7495103	May 20, 2027	DS DP		NPP	Apr 29, 2022
	8324242	Aug 05, 2027	U-1311		ODE-188	Mar 17, 2022
	8324242	Aug 05, 2027	U-1906		ODE-189	Jul 31, 2024
	8324242	Aug 05, 2027	U-2527		ODE-190	May 17, 2024
	8354427	Jul 06, 2026	U-1311		ODE-199	Aug 15, 2025
	8354427	Jul 06, 2026	U-1905		ODE-236	Apr 29, 2026
	8354427	Jul 06, 2026	U-2528			
	8410274	Dec 28, 2026	DP			
	8629162	Jun 24, 2025	U-2234			
	8629162	Jun 24, 2025	U-2529			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
	9670163	Dec 28, 2026	DP U-1311			
	9670163	Dec 28, 2026	DP U-2530			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10022352	Apr 09, 2027	DP U-2343		NPP	Jun 21, 2022
	10022352	Apr 09, 2027	DP U-2573		ODE-247	Jun 21, 2026
	10058546	Jul 15, 2033	U-2399			
	10058546	Jul 15, 2033	U-2572			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	9931334	Dec 28, 2026	DP U-2275			
	9931334	Dec 28, 2026	DP U-2575			
	9974781	Apr 09, 2027	DP U-2318			
	9974781	Apr 09, 2027	DP U-2574			
<u>IVACAFITOR; IVACAFITOR, TEZACAFITOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10022352	Apr 09, 2027	DP U-2343		NCE	Feb 12, 2023
	10022352	Apr 09, 2027	DP U-2573		NPP	Jun 21, 2022
	10058546	Jul 15, 2033	U-2399		ODE-173	Feb 12, 2025
	10058546	Jul 15, 2033	U-2572		ODE-247	Jun 21, 2026
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10239867	Apr 09, 2027	DS DP U-2512			
	10239867	Apr 09, 2027	DS DP U-2569			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-2246			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-2246			
	8598181	May 01, 2027	U-2246			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-2247			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033		U-2248		
	9670163	Dec 28, 2026	DP	U-2246		
	9931334	Dec 28, 2026	DP	U-2275		
	9931334	Dec 28, 2026	DP	U-2575		
	9974781	Apr 09, 2027	DP	U-2318		
	9974781	Apr 09, 2027	DP	U-2574		
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	10206939	Mar 13, 2034		U-1631		
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001 >A>	10449184	Mar 13, 2035	DP		ODE-242	May 02, 2026
	9474779	Aug 19, 2033	DS DP	U-2350		
	9474779	Aug 19, 2033	DS DP	U-2533		
	9474779	Aug 19, 2033	DS DP	U-2534		
	9850277	Jan 18, 2033	DS DP	U-2350		
	9850277	Jan 18, 2033	DS DP	U-2533		
	9850277	Jan 18, 2033	DS DP	U-2534		
	9968595	Mar 13, 2035	DP	U-2351		
	9968595	Mar 13, 2035	DP	U-2533		
	9968595	Mar 13, 2035	DP	U-2534		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	7442830	Nov 20, 2029	DS DP	U-2434		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	7442830	Nov 20, 2029	DS DP	U-2434		
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	7442830	Nov 20, 2029	DS DP	U-2434		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035		U-2470		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10172861	Nov 16, 2035	DS DP		NCE	Nov 26, 2023
	10285993	Nov 16, 2035		U-2470		
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10172861	Nov 16, 2035	DS		NCE	Nov 26, 2023
<u>LATANOPROST - XELPROS</u>						
N 206185 001	9539262	Oct 15, 2028		U-2400		
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10174017	Jan 27, 2030	DS DP	U-1524	NC	Mar 12, 2022
	8394826	Nov 10, 2030	DS DP	U-1524	NCE	Dec 18, 2022
	8450344	Jul 11, 2026	DS DP	U-1524		
	9096569	Jul 11, 2026	DS DP	U-1524		
	9415043	Mar 14, 2034	DS			
	9931336	Mar 14, 2034	DS DP	U-1524		
	9993470	Mar 14, 2034	DS DP	U-1524		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	10039779	Jan 30, 2034	DS DP	U-2369	ODE-136	Apr 07, 2024
	10039779	Jan 30, 2034	DS DP	U-2370	PED	Oct 07, 2024
	10039779*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP	U-1470		
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	DP U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002	10039779	Jan 30, 2034	DS DP U-1470			
	10039779*PED	Jul 30, 2034				
	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8088368	May 12, 2030	DS DP			
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	7964580	Mar 26, 2029	DS DP U-1470		>A> ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			>A> ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		>A> ODE-264	Aug 28, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 001	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 212477 002	7964580	Mar 26, 2029	DS DP U-1470		>A> ODE-262	Aug 28, 2026
	7964580*PED	Sep 26, 2029			>A> ODE-263	Aug 28, 2026
	8088368	May 12, 2030	DS DP		>A> ODE-264	Aug 28, 2026
	8088368*PED	Nov 12, 2030				
	8273341	May 12, 2030	U-1470			
	8273341*PED	Nov 12, 2030				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8822430	May 12, 2030	DS DP U-1470			
	8822430*PED	Nov 12, 2030				
	8841278	May 12, 2030	DP U-1470			
	8841278*PED	Nov 12, 2030				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9393256	Sep 14, 2032	U-1470			
	9393256*PED	Mar 14, 2033				
	9511056	May 12, 2030	U-1470			
	9511056*PED	Nov 12, 2030				
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
	9120727	May 23, 2031	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211672 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
	9120727	May 23, 2031	DS DP			
<u>LEFAMULIN ACETATE - XENLETA</u>						
N 211673 001	6753445	Jul 09, 2021	DS DP U-2619		NCE	Aug 19, 2024
	8071643	Jan 16, 2029	DS DP		GAIN	Aug 19, 2029
	8153689	Mar 19, 2028	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	7189740	Apr 11, 2023	U-1982		I-796	May 28, 2022
	7468363	Oct 07, 2023	U-1983		I-797	May 28, 2022
	7468363	Oct 07, 2023	U-2550		ODE-241	May 28, 2026
	7468363	Oct 07, 2023	U-2551		ODE-245	May 28, 2026
	7968569	Oct 07, 2023	U-1984			
	8404717	Apr 11, 2023	U-1982			
	8492406	Oct 07, 2023	U-2550			
	8530498	May 15, 2023	U-1984			
	8648095	May 15, 2023	U-1984			
	8741929	Mar 08, 2028	U-1983			
	9056120	Apr 11, 2023	U-1982			
	9101621	May 15, 2023	U-1985			
	9101622	May 15, 2023	U-1986			
	9155730	May 15, 2023	U-2550			
	9393238	May 15, 2023	U-2550			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-807	Sep 17, 2022
	10407393	Aug 26, 2035	DS			
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	10183012	Nov 26, 2028	U-2311			
<u>LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED)</u>						
N 209935 001	8962630	Dec 09, 2029	U-2505			
	9416136	Aug 20, 2029	U-2505			
	9868739	Nov 09, 2031	U-2505			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 001	8470367	Oct 31, 2027	DP			
<u>LEVETIRACETAM - ELEPSIA XR</u>						
N 204417 002	8470367	Oct 31, 2027	DP			
<u>LEVOCARNITINE - LEVOCARNITINE</u>						
A 211676 001					>A> CGT	Apr 13, 2020
<u>LEVOCARNITINE - LEVOCARNITINE SF</u>						
A 211676 002					>A> CGT	Apr 13, 2020
<u>LEVODOPA - INBRIJA</u>						
N 209184 001	6514482	Sep 19, 2020	DP U-2484		NP	Dec 21, 2021
	6613308	Sep 19, 2020	U-2484			
	6858199	Nov 04, 2021	U-2485			
	6921528	Jun 19, 2020	U-2485			
	6979437	Sep 19, 2020	U-2484			
	7146978	Apr 16, 2021	U-2486			
	7182961	Feb 22, 2024	DP			
	7384649	Nov 20, 2022	DP			
	7556798	Nov 04, 2021	U-2485			
	8404276	Mar 19, 2023	U-2484			
	8545878	Nov 16, 2032	DP			
	8586093	Mar 19, 2023	U-2484			
	8628754	Jun 19, 2020	U-2485			
	8685442	Nov 16, 2032	DP			
	8945612	Nov 16, 2032	DP			
	9155699	Mar 19, 2023	DP			
	9393210	Nov 16, 2032	DP			
	RE43711	Feb 03, 2029	U-2484			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 011	>A> 7691411	Mar 14, 2024	DP			
	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - TIROSINT</u>						
N 021924 012	>A> 7691411	Mar 14, 2024	DP			
	>A> 7723390	Mar 14, 2024	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 001	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 002	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 210632 003	10398669	Dec 01, 2036	DP			
	9782376	Dec 01, 2036	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8802628	Oct 30, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8802628	Oct 30, 2031	DP			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	6268343	Aug 22, 2022	DS DP U-968		NPP	Jun 17, 2022
	6268343*PED	Feb 22, 2023			PED	Dec 17, 2022
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8114833	Aug 13, 2025	DS DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	9265893	Sep 23, 2032	DP			
	9265893*PED	Mar 23, 2033				
	9968659	Jan 09, 2037	U-2313			
	9968659*PED	Jul 09, 2037				
	RE41956	Jan 21, 2021	DP			
	RE41956*PED	Jul 21, 2021				
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	10220155	Jul 17, 2026	DP			
	10220155*PED	Jan 17, 2027				
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	6268343	Aug 22, 2022	DS DP U-1255			
	6268343*PED	Feb 22, 2023				
	6899699	Jan 01, 2022	DP			
	6899699*PED	Jul 01, 2022				
	7762994	May 23, 2024	DP			
	7762994*PED	Nov 23, 2024				
	8114833	Aug 13, 2025	DP			
	8114833*PED	Feb 13, 2026				
	8579869	Jun 30, 2023	DP			
	8579869*PED	Dec 30, 2023				
	8672898	Jan 02, 2022	DP			
	8672898*PED	Jul 02, 2022				
	8684969	Oct 20, 2025	DP			
	8684969*PED	Apr 20, 2026				
	8846618	Jun 27, 2022	DP			
	8846618*PED	Dec 27, 2022				
	8920383	Jul 17, 2026	DP			
	8920383*PED	Jan 17, 2027				
	9108002	Jan 26, 2026	DP			
	9108002*PED	Jul 26, 2026				
	9132239	Feb 01, 2032	DP			
	9132239*PED	Aug 01, 2032				
	9457154	Sep 27, 2027	DP			
	9457154*PED	Mar 27, 2028				
	9486588	Jan 02, 2022	DP			
	9486588*PED	Jul 02, 2022				
	9616180	Jan 20, 2026	DP			
	9616180*PED	Jul 20, 2026				
	9687611	Feb 27, 2027	DP			
	9687611*PED	Aug 27, 2027				
	9775953	Jul 17, 2026	DP			
	9775953*PED	Jan 17, 2027				
	9861757	Jan 20, 2026	DP			
	9861757*PED	Jul 20, 2026				
	9968659	Jan 09, 2037	U-2438			
	9968659*PED	Jul 09, 2037				
	RE46363	Aug 03, 2026	DP			
	RE46363*PED	Feb 03, 2027				
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10265370	Nov 06, 2035	DP			
	10406199	Nov 06, 2035	U-1723			
	10406199	Nov 06, 2035	U-185			
	10406199	Nov 06, 2035	U-1864			
	10406199	Nov 06, 2035	U-1991			
	10406199	Nov 06, 2035	U-3			
	10406199	Nov 06, 2035	U-71			
	10406199	Nov 06, 2035	U-8			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 001	10201663	Mar 10, 2034	DP			
<u>LIXISENATIDE - ADLYXIN</u>						
N 208471 002	10201663	Mar 10, 2034	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO XR</u>						
N 208524 001	10226471	Aug 31, 2031	DP			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001 >A>	10420749	Jul 27, 2036	DS DP U-2633			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002 >A>	10420749	Jul 27, 2036	DS DP U-2633			
<u>LOTEPREDNOL ETABONATE - LOTEMAX SM</u>						
N 208219 001					NS	Feb 22, 2022
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	10058511	May 03, 2033	DP U-2492			
	9056057	May 03, 2033	DP U-2491			
	9393213	May 03, 2033	DP			
	9532955	May 03, 2033	U-2491			
	9737491	May 03, 2033	U-2492			
	9827191	May 03, 2033	DP U-2493			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8779187	Jan 23, 2027	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	10172874	Aug 08, 2031	DP			
	10183034	Aug 08, 2031	U-2490			
<u>METFORMIN HYDROCHLORIDE - RIOMET</u>						
N 021591 001	6890957	Aug 07, 2021	DP			
<u>METFORMIN HYDROCHLORIDE - RIOMET ER</u>						
N 212595 001	9962336	May 01, 2035	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	8628799	Jul 13, 2025	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	8628799	Jul 13, 2025	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	10231927	Jan 02, 2033	U-1349			
	10231927	Jan 02, 2033	U-1699			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	10376584	Apr 08, 2024	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 208271 001	10307417	Mar 10, 2031	DP			
	10376505	Mar 10, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				
	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	10039719	Dec 16, 2019	U-2357			
	10039719*PED	Jun 16, 2020				
	6419960	Dec 16, 2019	DP			
	6419960*PED	Jun 16, 2020				
	7083808	Dec 16, 2019	DP			
	7083808*PED	Jun 16, 2020				
	7247318	Dec 16, 2019	DP			
	7247318*PED	Jun 16, 2020				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	7438930	Dec 16, 2019	DP	Y		
	7438930*PED	Jun 16, 2020				
	8580310	Dec 16, 2019	DP			
	8580310*PED	Jun 16, 2020				
	9066869	Dec 16, 2019	DP			
	9066869*PED	Jun 16, 2020				
	9801823	Dec 16, 2019	DP			
	9801823*PED	Jun 16, 2020				
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10182995	Mar 23, 2032	DP			
	10292937	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006	10111839	Oct 30, 2035	U-2357		NP	Feb 27, 2022
	10292938	Oct 30, 2035	DP			
	10292939	Oct 30, 2035	DP U-2357			
>A>	10449159	Oct 30, 2035	U-2357			
	9974752	Oct 30, 2035	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	10238634	Jun 28, 2032	DP			
<u>MIDAZOLAM - NAYZILAM</u>						
N 211321 001	8217033	Jan 18, 2028	DP U-2526		NP	May 21, 2022
	8809322	Jan 18, 2028	DP		ODE-243	May 17, 2026
	9289432	Jan 18, 2028	DP U-2526			
	9687495	Jan 18, 2028	DP U-2526			
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	10195214	Jun 19, 2037	U-1643			
	10231983	Aug 22, 2038	U-1643			
	10314850	Aug 22, 2038	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10251873	May 30, 2038	U-2371			
	10383864	May 16, 2027	U-2371			
	10406143	May 16, 2027	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCYCLINE HYDROCHLORIDE</u>						
A 091424 002					PC	Aug 21, 2019
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 001	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 002	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 003	10314788	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND ER</u>						
N 206544 004	10314788	Aug 12, 2028	DP			
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	10166205	Jan 31, 2033	DP			
	10166206	Jan 31, 2033	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			
	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10143792	May 24, 2031	U-2476			
	10220158	Mar 20, 2035	DP U-2500			
	10314977	Nov 23, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	10322239	Feb 28, 2031	U-1907			
	10335549	Apr 30, 2025	DP			
<u>NETARSUDIL DIMESYLATE - RHOPRESSA</u>						
N 208254 001	10174017	Jan 27, 2030	DS DP U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	10233154	Sep 25, 2035	DS			
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 001					PC	Oct 01, 2019
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
A 207868 002					PC	Oct 01, 2019
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	10154990	Dec 20, 2025	U-2620		I-805	Sep 06, 2022
					>A> ODE-261	Sep 06, 2026
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	10154990	Dec 20, 2025	U-2620		I-805	Sep 06, 2022
					>A> ODE-261	Sep 06, 2026
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001					>A> I-813	Oct 23, 2022
					>A> I-814	Oct 23, 2022
<u>NITISINONE - NITYR</u>						
N 209449 001	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 002	10328029	Jan 05, 2035	DP U-1836			
<u>NITISINONE - NITYR</u>						
N 209449 003	10328029	Jan 05, 2035	DP U-1836			
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	10266822	Dec 05, 2025	DP U-1942			
	10266822	Dec 05, 2025	DP U-1943			
	10266822	Dec 05, 2025	DP U-1944			
	10436802	Sep 11, 2035	U-1941			
	10436802	Sep 11, 2035	U-1942			
	10436802	Sep 11, 2035	U-1943			
	10436802	Sep 11, 2035	U-1944			
	10436802	Sep 11, 2035	U-2093			
	10436802	Sep 11, 2035	U-2094			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	8143241	Aug 12, 2027	U-2101		ODE-226	Dec 19, 2025
	8143241	Aug 12, 2027	U-2103			
	8143241	Aug 12, 2027	U-2480			
	8143241	Aug 12, 2027	U-2481			
	8143241	Aug 12, 2027	U-2482			
	8143241	Aug 12, 2027	U-2483			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8912187	Mar 12, 2024	U-2101			
	8912187	Mar 12, 2024	U-2480			
	8912187	Mar 12, 2024	U-2481			
	8912187	Mar 12, 2024	U-2482			
	8912187	Mar 12, 2024	U-2483			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	8383610	Sep 23, 2030	DS			
	9265740	Mar 05, 2029	U-1569			
	9314475	Mar 18, 2031	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	10383884	Oct 31, 2037	U-2576			
	7326696	Sep 24, 2023	DS			
	7553828	Jun 02, 2023	DS			
	9265740	Mar 05, 2029	DP			
	9365500	Jun 29, 2021	U-1569			
	9365500	Jun 29, 2021	U-2576			
	9724358	Mar 05, 2029	U-1569			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2020	DP			
	5948818	May 13, 2020	DP			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777			
	10183020	Jan 02, 2035	DP U-2289			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	6245819	Jul 21, 2025	U-1370		I-793	Jan 25, 2022
	6245819	Jul 21, 2025	U-905			
	8236861	Aug 11, 2026	U-1369			
	8236861	Aug 11, 2026	U-1370			
	8236861	Aug 11, 2026	U-905			
	8470890	Feb 13, 2024	U-1369			
	8470890	Feb 13, 2024	U-1370			
	8470890	Feb 13, 2024	U-905			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	8772353	Feb 13, 2024	U-905			
	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
	9241915	Feb 13, 2024	U-905			
	9855224	Feb 13, 2024	U-1369			
	9855224	Feb 13, 2024	U-1370			
	9855224	Feb 13, 2024	U-905			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	10220042	Apr 13, 2027	U-2501			
	7910131	Apr 13, 2027	U-2041			
	9119791	Apr 13, 2027	U-2041			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	10272061	Apr 26, 2020	U-2525			
	>A> 10449173	Nov 06, 2029	DP U-2637			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005	10188644	Sep 02, 2036	DP U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
	9060976	Aug 06, 2022	DP		Y	
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	10369109	Jun 16, 2023	DP			
	10407434	Mar 30, 2025	DS			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 001	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 002	10314788	Aug 12, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - ROXYBOND</u>						
N 209777 003	10314788	Aug 12, 2028	DP			
<u>OXYMETAZOLINE HYDROCHLORIDE - RHOFADÉ</u>						
N 208552 001	10335391	Jun 11, 2035	U-2567			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Apr 06, 2020	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	>A> 7758891	Feb 21, 2026	U-1434		>A> ODE-52	Sep 06, 2020
	>A> 7758891*PED	Aug 21, 2026			>A> PED	Mar 06, 2021
	>A> 7820788	Oct 27, 2024	DP U-1092			
	>A> 7820788	Oct 27, 2024	DP U-1290			
	>A> 7820788	Oct 27, 2024	DP U-1434			
	>A> 7820788*PED	Apr 27, 2025				
	>A> 7923536	Dec 09, 2023	U-1117			
	>A> 7923536	Dec 09, 2023	U-1290			
	>A> 7923536	Dec 09, 2023	U-1434			
	>A> 7923536*PED	Jun 09, 2024				
	>A> 8138229	Dec 09, 2023	DP U-1092			
	>A> 8138229	Dec 09, 2023	DP U-1290			
	>A> 8138229	Dec 09, 2023	DP U-1434			
	>A> 8138229*PED	Jun 09, 2024				
	>A> 8314156	Dec 09, 2023	U-1290			
	>A> 8314156	Dec 09, 2023	U-1434			
	>A> 8314156*PED	Jun 09, 2024				
	>A> 8853260	Oct 10, 2020	DP U-1092			
	>A> 8853260	Oct 10, 2020	DP U-1290			
	>A> 8853260	Oct 10, 2020	DP U-1434			
	>A> 8853260*PED	Apr 10, 2021				
	>A> 9101543	Feb 21, 2026	U-1434			
	>A> 9101543*PED	Aug 21, 2026				
	>A> 9393318	Mar 04, 2032	U-1290			
	>A> 9393318*PED	Sep 04, 2032				
	>A> 9511046	Jan 12, 2034	U-1434			
	>A> 9511046*PED	Jul 12, 2034				
	>A> 9597409	Mar 04, 2032	U-1290			
	>A> 9597409*PED	Sep 04, 2032				
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1998			
	7456168	Jan 16, 2023	U-2515			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001					>A> NCE	Feb 03, 2020
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002					>A> NCE	Feb 03, 2020
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003					>A> NCE	Feb 03, 2020
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 004	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR KIT</u>						
N 203255 005	7473761	Dec 14, 2026	DS DP			
	7759308	Oct 25, 2026	DP			
	9351923	May 23, 2028	DP			
<u>PENICILLAMINE - PENICILLAMINE</u>						
A 210976 001					CGT	Dec 22, 2019
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10189833	May 05, 2036	U-2606		NCE	Aug 02, 2024
	>A> 10435404	Jul 24, 2038	DP		ODE-250	Aug 02, 2026
	7893075	Oct 13, 2028	DS			
	8404700	Nov 21, 2027	DS			
	8461169	Apr 19, 2028	U-2606			
	8722702	Nov 21, 2027	DS			
	9169250	Nov 21, 2027	DS			
	9358235	Jun 08, 2033	U-2606			
	9802932	May 05, 2036	DS			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	>A> 10028944	Jan 15, 2024	U-1974			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002					NCE	Apr 29, 2021
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 210793 001	>A> 10028944	Jan 15, 2024	U-1974			
	>A> 10449185	Aug 27, 2038	DP			
	>A> 9566271	Jan 15, 2024	U-1974			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	8383150	Sep 22, 2026	DP U-1607			
	8383150	Sep 22, 2026	DP U-2361			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 001	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 002	10188637	Mar 28, 2037	DP			
<u>PIRFENIDONE - ESBRIET</u>						
N 208780 003	10188637	Mar 28, 2037	DP			
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 001	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 002	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITAVASTATIN CALCIUM - LIVALO</u>						
N 022363 003	5856336	Dec 25, 2020	DS	U-998	NPP	May 16, 2022
	5856336*PED	Jun 25, 2021			PED	Nov 16, 2022
	7022713	Feb 19, 2024		U-998		
	7022713*PED	Aug 19, 2024				
	8557993	Feb 02, 2024	DP			
	8557993*PED	Aug 02, 2024				
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022		U-1101	ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026		U-1101		
	8486947	Sep 26, 2029		U-1101		
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002	7169928	Feb 02, 2020	DS DP		NCE	Aug 14, 2024
	7910605	Sep 23, 2022		U-1101	ODE-255	Aug 14, 2026
	8207197	Feb 25, 2029	DS DP			
	8354430	Feb 26, 2026		U-1101		
	8486947	Sep 26, 2029		U-1101		
<u>PREGABALIN - LYRICA</u>						
N 021446 001					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 002					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 003					NPP	May 23, 2022
					PED	Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 004					NPP	May 23, 2022
					PED	Nov 23, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREGABALIN - LYRICA</u>						
N 021446 005					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 006					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 007					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 021446 008					NPP PED	May 23, 2022 Nov 23, 2022
<u>PREGABALIN - LYRICA</u>						
N 022488 001					NPP PED	May 23, 2022 Nov 23, 2022
<u>PRETOMANID - PRETOMANID</u>						
N 212862 001					NCE ODE-253 GAIN	Aug 14, 2024 Aug 14, 2026 Aug 14, 2029
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8987262	Oct 16, 2028	U-1988			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
A 211694 001					CGT	Sep 04, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 001					PC	May 27, 2019
<u>RANOLAZINE - RANOLAZINE</u>						
A 201046 002					PC	May 27, 2019
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	RE47301	Feb 02, 2027	DP			
	RE47351	Jun 22, 2019	DS DP U-869			
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	10343995	Mar 10, 2025	U-2440			
	8541451	Aug 25, 2031	DS			
	9765028	Jul 14, 2030	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	10314828	Oct 02, 2029	U-1481			
	10335397	Oct 02, 2029	U-2579			
>A>	10456384	Feb 26, 2029	U-2643			
>A>	10456384	Feb 26, 2029	U-2644			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 001	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			
<u>RISPERIDONE - PERSERIS KIT</u>						
N 210655 002	10376590	Feb 13, 2028	U-2608			
	10406160	Jun 26, 2026	DP U-2608			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	>A> 7592339	Dec 11, 2020	U-1167		>A> I-810	Oct 11, 2022
	>A> 7592339	Dec 11, 2020	U-1200			
	>A> 7592339	Dec 11, 2020	U-1301			
	>A> 7592339	Dec 11, 2020	U-1302			
	>A> 7592339	Dec 11, 2020	U-1303			
	>A> 7592339	Dec 11, 2020	U-2142			
	>A> 7592339	Dec 11, 2020	U-2640			
	>A> 9415053	Nov 13, 2024	DP U-1167			
	>A> 9415053	Nov 13, 2024	DP U-1200			
	>A> 9415053	Nov 13, 2024	DP U-1301			
	>A> 9415053	Nov 13, 2024	DP U-1302			
	>A> 9415053	Nov 13, 2024	DP U-2142			
	>A> 9415053	Nov 13, 2024	DP U-2640			
	>A> 9539218	Feb 17, 2034	U-1953			
	>A> 9539218	Feb 17, 2034	U-1954			
	>A> 9539218	Feb 17, 2034	U-1955			
	>A> 9539218	Feb 17, 2034	U-1957			
	>A> 9539218	Feb 17, 2034	U-2143			
	>A> 9539218	Feb 17, 2034	U-2641			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002					>A> I-810	Oct 11, 2022
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003					>A> I-810	Oct 11, 2022
<u>RIVAROXABAN - XARELTO</u>						
N 022406 004					>A> I-810	Oct 11, 2022
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 001	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 002	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 003	10413543	Feb 12, 2036	DP			
<u>ROSUVASTATIN CALCIUM - EZALLOR</u>						
N 208647 004	10413543	Feb 12, 2036	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 001	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 002	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 003	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 004	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 005	10350174	Dec 22, 2030	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N 021829 006	10350174	Dec 22, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 001	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 002	10278974	Feb 10, 2031	DP			
<u>RUCAPARIB CAMSYLATE - RUBRACA</u>						
N 209115 003	10278974	Feb 10, 2031	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	10016429	Jun 12, 2028	U-2536		I-799	May 24, 2022
	9814722	Dec 12, 2026	U-2536		ODE-238	May 24, 2026
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				
	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	7468390*PED	May 27, 2024			NPP	Oct 01, 2022
	8101659	Jan 14, 2023	DP		PED	Jan 07, 2021
	8101659*PED	Jul 14, 2023			PED	Apr 01, 2023
	8404744	Jan 14, 2023	DP			
	8404744*PED	Jul 14, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	8796331	Jan 14, 2023	U-1723			
	8796331*PED	Jul 14, 2023				
	8877938	May 27, 2027	DS DP			
	8877938*PED	Nov 27, 2027				
	9388134	Nov 08, 2026	U-1723			
	9388134*PED	May 08, 2027				
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10335390	Sep 04, 2035	U-2583			
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 001					NCE	Apr 30, 2024
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	8999996	Sep 15, 2032	DS DP		NCE	Jul 03, 2024
	9079865	Jul 26, 2032	U-2584		ODE-257	Jul 03, 2026
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	10220155	Jul 17, 2026	DP			
	10335462	Jun 21, 2033	U-2580			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10086047	Dec 16, 2031	DP		NCE	Dec 05, 2022
	10278923	May 02, 2034	U-2628		NP	Sep 20, 2022
	8129343	Jan 29, 2029	DS DP U-2628			
	8536122	Mar 20, 2026	DS DP U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SILDENAFIL CITRATE - SILDENAFIL CITRATE</u>						
A 212260 001					CGT	Nov 27, 2019
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 001 >A>	10300041	Apr 26, 2027	DP			
<u>SIMVASTATIN - FLOLIPID</u>						
N 206679 002 >A>	10300041	Apr 26, 2027	DP			
<u>SINECATECHINS - VEREGEN</u>						
N 021902 001	10434059	Nov 18, 2022	DP U-172			
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 001	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIPONIMOD FUMARIC ACID - MAYZENT</u>						
N 209884 002	7939519	May 19, 2024	DS DP		NCE	Mar 26, 2024
	8492441	Nov 30, 2030	U-2511			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-244	Aug 12, 2022
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-244	Aug 12, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10213400	Mar 15, 2033	U-2499		ODE-231	Oct 26, 2025
	7668730	Jun 16, 2024	U-1110	Y		
	7668730*PED	Dec 16, 2024				
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 001	10300087	Oct 14, 2035	DS	U-2312		
	10335432	Feb 10, 2032		U-2312		
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SODIUM ZIRCONIUM CYCLOSILICATE - LOKELMA</u>						
N 207078 002	10300087	Oct 14, 2035	DS	U-2312		
	10398730	Feb 10, 2032		U-2312		
	10413569	Feb 10, 2032	DS			
	9913860	Oct 22, 2033	DS	U-2312		
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	7964580	Mar 26, 2029	DS DP	U-1470	NPP	Apr 07, 2020
	7964580*PED	Sep 26, 2029			ODE-135	Apr 07, 2024
	8334270	Mar 21, 2028	DS DP	U-1470	PED	Oct 07, 2024
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP	U-1470		
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP	U-1470		
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP	U-1470		
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP	U-1470		
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP	U-1470		
	9284342*PED	Mar 13, 2031				
	9549941	Mar 26, 2029		U-1958		
	9549941*PED	Sep 26, 2029				
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002	7964580	Mar 26, 2029	DS DP	U-1470		
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP	U-1470		
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP	U-1470		
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP	U-1470		
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP	U-1470		
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029		DP U-1470		
	8889159*PED	Sep 26, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 001	7964580	Mar 26, 2029	DS DP U-1470		>A> ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR - SOVALDI</u>						
N 212480 002	7964580	Mar 26, 2029	DS DP U-1470		>A> ODE-258	Aug 28, 2026
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001	7964580	Mar 26, 2029	DS DP U-1470			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	7964580	Mar 26, 2029	DS DP U-2039			
	7964580	Mar 26, 2029	DS DP U-2040			
	7964580*PED	Sep 26, 2029				
	8334270	Mar 21, 2028	DS DP U-2039			
	8334270	Mar 21, 2028	DS DP U-2040			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	8334270*PED	Sep 21, 2028				
	8580765	Mar 21, 2028	DS DP U-2039			
	8580765	Mar 21, 2028	DS DP U-2040			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-2039			
	8618076	Dec 11, 2030	DS DP U-2040			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-2039			
	8633309	Mar 26, 2029	DS DP U-2040			
	8633309*PED	Sep 26, 2029				
	8889159	Mar 26, 2029	DS DP U-2039			
	8889159	Mar 26, 2029	DS DP U-2040			
	8889159*PED	Sep 26, 2029				
	9085573	Mar 21, 2028	DS DP U-2039			
	9085573	Mar 21, 2028	DS DP U-2040			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-2039			
	9284342	Sep 13, 2030	DS DP U-2040			
	9284342*PED	Mar 13, 2031				
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 001	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL - SUNOSI</u>						
N 211230 002	10195151	Sep 05, 2037	DP		NCE	Jun 17, 2024
	10351517	Jun 07, 2026	U-2548		ODE-254	Jun 17, 2026
	8440715	Aug 25, 2027	U-2548			
	8877806	Jun 07, 2026	U-2548			
	9604917	Jun 07, 2026	U-2548			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 008	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 009	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 010	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			
<u>SOMATROPIN - NORDITROPIN FLEXPRO</u>						
N 021148 011	10220155	Jul 17, 2026	DP			
	10357616	Jan 20, 2026	DP			
	10376652	Jan 20, 2026	DP			
	7762994	May 23, 2024	DP			
	8579869	Jun 30, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTALOL HYDROCHLORIDE - SOTYLIZE</u>						
N 205108 001	10206895	Apr 01, 2034	DP U-2096			
	10206895	Apr 01, 2034	DP U-2494			
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10245228	Jan 05, 2027	DP U-1351			
	10342762	Jan 05, 2027	DP			
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001	10232061	Jul 06, 2038	DP			
	10335502	Jul 06, 2038	DP			
<u>SUMATRIPTAN - TOSYMRA</u>						
N 210884 001	8268791	May 09, 2026	DP			
	8440631	May 09, 2026	DP U-1719			
	9211282	Jul 19, 2031	DP U-1719			
>A>	9283280	May 09, 2026	DP			
	9610280	Jun 16, 2030	DP U-1719			
	9974770	Jun 16, 2030	DP U-1719			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	10398859	Dec 19, 2027	DP			
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 001	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 002	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 003	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>SUNITINIB MALATE - SUTENT</u>						
N 021938 004	6573293	Feb 15, 2021	DS DP U-1154		I-755	Nov 16, 2020
	6573293	Feb 15, 2021	DS DP U-2171		PED	May 16, 2021
	6573293*PED	Aug 15, 2021				
	7125905	Feb 15, 2021	DS DP			
	7125905*PED	Aug 15, 2021				
	7211600	Dec 22, 2020	U-883			
	7211600*PED	Jun 22, 2021				
<u>TACROLIMUS - ENVARISUS XR</u>						
N 206406 001	10166190	May 30, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	10166190	May 30, 2028	DP			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	10166190	May 30, 2028	DP			
<u>TADALAFIL - CIALIS</u>						
N 021368 003	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TADALAFIL - CIALIS</u>						
N 021368 004	7182958	Apr 26, 2020	DP U-155	Y		
	7182958*PED	Oct 26, 2020				
<u>TAFAMIDIS - VYNDAMAX</u>						
N 212161 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	9770441	Aug 31, 2035	DS DP U-2524			
<u>TAFAMIDIS MEGLUMINE - VYNDAQEL</u>						
N 211996 001	7214695	Apr 27, 2024	DS DP		NCE	May 03, 2024
	7214696	Dec 19, 2023	U-2524		ODE-237	May 03, 2026
	8168663	Dec 19, 2023	DS DP			
	8653119	Jan 28, 2024	U-2524			
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10342791	Dec 02, 2035	U-2582			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 001	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 211651 002	10189837	Oct 20, 2031	DS DP		NCE	Oct 16, 2023
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10376487	Jul 27, 2035	U-2615			
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001					NCE	Jul 07, 2019
					PED	Jan 07, 2020
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	10065947	Feb 03, 2030	DP			
	9624250	Feb 03, 2030	DS DP U-2507			
	9988406	Feb 03, 2030	DP			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320		ODE-240	May 16, 2026
	5789379*PED	Oct 14, 2020			ODE-37	Dec 21, 2019
	7056886	Sep 18, 2022	DP U-1320		PED	Jun 21, 2020
	7056886*PED	Mar 18, 2023				
	7847061	Nov 01, 2025	U-1320			
	7847061*PED	May 01, 2026				
	9060992	Nov 01, 2025	U-1320			
	9060992*PED	May 01, 2026				
	9539310	Nov 01, 2025	U-1320			
	9539310*PED	May 01, 2026				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	9545434	Nov 01, 2025	U-1320			
	9545434*PED	May 01, 2026				
	9545435	Nov 01, 2025	U-1320			
	9545435*PED	May 01, 2026				
	9555079	Nov 01, 2025	U-1320			
	9555079*PED	May 01, 2026				
	9572867	Nov 01, 2025	U-1320			
	9572867*PED	May 01, 2026				
	9592273	Nov 01, 2025	U-1320			
	9592273*PED	May 01, 2026				
	9592274	Nov 01, 2025	U-1320			
	9592274*PED	May 01, 2026				
	9968655	Nov 01, 2025	U-2308			
	9968655*PED	May 01, 2026				
	9968656	Nov 01, 2025	U-2308			
	9968656*PED	May 01, 2026				
	9968658	Nov 01, 2025	U-1320			
	9968658*PED	May 01, 2026				
	9974835	Nov 01, 2025	U-1320			
	9974835*PED	May 01, 2026				
	9974837	Nov 01, 2025	U-1320			
	9974837*PED	May 01, 2026				
	9981014	Nov 01, 2025	U-1320			
	9981014*PED	May 01, 2026				
	9981016	Nov 01, 2025	U-1320			
	9981016*PED	May 01, 2026				
	9987334	Nov 01, 2025	U-1320			
	9987334*PED	May 01, 2026				
	9987335	Nov 01, 2025	U-1320			
	9987335*PED	May 01, 2026				
	9993528	Nov 01, 2025	U-1320			
	9993528*PED	May 01, 2026				
<u>TENAPANOR HYDROCHLORIDE - IBSRELA</u>						
N 211801 001	8541448	Dec 30, 2029	DS DP		NCE	Sep 12, 2024
	8969377	Dec 30, 2029	DS DP			
	9006281	May 02, 2030	U-2626			
	9408840	Dec 30, 2029	U-2626			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 001	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 002	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>TESTOSTERONE UNDECANOATE - JATENZO</u>						
N 206089 003	8241664	Mar 29, 2029	DP U-2506		NP	Mar 27, 2022
	8492369	Dec 20, 2030	DP U-2506			
	8778916	Apr 12, 2030	DP			
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 001					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 002					CGT	Oct 02, 2019
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642 003					CGT	Oct 02, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTHIXENE - THIOTHIXENE</u>						
A 211642	004				CGT	Oct 02, 2019
<u>TICAGRELOR - BRILINTA</u>						
N 022433	001	10300065	Jan 27, 2036	U-2541		
		10300065	Jan 27, 2036	U-2542		
<u>TICAGRELOR - BRILINTA</u>						
N 022433	002	10300065	Jan 27, 2036	U-2541		
		10300065	Jan 27, 2036	U-2542		
<u>TIOPRONIN - THIOLA</u>						
N 019569	001				>A> ODE-267	Jun 28, 2026
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981	001	>A> 10456399	Feb 03, 2037	U-2642	I-794	Feb 22, 2022
		>A> 10457666	Jun 17, 2034	DS DP	ODE-229	Feb 22, 2026
		RE46284	Dec 16, 2026	U-1751		
		RE46284	Dec 16, 2026	U-2503		
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981	002	>A> 10456399	Feb 03, 2037	U-2642	I-794	Feb 22, 2022
		>A> 10457666	Jun 17, 2034	DS DP	ODE-229	Feb 22, 2026
		RE46284	Dec 16, 2026	U-1751		
		RE46284	Dec 16, 2026	U-2503		
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688	001	10207066	Nov 04, 2030	DP U-909		
		8664187	Jun 20, 2025	U-909		
		8869794	Sep 12, 2028	DP U-909		
		9421166	Dec 19, 2022	DP U-909		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	002	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	003	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	004	10314790	Nov 16, 2027	DP U-1675		
		10314790	Nov 16, 2027	DP U-1992		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	001	10363224	Mar 19, 2033	U-766		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	002	10363224	Mar 19, 2033	U-766		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	003	10363224	Mar 19, 2033	U-766		
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122	004	10363224	Mar 19, 2033	U-766		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	10363224	Mar 19, 2033	U-766			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712		>A> M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712		>A> M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712		>A> M-246	Oct 06, 2022
	8703781	Oct 15, 2030	DS DP U-2020			
	8703781	Oct 15, 2030	DS DP U-2037			
	8703781	Oct 15, 2030	DS DP U-2302			
	8703781	Oct 15, 2030	DS DP U-2305			
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 001					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 002					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 003					PC	Sep 21, 2019
<u>TREPROSTINIL - TREPROSTINIL</u>						
A 203649 004					PC	Sep 21, 2019
<u>TRETINOIN - ALTRENO</u>						
N 209353 001	6517847	Aug 03, 2020	DP U-2368			
<u>TRICLABENDAZOLE - EGATEN</u>						
N 208711 001					NCE ODE-228	Feb 13, 2024 Feb 13, 2026
<u>TRIFAROTENE - AKLIEF</u>						
N 211527 001	>A> 7807708	Oct 01, 2026	DS DP		>A> NCE	Oct 04, 2024
	>A> 8227507	Dec 21, 2025	U-818			
	>A> 8470871	Dec 21, 2025	U-2639			
	>A> 9084778	May 30, 2033	DP U-134			
<u>TRIPTORELIN PAMOATE - TRELSTAR</u>						
N 022437 001	10166181	Feb 10, 2029	DP			
<u>TRIPTORELIN PAMOATE - TRIPTODUR KIT</u>						
N 208956 001	10166181	Feb 10, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	10159681	Apr 13, 2030	U-2510			
	9844510	Dec 08, 2028	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					M-245	Jun 09, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	8962629	Jan 15, 2031	DS U-2616		NCE	Aug 16, 2024
	9951080	Oct 17, 2036	DS DP			
	9963459	Oct 17, 2036	DP			
	RE47221	Dec 01, 2030	DS			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	6258795	Jul 10, 2023	DP			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2023	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	10039804	Nov 06, 2035	DP U-282			
	10188697	Nov 06, 2035	DP U-282			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-237 PED	Feb 22, 2022 Aug 22, 2022
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	9174982	May 26, 2030	U-2323		I-795	May 15, 2022
	9174982	May 26, 2030	U-2445		ODE-239	May 15, 2026
	9174982	May 26, 2030	U-2446			
	9174982	May 26, 2030	U-2537			
	9539251	Sep 06, 2033	U-2538			
<u>VORICONAZOLE - VFEND</u>						
N 021266 001					NPP	Jan 29, 2022

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2019

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORICONAZOLE - VFEND</u>						
N 021266	002				NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021267	001				NPP	Jan 29, 2022
<u>VORICONAZOLE - VFEND</u>						
N 021630	001				NPP	Jan 29, 2022

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 39<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)